Sopharma AD
skrót: SPH
Ostatnie notowanie z: 21.01.2021 15:36
Aktualny kurs | 9,55 | 3,24 % | 0,30 zł |
Otwarcie | 9,30 | 0,54% |
Minimum | 9,25 | 0,00% |
Maksimum | 9,55 | 3,24% |
Wolumen (szt.) | 2722 |
Kurs odniesienia | 9,25 |
Widełki dolne | 8,40 |
Widełki górne | 10,20 |
Obroty (tyś. zł) | 26 |
Kupno | ||
---|---|---|
Liczba zleceń | Wolumen | Limit cen |
2 | 206 | 9,25 |
2 | 129 | 9,20 |
2 | 255 | 9,10 |
3 | 766 | 9,05 |
1 | 110 | 9,00 |
Sprzedaż | |||
---|---|---|---|
Limit cen | Wolumen | Liczba zleceń | |
9,55 | 37 | 1 | |
9,60 | 165 | 1 | |
9,65 | 80 | 1 | |
9,70 | 86 | 1 | |
9,80 | 600 | 3 |
Nazwa | Komentarz | Akcje | (%) | Prawa głosu | (%) |
---|---|---|---|---|---|
Donev, Ognian Ivanov | wraz z Donev Investments Holding | 38 729 610 | 28,73% | 38 729 610 | 30,82% |
Telekomplekt AD | 27 056 752 | 20,07% | 27 056 752 | 21,53% | |
Pavlov, Liubomir Vladimirov | poprzez Financial Consulting Company EOOD | 17 387 853 | 12,90% | 17 387 853 | 13,83% |
Rompharm Company OOD | 12 545 000 | 9,31% | 12 545 000 | 9,98% | |
Sopharma AD | 9 113 467 | 6,76% | 9 113 467 | 7,25% | |
CUPF Allianz Bulgaria | 6 861 213 | 5,09% | 6 861 213 | 5,46% |
- pdf
18.06.2018
Alior, PKO BP, mBank, PKP Cargo, Agora, GetBack, Inpro, Kino Polska, Sopharma, Warimpex, Wojas
Alior, PKO BP, mBank, PKP Cargo, Agora, GetBack, Inpro, Kino Polska, Sopharma, Warimpex, Wojas
- pdf
18.06.2018
Alior, PKO BP, mBank, PKP Cargo, Agora, GetBack, Inpro, Kino Polska, Sopharma, Warimpex, Wojas
Alior, PKO BP, mBank, PKP Cargo, Agora, GetBack, Inpro, Kino Polska, Sopharma, Warimpex, Wojas
- 11.01.2021 13:03
SOPHARMA AD (2/2021) Sales revenues for December 2020
11.01.2021 13:03SOPHARMA AD (2/2021) Sales revenues for December 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that for December 2020 the Company recorded an increase in sales of 27% compared to the same month of 2019, incl. 1% increase of domestic sales and 63% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.01.2021 15:15
SOPHARMA AD (1/2021) "Sopharma" AD now owns 100% of the capital of the subsidiary BRIZ, Latvia
08.01.2021 15:15SOPHARMA AD (1/2021) "Sopharma" AD now owns 100% of the capital of the subsidiary BRIZ, Latvia
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, January 8, 2021 - According to the requirements of art. 100t of LPOS, "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 28, 2020 as a result of long and successful negotiations with the remaining shareholders of BRIZ a change in the shareholders' structure was finalized with the Commercial Register of the Republic of Latvia, which makes "Sopharma" AD the only shareholder owning 100% of the shares in the company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.01.2021 14:11
SOPHARMA AD (161/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2020.
04.01.2021 14:11SOPHARMA AD (161/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.01.2021 14:05
SOPHARMA AD (160/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2020.
04.01.2021 14:05SOPHARMA AD (160/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.01.2021 13:57
SOPHARMA AD (159/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 29, 2020.
04.01.2021 13:57SOPHARMA AD (159/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 29, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 29, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.01.2021 13:40
SOPHARMA AD (158/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 29, 2020.
04.01.2021 13:40SOPHARMA AD (158/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 29, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 29, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.12.2020 11:58
SOPHARMA AD (157/2020) "Sopharma" AD sold the shares of its subsidiary "Aromania" AD
29.12.2020 11:58SOPHARMA AD (157/2020) "Sopharma" AD sold the shares of its subsidiary "Aromania" AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that the company sold its shares in the capital of the subsidiary "Aromania" AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 24.12.2020 09:45
SOPHARMA AD (156/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 23, 2020.
24.12.2020 09:45SOPHARMA AD (156/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 23, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 23, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.12.2020 15:34
SOPHARMA AD (155/2020) The Board of Directors gave a mandate for negotiations for the sale of the shares owned by the Company in its subsidiaries "Veta Pharma" AD and "Aromania" AD
23.12.2020 15:34SOPHARMA AD (155/2020) The Board of Directors gave a mandate for negotiations for the sale of the shares owned by the Company in its subsidiaries "Veta Pharma" AD and "Aromania" AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, December 23, 2020 - According to the requirements of art. 100t of LPOS, "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that the Board of Directors gave a mandate to the Executive director and the Procurator of the company to negotiate for the sale of the shares owned by "Sopharma" AD in its subsidiaries "Veta Pharma" AD and "Aromania" AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.12.2020 14:55
SOPHARMA AD (154/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 22, 2020.
23.12.2020 14:55SOPHARMA AD (154/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 22, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 22, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.12.2020 08:12
SOPHARMA AD (153/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 22, 2020.
23.12.2020 08:12SOPHARMA AD (153/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 22, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 22, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.12.2020 12:44
SOPHARMA AD (152/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 21, 2020.
22.12.2020 12:44SOPHARMA AD (152/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 21, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 21, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.12.2020 09:00
SOPHARMA AD (151/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 21, 2020.
22.12.2020 09:00SOPHARMA AD (151/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 21, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 21, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.12.2020 10:18
SOPHARMA AD (150/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2020.
18.12.2020 10:18SOPHARMA AD (150/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.12.2020 10:33
SOPHARMA AD (149/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 16, 2020.
17.12.2020 10:33SOPHARMA AD (149/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 16, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 16, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.12.2020 10:24
SOPHARMA AD (148/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 15, 2020.
16.12.2020 10:24SOPHARMA AD (148/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 15, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 15, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.12.2020 10:07
SOPHARMA AD (147/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 14, 2020.
15.12.2020 10:07SOPHARMA AD (147/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 14, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 14, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.12.2020 09:34
SOPHARMA AD (146/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2020.
14.12.2020 09:34SOPHARMA AD (146/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.12.2020 14:35
SOPHARMA AD (145/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2020.
11.12.2020 14:35SOPHARMA AD (145/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.12.2020 10:15
SOPHARMA AD (144/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2020.
11.12.2020 10:15SOPHARMA AD (144/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.12.2020 10:18
SOPHARMA AD (143/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2020.
10.12.2020 10:18SOPHARMA AD (143/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.12.2020 10:12
SOPHARMA AD (142/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2020.
10.12.2020 10:12SOPHARMA AD (142/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.12.2020 10:27
SOPHARMA AD (141/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 8, 2020.
09.12.2020 10:27SOPHARMA AD (141/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 8, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 8, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.12.2020 10:22
SOPHARMA AD (140/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 8, 2020.
09.12.2020 10:22SOPHARMA AD (140/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 8, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 8, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2020 11:11
SOPHARMA AD (139/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 7, 2020.
08.12.2020 11:11SOPHARMA AD (139/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 7, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 7, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2020 11:05
SOPHARMA AD (138/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 7, 2020.
08.12.2020 11:05SOPHARMA AD (138/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 7, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 7, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.12.2020 13:03
SOPHARMA AD (137/2020) Sales revenues for November 2020
07.12.2020 13:03SOPHARMA AD (137/2020) Sales revenues for November 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, December 7, 2020 - According to the requirements of art. 100t of LPOS, "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for November 2020 the Company recorded a decrease in sales of 9% compared to the same month of 2019, incl. 58% decrease in domestic sales and 38% increase in export sales.
In the eleven months of 2020 the revenues from sales of production decrease by 14% compared to the same period of 2019, incl. 27% decrease of sales for the domestic market and 5% decrease in export sales
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.12.2020 11:06
SOPHARMA AD (136/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2020.
07.12.2020 11:06SOPHARMA AD (136/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.12.2020 09:54
SOPHARMA AD (135/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2020.
07.12.2020 09:54SOPHARMA AD (135/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.12.2020 11:54
SOPHARMA AD (134/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2020.
04.12.2020 11:54SOPHARMA AD (134/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.12.2020 09:54
SOPHARMA AD (133/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2020.
04.12.2020 09:54SOPHARMA AD (133/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.12.2020 13:13
SOPHARMA AD (132/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2020.
03.12.2020 13:13SOPHARMA AD (132/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.12.2020 13:09
SOPHARMA AD (131/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 1, 2020.
03.12.2020 13:09SOPHARMA AD (131/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 1, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 1, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.12.2020 10:51
SOPHARMA AD (130/2020) Notification from Simeon Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2020.
03.12.2020 10:51SOPHARMA AD (130/2020) Notification from Simeon Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Simeon Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.12.2020 10:44
SOPHARMA AD (129/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2020.
03.12.2020 10:44SOPHARMA AD (129/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.12.2020 09:24
SOPHARMA AD (128/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 1, 2020.
02.12.2020 09:24SOPHARMA AD (128/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 1, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 1, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.11.2020 14:39
SOPHARMA AD (127/2020) Consolidated Financial Report as at 30 September 2020.
30.11.2020 14:39SOPHARMA AD (127/2020) Consolidated Financial Report as at 30 September 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Consolidated Financial Report as at 30 September 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.11.2020 13:03
SOPHARMA AD (126/2020) "Sopharma" AD will start the payment of 6-month dividend on November 23, 2020
16.11.2020 13:03SOPHARMA AD (126/2020) "Sopharma" AD will start the payment of 6-month dividend on November 23, 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, November 16, 2020 - "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that the Company will initiate dividend payment of the voted on the Extraordinary General Meeting held on September 25, 2020 dividend of 0.04 BGN per share on November 23, 2020.
The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the Extraordinary General Meeting, i.e. October 9, 2020.
In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Postbank in the country until November 23, 2021 (after that date, shareholders who have not received their dividend in the appropriate order may do that at the cash desk of the Company in Sofia, 16 Iliensko Shose Str. every business day between 10:00 a.m. - 12:00 p.m. and 14:00 p.m. - 16:00 p.m., tel. 02/8134 283)
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.11.2020 13:07
SOPHARMA AD (125/2020) Sales revenues for October 2020
05.11.2020 13:07SOPHARMA AD (125/2020) Sales revenues for October 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that for October 2020 the Company recorded a decrease in sales of 38% compared to the same month of 2019, incl. 40% decrease in domestic sales and 37% decrease in export sales.
In the first ten months of 2020 the revenues from sales of production decrease by 15% compared to the same period of 2019, incl. 21% decrease of sales for the domestic market and 11% decrease in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.10.2020 12:28
SOPHARMA AD (124/2020) Individual financial report according to IFRS as at 30 September 2020
30.10.2020 12:28SOPHARMA AD (124/2020) Individual financial report according to IFRS as at 30 September 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Individual financial report according to IFRS as at 30 September 2020
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.10.2020 13:10
SOPHARMA AD (123/2020) Sales revenues for September 2020
05.10.2020 13:10SOPHARMA AD (123/2020) Sales revenues for September 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD (the Company) notifies that for September 2020 the Company recorded a decrease in sales of 14% compared to the same month of 2019, incl. 10% increase in domestic sales and 29% decrease in export sales.
In the first nine months of 2020 the revenues from sales of production decrease by 11% compared to the same period of 2019, incl. 19% decrease of sales for the domestic market and 6% decrease in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.10.2020 11:51
SOPHARMA AD (122/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 30, 2020.
02.10.2020 11:51SOPHARMA AD (122/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 30, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 30, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.10.2020 08:26
SOPHARMA AD (121/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 30, 2020.
01.10.2020 08:26SOPHARMA AD (121/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 30, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 30, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.09.2020 15:13
SOPHARMA AD (120/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 29, 2020.
30.09.2020 15:13SOPHARMA AD (120/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 29, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 29, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.09.2020 10:16
SOPHARMA AD (119/2020) Notification for acquisition of own shares
30.09.2020 10:16SOPHARMA AD (119/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, September 28, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on September 29, 2020 the Company bought 65 000 own shares representing 0.0482% of the share capital of the Company, at a total value of BGN 200 200 on the Bulgarian Stock Exchange, the average price per share was 3.0800 BGN.
The total number of treasury shares after this transaction is 9 011 467, representing 6.685% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.09.2020 10:08
SOPHARMA AD (118/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 29, 2020.
30.09.2020 10:08SOPHARMA AD (118/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 29, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 29, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.09.2020 09:25
SOPHARMA AD (117/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 25, 2020.
29.09.2020 09:25SOPHARMA AD (117/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 25, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 25, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.09.2020 09:17
SOPHARMA AD (116/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 28, 2020.
29.09.2020 09:17SOPHARMA AD (116/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 28, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 28, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.09.2020 15:05
SOPHARMA AD (115/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 24, 2020.
28.09.2020 15:05SOPHARMA AD (115/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 24, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 24, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.09.2020 14:03
SOPHARMA AD (114/2020) Notification on the adoption of a new Policy for formation of the remuneration of the members of the Board of Directors of "Sopharma" AD
28.09.2020 14:03SOPHARMA AD (114/2020) Notification on the adoption of a new Policy for formation of the remuneration of the members of the Board of Directors of "Sopharma" AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, September 28, 2020 - In accordance with the requirements of art. 100t of LPOS "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that at the Extraordinary General Meeting of Shareholders of "Sopharma" AD, held on September 25, 2020 at 11:00 a.m. (UTC 8:00 a.m.), with a majority of 97.61% of the represented capital, in accordance with § 20 of The transitional and final provisions of Ordinance no. 48 of March 20, 2013 of the Financial Supervision Commission /promulgated, SG, no. 32 of 2.04.2013, amended and supplemented, no. 41 of 21.05.2019, amended, no. 66 of 20.08.2019, amended and supplemented, no. 61 of 10.07.2020/ a new Policy for formation of the remuneration of the members of the Board of Directors of "Sopharma" AD was adopted.
The Current Policy is available on the Company's website:
https://www.sopharmagroup.com/sites/sopharma2016corp/files/3jr_remuneration_policy_2020_en_1.pdf
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.09.2020 13:44
SOPHARMA AD (113/2020) Notification for acquisition of own shares
28.09.2020 13:44SOPHARMA AD (113/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, September 28, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on September 25, 2020 the Company sold 9 000 own shares representing 0.0067% of the share capital of the Company, at a total value of BGN 28 260 on the Bulgarian Stock Exchange, the average price per share was 3.1400 BGN.
The total number of treasury shares after this transaction is 8 946 467, representing 6.637% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.09.2020 13:38
SOPHARMA AD (112/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 25, 2020.
28.09.2020 13:38SOPHARMA AD (112/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 25, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 25, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2020 15:48
SOPHARMA AD (111/2020) Minutes of the Extraordinary General Meeting of Shareholders of Sopharma AD, held on September 25, 2020 from 11:30 a.m. (UTC 8:30 a.m.)
25.09.2020 15:48SOPHARMA AD (111/2020) Minutes of the Extraordinary General Meeting of Shareholders of Sopharma AD, held on September 25, 2020 from 11:30 a.m. (UTC 8:30 a.m.)
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Minutes of the Extraordinary General Meeting of Shareholders of Sopharma AD, held on September 25, 2020 from 11:30 a.m. (UTC 8:30 a.m.)
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2020 15:42
SOPHARMA AD (110/2020) Minutes of the Extraordinary General Meeting of Shareholders of Sopharma AD, held on September 25, 2020 from 11:00 a.m. (UTC 8:00 a.m.)
25.09.2020 15:42SOPHARMA AD (110/2020) Minutes of the Extraordinary General Meeting of Shareholders of Sopharma AD, held on September 25, 2020 from 11:00 a.m. (UTC 8:00 a.m.)
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Minutes of the Extraordinary General Meeting of Shareholders of Sopharma AD, held on September 25, 2020 from 11:00 a.m. (UTC 8:00 a.m.)
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2020 13:22
SOPHARMA AD (109/2020) Notification for acquisition of own shares
25.09.2020 13:22SOPHARMA AD (109/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, September 25, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on September 24, 2020 the Company sold 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of BGN 15 700 on the Bulgarian Stock Exchange, the average price per share was 3.1400 BGN..
The total number of treasury shares after this transaction is 8 955 467, representing 6.644% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2020 13:08
SOPHARMA AD (108/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 24, 2020.
25.09.2020 13:08SOPHARMA AD (108/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 24, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 24, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2020 11:26
SOPHARMA AD (107/2020) Notification on the terms and conditions for distribution of the dividend
25.09.2020 11:26SOPHARMA AD (107/2020) Notification on the terms and conditions for distribution of the dividend
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
In accordance with Art. 115c, para. 4 of the Law on Public Offering of Securities "Sopharma" AD hereby notifies all shareholders of the Company about the decision of the Extraordinary General Meeting of shareholders of "Sopharma" AD that took place on September 25, 2020 from 11:00 a.m. (UTC 8:00 a.m.) regarding the amount and type of dividend distributed and the terms and conditions for its distribution:
The General Meeting of shareholders approves the proposal by the Board of Directors for the distribution of 6-month dividend at the amount of 0.04 BGN /four stotinki / per share.
The persons eligible for dividend are those present in the register of the "Central Depository" AD 14 days after the day of the General Meeting on which the 6-Month Financial Report for the first half of 2020 was approved and the decision for dividend was taken, namely October 9, 2020 (record date) - ex dividend date October 8, 2020.
The dividend payment will start on November 23, 2020 (Monday). In accordance with the Regulations of the "Central Depository" AD, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of "Eurobank EFG - Bulgaria" AD /Postbank/ in the country.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 24.09.2020 14:32
SOPHARMA AD (106/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 23, 2020.
24.09.2020 14:32SOPHARMA AD (106/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 23, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 23, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 24.09.2020 09:18
SOPHARMA AD (105/2020) Notification for acquisition of own shares
24.09.2020 09:18SOPHARMA AD (105/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, September 24, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on September 23, 2020 the Company sold 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of BGN 15 700 on the Bulgarian Stock Exchange, the average price per share was 3.1400 BGN.
The total number of treasury shares after this transaction is 8 960 467, representing 6.647% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 24.09.2020 09:06
SOPHARMA AD (104/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 23, 2020.
24.09.2020 09:06SOPHARMA AD (104/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 23, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 23, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.09.2020 11:51
SOPHARMA AD (103/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 21, 2020.
23.09.2020 11:51SOPHARMA AD (103/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 21, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 21, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.09.2020 09:44
SOPHARMA AD (102/2020) Notification for acquisition of own shares
23.09.2020 09:44SOPHARMA AD (102/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, September 23, 2020 - According to art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on September 21, 2020 the Company sold 9 000 own shares representing 0.0067% of the share capital of the Company, at a total value of BGN 28 260 on the Bulgarian Stock Exchange, the average price per share was 3.1400 BGN.
The total number of treasury shares after this transaction is 8 965 467, representing 6.651% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.09.2020 09:31
SOPHARMA AD (101/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 21, 2020.
23.09.2020 09:31SOPHARMA AD (101/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 21, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 21, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.09.2020 11:03
SOPHARMA AD (100/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 18, 2020.
21.09.2020 11:03SOPHARMA AD (100/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 18, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 18, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.09.2020 08:21
SOPHARMA AD (99/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 18, 2020.
21.09.2020 08:21SOPHARMA AD (99/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 18, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 18, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.09.2020 08:50
SOPHARMA AD (98/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 17, 2020.
18.09.2020 08:50SOPHARMA AD (98/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 17, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 17, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.09.2020 08:44
SOPHARMA AD (97/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 16, 2020.
17.09.2020 08:44SOPHARMA AD (97/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 16, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 16, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.09.2020 08:41
SOPHARMA AD (96/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 15, 2020.
16.09.2020 08:41SOPHARMA AD (96/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 15, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 15, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.09.2020 13:06
SOPHARMA AD (95/2020) Notification from Rositsa Doneva under Art. 19 of Regulation (EU) No 596/2014 of September 14, 2020.
15.09.2020 13:06SOPHARMA AD (95/2020) Notification from Rositsa Doneva under Art. 19 of Regulation (EU) No 596/2014 of September 14, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Rositsa Doneva under Art. 19 of Regulation (EU) No 596/2014 of September 14, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.09.2020 09:52
SOPHARMA AD (94/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 14, 2020.
15.09.2020 09:52SOPHARMA AD (94/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 14, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 14, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.09.2020 09:42
SOPHARMA AD (93/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 14, 2020.
15.09.2020 09:42SOPHARMA AD (93/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 14, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 14, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.09.2020 13:41
SOPHARMA AD (92/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 11, 2020.
14.09.2020 13:41SOPHARMA AD (92/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 11, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 11, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.09.2020 13:08
SOPHARMA AD (91/2020) Online meeting with investors and exercising the right to vote by correspondence at the Extraordinary General Meetings of Shareholders convened on 25 September, 2020 from 11:00 and 11:30Online meeting with inv
14.09.2020 13:08SOPHARMA AD (91/2020) Online meeting with investors and exercising the right to vote by correspondence at the Extraordinary General Meetings of Shareholders convened on 25 September, 2020 from 11:00 and 11:30Online meeting with inv
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, 14 September, 2020 - According to the requirements of Art. 100t of the Law on Public Offering of Securities, "Sopharma" AD ("The Company") (3JR: "BSE - Sofia", SPH: Warsaw Stock Exchange) invites all shareholders of the Company to exercise their voting right on the announced agenda items of the Extraordinary General Meetings convened for 25 September, 2020 from 11:00 and 11:30 through correspondence. In an effort to preserve the normal operation of all the bodies of "Sopharma" AD and at the same time not to jeopardize the health of the interested parties in the conditions of a pandemic, the Board of Directors provide an opportunity for shareholders to exercise their voting rights in advance. The rules for voting by correspondence are described in detail in the invitations to convene the General Meetings. A declaration for voting by correspondence is attached to them.
On the day of the General Meetings - 25 September (Friday) the Company will hold an online meeting with investors from 12:00 to 13:00. Shareholders, investors and interested parties who wish to participate in the online meeting can request this by sending an email to irevents@sopharma.bg in order to receive a registration form and information on how to join, as well as the opportunity to ask their questions in advance. The deadline for sending the registration forms is by 17:30 on 23 September 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.09.2020 08:52
SOPHARMA AD (90/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 11, 2020.
14.09.2020 08:52SOPHARMA AD (90/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 11, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 11, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2020 08:55
SOPHARMA AD (89/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 10, 2020.
11.09.2020 08:55SOPHARMA AD (89/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 10, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 10, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2020 08:46
SOPHARMA AD (88/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 10, 2020.
11.09.2020 08:46SOPHARMA AD (88/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 10, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 10, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.09.2020 09:07
SOPHARMA AD (87/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 9, 2020.
10.09.2020 09:07SOPHARMA AD (87/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 9, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 9, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.09.2020 08:45
SOPHARMA AD (86/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 9, 2020.
10.09.2020 08:45SOPHARMA AD (86/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 9, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 9, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.09.2020 10:37
SOPHARMA AD (85/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 8, 2020.
09.09.2020 10:37SOPHARMA AD (85/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 8, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 8, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.09.2020 08:53
SOPHARMA AD (84/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 8, 2020.
09.09.2020 08:53SOPHARMA AD (84/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 8, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 8, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.09.2020 13:07
SOPHARMA AD (83/2020) Sales revenues for August 2020
08.09.2020 13:07SOPHARMA AD (83/2020) Sales revenues for August 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD (the Company) notifies that for August 2020 the Company recorded a decrease in sales of 34% compared to the same month of 2019, incl. 44% decrease in domestic sales and 28% decrease in export sales.
In the first eight months of 2020 the revenues from sales of production decrease by 10% compared to the same period of 2019, incl. 23% decrease of sales for the domestic market and 2% decrease in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.09.2020 10:56
SOPHARMA AD (82/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 4, 2020.
08.09.2020 10:56SOPHARMA AD (82/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 4, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of September 4, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.09.2020 09:07
SOPHARMA AD (81/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 4, 2020.
08.09.2020 09:07SOPHARMA AD (81/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 4, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 4, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.09.2020 08:38
SOPHARMA AD (80/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 3, 2020.
04.09.2020 08:38SOPHARMA AD (80/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 3, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 3, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.09.2020 08:55
SOPHARMA AD (79/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 2, 2020.
03.09.2020 08:55SOPHARMA AD (79/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 2, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 2, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.09.2020 12:51
SOPHARMA AD (78/2020) Notification from Rositsa Doneva under Art. 19 of Regulation (EU) No 596/2014 of September 1, 2020.
02.09.2020 12:51SOPHARMA AD (78/2020) Notification from Rositsa Doneva under Art. 19 of Regulation (EU) No 596/2014 of September 1, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Rositsa Doneva under Art. 19 of Regulation (EU) No 596/2014 of September 1, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.09.2020 08:58
SOPHARMA AD (77/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 1, 2020.
02.09.2020 08:58SOPHARMA AD (77/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 1, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of September 1, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 31.08.2020 13:39
SOPHARMA AD (76/2020) Consolidated Financial Report as at 30 June 2020.
31.08.2020 13:39SOPHARMA AD (76/2020) Consolidated Financial Report as at 30 June 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Consolidated Financial Report as at 30 June 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.08.2020 13:43
SOPHARMA AD (75/2020) Materials for EGM of "Sopharma" AD for 25.09.2020 at 11:30 a.m. (UTC 08:30 a.m.)
20.08.2020 13:43SOPHARMA AD (75/2020) Materials for EGM of "Sopharma" AD for 25.09.2020 at 11:30 a.m. (UTC 08:30 a.m.)
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Materials for EGM of "Sopharma" AD for 25.09.2020 at 11:30 a.m. (UTC 08:30 a.m.)
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.08.2020 13:03
SOPHARMA AD (73/2020) Sales revenues for July 2020
05.08.2020 13:03SOPHARMA AD (73/2020) Sales revenues for July 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD (the Company) notifies that for July 2020 the Company recorded a decrease in sales of 52% compared to the same month of 2019, incl. 25% decrease in domestic sales and 66% decrease in export sales.
In the first seven months of 2020 the revenues from sales of production decrease by 6% compared to the same period of 2019, incl. 20% decrease of sales for the domestic market and 2% increase in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.06.2020 11:16
SOPHARMA AD (58/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 24, 2020.
25.06.2020 11:16SOPHARMA AD (58/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 24, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 24, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.06.2020 10:21
SOPHARMA AD (57/2020) Notification for acquisition of own shares
25.06.2020 10:21SOPHARMA AD (57/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, June 25, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 24, 2020 the Company sold 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of BGN 15 750 on the Bulgarian Stock Exchange, the average price per share was 3.1500 BGN.
The total number of treasury shares after this transaction is 9 053 467, representing 6.716% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.06.2020 10:08
SOPHARMA AD (56/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 24, 2020.
25.06.2020 10:08SOPHARMA AD (56/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 24, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 24, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 24.06.2020 14:09
SOPHARMA AD (55/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 23, 2020.
24.06.2020 14:09SOPHARMA AD (55/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 23, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 23, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 24.06.2020 13:58
SOPHARMA AD (54/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 22, 2020.
24.06.2020 13:58SOPHARMA AD (54/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 22, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 22, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 24.06.2020 12:22
SOPHARMA AD (53/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 23, 2020.
24.06.2020 12:22SOPHARMA AD (53/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 23, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 23, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.06.2020 11:21
SOPHARMA AD (52/2020) Notification for acquisition of own shares
23.06.2020 11:21SOPHARMA AD (52/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, June 23, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 22, 2020 the Company sold 25 000 own shares representing 0.0185% of the share capital of the Company, at a total value of BGN 78 750 on the Bulgarian Stock Exchange, the average price per share was 3.1500 BGN.
The total number of treasury shares after this transaction is 9 058 467, representing 6.720% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.06.2020 11:09
SOPHARMA AD (51/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 22, 2020.
23.06.2020 11:09SOPHARMA AD (51/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 22, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 22, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.06.2020 16:09
SOPHARMA AD (50/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 19, 2020.
22.06.2020 16:09SOPHARMA AD (50/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 19, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 19, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.06.2020 10:28
SOPHARMA AD (49/2020) Notification for acquisition of own shares
22.06.2020 10:28SOPHARMA AD (49/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, June 22, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 19, 2020 the Company sold 6 000 own shares representing 0.0045% of the share capital of the Company, at a total value of BGN 18 870 on the Bulgarian Stock Exchange, the average price per share was 3.1450 BGN.
The total number of treasury shares after this transaction is 9 083 467, representing 6.739% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.06.2020 10:14
SOPHARMA AD (48/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 19, 2020.
22.06.2020 10:14SOPHARMA AD (48/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 19, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 19, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.06.2020 14:56
SOPHARMA AD (47/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 18, 2020.
19.06.2020 14:56SOPHARMA AD (47/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 18, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 18, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.06.2020 14:42
SOPHARMA AD (46/2020) Notification for acquisition of own shares
19.06.2020 14:42SOPHARMA AD (46/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, June 19, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) ) notifies that on June 18, 2020 the Company sold 4 000 own shares representing 0.0030% of the share capital of the Company, at a total value of BGN 12 540 on the Bulgarian Stock Exchange, the average price per share was 3.1350 BGN.
The total number of treasury shares after this transaction is 9 089 467, representing 6.743% of the share capital of the Company
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.06.2020 11:38
SOPHARMA AD (45/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 17, 2020.
19.06.2020 11:38SOPHARMA AD (45/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 17, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 17, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.06.2020 11:15
SOPHARMA AD (44/2020) Notification for acquisition of own shares
19.06.2020 11:15SOPHARMA AD (44/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, June 19, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 17, 2020 the Company sold 21 000 own shares representing 0.0156% of the share capital of the Company, at a total value of 68 030 BGN on the Bulgarian Stock Exchange, the average price per share was 3.2395 BGN.
The total number of treasury shares after this transaction is 9 093 467, representing 6.746% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.06.2020 10:58
SOPHARMA AD (43/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 17, 2020.
19.06.2020 10:58SOPHARMA AD (43/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 17, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 17, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.06.2020 14:41
SOPHARMA AD (42/2020) Notification for technical error correction
18.06.2020 14:41SOPHARMA AD (42/2020) Notification for technical error correction
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, June 18, 2020 - According to the requirements of art. 111, para. 8 of LPOS "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that due to a technical error in the Notification for treasury shares, number 194-00-31 / 16.06.2020 should be read:
"Sofia, Bulgaria, June 16, 2020 - According to the requirements of art. 111, para. 8 of LPOS "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 15, 2020 the Company sold 85 748 own shares representing 0.0636% of the share capital of the Company, at a total value of 277 823,52 BGN on the Bulgarian Stock Exchange, the average price per share was 3.240 BGN.
The total number of treasury shares after this transaction is 9 114 467, representing 6.762% of the share capital of the Company."
We apologize for the inconvenience.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.06.2020 09:12
SOPHARMA AD (41/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 16, 2020.
17.06.2020 09:12SOPHARMA AD (41/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 16, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 16, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.06.2020 08:37
SOPHARMA AD (40/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 15, 2020.
17.06.2020 08:37SOPHARMA AD (40/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 15, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 15, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.06.2020 15:57
SOPHARMA AD (39/2020) The Board of directors of "Sopharma" AD assigned a procurator of the Company
16.06.2020 15:57SOPHARMA AD (39/2020) The Board of directors of "Sopharma" AD assigned a procurator of the Company
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD (the Company) notifies that to improve the operational management of the Company the Board of Directors assigned Mr. Simeon Donev, Director Business Development of "Sopharma" AD as a procurator.
The change was announced by the Commercial Register, Registry agency with number 20200616134043 from June 16, 2020.
Mr. Donev has nearly 5 years of experience in areas as international projects, commerce, marketing and strategic planning. For more than 3 years Mr. Donev leads the Business Development tam and has a number of successful projects behind him.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.06.2020 11:37
SOPHARMA AD (38/2020) Notification for acquisition of own shares
16.06.2020 11:37SOPHARMA AD (38/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on June 15, 2020 the Company bought 85 748 own shares representing 0.0636% of the share capital of the Company, at a total value of 277 823,52 BGN on the Bulgarian Stock Exchange, the average price per share was 3.240 BGN.
The total number of treasury shares after this transaction is 9 285 963, representing 6.89% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.06.2020 11:09
SOPHARMA AD (37/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 15, 2020.
16.06.2020 11:09SOPHARMA AD (37/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 15, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 15, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.06.2020 11:32
SOPHARMA AD (36/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 12, 2020.
15.06.2020 11:32SOPHARMA AD (36/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 12, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 12, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.06.2020 11:24
SOPHARMA AD (35/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 12, 2020.
15.06.2020 11:24SOPHARMA AD (35/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 12, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 12, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.06.2020 15:47
SOPHARMA AD (34/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 11, 2020.
12.06.2020 15:47SOPHARMA AD (34/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 11, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 11, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.06.2020 09:09
SOPHARMA AD (33/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 11, 2020.
12.06.2020 09:09SOPHARMA AD (33/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 11, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 11, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.06.2020 09:04
SOPHARMA AD (32/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 10, 2020.
11.06.2020 09:04SOPHARMA AD (32/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 10, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 10, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.06.2020 09:47
SOPHARMA AD (31/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 9, 2020.
10.06.2020 09:47SOPHARMA AD (31/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 9, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 9, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.06.2020 13:59
SOPHARMA AD (30/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 8, 2020.
09.06.2020 13:59SOPHARMA AD (30/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 8, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 8, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.06.2020 09:19
SOPHARMA AD (29/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 5, 2020.
09.06.2020 09:19SOPHARMA AD (29/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 5, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 5, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.06.2020 09:17
SOPHARMA AD (28/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 8, 2020.
09.06.2020 09:17SOPHARMA AD (28/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 8, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 8, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.06.2020 15:48
SOPHARMA AD (27/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 4, 2020.
08.06.2020 15:48SOPHARMA AD (27/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 4, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 4, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.06.2020 10:14
SOPHARMA AD (26/2020) Minutes of the Annual General Meeting of Shareholders of Sopharma AD, held on 5 June 2020
08.06.2020 10:14SOPHARMA AD (26/2020) Minutes of the Annual General Meeting of Shareholders of Sopharma AD, held on 5 June 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Minutes of the Annual General Meeting of Shareholders of Sopharma AD, held on 5 June 2020
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.06.2020 13:10
SOPHARMA AD (25/2020) Sales revenues for May 2020
05.06.2020 13:10SOPHARMA AD (25/2020) Sales revenues for May 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD (the Company) notifies that for May 2020 the Company recorded a decrease in sales of 6% compared to the same month of 2019, incl. 9% decrease in domestic sales and 5% decrease in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.06.2020 10:39
SOPHARMA AD (23/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 3, 2020.
04.06.2020 10:39SOPHARMA AD (23/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 3, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 3, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.06.2020 09:40
SOPHARMA AD (22/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 3, 2020.
04.06.2020 09:40SOPHARMA AD (22/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 3, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 3, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.06.2020 15:57
SOPHARMA AD (21/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.
03.06.2020 15:57SOPHARMA AD (21/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.06.2020 15:54
SOPHARMA AD (20/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.
03.06.2020 15:54SOPHARMA AD (20/2020) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.06.2020 09:42
SOPHARMA AD (19/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.
03.06.2020 09:42SOPHARMA AD (19/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.06.2020 10:53
SOPHARMA AD (18/2020) Notification for acquisition of own shares
02.06.2020 10:53SOPHARMA AD (18/2020) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD notifies that on June 1, 2020 the Company bought 86 748 own shares representing 0.0644% of the share capital of the Company, at a total value of 260 244 BGN on the Bulgarian Stock Exchange, the average price per share was 3.00 BGN.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.06.2020 10:42
SOPHARMA AD (17/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 1, 2020.
02.06.2020 10:42SOPHARMA AD (17/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 1, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 1, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.06.2020 14:02
SOPHARMA AD (16/2020) Consolidated Financial Report as at 31 March 2020
01.06.2020 14:02SOPHARMA AD (16/2020) Consolidated Financial Report as at 31 March 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Consolidated Financial Report as at 31 March 2020
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 26.05.2020 13:05
SOPHARMA AD (15/2020) Online meeting with investors and exercising the right to vote by correspondence at the General Meeting of Shareholders convened on June 5, 2020
26.05.2020 13:05SOPHARMA AD (15/2020) Online meeting with investors and exercising the right to vote by correspondence at the General Meeting of Shareholders convened on June 5, 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD invites all shareholders of the Company to exercise their voting right on the announced agenda items of the Annual General Meeting convened for 5 June 2020 through correspondence. In an effort to preserve the normal operation of all the bodies of "Sopharma" AD and at the same time not to jeopardize the health of the interested parties in the conditions of a pandemic, the Board of Directors provide an opportunity for shareholders to exercise their voting rights in advance. On the day of the General Meeting the Company will hold an online meeting with Ognyan Donev, PhD, Executive Director and Chairman of the Board of Directors of "Sopharma" AD, Dimitar Dimitrov, Executive Director of "Sopharma Trading" AD and Alexander Hristov, Executive Director of "Doverie Obedinen Holding" AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.05.2020 17:08
SOPHARMA AD (14/2020) Sales revenues for April 2020
05.05.2020 17:08SOPHARMA AD (14/2020) Sales revenues for April 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sales revenues for April 2020
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.05.2020 15:50
SOPHARMA AD (13/2020) Publication of materials for holding a Regular General Meeting of Shareholders of "Sopharma" AD, scheduled for 5 June 2020
05.05.2020 15:50SOPHARMA AD (13/2020) Publication of materials for holding a Regular General Meeting of Shareholders of "Sopharma" AD, scheduled for 5 June 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Publication of materials for holding a Regular General Meeting of Shareholders of "Sopharma" AD, scheduled for 5 June 2020
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.05.2020 20:37
SOPHARMA AD (12/2020) Consolidated Audited Financial Report according to IFRS as at 31 December 2019
04.05.2020 20:37SOPHARMA AD (12/2020) Consolidated Audited Financial Report according to IFRS as at 31 December 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Consolidated Audited Financial Report according to IFRS as at 31 December 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.04.2020 14:56
SOPHARMA AD (11/2020) Publishing of the Consolidated Audited Financial Statements for 2019 made public in the terms envisaged in §45, item 2 of the TAP of the Law for the measures and actions under extraordinary circumstances
29.04.2020 14:56SOPHARMA AD (11/2020) Publishing of the Consolidated Audited Financial Statements for 2019 made public in the terms envisaged in §45, item 2 of the TAP of the Law for the measures and actions under extraordinary circumstances
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, April 6, 2020 - "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that the Consolidated Audited Financial Statements for 2019 will be made public in the terms envisaged in §45, item 2 of the TAP of the Law for the measures and actions under extraordinary circumstances. The delayed publishing of the Report is due to the extraordinary conditions in a number of countries in which the companies from the Group operate. Measures have been taken within the Company to decrease to a maximum the timeframe for finalizing and publishing of all documents part of the Report.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.04.2020 14:15
SOPHARMA AD (10/2020) Q1 2020 Individual Financial report of Sopharma AD
28.04.2020 14:15SOPHARMA AD (10/2020) Q1 2020 Individual Financial report of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Q1 2020 Individual Financial report of Sopharma AD
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.04.2020 13:32
SOPHARMA AD (9/2020) Notification from Telso AD under Art. 19 of Regulation (EU) No 596/2014 of April 3, 2020.
06.04.2020 13:32SOPHARMA AD (9/2020) Notification from Telso AD under Art. 19 of Regulation (EU) No 596/2014 of April 3, 2020.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Telso AD under Art. 19 of Regulation (EU) No 596/2014 of April 3, 2020.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.04.2020 13:00
SOPHARMA AD (8/2020) Sales revenues for March 2020
06.04.2020 13:00SOPHARMA AD (8/2020) Sales revenues for March 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD (the "Company") notifies that for March 2020 the Company recorded an increase in sales of 11% compared to the same month of 2019, incl. fulfillment of sales for the domestic market and 21% increase in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.03.2020 13:34
SOPHARMA AD (7/2020) Annual Audited Individual Financial Statements for 2019 of Sopharma AD
19.03.2020 13:34SOPHARMA AD (7/2020) Annual Audited Individual Financial Statements for 2019 of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Annual Audited Individual Financial Statements for 2019 of Sopharma AD:
Individual Audited Financial Report according to IFRS as at 31 December 2019
Notes to the Individual Audited financial report as at 31 December 2019
Management report as at 31 December 2019
Individual Audited Financial Report according to BFSC standards as at 31 December 2019
Auditor's declaration as at 31 December 2019
Auditor's report as at 31 December 2019
Corporate Governance Declaration as at 31 December 2019
Report regarding the application of the remuneration policy as at 31 December 2019
Declaration by responsible directors as at 31 December 2019
Non-financial Declaration to the Annual Financial Report as at 31 December 2019
Individual Audited Financial Report according to IFRS as at 31 December 2019 - xls
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.03.2020 13:07
SOPHARMA AD (6/2020) Sales revenues for February 2020
05.03.2020 13:07SOPHARMA AD (6/2020) Sales revenues for February 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (the "Company") notifies that for February 2020 the Company recorded a decrease in sales of 22% compared to the same month of 2019, incl. 1% decrease in sales for the domestic market and 30% decrease in export sales.
In the first two months of 2020 the revenues from sales of production decreased by 15% compared to the same period of 2019, incl. 2% decrease in domestic sales and 20% increase in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.03.2020 13:54
SOPHARMA AD (5/2020) Q4 2019 Consolidated Financial report of Sopharma Group.
02.03.2020 13:54SOPHARMA AD (5/2020) Q4 2019 Consolidated Financial report of Sopharma Group.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Consolidated financial report according to IFRS as at 31 December 2019
Notes to the consolidated financial report as at 31 December 2019
Consolidated management report as at 31 December 2019
Insider information as at 31 December 2019
Additional information as at 31 December 2019
Consolidated financial report according to BFSC standards as at 31 December 2019
Information according to Annex 9 of Ordinance 2 as at 31 December 2019
Declaration by the responsible directors as at 31 December 2019
Consolidated financial report according to IFRS as at 31 December 2019 - Excel
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.02.2020 13:19
SOPHARMA AD (4/2020) Sales revenues for January 2020
05.02.2020 13:19SOPHARMA AD (4/2020) Sales revenues for January 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (the "Company") notifies that for January 2020 the Company recorded a decrease in sales of 8% compared to the same month of 2019, incl. 2% decrease in sales for the domestic market and 10% decrease in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.01.2020 14:01
SOPHARMA AD (3/2020) Q4 2019 Individual Financial report of Sopharma AD
30.01.2020 14:01SOPHARMA AD (3/2020) Q4 2019 Individual Financial report of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Q4 2019 Individual Financial report of Sopharma AD:
Individual financial report according to IFRS as at 31 December 2019
Notes to the individual financial report as at 31 December 2019
Management report as at 31 December 2019
Insider information as at 31 December 2019
Additional information as at 31 December 2019
Individual financial report according to BFSC standards as at 31 December 2019
Information according to Annex 9 of Ordinance 2 as at 31 December 2019
Declaration by the responsible directors as at 31 December 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.01.2020 13:33
SOPHARMA AD (2/2020) Sopharma AD starts the payment of the 6-month dividend on January 22, 2020
16.01.2020 13:33SOPHARMA AD (2/2020) Sopharma AD starts the payment of the 6-month dividend on January 22, 2020
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that the Company will initiate gross dividend payment of the voted on the EGM held on December 13, 2019 dividend of 0.05 BGN per share on January 22, 2020.
The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. December 27, 2019.
In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Postbank in the country until April 30, 2020 (after that date, shareholders who have not received their dividend in the appropriate order may do that at the cash desk of the Company in Sofia, 16 Iliensko Shose Str. every business day between 10:00-12:00 and 14:00-16:00, tel. 02 8134 283).
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.01.2020 13:27
SOPHARMA AD (1/2020) Sales revenues for December 2019
10.01.2020 13:27SOPHARMA AD (1/2020) Sales revenues for December 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (the "Company") notifies that for December 2019 the Company recorded an increase in sales of 16% compared to the same month of 2018, incl. 5% increase in sales for the domestic market and 27% increase in export sales.
In 2019 the revenues from sales of production increased by 9% compared to the same period of 2018, incl. keeping sales in domestic market and 15% increase in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2020 10:32
SOPHARMA AD (106/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2019
02.01.2020 10:32SOPHARMA AD (106/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2020 10:28
SOPHARMA AD (105/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 27, 2019
02.01.2020 10:28SOPHARMA AD (105/2020) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 27, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 27, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.12.2019 14:46
SOPHARMA AD (104/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 23, 2019
27.12.2019 14:46SOPHARMA AD (104/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 23, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 23, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.12.2019 13:45
SOPHARMA AD (103/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 20, 2019
27.12.2019 13:45SOPHARMA AD (103/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 20, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 20, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.12.2019 13:27
SOPHARMA AD (102/2019) Notification for acquisition of own shares
27.12.2019 13:27SOPHARMA AD (102/2019) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on December 20, 2019 the Company bought 800 own shares representing 0.0006% of the share capital of the Company, at a total value of 2 760 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4500 BGN.
The total number of treasury shares after this transaction is 9 113 467, representing 6.761% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2019 14:16
SOPHARMA AD (101/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 19, 2019
20.12.2019 14:16SOPHARMA AD (101/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 19, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 19, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2019 14:08
SOPHARMA AD (100/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 18, 2019
20.12.2019 14:08SOPHARMA AD (100/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 18, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 18, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2019 10:11
SOPHARMA AD (99/2019) Notification for acquisition of own shares
20.12.2019 10:11SOPHARMA AD (99/2019) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, December 20, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 19, 2019 the Company bought 2 000 own shares representing 0.0015% of the share capital of the Company, at a total value of 6 890 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4450 BGN.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2019 08:51
SOPHARMA AD (98/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 19, 2019.
20.12.2019 08:51SOPHARMA AD (98/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 19, 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 19, 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2019 08:56
SOPHARMA AD (97/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 18, 2019
19.12.2019 08:56SOPHARMA AD (97/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 18, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 18, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.12.2019 11:07
SOPHARMA AD (96/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2019
18.12.2019 11:07SOPHARMA AD (96/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.12.2019 09:46
SOPHARMA AD (95/2019) Notification for acquisition of own shares
18.12.2019 09:46SOPHARMA AD (95/2019) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, December 18, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 17, 2019 the Company bought 28 390 own shares representing 0.0211% of the share capital of the Company, at a total value of 98 346,20 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4641 BGN.
The total number of treasury shares after this transaction is 9 110 667, representing 6.76% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.12.2019 09:40
SOPHARMA AD (94/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2019
18.12.2019 09:40SOPHARMA AD (94/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.12.2019 16:03
SOPHARMA AD (93/2019) Notification for technical errors correction
17.12.2019 16:03SOPHARMA AD (93/2019) Notification for technical errors correction
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, December 17, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) - Please apologize us for the following technical errors:
- In the Notification for treasury shares, published on December 11, 2019, please read the total number of treasury shares "8 906 832", instead of "8 904 182".
- In the Notification for treasury shares, published on December 13, 2019, please read number of shares "46 320", instead of "41 320" and the total number of treasury shares "9 037 320", instead of "9 032 320".
- In the Notification for treasury shares, published on December 16, 2019, please read the text "Тhe Company bought 14 760 own shares representing 0.0109% of the share capital of the Company, at a total value of 50 922 BGN on the Bulgarian Stock Exchange, the average price per share was 3.45 BGN. The total number of treasury shares after this transaction is 9 052 080, representing 6.715% of the share capital of the Company" ,instead of "Тhe Company bought 46 320 own shares representing 0.0344% of the share capital of the Company, at a total value of 159 693,26 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4476 BGN. The total number of treasury shares after this transaction is 9 078 640, representing 6.74% of the share capital of the Company".
- In the Notification for treasury shares, published on December 17, 2019, please read the total number of treasury shares "9 082 277" representing 6.738% of the share capital of the Company, instead of "9 108 837" representing 6.76% of the share capital of the Company.
We apologize for the inconvenience.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.12.2019 11:42
SOPHARMA AD (92/2019) Notification for acquisition of own shares
17.12.2019 11:42SOPHARMA AD (92/2019) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on December 16, 2019 the Company bought 30 197 own shares representing 0.0224% of the share capital of the Company, at a total value of 104 381,63 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4567 BGN.
The total number of treasury shares after this transaction is 9 108 837, representing 6.76% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.12.2019 09:11
SOPHARMA AD (91/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 16, 2019
17.12.2019 09:11SOPHARMA AD (91/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 16, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 16, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.12.2019 14:43
SOPHARMA AD (90/2019) Notification for acquisition of own shares
16.12.2019 14:43SOPHARMA AD (90/2019) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, December 16, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 13, 2019 the Company bought 46 320 own shares representing 0.0344% of the share capital of the Company, at a total value of 159 693,26 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4476 BGN.
The total number of treasury shares after this transaction is 9 078 640, representing 6.74% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.12.2019 14:04
SOPHARMA AD (89/2019) Minutes from a Extraordinary General meeting of shareholders of Sopharma AD held on December 13, 2019
16.12.2019 14:04SOPHARMA AD (89/2019) Minutes from a Extraordinary General meeting of shareholders of Sopharma AD held on December 13, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Minutes from a Extraordinary General meeting of shareholders of Sopharma AD
Protocol of the Commission for Verification of the Quorum for the Extraordinary General meeting of shareholders of Sopharma AD
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.12.2019 09:58
SOPHARMA AD (88/2019) Notification for technical error correction
16.12.2019 09:58SOPHARMA AD (88/2019) Notification for technical error correction
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, December 16, 2019 - Sopharma AD notifies that due to a technical error in the Notification for treasury shares, published on December 13, 2019, please read the sum of the total value of treasury shares "BGN 142 442,436", instead of "BGN 412 443,26".
We apologize for the inconvenience.
Please, on the grounds of Art. 100k, para. 1 of the POSA make the above information public.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2019 15:23
SOPHARMA AD (87/2019) Notification for acquisition of own shares
13.12.2019 15:23SOPHARMA AD (87/2019) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on December 12, 2019 the Company bought 41 320 own shares representing 0.0307% of the share capital of the Company, at a total value of 412 443,26 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4473 BGN.
The total number of treasury shares after this transaction is 9 032 320, representing 6.70% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2019 15:15
SOPHARMA AD (86/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 12, 2019
13.12.2019 15:15SOPHARMA AD (86/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 12, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 12, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2019 15:07
SOPHARMA AD (85/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 12, 2019
13.12.2019 15:07SOPHARMA AD (85/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 12, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 12, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2019 15:02
SOPHARMA AD (84/2019) Notification from Telso AD under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2019
13.12.2019 15:02SOPHARMA AD (84/2019) Notification from Telso AD under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Telso AD under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2019 11:09
SOPHARMA AD (83/2019) Notification on the terms and conditions for distribution of the dividend
13.12.2019 11:09SOPHARMA AD (83/2019) Notification on the terms and conditions for distribution of the dividend
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
In accordance with Art. 115c, para. 4 of the Public Offering of Securities Act Sopharma AD hereby notifies all shareholders of the Company about the decision of the EGM of Sopharma AD that took place on December 13, 2019 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:
AGM approves the proposal by the Board of Directors for the distribution of 6 - month dividend at the amount of 0.05 BGN /five stotinki/ per share with dividend right.
The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the 6 - Month Financial Report was approved and the decision for dividend was taken, namely December 27, 2019 (record date) - ex dividend date December 23, 2019.
In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.
We would like to thank all shareholders for their understanding and cooperation.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2019 11:02
SOPHARMA AD (82/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2019
12.12.2019 11:02SOPHARMA AD (82/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2019 10:52
SOPHARMA AD (81/2019) Notification for acquisition of own shares
12.12.2019 10:52SOPHARMA AD (81/2019) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, December 12, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 11, 2019 the Company bought 84 168 own shares representing 0.0624% of the share capital of the Company, at a total value of 290 379,60 BGN on the Bulgarian Stock Exchange, the average price per share was 3.45 BGN.
The total number of treasury shares after this transaction is 8 991 000, representing 6.67% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2019 10:39
SOPHARMA AD (80/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2019.
12.12.2019 10:39SOPHARMA AD (80/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.12.2019 11:55
SOPHARMA AD (79/2019) Notification for acquisition of own shares
11.12.2019 11:55SOPHARMA AD (79/2019) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on December 10, 2019 the Company bought 25 000 own shares representing 0.0185% of the share capital of the Company, at a total value of 85 800 BGN on the Bulgarian Stock Exchange, the average price per share was 3.432 BGN.
The total number of treasury shares after this transaction is 8 904 182, representing 6.61% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.12.2019 11:05
SOPHARMA AD (78/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2019.
11.12.2019 11:05SOPHARMA AD (78/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.12.2019 11:12
SOPHARMA AD (77/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2019
10.12.2019 11:12SOPHARMA AD (77/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.12.2019 10:19
SOPHARMA AD (76/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2019.
10.12.2019 10:19SOPHARMA AD (76/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2019.
Podstawa prawna: Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.12.2019 13:06
SOPHARMA AD (75/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 6, 2019
09.12.2019 13:06SOPHARMA AD (75/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 6, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 6, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.12.2019 13:00
SOPHARMA AD (74/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 5, 2019
09.12.2019 13:00SOPHARMA AD (74/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 5, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 5, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.12.2019 10:41
SOPHARMA AD (73/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 6, 2019
09.12.2019 10:41SOPHARMA AD (73/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 6, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 6, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.12.2019 12:59
SOPHARMA AD (72/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 5, 2019
06.12.2019 12:59SOPHARMA AD (72/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 5, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 5, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.12.2019 13:43
SOPHARMA AD (71/2019) Sales revenues for November 2019
05.12.2019 13:43SOPHARMA AD (71/2019) Sales revenues for November 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (the "Company") that for November 2019 the Company recorded an increase in sales of 24% compared to the same month of 2018, incl. 21% increase in sales for the domestic market and 27% increase in export sales.
In the first eleven months of 2019 the revenues from sales of production increased by 8% compared to the same period of 2018, incl. 1% decrease in domestic sales and 14% increase in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.12.2019 12:47
SOPHARMA AD (70/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2019
05.12.2019 12:47SOPHARMA AD (70/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.12.2019 12:26
SOPHARMA AD (69/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019
05.12.2019 12:26SOPHARMA AD (69/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.12.2019 11:14
SOPHARMA AD (68/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019.
04.12.2019 11:14SOPHARMA AD (68/2019) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.12.2019 11:02
SOPHARMA AD (67/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019.
04.12.2019 11:02SOPHARMA AD (67/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.12.2019 12:46
SOPHARMA AD (66/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2019
03.12.2019 12:46SOPHARMA AD (66/2019) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.11.2019 13:52
SOPHARMA AD (65/2019) Q3 2019 Consolidated Financial report of Sopharma Group.
29.11.2019 13:52SOPHARMA AD (65/2019) Q3 2019 Consolidated Financial report of Sopharma Group.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Consolidated financial report according to IFRS as at 30 September 2019
Notes to the consolidated financial report as at 30 September 2019
Consolidated management report as at 30 September 2019
Insider information as at 30 September 2019
Additional information as at 30 September 2019
Consolidated financial report according to BFSC standards as at 30 September 2019
Information according to Annex 9 of Ordinance 2 as at 30 September 2019
Declaration by the responsible directors as at 30 September 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.11.2019 13:39
SOPHARMA AD (64/2019) Sopharma AD is among the largest investors in Moldova
14.11.2019 13:39SOPHARMA AD (64/2019) Sopharma AD is among the largest investors in Moldova
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 12 November, with the participation of His Excellency Evgueni Stoytchev, the Ambassador of the Republic of Bulgaria in Moldova, Sopharma AD celebrated the opening of a new warehouse and administrative building in Kishinev with a total area of 5000 sq. m. The warehouse will provide 75 new working places and will support the distribution activities of pharmaceutical and other health related products of Sopharma AD in Moldova, further the centralization will lead to improved efficiency and optimization of the processes.
Following its intentions to grow in Moldova, Sopharma AD purchased 29% of the capital of RAP Pharma International and reached 80% ownership in the company. RAP Pharma International also has a new Executive director Mr. Victor Tomsha - a young specialist with economic education and professional experience in large European companies.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.11.2019 13:02
Sopharma chce wypłacić 0,05 BGN dywidendy na akcję za I półr. '19
07.11.2019 13:02Sopharma chce wypłacić 0,05 BGN dywidendy na akcję za I półr. '19
Za pierwsze półrocze 2018 roku spółka również wypłaciła 0,05 BGN dywidendy na akcję. (PAP Biznes)
doa/ osz/
- 07.11.2019 12:13
SOPHARMA AD (63/2019) Invitation and materials for an Extraordinary General Meeting of Shareholders of Sopharma AD for 13 December 2019
07.11.2019 12:13SOPHARMA AD (63/2019) Invitation and materials for an Extraordinary General Meeting of Shareholders of Sopharma AD for 13 December 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Invitation and materials for an Extraordinary General Meeting of Shareholders of Sopharma AD for 13 December 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.11.2019 13:18
SOPHARMA AD (62/2019) Sales revenues for October 2019
05.11.2019 13:18SOPHARMA AD (62/2019) Sales revenues for October 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for October 2019 the Company recorded an increase in sales of 40% compared to the same month of 2018, incl. 30% increase in sales for the domestic market and 48% increase in export sales.
In the first ten months of 2019 the revenues from sales of production increased by 6% compared to the same period of 2018, incl. 4% decrease in domestic sales and 13% increase in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.10.2019 13:26
SOPHARMA AD (61/2019) Q3 2019 Individual Financial report of Sopharma AD
30.10.2019 13:26SOPHARMA AD (61/2019) Q3 2019 Individual Financial report of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Individual financial report according to IFRS as at 30 September 2019
Notes to the individual financial report as at 30 September 2019
Management report as at 30 September 2019
Insider information as at 30 September 2019
Additional information as at 30 September 2019
Individual financial report according to BFSC standards as at 30 September 2019
Information according to Annex 9 of Ordinance 2 as at 30 September 2019
Declaration by the responsible directors as at 30 September 2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.10.2019 13:54
SOPHARMA AD (60/2019) Sales revenues for September 2019
07.10.2019 13:54SOPHARMA AD (60/2019) Sales revenues for September 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (the "Company") notifies that for September 2019 the Company recorded an increase in sales of 31% compared to the same month of 2018, incl. 5% decrease in sales for the domestic market and 66% increase in export sales.
In the first nine months of 2019 the revenues from sales of production increased by 2% compared to the same period of 2018, incl. 9% decrease in domestic sales and 10% increase in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.10.2019 12:57
SOPHARMA AD (59/2019) Notification from Rositsa Doneva in accordance with article 19 of Regulation 596/2014 for transactions from 30 September 2019.
01.10.2019 12:57SOPHARMA AD (59/2019) Notification from Rositsa Doneva in accordance with article 19 of Regulation 596/2014 for transactions from 30 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Rositsa Doneva in accordance with article 19 of Regulation 596/2014 for transactions from 30 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.10.2019 12:45
SOPHARMA AD (58/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 30.09.2019
01.10.2019 12:45SOPHARMA AD (58/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 30.09.2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 30.09.2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.10.2019 12:36
SOPHARMA AD (57/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 30.09.2019
01.10.2019 12:36SOPHARMA AD (57/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 30.09.2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 30.09.2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.10.2019 10:04
SOPHARMA AD (56/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 30 September 2019.
01.10.2019 10:04SOPHARMA AD (56/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 30 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 30 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.09.2019 15:03
SOPHARMA AD (55/2019) Notification for acquisition of own shares
27.09.2019 15:03SOPHARMA AD (55/2019) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on September 26, 2019 the Company bought 182 own shares representing 0.0001% of the share capital of the Company, at a total value of 607.88 BGN on the Bulgarian Stock Exchange, the average price per share was 3.34 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 881 832, representing 6.59% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.09.2019 12:21
SOPHARMA AD (54/2019) Notification from Rositsa Doneva in accordance with article 19 of Regulation 596/2014 for transactions from 25 September 2019.
27.09.2019 12:21SOPHARMA AD (54/2019) Notification from Rositsa Doneva in accordance with article 19 of Regulation 596/2014 for transactions from 25 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Rositsa Doneva in accordance with article 19 of Regulation 596/2014 for transactions from 25 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.09.2019 10:39
SOPHARMA AD (53/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 16.09.2019
27.09.2019 10:39SOPHARMA AD (53/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 16.09.2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 16.09.2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 26.09.2019 09:39
SOPHARMA AD (52/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 25 September 2019.
26.09.2019 09:39SOPHARMA AD (52/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 25 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 25 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2019 12:10
SOPHARMA AD (51/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 24 September 2019.
25.09.2019 12:10SOPHARMA AD (51/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 24 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 24 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.09.2019 17:16
SOPHARMA AD (50/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 20.09.2019
20.09.2019 17:16SOPHARMA AD (50/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 20.09.2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 20.09.2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.09.2019 10:17
SOPHARMA AD (49/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 19 September 2019.
20.09.2019 10:17SOPHARMA AD (49/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 19 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 19 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.09.2019 09:20
SOPHARMA AD (48/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 18 September 2019.
19.09.2019 09:20SOPHARMA AD (48/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 18 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 18 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.09.2019 09:28
SOPHARMA AD (47/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 17 September 2019.
18.09.2019 09:28SOPHARMA AD (47/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 17 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 17 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.09.2019 14:16
SOPHARMA AD (46/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 16 September 2019.
17.09.2019 14:16SOPHARMA AD (46/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 16 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 16 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.09.2019 09:06
SOPHARMA AD (45/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 13 September 2019.
16.09.2019 09:06SOPHARMA AD (45/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 13 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 13 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2019 11:43
SOPHARMA AD (44/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 11.09.2019
12.09.2019 11:43SOPHARMA AD (44/2019) Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 11.09.2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 11.09.2019
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2019 09:03
SOPHARMA AD (43/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 11 September 2019.
12.09.2019 09:03SOPHARMA AD (43/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 11 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 11 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2019 09:42
SOPHARMA AD (42/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 10 September 2019.
11.09.2019 09:42SOPHARMA AD (42/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 10 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 10 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.09.2019 13:07
SOPHARMA AD (41/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 9 September 2019.
10.09.2019 13:07SOPHARMA AD (41/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 9 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 9 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.09.2019 16:56
SOPHARMA AD (40/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 5 September 2019.
05.09.2019 16:56SOPHARMA AD (40/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 5 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 5 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.09.2019 13:03
SOPHARMA AD (39/2019) Sales revenues for August 2019
05.09.2019 13:03SOPHARMA AD (39/2019) Sales revenues for August 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for August 2019 the Company recorded a decrease in sales of 3% compared to the same month of 2018, incl. 2% decrease in sales for the domestic market and 3% decrease in export sales.
In the first eight months of 2019 the revenues from sales of production decreased by 1% compared to the same period of 2018, incl. 9% decrease in domestic sales and 4% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.09.2019 09:01
SOPHARMA AD (38/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 4 September 2019.
05.09.2019 09:01SOPHARMA AD (38/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 4 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 4 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.09.2019 09:05
SOPHARMA AD (37/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 3 September 2019.
04.09.2019 09:05SOPHARMA AD (37/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 3 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 3 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.09.2019 11:15
SOPHARMA AD (36/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 2 September 2019.
03.09.2019 11:15SOPHARMA AD (36/2019) Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 2 September 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 2 September 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.08.2019 13:32
SOPHARMA AD (35/2019) Consolidated financial report of Sopharma Group for Q2 2019
29.08.2019 13:32SOPHARMA AD (35/2019) Consolidated financial report of Sopharma Group for Q2 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Financial report according to IFRS as at 30 June 2019 - consolidated
Notes to the financial report as at 30 June 2019 - consolidated
Management report as at 30 June 2019 - consolidated
Insider information as at 30 June 2019 - consolidated
Additional information as at 30 June 2019 - consolidated
Financial report according to BFCS standards as at 30 June 2019 - consolidated
Annex 9 as at 30 June 2019 - consolidated
Declaration as at 30 June 2019 - consolidated
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.06.2019 13:01
SOPHARMA AD (14/2019) Notification concerning the Annual General meeting of shareholders - 07.06.2019
03.06.2019 13:01SOPHARMA AD (14/2019) Notification concerning the Annual General meeting of shareholders - 07.06.2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that for the convenience of all shareholders the registration for participation in the Annual General meeting convened for 7 June 2019 will end at 10:45 am in order to allow for timely start of the General meeting.
Please note that for the first year the General meeting will be held at the new Event Center, which is located on the Ground floor of Sopharma Business Towers.
For registration and participation in the AGM, physical persons - shareholders must present an identity document. Legal entities - shareholders must provide an original or a certified copy of a valid commercial/court registration certificate as well as the legal representative's identity document.
For securing the registration procedure for participation in the General meeting of shareholders, copies of the issued powers of attorney should be submitted to the Company in hard copy or in electronic form at the latest by the end of the business day preceding the date of the General meeting, namely 17.00 hours on 6 June 2019.
Sopharma AD will receive and accept valid electronic notices and proxies by e-mail to the following e-mail address: ir@sopharma.bg according to the instructions described in the Invitation for convening the Annual General meeting of shareholders.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.05.2019 13:48
SOPHARMA AD (13/2019) Consolidated Financial report of Sopharma AD for the first quarter of 2019.
30.05.2019 13:48SOPHARMA AD (13/2019) Consolidated Financial report of Sopharma AD for the first quarter of 2019.
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Financial report according to IFRS as at 31 March 2019 consolidated
Notes to the financial report as at 31 March 2019 consolidated
Management report as at 31 March 2019 consolidated
Insider information as at 31 March 2019 consolidated
Additional information as at 31 March 2019 consolidated
Financial report according to BFCS standards as at 31 March 2019 consolidated
Annex 9 as at 31 March 2019 consolidated
Declaration of the responsible directors
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.03.2019 19:05
SOPHARMA AD (7/2019) Annual Audited Individual Financial Statements of Sopharma AD
29.03.2019 19:05SOPHARMA AD (7/2019) Annual Audited Individual Financial Statements of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial report according to IFRS as at 31 December 2018
2. Notes to the financial report as at 31 December 2018
3. Management report as at 31 December 2018
4. Non-financial declaration
5. Corporate governance declaration
6. Financial report according to BFCS standards as at 31 December 2018
7. Remuneration Policy Report
8. Declaration as at 31 December 2018
9. Auditors Report
10. Auditors Declaration
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.03.2019 13:03
SOPHARMA AD (6/2019) Sales revenues for February 2019
06.03.2019 13:03SOPHARMA AD (6/2019) Sales revenues for February 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (the "Company") notifies that for February 2019 the Company recorded a decrease of sales revenues of 14% compared to the same month of 2018, including 38% decrease of domestic sales and an increase of 1% of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.03.2019 13:54
SOPHARMA AD (5/2019) Consolidated preliminary financial statements of Sopharma Group for 2018
01.03.2019 13:54SOPHARMA AD (5/2019) Consolidated preliminary financial statements of Sopharma Group for 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Consolidated preliminary financial statements of Sopharma Group for 2018
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.02.2019 13:00
SOPHARMA AD (4/2019) Sales revenues for January 2019
05.02.2019 13:00SOPHARMA AD (4/2019) Sales revenues for January 2019
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for January 2019 the Company recorded an increase of sales revenues of 1% compared to the same month of 2018, including 15% decrease of domestic sales and an increase of 13% of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.01.2019 13:06
SOPHARMA AD (3/2019) Preliminary individual annual financial report of Sopharma AD for 2018
30.01.2019 13:06SOPHARMA AD (3/2019) Preliminary individual annual financial report of Sopharma AD for 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial report according to IFRS as at 31 December 2018
2. Notes to the financial report as at 31 December 2018
3. Management report as at 31 December 2018
4. Insider information as at 31 December 2018
5. Additional information as at 31 December 2018
6. Financial report according to BFCS standards as at 31 December 2018
7. Annex 9 as at 31 December 2018
8. Declaration as at 31 December 2018
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.01.2019 12:44
SOPHARMA AD (2/2019) The shareholding of CUPF Alianz Bulgaria in the capital of Sopharma AD
30.01.2019 12:44SOPHARMA AD (2/2019) The shareholding of CUPF Alianz Bulgaria in the capital of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD received a a notification for disclosure of a shareholding under Art. 145 of the CUPF Allianz Bulgaria for acquiring shares from the capital of Sopharma AD, as a result of which the shareholding of CUPF Allianz Bulgaria in the capital of Sopharma AD exceeds the limit of 5% and reaches 5.09%.
The date of the registration of the transaction with the Central Depository is January 23, 2019.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.01.2019 12:57
SOPHARMA AD (1/2019) Sales revenues for December 2018
11.01.2019 12:57SOPHARMA AD (1/2019) Sales revenues for December 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for December 2018 the Company recorded an increase of sales revenues of 26% compared to the same month of 2017, including 75% increase of domestic sales and a decrease of 1% of export sales.
In 2018 revenue from sales of goods decreased by 3% compared to the same period in 2017, incl. 3% increase in sales for the domestic market and 7% decrease in export sales.
"It's been a year of review - on our 85th anniversary, we looked back to enjoy our successes, to thank the people with whome we've achieved them and celebrate with everyone we want to share our future with. Thank you for sharing! We are proud to have been among the pioneers with two major initiatives - we have distributed shares to all our employees according to their length of service and contribution to the company's successes and distributed the first interim dividend. We have received support from our shareholders for both initiatives, which has always been an important indication for us confirming that we are doing the right thing.", commented Mr. Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of Sopharma AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2019 13:14
SOPHARMA AD (185/2018) Notification from Ognian Donev
02.01.2019 13:14SOPHARMA AD (185/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2019 13:11
SOPHARMA AD (184/2018) Notification for acquisition of own shares
02.01.2019 13:11SOPHARMA AD (184/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on December 28, 2018 the Company bought 314 own shares representing 0.0002% of the share capital of the Company, at a total value of 1 105.28 BGN on the Bulgarian Stock Exchange, the average price per share was 3.52 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 881 650, representing 6.59% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2019 13:08
SOPHARMA AD (183/2018) Notification from Ognian Donev
02.01.2019 13:08SOPHARMA AD (183/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2019 13:05
SOPHARMA AD (182/2018) Notification from Ognian Donev
02.01.2019 13:05SOPHARMA AD (182/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2019 13:02
SOPHARMA AD (181/2018) Notification from Donev Investments Holding AD
02.01.2019 13:02SOPHARMA AD (181/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2019 12:57
SOPHARMA AD (180/2018) Notification for acquisition of own shares
02.01.2019 12:57SOPHARMA AD (180/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on December 21, 2018 the Company bought 3 500 own shares representing 0.0026% of the share capital of the Company, at a total value of 12 425.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.55 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 881 336, representing 6.59% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.12.2018 12:14
SOPHARMA AD (179/2018) Notification from Telecomplect Invest AD
21.12.2018 12:14SOPHARMA AD (179/2018) Notification from Telecomplect Invest AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Telecomplect Invest AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.12.2018 09:09
SOPHARMA AD (178/2018) Notification from Donev Investments Holding AD
21.12.2018 09:09SOPHARMA AD (178/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.12.2018 08:17
SOPHARMA AD (177/2018) Notification from Ognian Donev
21.12.2018 08:17SOPHARMA AD (177/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2018 12:46
SOPHARMA AD (176/2018) Notification from Telecomplect Invest AD
20.12.2018 12:46SOPHARMA AD (176/2018) Notification from Telecomplect Invest AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Telecomplect Invest AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2018 10:27
SOPHARMA AD (175/2018) Notification from Ognian Donev
20.12.2018 10:27SOPHARMA AD (175/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2018 14:39
SOPHARMA AD (174/2018) Notification from Telecomplect Invest AD
19.12.2018 14:39SOPHARMA AD (174/2018) Notification from Telecomplect Invest AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Telecomplect Invest AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2018 14:36
SOPHARMA AD (173/2018) Notification from Telecomplect Invest AD
19.12.2018 14:36SOPHARMA AD (173/2018) Notification from Telecomplect Invest AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Telecomplect Invest AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2018 14:33
SOPHARMA AD (172/2018) Notification from Donev Investments Holding AD
19.12.2018 14:33SOPHARMA AD (172/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2018 14:24
SOPHARMA AD (171/2018) Notification from Donev Investments Holding AD
19.12.2018 14:24SOPHARMA AD (171/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2018 14:22
SOPHARMA AD (170/2018) Notification from Donev Investments Holding AD
19.12.2018 14:22SOPHARMA AD (170/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2018 14:18
SOPHARMA AD (169/2018) Treasury shares
19.12.2018 14:18SOPHARMA AD (169/2018) Treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 18, 2018 the Company sold 3 000 own shares representing 0.0022% of the share capital of the Company, at a total value of 10 770.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.59 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 877 836, representing 6.59% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2018 14:08
SOPHARMA AD (168/2018) Notification from Ognian Donev
19.12.2018 14:08SOPHARMA AD (168/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.12.2018 09:40
SOPHARMA AD (167/2018) Notification for acquisition of own shares
18.12.2018 09:40SOPHARMA AD (167/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 17, 2018 the Company bought 17 000 own shares representing 0.0126% of the share capital of the Company, at a total value of 61 200.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.60 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 880 836, representing 6.59% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.12.2018 09:36
SOPHARMA AD (166/2018) Notification from Ognian Donev
18.12.2018 09:36SOPHARMA AD (166/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.12.2018 09:50
SOPHARMA AD (165/2018) Notification for acquisition of own shares
17.12.2018 09:50SOPHARMA AD (165/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 14, 2018 the Company bought 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of 18 000.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.60 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 863 836, representing 6.58% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.12.2018 09:47
SOPHARMA AD (164/2018) Notification from Donev Investments Holding AD
17.12.2018 09:47SOPHARMA AD (164/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.12.2018 09:42
SOPHARMA AD (163/2018) Notification from Ognian Donev
17.12.2018 09:42SOPHARMA AD (163/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.12.2018 09:32
SOPHARMA AD (162/2018) Notification for acquisition of own shares
14.12.2018 09:32SOPHARMA AD (162/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 13, 2018 the Company bought 1 000 own shares representing 0.0007% of the share capital of the Company, at a total value of 3 600.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.60 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 858 836, representing 6.57% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.12.2018 09:29
SOPHARMA AD (161/2018) Notification from Ognian Donev
14.12.2018 09:29SOPHARMA AD (161/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2018 15:35
SOPHARMA AD (160/2018) Treasury shares
13.12.2018 15:35SOPHARMA AD (160/2018) Treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 13, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 500 own shares representing 0.0004% of the capital of the Company.
The total number of treasury shares after this transfer is 8 857 836, representing 6.57% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2018 15:31
SOPHARMA AD (159/2018) Notification from Ivan Badinski
13.12.2018 15:31SOPHARMA AD (159/2018) Notification from Ivan Badinski
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ivan Badinski - member of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2018 09:46
SOPHARMA AD (158/2018) Notification from Donev Investments Holding AD
13.12.2018 09:46SOPHARMA AD (158/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2018 09:43
SOPHARMA AD (157/2018) Treasury shares
13.12.2018 09:43SOPHARMA AD (157/2018) Treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 12, 2018 the Company bought 3 000 own shares representing 0.0022% of the share capital of the Company, at a total value of 10 800.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.60 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 858 336, representing 6.57% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2018 09:41
SOPHARMA AD (156/2018) Notification from Ognian Donev
13.12.2018 09:41SOPHARMA AD (156/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2018 10:57
SOPHARMA AD (155/2018) Notification from Ognian Donev
12.12.2018 10:57SOPHARMA AD (155/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2018 10:54
SOPHARMA AD (154/2018) Notification for acquisition of own shares
12.12.2018 10:54SOPHARMA AD (154/2018) Notification for acquisition of own shares
Podstawa prawna: Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 11, 2018 the Company bought 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of 18 250.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.65 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 855 336, representing 6.57% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2018 10:48
SOPHARMA AD (153/2018) Notification for acquisition of own shares
12.12.2018 10:48SOPHARMA AD (153/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 11, 2018 the Company bought 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of 18 250.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.65 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 855 336, representing 6.57% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.12.2018 09:59
SOPHARMA AD (152/2018) Notification for acquisition of own shares
11.12.2018 09:59SOPHARMA AD (152/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on December 10, 2018 the Company bought 5 620 own shares representing 0.0042% of the share capital of the Company, at a total value of 20 792.80 BGN on the Bulgarian Stock Exchange, the average price per share was 3.70 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 850 336, representing 6.57% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.12.2018 09:56
SOPHARMA AD (151/2018) Notification from Ognian Donev
11.12.2018 09:56SOPHARMA AD (151/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.12.2018 09:54
SOPHARMA AD (150/2018) Notification from Donev Investments Holding AD
10.12.2018 09:54SOPHARMA AD (150/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.12.2018 09:51
SOPHARMA AD (149/2018) Notification from Ognian Donev
10.12.2018 09:51SOPHARMA AD (149/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.12.2018 09:13
SOPHARMA AD (148/2018) Notification from Donev Investments Holding AD
07.12.2018 09:13SOPHARMA AD (148/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.12.2018 08:08
SOPHARMA AD (147/2018) Notification from Ognian Donev
07.12.2018 08:08SOPHARMA AD (147/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.12.2018 08:05
SOPHARMA AD (146/2018) Treasury shares
07.12.2018 08:05SOPHARMA AD (146/2018) Treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 6, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 550 own shares representing 0.0004% of the capital of the Company.
The total number of treasury shares after this transfer is 8 844 716, representing 6.56% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.12.2018 13:22
SOPHARMA AD (145/2018) Notification for acquisition of own shares
06.12.2018 13:22SOPHARMA AD (145/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on December 5, 2018 the Company bought 1 000 own shares representing 0.0007% of the share capital of the Company, at a total value of 3 690.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.69 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 845 266, representing 6.56% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.12.2018 10:10
SOPHARMA AD (144/2018) Notification from Donev Investments Holding AD
06.12.2018 10:10SOPHARMA AD (144/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.12.2018 09:57
SOPHARMA AD (143/2018) Notification from Ognian Donev
06.12.2018 09:57SOPHARMA AD (143/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.12.2018 13:09
SOPHARMA AD (142/2018) Sales revenues for November 2018
05.12.2018 13:09SOPHARMA AD (142/2018) Sales revenues for November 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for November 2018 the Company recorded a decrease of sales revenues of 9% compared to the same month of 2017, including 10% increase of domestic sales and a decrease of 23% of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.12.2018 10:57
SOPHARMA AD (141/2018) Notification from Donev Investments Holding AD
05.12.2018 10:57SOPHARMA AD (141/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.12.2018 10:54
SOPHARMA AD (140/2018) Notification from Ognian Donev
05.12.2018 10:54SOPHARMA AD (140/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.12.2018 10:51
SOPHARMA AD (139/2018) Treasury shares
05.12.2018 10:51SOPHARMA AD (139/2018) Treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 4, 2018 the Company bought 7 000 own shares representing 0.0052% of the share capital of the Company, at a total value of 26 360.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.77 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 844 266, representing 6.56% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.12.2018 13:50
SOPHARMA AD (138/2018) Treasury shares
04.12.2018 13:50SOPHARMA AD (138/2018) Treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 4, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 100 own shares representing 0.0001% of the capital of the Company.
The total number of treasury shares after this transfer is 8 837 266, representing 6.56% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.12.2018 13:47
SOPHARMA AD (137/2018) Notification for acquisition of own shares
04.12.2018 13:47SOPHARMA AD (137/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on December 3, 2018 the Company bought 1 000 own shares representing 0.0007% of the share capital of the Company, at a total value of 3 740.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.74 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transaction is 8 837 366, representing 6.56% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.12.2018 10:01
SOPHARMA AD (136/2018) Notification from Ognian Donev
04.12.2018 10:01SOPHARMA AD (136/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.11.2018 13:15
SOPHARMA AD (135/2018) Interim consolidated report for the nine months of 2018 of Sopharma Group
29.11.2018 13:15SOPHARMA AD (135/2018) Interim consolidated report for the nine months of 2018 of Sopharma Group
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1.Financial report according to IFRS as at 30 September 2018
2.Notes to the financial report as at 30 September 2018
3.Management report as at 30 September 2018
4.Insider information as at 30 September 2018
5.Additional information as at 30 September 2018
6.Financial report according to BFCS standards as at 30 September 2018
7.Annex 9 as at 30 September 2018
8.Declaration as at 30 September 2018
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.11.2018 13:15
SOPHARMA AD (134/2018) The annual meeting with the investors of Sopharma AD and Sopharma Trading AD was held
20.11.2018 13:15SOPHARMA AD (134/2018) The annual meeting with the investors of Sopharma AD and Sopharma Trading AD was held
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) announces that on November 16, 2018 in Sofia, 16, Rozhen Blvd was held an annual meeting with the investors of Sopharma AD and Sopharma Trading AD, which started at 13:30 and ended at 17:00. 62 guests were registered for the meeting.
The meeting started with questions from the investors towards the management of Sopharma AD and Sopharma Trading AD.
Mr. Dimitrov presented the largest logistic center of Sopharma Trading AD which is stretched over an area of 15 000 m2 and the storage area is 10 000 m2. In the center is implemented the automated system for warehouse management and medicine distribution - KNAPP, which has no analogue on the Balkan Peninsula. The modern technology accelerates the processing of customer orders 7 times.
The guests of the meeting had the opportunity to visit the Regional distribution center of Sopharma Trading AD, automated with the KNAPP system.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.11.2018 12:52
SOPHARMA AD (133/2018) Sales revenues for October 2018
05.11.2018 12:52SOPHARMA AD (133/2018) Sales revenues for October 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for October 2018 the Company recorded a decrease of sales revenues of 16% compared to the same month of 2017, including 23% decrease of domestic sales and a decrease of 11% of export sales.
In the ten months of 2018 revenue from sales of goods decreased by 5% compared to the same period in 2017, incl. 5% decrease in sales for the domestic market and 5% decrease in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.11.2018 12:59
SOPHARMA AD (132/2018) Treasury shares
01.11.2018 12:59SOPHARMA AD (132/2018) Treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on October 31, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 500 own shares representing 0.0004% of the capital of the Company.
The total number of treasury shares after this transfer is 8 836 366, representing 6.56% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.10.2018 13:03
SOPHARMA AD (131/2018) Financial report for the third quarter of 2018
30.10.2018 13:03SOPHARMA AD (131/2018) Financial report for the third quarter of 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial report according to IFRS as at 30 September 2018
2. Notes to the financial report as at 30 September 2018
3. Management report as at 30 September 2018
4. Insider information as at 30 September 2018
5. Additional information as at 30 September 2018
6. Financial report according to BFCS standards as at 30 September 2018
7. Annex 9 as at 30 September 2018
8. Declaration as at 30 September 2018
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.10.2018 14:52
SOPHARMA AD (130/2018) Treasury shares
29.10.2018 14:52SOPHARMA AD (130/2018) Treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on October 29, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 9 450 own shares representing 0.070% of the capital of the Company.
The total number of treasury shares after this transfer is 8 836 866, representing 6.56% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.10.2018 11:16
SOPHARMA AD (129/2018) Treasury shares
25.10.2018 11:16SOPHARMA AD (129/2018) Treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on October 22, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 277 400 own shares representing 0.2050% of the capital of the Company.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
The total number of treasury shares after this transfer is 8 846 316, representing 6.56% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.10.2018 11:13
SOPHARMA AD (128/2018) Notification from Alexandar Tchaushev
25.10.2018 11:13SOPHARMA AD (128/2018) Notification from Alexandar Tchaushev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Alexandar Tchaushev - member of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.10.2018 11:10
SOPHARMA AD (127/2018) Notification from Ivan Badinski
25.10.2018 11:10SOPHARMA AD (127/2018) Notification from Ivan Badinski
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ivan Badinski - member of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.10.2018 11:08
SOPHARMA AD (126/2018) Notification from Ognian Palaveev
25.10.2018 11:08SOPHARMA AD (126/2018) Notification from Ognian Palaveev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Palaveev - member of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.10.2018 11:05
SOPHARMA AD (125/2018) Notification from Vessela Stoeva
25.10.2018 11:05SOPHARMA AD (125/2018) Notification from Vessela Stoeva
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Vessela Stoeva - deputy chairperson of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.10.2018 11:01
SOPHARMA AD (124/2018) Notification from Ognian Donev
25.10.2018 11:01SOPHARMA AD (124/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.10.2018 14:12
SOPHARMA AD (123/2018) Notification for the distribution of bonus shares for the 85th anniversary of Sopharma AD
23.10.2018 14:12SOPHARMA AD (123/2018) Notification for the distribution of bonus shares for the 85th anniversary of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) announces that yesterday it distributed 277 400 shares to 1 733 employees in compliance with the decision of the General Meeting of Shareholders of June 15, 2018 to distribute bonus shares among the employees of the Company for its 85th anniversary. The procedure involved training of all employees for the respective rights they would have as shareholders in the company. The shares of some employees on maternity / paternity leave or long-term sick leave have not yet been allocated.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.10.2018 14:06
SOPHARMA AD (122/2018) Meeting with investors
23.10.2018 14:06SOPHARMA AD (122/2018) Meeting with investors
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) kindly invites you to the Annual Investor Relations Meeting that will take place on November 16, 2018, starting at 13:30 in Sofia, 16, Rozhen Blvd., and will include a meeting with the management of the two companies and a visit to the Regional Distribution Center of Sopharma Trading AD automated with the KNAPP system.
You can apply for participation by filling out the attached registration form and sending it to irevents@sopharma.bg. For further information or assistance, please call 02 8134 319. Please refer to the content of the "Privacy Notice for Direct Marketing of Sopharma AD", which is part of the registration form.
The deadline for registration is November 9, 2018.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.10.2018 13:10
SOPHARMA AD (121/2018) Notification on the terms and conditions for payment of the 6-month dividend for the first half of 2018
10.10.2018 13:10SOPHARMA AD (121/2018) Notification on the terms and conditions for payment of the 6-month dividend for the first half of 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that the Company will initiate dividend payment of the voted on the EGM held on September, 14 2018 dividend of 0.05 BGN on October, 22 2018.
The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. September, 28 2018.
In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.10.2018 16:00
SOPHARMA AD (120/2018) Sales revenues for September 2018
05.10.2018 16:00SOPHARMA AD (120/2018) Sales revenues for September 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (the "Company") notifies that for September 2018 the Company recorded decrease of sales revenues of 7% compared to the same month of 2017, including 55% increase of domestic sales and a decrease of 28% of export sales.
Revenue in the third quarter of 2018 increases compared to the same period in 2017, respectively, by 5%, incl. 10% increase of sales for the domestic market and 2% increase in export sales. Successful work during the quarter contributes to reducing the rate of decline in revenue and for the first nine months of this year, revenues from sales of products decreased by 4% (8% as at 30.06.2018) compared to the same period of 2017, including 1% decrease of domestic sales and 6% decrease of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.10.2018 08:16
SOPHARMA AD (119/2018) Notification from Donev Investments Holding AD
02.10.2018 08:16SOPHARMA AD (119/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.09.2018 12:37
SOPHARMA AD (118/2018) Notification from Ognian Donev
29.09.2018 12:37SOPHARMA AD (118/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.09.2018 12:33
SOPHARMA AD (117/2018) Notification for acquisition of own shares
29.09.2018 12:33SOPHARMA AD (117/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 28 September 2018 the Company bought 10 000 own shares representing 0.0074% of the share capital of the Company, at a total value of 40 910.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.09 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after this transaction is 9 123 716, representing 6.77% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.09.2018 09:46
SOPHARMA AD (116/2018) Notification from Donev Investments Holding AD
28.09.2018 09:46SOPHARMA AD (116/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.09.2018 09:14
SOPHARMA AD (115/2018) Notification from Ognian Donev
28.09.2018 09:14SOPHARMA AD (115/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.09.2018 10:17
SOPHARMA AD (114/2018) Notification from Donev Investments Holding AD
27.09.2018 10:17SOPHARMA AD (114/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.09.2018 08:32
SOPHARMA AD (113/2018) Notification from Ognian Donev
27.09.2018 08:32SOPHARMA AD (113/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 26.09.2018 13:15
SOPHARMA AD (112/2018) Notification for acquisition of own shares
26.09.2018 13:15SOPHARMA AD (112/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 25 September 2018 the Company bought 2 947 own shares representing 0.0022% of the share capital of the Company, at a total value of 12 023.76 BGN on the Bulgarian Stock Exchange, the average price per share was 4.08 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after this transaction is 9 113 699, representing 6.76% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 26.09.2018 09:35
SOPHARMA AD (111/2018) Notification from Ognian Donev
26.09.2018 09:35SOPHARMA AD (111/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2018 13:18
SOPHARMA AD (110/2018) Notification for acquisition of own shares
25.09.2018 13:18SOPHARMA AD (110/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 21 September 2018 the Company bought 3 375 own shares representing 0.0025% of the share capital of the Company, at a total value of 13 770.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.08 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
As a result of the merger of Unipharm AD into Sopharma AD 70 623 shares of the treasury shares of the Company were transferred to the shareholders of Unipharm AD. The total number of treasury shares after this transfer is 9 110 752, representing 6.76% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2018 11:00
SOPHARMA AD (109/2018) Notification from Donev Investments Holding AD
25.09.2018 11:00SOPHARMA AD (109/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2018 10:53
SOPHARMA AD (108/2018) Notification from Ognian Donev
25.09.2018 10:53SOPHARMA AD (108/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.09.2018 11:06
SOPHARMA AD (107/2018) Notification from Donev Investments Holding AD
21.09.2018 11:06SOPHARMA AD (107/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.09.2018 10:32
SOPHARMA AD (106/2018) Notification from Ognian Donev
21.09.2018 10:32SOPHARMA AD (106/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.09.2018 14:26
SOPHARMA AD (105/2018) Notification for technical error
20.09.2018 14:26SOPHARMA AD (105/2018) Notification for technical error
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that in the publication for payment of a cash dividend published in www.x3news.com on September 14, 2018, at 12:53 o'clock there was a technical error. On the fifth line is written "... dividend per share net (only for shareholders - physical persons) - 0.05 (only for shareholders - physical persons) BGN" but read: "... dividend per share net (only for shareholders - physical persons) - 0.0475 (only for shareholders - physical persons) BGN "
We apologize for the inconvenience caused. Again, we note that the net dividend value does not include a 5% withholding tax for physical persons.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.09.2018 13:07
SOPHARMA AD (104/2018) Notification for acquisition of own shares
20.09.2018 13:07SOPHARMA AD (104/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 19 September 2018 the Company bought 13 000 own shares representing 0.0096% of the share capital of the Company, at a total value of 53 350.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.10 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 178 000, representing 6.81% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.09.2018 12:43
SOPHARMA AD (103/2018) Notification from Donev Investments Holding AD
20.09.2018 12:43SOPHARMA AD (103/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.09.2018 12:38
SOPHARMA AD (102/2018) Notification from Ognian Donev
20.09.2018 12:38SOPHARMA AD (102/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.09.2018 13:12
SOPHARMA AD (101/2018) Notification for acquisition of own shares
19.09.2018 13:12SOPHARMA AD (101/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 18 September 2018 the Company bought 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of 20 700.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.14 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 165 000, representing 6.80% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.09.2018 09:49
SOPHARMA AD (100/2018) Notification from Donev Investments Holding AD
19.09.2018 09:49SOPHARMA AD (100/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.09.2018 09:45
SOPHARMA AD (99/2018) Notification from Ognian Donev
19.09.2018 09:45SOPHARMA AD (99/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.09.2018 13:05
SOPHARMA AD (98/2018) Notification for acquisition of own shares
18.09.2018 13:05SOPHARMA AD (98/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 17 September 2018 the Company bought 1 690 own shares representing 0.0013% of the share capital of the Company, at a total value of 7 013.50 BGN on the Bulgarian Stock Exchange, the average price per share was 4.15 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 160 000, representing 6.80% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.09.2018 09:24
SOPHARMA AD (97/2018) Notification from Donev Investments Holding AD
18.09.2018 09:24SOPHARMA AD (97/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.09.2018 09:17
SOPHARMA AD (96/2018) Notification from Ognian Donev
18.09.2018 09:17SOPHARMA AD (96/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.09.2018 17:11
SOPHARMA AD (95/2018) Notification from Donev Investments Holding AD
14.09.2018 17:11SOPHARMA AD (95/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.09.2018 16:40
SOPHARMA AD (94/2018) Notification for acquisition of own shares
14.09.2018 16:40SOPHARMA AD (94/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 13 September 2018 the Company bought 4 000 own shares representing 0.003% of the share capital of the Company, at a total value of 16 600.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.15 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 158 310, representing 6.79% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.09.2018 15:54
SOPHARMA AD (93/2018) Minutes from a General shareholders meeting
14.09.2018 15:54SOPHARMA AD (93/2018) Minutes from a General shareholders meeting
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
The Extraordinary General Meeting of Shareholders of Sopharma AD was held on 14 September 2018, at 11.00 in Sofia, 5 Lachezar Stanchev Str., building B of commercial complex Sopharma Business Towers. It was attended by shareholders and their representatives, as per the annex to the Minutes listing the present shareholders and representatives of shareholders, containing the number of shares present and represented.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.09.2018 14:11
Sopharma wypłaci 0,05 BGN dywidendy na akcję za I półr. '18
14.09.2018 14:11Sopharma wypłaci 0,05 BGN dywidendy na akcję za I półr. '18
Dzień dywidendy to 28 września 2018 roku.
W czerwcu akcjonariusze zdecydowali o przeznaczeniu na dywidendę z zysku osiągniętego w 2017 roku oraz z niepodzielonego zysku z poprzednich lat łącznie 43 mln BGN, co da 0,11 BGN dywidendy na akcję. (PAP Biznes)
sar/ osz/
- 14.09.2018 11:56
SOPHARMA AD (92/2018) Notification on the terms and conditions for distribution of the dividend
14.09.2018 11:56SOPHARMA AD (92/2018) Notification on the terms and conditions for distribution of the dividend
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
In accordance with Art. 115c, para. 2 of the Public Offering of Securities Act Sopharma AD hereby notifies all shareholders of the Company about the decision of the EGM of Sopharma AD that took place on September 14, 2018 regarding the amount and type of 6-month dividend distributed and the terms and conditions for its distribution:
EGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.05 BGN /five stotinki/ per share with dividend right.
The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the EGM on which the 6-Month Financial Report for the first half of 2018 was approved and the decision for dividend was taken, namely the record date: September 28, 2018 (ex-dividend date: September 27, 2018).
In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.
The company is obligated to pay the dividend within 60 days of the respective GM. The date on which the dividend payment will commence and the total amount of dividend will be announced accordingly.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.09.2018 16:55
SOPHARMA AD (91/2018) Unipharm AD is now merged into Sopharma AD
13.09.2018 16:55SOPHARMA AD (91/2018) Unipharm AD is now merged into Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that the procedure for merger of Unipharm AD into Sopharma AD finished today with an entry in the Commercial register number 20180913171143.
Sopharma AD will take actions to deregister Unipharm AD from the list of public companies and from the BSE - Sofia AD, to register the new shareholders in the Central Depository and to register the merger into the Registry agency.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.09.2018 11:10
SOPHARMA AD (90/2018) Notification from Rositsa Doneva
13.09.2018 11:10SOPHARMA AD (90/2018) Notification from Rositsa Doneva
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Rositsa Doneva under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.09.2018 11:06
SOPHARMA AD (89/2018) Notification from Elpharma AD
13.09.2018 11:06SOPHARMA AD (89/2018) Notification from Elpharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Elpharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.09.2018 11:03
SOPHARMA AD (88/2018) Notification for acquisition of own shares
13.09.2018 11:03SOPHARMA AD (88/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 12 September 2018 the Company bought 5 434 own shares representing 0.004% of the share capital of the Company, at a total value of 22 528.43 BGN on the Bulgarian Stock Exchange, the average price per share was 4.146 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 154 310, representing 6.79% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.09.2018 11:00
SOPHARMA AD (87/2018) Notification from Ognian Donev
13.09.2018 11:00SOPHARMA AD (87/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2018 13:07
SOPHARMA AD (86/2018) Notification for acquisition of own shares
12.09.2018 13:07SOPHARMA AD (86/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 11 September 2018 the Company bought 28 own shares representing 0.00002% of the share capital of the Company, at a total value of 115.64 BGN on the Bulgarian Stock Exchange, the average price per share was 4.13 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 148 876, representing 6.79% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2018 10:10
SOPHARMA AD (85/2018) Notification from Donev Investments Holding AD
12.09.2018 10:10SOPHARMA AD (85/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2018 08:00
SOPHARMA AD (84/2018) Notification from Ognian Donev
12.09.2018 08:00SOPHARMA AD (84/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2018 13:05
SOPHARMA AD (83/2018) Notification concerning the Extraordinary General meeting of shareholders - 14.09.2018
11.09.2018 13:05SOPHARMA AD (83/2018) Notification concerning the Extraordinary General meeting of shareholders - 14.09.2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) draws attention to the fact that the registration for participation in the Extraordinary General meeting convened on 14 September 2018 will end at 10:45 am to comply with the opening hours announced for the start of the general meeting for the convenience of all shareholders.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2018 09:57
SOPHARMA AD (82/2018) Notification from Donev Investments Holding AD
11.09.2018 09:57SOPHARMA AD (82/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2018 08:54
SOPHARMA AD (81/2018) Notification for acquisition of own shares
11.09.2018 08:54SOPHARMA AD (81/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 10 September 2018 the Company bought 538 own shares representing 0.0004% of the share capital of the Company, at a total value of 2 221.94 BGN on the Bulgarian Stock Exchange, the average price per share was 4.13 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 148 848, representing 6.79% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2018 07:47
SOPHARMA AD (80/2018) Notification from Ognian Donev
11.09.2018 07:47SOPHARMA AD (80/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.09.2018 07:32
SOPHARMA AD (79/2018) Notification from Ognian Donev
10.09.2018 07:32SOPHARMA AD (79/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.09.2018 12:59
SOPHARMA AD (78/2018) Sales revenues for August 2018
05.09.2018 12:59SOPHARMA AD (78/2018) Sales revenues for August 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for August 2018 the Company recorded an increase of sales revenues of 11% compared to the same month of 2017, including 7% decrease of domestic sales and an increase of 25% of export sales.
For the first eight months of this year, revenues from sales of products decreased by 4% compared to the same period of 2017, including 5% decrease of domestic sales and 3% decrease of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.09.2018 09:24
SOPHARMA AD (77/2018) Notification from Donev Investments Holding AD
05.09.2018 09:24SOPHARMA AD (77/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.09.2018 07:50
SOPHARMA AD (76/2018) Notification from Ognian Donev
05.09.2018 07:50SOPHARMA AD (76/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.09.2018 10:14
SOPHARMA AD (75/2018) Notification from Donev Investments Holding AD
04.09.2018 10:14SOPHARMA AD (75/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.09.2018 07:37
SOPHARMA AD (74/2018) Notification from Ognian Donev
04.09.2018 07:37SOPHARMA AD (74/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.08.2018 12:35
SOPHARMA AD (73/2018) Consolidated financial report of Sopharma Group for the first half of 2018
29.08.2018 12:35SOPHARMA AD (73/2018) Consolidated financial report of Sopharma Group for the first half of 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial report according to IFRS as at 30 June 2018
2. Notes to the financial report as at 30 June 2018
3. Management report as at 30 June 2018
4. Insider information as at 30 June 2018
5. Additional information as at 30 June 2018
6. Financial report according to BFCS standards as at 30 June 2018
7. Annex 9 as at 30 June 2018
8. Declaration as at 30 June 2018
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.08.2018 12:43
SOPHARMA AD (72/22082018) Dividend payment to clients of investement intermediry Beta Corp AD
22.08.2018 12:43SOPHARMA AD (72/22082018) Dividend payment to clients of investement intermediry Beta Corp AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that, shareholders of Sopharma AD who have right to dividend, voted on the AGM held on June 15, 2018 and had accounts with the investment intermediary Beta Corp AD whose license has been suspended by the FSC with decision 675-II/09.07.2018, can receive their dividend at the cashier of the company in Sofia at 16, Iliensko Shose Str. every working day between 10-12 am and 2-4 pm.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.08.2018 12:19
SOPHARMA AD (71/2018) Sales revenues for July 2018
03.08.2018 12:19SOPHARMA AD (71/2018) Sales revenues for July 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that for July 2018 the Company recorded an increase of sales revenues of 10% compared to the same month of 2017, including an increase of 14% of export sales and a 3% increase of domestic sales.
For the first seven months of this year, revenues from sales of products decreased by 6% compared to the same period of 2017, including 5% decrease of domestic sales and 6% decrease of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.08.2018 14:03
SOPHARMA AD (70/2018) Minutes of the Extraordinary General meeting of shareholders of Sopharma AD - 1 August 2018
01.08.2018 14:03SOPHARMA AD (70/2018) Minutes of the Extraordinary General meeting of shareholders of Sopharma AD - 1 August 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Minutes of the Extraordinary General meeting of shareholders of Sopharma AD - 1 August 2018
2. Protocol to verify the quorum and the represented capital for participation in the EGM
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.07.2018 11:28
SOPHARMA AD (69/2018) Individual financial statements for the period ending 30.06.2018
30.07.2018 11:28SOPHARMA AD (69/2018) Individual financial statements for the period ending 30.06.2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial report according to IFRS as at 30 June 2018
2. Notes to the financial report as at 30 June 2018
3. Management report as at 30 June 2018
4. Insider information as at 30 June 2018
5. Additional information as at 30 June 2018
6. Financial report according to BFCS standards as at 30 June 2018
7. Annex 9 as at 30 June 2018
8. Declaration as at 30 June 2018
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.07.2018 11:22
SOPHARMA AD (68/2018) Notification concerning the Extraordinary General meeting of shareholders - 01.08.2018
30.07.2018 11:22SOPHARMA AD (68/2018) Notification concerning the Extraordinary General meeting of shareholders - 01.08.2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD draws attention to the fact that the registration for participation in the Extraordinary General meeting convened on 1 August 2018 will end at 10:45 am to comply with the opening hours announced for the start of the general meeting for the convenience of all shareholders.
For registration and participation in IOSA, natural persons - shareholders must present an identity document. Legal entities - shareholders must provide an original or a certified copy of a current commercial / court registration certificate as well as a legal representative's identity document.
In view of the technical provision of the registration procedure for participation in the General meeting of shareholders, copies of the issued power of attorney should be submitted to the Company in hard copy or in electronic form at the latest by the end of the business day preceding the date of the General meeting, namely 17.00 on 31.07.2018.
Sopharma AD will receive and accept valid electronic notices and proxies by e-mail to the following e-mail address: ir@sopharma.bg according to the instructions described in the Invitation to convene the General Meeting.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.07.2018 13:10
SOPHARMA AD (67/2018) Notification on the terms and conditions for payment of the dividend for 2017
16.07.2018 13:10SOPHARMA AD (67/2018) Notification on the terms and conditions for payment of the dividend for 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that the Company will initiate dividend payment of the voted on the AGM held on June, 15 2018 dividend of 0.11 BGN on July, 23 2018.
The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. June, 29 2018.
In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.07.2018 13:09
SOPHARMA AD (66/2018) Sales revenues for June 2018
05.07.2018 13:09SOPHARMA AD (66/2018) Sales revenues for June 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (the "Company") notifies that for June 2018 the Company recorded a decrease of sales revenues of 22% compared to the same month of 2017, including 2% decrease of domestic sales and a decrease of 34% of export sales.
For the first six months of this year, revenues from sales of products decreased by 8% compared to the same period of 2017, including 6% decrease of domestic sales and 10% decrease of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.07.2018 09:07
SOPHARMA AD (65/2018) Notification from Donev Investments Holding AD
02.07.2018 09:07SOPHARMA AD (65/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.07.2018 09:03
SOPHARMA AD (64/2018) Notification for acquisition of own shares
02.07.2018 09:03SOPHARMA AD (64/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 29 June 2018 the Company bought 8 500 own shares representing 0.0063% of the share capital of the Company, at a total value of 34 825.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.097 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 148 310, representing 6.79% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.07.2018 08:55
SOPHARMA AD (63/2018) Notification from Ognian Donev
02.07.2018 08:55SOPHARMA AD (63/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.06.2018 10:10
SOPHARMA AD (62/2018) Invitation and materials for the Extraordinary General Meeting of shareholders of Sopharma AD
29.06.2018 10:10SOPHARMA AD (62/2018) Invitation and materials for the Extraordinary General Meeting of shareholders of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
The Board of Directors, on the grounds of Art. 223 of the Commercial Law and Art. 115 of the Public Offering of Securities Act, convenes an Extraordinary General Meeting of Shareholders of Sopharma AD, which will be held on 01 August 2018 at 11.00 at the Company's registered office in Sofia, with place of holding: 5, Lachezar Stanchev Str., Sopharma Business Towers, building B, floor 3 and in the absence of a quorum on that date - on 15 August 2018 at the same place, with the same starting hour and the same agenda:
1. Taking a decision on the transformation by merger of Unipharm AD into Sopharma AD; Draft decision: GMS transforms Sopharma AD by merging Unipharm AD into it. As a result of the merger, the entire property of Unipharm AD will be transferred to Sopharma AD under the conditions of a joint succession.
2. Approval of a Transformation Agreement through merger of Unipharm AD into Sopharma AD, concluded on 17 May 2018 and of Additional Agreement No 1 of 13 June 2018; Draft decision: The GMS approves the Transformation Agreement through merger of Unipharm AD with Sopharma AD, concluded on 17 May 2018 and Additional Agreement No. 1 of 13 June 2018.
3. Approval of the Report of the Board of Directors of Sopharma AD to the shareholders of the Company regarding the merger of Unipharm AD into Sopharma AD; Draft decision: The GMS approves the Report of the Board of Directors of Sopharma AD to the shareholders of the Company regarding the merger of Unipharm AD into Sopharma AD.
4. Approval of the Auditor's Report under Art. 262m of the Commercial Law on the transformation by merger of Unipharm AD into Sopharma AD; Draft decision: The GMS approves the Auditor's Report under Art. 262m of the Commercial Law on the transformation by merger of Unipharm AD into Sopharma AD.
5. Approval of a Substantiated Report of the Board of Directors for transactions within the scope of Art. 114 of POSA; Draft decision: The GMS approves a Substantiated Report of the Board of Directors for Transactions within the scope of Article 114 of the POSA.
6. Empowerment within the meaning of Art.114, para 1 of the Public Offering of Securities Act, regarding the conclusion of a transaction, according to the Substantiated Report prepared by the Board of Directors; Draft decision: The GMS empowers the Board of Directors to conclude transactions for the inception of Sopharma AD as a co-debtor under the conditions of solidarity under an Investment Credit Agreement for the implementation of a project under an operational program and under a Contract for a credit line for working capital that is forthcoming to be concluded between DSK Bank EAD as a creditor and the subsidiary of Sopharma AD, Biopharm-Engineering AD, Sliven, as a borrower under the terms and conditions specified Substantiated Report prepared by the Board of Directors.
7. Election of a member of the Board of Directors of the Company; Draft decision: GMS elects Ivan Venetskov Badinsky for a member of the board of directors of Sopharma AD.
8. Miscellaneous
All shareholders of the company are invited to take part in the work of the General Meeting personally or through a representative.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.06.2018 09:22
SOPHARMA AD (61/2018) Notification for acquisition of own shares
29.06.2018 09:22SOPHARMA AD (61/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 28 June 2018 the Company bought 233 own shares representing 0.00017% of the share capital of the Company, at a total value of 959.96 BGN on the Bulgarian Stock Exchange, the average price per share was 4.12 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 139 810, representing 6.78% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.06.2018 11:11
SOPHARMA AD (60/2018) Notification for acquisition of own shares
28.06.2018 11:11SOPHARMA AD (60/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 27 June 2018 the Company bought 11857 own shares representing 0.0088% of the share capital of the Company, at a total value of 50 273.68 BGN on the Bulgarian Stock Exchange, the average price per share was 4.24 BGN.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.06.2018 14:44
SOPHARMA AD (59/2018) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
27.06.2018 14:44SOPHARMA AD (59/2018) Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.06.2018 11:44
SOPHARMA AD (58/2018) Acquisition of own shares
27.06.2018 11:44SOPHARMA AD (58/2018) Acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 26 June 2018 the Company bought 19 373 own shares representing 0.0144% of the share capital of the Company, at a total value of 82 568.31 BGN on the Bulgarian Stock Exchange, the average price per share was 4.26 BGN.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 26.06.2018 12:15
SOPHARMA AD (57/2018) NOTIFICATION OF INSIDERS' TRANSACTIONS
26.06.2018 12:15SOPHARMA AD (57/2018) NOTIFICATION OF INSIDERS' TRANSACTIONS
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 26.06.2018 12:10
SOPHARMA AD (56/2018) ACQUISITION OF OWN SHARES
26.06.2018 12:10SOPHARMA AD (56/2018) ACQUISITION OF OWN SHARES
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 25 June 2018 the Company bought 28 951 own shares representing 0.021% of the share capital of the Company, at a total value of 123 372.40 BGN on the Bulgarian Stock Exchange, the average price per share was 4.26 BGN.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.06.2018 09:50
SOPHARMA AD (55/2018) Notification from Ognian Donev
25.06.2018 09:50SOPHARMA AD (55/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.06.2018 09:47
SOPHARMA AD (54/2018) Notification for acquisition of own shares
25.06.2018 09:47SOPHARMA AD (54/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 22 June 2018 the Company bought 4 740 own shares representing 0.0035% of the share capital of the Company, at a total value of 20 002.80 BGN on the Bulgarian Stock Exchange, the average price per share was 4.22 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 079 396, representing 6.74% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.06.2018 09:37
SOPHARMA AD (53/2018) Notification from Donev Investments Holding AD
25.06.2018 09:37SOPHARMA AD (53/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.06.2018 08:56
SOPHARMA AD (52/2018) Notification from Ognian Donev
22.06.2018 08:56SOPHARMA AD (52/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.06.2018 08:49
SOPHARMA AD (51/2018) Notification for acquisition of own shares
22.06.2018 08:49SOPHARMA AD (51/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 21 June 2018 the Company bought 4 250 own shares representing 0.0032% of the share capital of the Company, at a total value of 18 006.88 BGN on the Bulgarian Stock Exchange, the average price per share was 4.24 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 074 656, representing 6.73% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.06.2018 08:43
SOPHARMA AD (50/2017) Notification from Ognian Donev
21.06.2018 08:43SOPHARMA AD (50/2017) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 .
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.06.2018 08:37
SOPHARMA AD (49/2018) Notification for acquisition of own shares
21.06.2018 08:37SOPHARMA AD (49/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 20 June 2018 the Company bought 2 200 own shares representing 0.00163% of the share capital of the Company, at a total value of 9 340.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 070 406, representing 6.73% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.06.2018 16:12
SOPHARMA AD (48/2018) Notification for acquisition of own shares
20.06.2018 16:12SOPHARMA AD (48/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 19 June 2018 the Company bought 106 own shares representing 0.0000786% of the share capital of the Company, at a total value of 450.50 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 068 206, representing 6.73% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.06.2018 08:00
SOPHARMA AD (47/2018) Notification from Ognian Donev
20.06.2018 08:00SOPHARMA AD (47/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.06.2018 13:48
SOPHARMA AD (46/2018) Minutes of the GMS of Sopharma AD
19.06.2018 13:48SOPHARMA AD (46/2018) Minutes of the GMS of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
The Annual General Meeting of Shareholders of Sopharma AD was held on 15 June 2018, at 11.00 in Sofia, 5 Lachezar Stanchev Str., building B of commercial complex Sopharma Business Towers.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.06.2018 10:28
SOPHARMA AD (45/2018) Notification from Donev Investments Holding AD
19.06.2018 10:28SOPHARMA AD (45/2018) Notification from Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 .
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.06.2018 08:07
SOPHARMA AD (44/2018) Notification from Ognian Donev
19.06.2018 08:07SOPHARMA AD (44/2018) Notification from Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.06.2018 09:53
SOPHARMA AD (43/2018) Notification for acquisition of own shares
18.06.2018 09:53SOPHARMA AD (43/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 15 June 2018 the Company bought 2 272 own shares representing 0.0017% of the share capital of the Company, at a total value of 9 652.72 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 068 100, representing 6.73% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.06.2018 09:48
SOPHARMA AD (42/2018) Notification from Ognian Donev - Executive director of Sopharma AD
18.06.2018 09:48SOPHARMA AD (42/2018) Notification from Ognian Donev - Executive director of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.06.2018 16:28
SOPHARMA AD (41/2018) Notification from Ognian Donev
15.06.2018 16:28SOPHARMA AD (41/2018) Notification from Ognian Donev
Podstawa prawna: Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 - Secondary publication.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.06.2018 16:13
SOPHARMA AD (40/2018) Notification for treasury shares
15.06.2018 16:13SOPHARMA AD (40/2018) Notification for treasury shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 14 June 2018 the Company bought 1 000 own shares representing 0.00074% of the share capital of the Company, at a total value of 4 260.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.26 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 065 828, representing 6.73% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.06.2018 13:34
Sopharma wypłaci 0,11 BGN dywidendy na akcję
15.06.2018 13:34Sopharma wypłaci 0,11 BGN dywidendy na akcję
W 2017 roku akcjonariusze spółki zdecydowali o wypłacie 0,10 BGN dywidendy na akcję. (PAP Biznes)
sar/ osz/
- 15.06.2018 13:15
SOPHARMA AD (39/2018) Notification on the terms and conditions for distribution of the dividend
15.06.2018 13:15SOPHARMA AD (39/2018) Notification on the terms and conditions for distribution of the dividend
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies all shareholders of the Company about the decision of the AGM of Sopharma AD that took place on June 15, 2018 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:
AGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.11 BGN /eleven stotinki/ per share with dividend right.
The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken, namely June 29, 2018.
In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.06.2018 14:07
SOPHARMA AD (38/2018) Notification for acquisition of own shares
14.06.2018 14:07SOPHARMA AD (38/2018) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 13 June 2018 the Company bought 24 062 own shares representing 0.0179% of the share capital of the Company, at a total value of 102 654.12 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 064 828, representing 6.72% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.06.2018 10:50
SOPHARMA AD (37/2018) Notification by Donev Investments Holding AD
14.06.2018 10:50SOPHARMA AD (37/2018) Notification by Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification by Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.06.2018 09:07
SOPHARMA AD (36/2018) Insider trading disclosure of June, 13 2018 received by Ognian Donev
14.06.2018 09:07SOPHARMA AD (36/2018) Insider trading disclosure of June, 13 2018 received by Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.06.2018 08:48
SOPHARMA AD (35/2018) Insider trading disclosure of June, 12 2018 received by Ognian Donev
13.06.2018 08:48SOPHARMA AD (35/2018) Insider trading disclosure of June, 12 2018 received by Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.06.2018 08:51
SOPHARMA AD (34/2018) Insider trading disclosure of June, 11 2018 received by Ognian Donev
12.06.2018 08:51SOPHARMA AD (34/2018) Insider trading disclosure of June, 11 2018 received by Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.06.2018 08:15
SOPHARMA AD (33/2018) Insider trading disclosure of June, 8 2018 received by Ognian Donev
11.06.2018 08:15SOPHARMA AD (33/2018) Insider trading disclosure of June, 8 2018 received by Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.06.2018 10:10
SOPHARMA AD (32/2018) Insider trading disclosure of June, 7 2018 received by Donev Investments Holding AD
08.06.2018 10:10SOPHARMA AD (32/2018) Insider trading disclosure of June, 7 2018 received by Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.06.2018 09:38
SOPHARMA AD (31/2018) Insider trading disclosure of June, 7 2018 received by Ognian Donev
08.06.2018 09:38SOPHARMA AD (31/2018) Insider trading disclosure of June, 7 2018 received by Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.06.2018 14:22
SOPHARMA AD (30/2018) Insider trading disclosure of June, 4 2018 received by Donev Investments Holding AD
07.06.2018 14:22SOPHARMA AD (30/2018) Insider trading disclosure of June, 4 2018 received by Donev Investments Holding AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.06.2018 07:59
SOPHARMA AD (29/2018) Insider trading disclosure of June, 6 2018 received by Ognian Donev
07.06.2018 07:59SOPHARMA AD (29/2018) Insider trading disclosure of June, 6 2018 received by Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.06.2018 08:43
SOPHARMA AD (28/2018) Notification by Ognian Donev
06.06.2018 08:43SOPHARMA AD (28/2018) Notification by Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 - Secondary publication.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.06.2018 13:14
SOPHARMA AD (27/2018) Sales revenues for May 2018
05.06.2018 13:14SOPHARMA AD (27/2018) Sales revenues for May 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that for May 2018 the Company recorded a decrease of sales revenues of 11% compared to the same month of 2017, including 1% increase of domestic sales and a decrease of 16% of export sales.
For the first five months of this year, revenues from sales of products decreased by 2% compared to the same period of 2017, including 1% increase of domestic sales and 3% decrease of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.06.2018 13:06
SOPHARMA AD (26/2018) ACQUISITION OF OWN SHARES
05.06.2018 13:06SOPHARMA AD (26/2018) ACQUISITION OF OWN SHARES
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD hereby informs that on 4 June 2018 the Company bought 6 600 own shares representing 0.00490% of the share capital of the Company, at a total value of 27900.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.23 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.
The total number of treasury shares after these transactions is 9 040 766, representing 6.707% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.06.2018 07:43
SOPHARMA AD (25/2018) Notification by Ognian Donev
05.06.2018 07:43SOPHARMA AD (25/2018) Notification by Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.06.2018 13:04
SOPHARMA AD (24/2018) Notification
04.06.2018 13:04SOPHARMA AD (24/2018) Notification
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
With deep sorrow we announce that Mr. Andrey Breshkov, a member of the Board of Directors of Sopharma AD, unexpectedly passed away. May he rest in peace!
Until the Company elects a Member of the Board of Directors in accordance with the Commercial Law and the Public Offering of Securities Act, the Board will continue to perform its functions with four members.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.06.2018 07:40
SOPHARMA AD (23/2018) Insider trading disclosure of June, 1 2018 received by Ognian Donev
04.06.2018 07:40SOPHARMA AD (23/2018) Insider trading disclosure of June, 1 2018 received by Ognian Donev
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.05.2018 13:23
SOPHARMA AD (22/2018) Interim condensed consolidated financial statements for the three-month period ending March, 31 2018
30.05.2018 13:23SOPHARMA AD (22/2018) Interim condensed consolidated financial statements for the three-month period ending March, 31 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1.Financial report according to IFRS
2.Notes to the financial report
3.Management report
4.Insider information
5.Additional information
6.Financial report according to BFCS standards
7.Annex 9
8.Declaration
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.05.2018 14:06
SOPHARMA AD (21/2018) Termination of the previous and start a new transformation procedure through the merger of Unipharm AD into Sopharma AD
15.05.2018 14:06SOPHARMA AD (21/2018) Termination of the previous and start a new transformation procedure through the merger of Unipharm AD into Sopharma AD
Podstawa prawna: Sopharma AD notifies that due to the refusal issued by the Registry agency for the registration of the transformation through merger of Unipharm AD into Sopharma AD that started in September 2017, the Board of directors of Sopharma AD took a decision to close the previous and start a new procedure for transformation of Sopharma AD under the conditions of Chapter XVI of the Commercial Law and Art. 122 and et seq of the Public Offering of Securities Law, to be implemented through the merger of Unipharm AD, UIC 831537465, with headquarters and address of management in Sofia, Studentski district, Darvenitsa, 3 Trayko Stanoev Str. into Sopharma AD. The Board of Directors of the Company elects the investment intermediary Elana Trading AD, UIC 831470130, with headquarters and address of management in Sofia, 5, Lachezar Stanchev Str., as consultant in connection with the implementation of the transformation procedure.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.05.2018 13:36
SOPHARMA AD (20/2018) Sales revenues for April 2018
09.05.2018 13:36SOPHARMA AD (20/2018) Sales revenues for April 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (the "Company") notifies that for April 2018 the Company recorded an increase of sales revenues of 12% compared to the same month of 2017, including 1% increase of domestic sales and an increase of 21% of export sales.
For the first four months of this year, revenues from sales of products increased by 0,3% compared to the same period of 2017, including 0.5% increase of domestic sales and 0,1% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.05.2018 07:11
Sopharma planuje wypłacić 0,11 BGN dywidendy na akcję
04.05.2018 07:11Sopharma planuje wypłacić 0,11 BGN dywidendy na akcję
Walne Sopharmy zwołano na 15 czerwca.
W 2017 roku akcjonariusze spółki zdecydowali o wypłacie 0,10 BGN dywidendy na akcję.(PAP Biznes)
seb/
- 03.05.2018 13:50
SOPHARMA AD (19/2018) Invitation and materials for the General meeting of shareholders of Sopharma AD
03.05.2018 13:50SOPHARMA AD (19/2018) Invitation and materials for the General meeting of shareholders of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"The Board of Directors, on the grounds of Art. 223 of the Commercial Law and Art.115 of the Public Offering of Securities Act, convenes a General Meeting of Shareholders of Sopharma AD, which will be held on 15 June 2018 at 11.00 at the Company's registered office in Sofia, with place of holding: 5, Lachezar Stanchev Str., building B, and in the absence of a quorum on that date - on 29 June 2018 at the same place, with the same starting hour and the same agenda:
1. Approval of the annual report of the Board of Directors on the company's activities in 2017;
Draft decision: GMS approves the Annual Report of the Board of Directors on the company's activities in 2017.
2. Approval of the Report of the Investor Relations Director in 2017;
Draft decision: The GMS approves the Report of the Investor Relations Director in 2017.
3. Approval of the Audited Annual Individual Financial Statement of the Company for 2017;
Draft decision: The GMS approves the audited Annual Individual Financial Statement of the Company for 2017.
4. Approval of the Audited Annual Consolidated Financial Statement of the Company for 2017;
Draft decision: The GMS approves the audited Annual Consolidated Financial Statement of the Company for 2017;
5. Approval the Auditor's Report on the Audit of the Annual Individual Financial Statements of the Company for the year 2017;
Draft decision: The GMS approves the Auditor's Report on the Audit of the Annual Individual Financial Statements of the Company for the year 2017.
6. Approval the Auditor's Report on the Audit of the Annual Consolidated Financial Statements of the Company for the year 2017;
Draft decision: The GMS approves the Auditor's Report on the Audit of the Annual Consolidated Financial Statements of the Company for the year 2017.
7. Approval of a decision to distribute the Company's profit realized in 2017 and retained earnings from past periods;
Draft decision: GMS approves the proposal of the Board of Directors for the distribution of the company's profit in 2017 and undistributed profits from previous periods as follows: The total amount of the profit to be distributed amounts to BGN 43,010,955.52 (forty three million ten thousand nine hundred fifty-five leva and fifty-two stotinki) of which BGN 42,237,884.12 (forty two million two hundred thirty seven thousand eight hundred eighty four and twelve stotinki) profits realized in 2017 and BGN 773,071.40 (seven hundred seventy-three thousand seventy-one leva and forty cents) undistributed profits from past periods. After allocating 10% to a mandatory reserve, a dividend of BGN 0.11 per share is distributed. The amount left over after the allocation should be taken as an additional reserve of the company. The right to receive a dividend shall have the persons entered in the registers of the Central Depository as shareholders on the 14th day following the day of the General Meeting at which the Annual Financial Statement has approved a decision on the distribution of the profit was taken. The Company shall ensure the payment of the dividend voted to the shareholders at the General Meeting within 60 days of its execution. The costs of dividend payment are at the company's expense. The payment of the dividend is made with the assistance of the Central Depository. The shareholders with open accounts with an investment intermediary will receive their dividend through the respective intermediary and those shareholders who do not use the services of an investment intermediary will receive their dividends from the branches of Eurobank Bulgaria AD (Postbank) in the country.
8. Approval of the Audit Committee's report in 2017;
Draft decision: The GMS approves the Audit Committee's report on its activities in 2017.
9. Approval of a decision to discharge the members of the Board of Directors for their activity in 2017;
Draft decision: The GMS releases the members of the Board of Directors from responsibility for their activities in 2017.
10. Election of a registered auditor of the Company for 2018;
Draft decision: The GMS elects a registered auditor to verify and certify the Annual Financial Statements of the Company for 2018, as proposed by the Audit Committee, included in the items on the agenda.
11. Approval of the Report of the Board of Directors on the implementation of the Remuneration Policy of the members of the Board of Directors of the Company for 2017;
Draft decision: The General Meeting approves the Report of the Board of Directors on the Application of the Remuneration Policy of the Members of the Board of Directors of the Company for 2017.
12. Determination of the remuneration of the members of the Board of Directors for 2018;
Draft decision: Pursuant to Art. 24, para 3, letter A of the Articles of Association of the company, the GMS decided: the permanent remuneration of the members of the Board of Directors and the permanent remuneration of the Executive Director in 2018 remain unchanged.
13. Approval of a decision under Art. 24, para 3, letter B of the Articles of Association of the company;
Draft decision: Pursuant to Art. 24, para 3, letter B of the Articles of Association, the Executive Director of the company shall be paid an additional remuneration of 1% (one percent) of the amount of profits realized in 2017 according to the approved Annual Financial report.
14. Approval of a decision to determine a percentage of the profit realized in 2017 to be distributed among the members of the senior management team of the company, subject to the requirements of Art. 26a, item 12 of the Articles of Association of the company;
Draft decision: The General Meeting adopts a decision of 2% (two percent) of the profit realized in 2017 to be distributed among the members of the company's senior management team, subject to the requirements of Art. 26a, item 12 of the Articles of Association of the Company.
15. Approval of a Substantiated Report of the Board of Directors for transactions within the scope of Art. 114, para 1 of POSA;
Draft decision: GMS adopts the Substantiated Report of the Board of Directors for transactions within the scope of Art. 114, para 1 of POSA.
16. Empowerment within the meaning of Art. 114, para 1 of POSA regarding a transaction between Sopharma AD and Telecomplect AD;
Draft decision: GMS empowers the representative of the public company Sopharma AD to conclude on behalf of the company as a contracting entity a transaction with Telecomplect AD as a contractor falling within the scope of Art. 114, para 1, in conjunction with paragraph 6 of the same provision of POSA, under the conditions specified in the Substantiated Report.
17. Empowerment within the meaning of Art. 114, para 1 of POSA regarding a transaction between Sopharma AD and Sopharma Trading AD;
Draft decision: GMS empowers the representative of the public company Sopharma AD as a seller to conclude a transaction with Sopharma Trading AD as a buyer falling within the scope of Art. 114, para 1 of the POSA, under the conditions specified in the Substantiated Report.
18. Empowerment within the meaning of Art.114, para 1 of POSA concerning the assumption of a commitment as a co-debtor by Sopharma AD under an overdraft loan agreement between Eurobank Bulgaria AD as creditor and Momina krepost AD as a debtor.
Draft decision: The GMS empowers the representative of the public company Sopharma AD to conclude on behalf of the company as a co-debtor an overdraft loan agreement with creditor Eurobank Bulgaria AD and Momina Krepost AD as a debtor - a transaction falling within the scope of Art. 114, para 1 of POSA, according to the conditions stated in the Substantiated Report.
19. Empowerment within the meaning of Art.114, para 1 of POSA regarding a transaction between Sopharma AD and Sopharma Properties REIT;
Draft decision: The GMS empowers the representative of the public company Sopharma AD to conclude a transaction with Sopharma Properties REIT - a transaction falling within the scope of Art. 114, para 1 of POSA, according to the conditions stated in the Substantiated Report.
20. Approval of a decision for granting of shares in the capital of the company as a bonus for 2018 for the persons working in Sopharma AD on a labor contract or a management contract;
Draft decision: The GMS decided shares of the Company to be granted as a bonus for 2018 on the occasion of the 85th anniversary of the Company to all persons having an employment relationship with the Company or working under a management contract at the date of this decision taking the bonus is at the expense of the Company's own shares. The proposal of the Board of Directors included in the agenda items contains detailed information on how to determine the number of shares to be given to each person. The GMS empowers the Chairman of the Board of Directors and Executive Director to perform all necessary actions for the final transfer from the Company of the shares provided as a bonus to the employees.
21. Miscellaneous
All shareholders of the company are invited to take part in the work of the General Meeting personally or through a representative.
Written materials for the GMS are available to shareholders at the headquarters of the Company in Sofia, 16 Iliensko shose Str., the Records Department, every workday from 8:30 AM to 5:00 PM. The invitation, together with the written materials related to the items of the agenda of the Meeting, have been sent to the Financial Supervision Commission, are disclosed to the public and are published on the website of Sopharma AD - www.sopharmagroup.com from the moment the invitation is announced in the Commercial Register until the completion of the GMS.
Pursuant to Art. 115b, para 1 of POSA the right to vote in the General Meeting is exercised by the persons registered as such with the right to vote in the registers of the Central Depository 14 days before the date of the General Meeting, the respective valid date for the current Regular General Meeting of Shareholders, is 1 June 2018. Persons registered as such with voting rights at that date are entitled to participate and exercise their voting rights at the General Meeting. To determine the circle of voting persons at the General Meeting, scheduled for 15 June 2018, the company will obtain a Book of Shareholders from the Central Depository AD valid as at 1 June 2018.
According to the provision of Art. 187a, para 3 of the Commercial Law, the exercise of all rights, including the right to vote, on the treasury shares bought back by the company shall cease until the moment of their transfer.
On the grounds of Art. 118, para 2, item 4 of POSA, persons holding together or separately at least 5 per cent of the capital of the public company Sopharma AD may request the inclusion of agenda items and propose resolutions on already included agenda items for the General Meeting under the provisions of Art. 223a of the Commercial Law. Not later than 15 days before the opening of the General Meeting, these shareholders shall submit for announcement with the Commercial Register a list of the items that will be included in the agenda and the respective proposals for decisions on them, respectively proposals for decisions on items already on the agenda. With the announcement in the Commercial Register, the items are considered included in the proposed agenda of the General Meeting, respectively proposals for decisions on items already on the agenda. At the latest on the next business day, following the announcement, the shareholders shall submit the list of items, the proposals for decisions and the written materials at the address of the company's management, as well as to the Financial Supervision Commission and the regulated market in which the shares of the company are admitted to trading.
Shareholders have the right, subject to the requirements of the law, to make substantive proposals for decisions on any item included on the agenda until the debate on this item, is terminated and before the General Meeting votes a resolution on the respective item. In exercising this right, the restriction provided in Art. 118, para 3 of the Public Offering of Securities Act is valid.
During the General Meeting, the shareholders of the company have the right to ask questions on all items of the agenda, as well as questions about the economic and financial situation and the commercial activity of the company, whether these are related to the agenda or not.
The registration of the shareholders for participation in the General Meeting will take place on the announced day of its holding from 9:30 to 11:00 AM.
For registration and participation in the GMS, the natural persons - shareholders present an identity document. Legal entities - shareholders shall present an original or a certified copy of a current commercial / judicial registration certificate as well as an identity document of the legal representative.
Rules for proxy voting: Pursuant to the provisions of Art. 18, para 2 of the Articles of Association of the Company a proxy of shareholders in the General Meeting must contain an explicit written letter of attorney for the particular General Meeting with a minimum content as per Art.116, para 1 of POSA.
In case a shareholder - legal entity is represented by a physical person, the authorized person must provide their identity document, original or a certified copy, of a current certificate of commercial/court registration of the shareholder - legal entity, as well as an explicit written letter of attorney for the particular General Meeting with content as per Art. 116, para 1 of POSA, signed by the legal representative of the shareholder - legal entity, entered in the current certificate of commercial/court registration.
In case a shareholder is represented by a legal entity, the person, representing the proxy, apart from their identification document, must present an original or a certified copy of a current certificate of commercial/court registration of the proxy - legal entity, an explicit written letter of attorney for the particular General Meeting with content as per Art. 116, para 1 of POSA, issued by the shareholder. If the shareholder is a legal person, the person representing the proxy must also present an original or a certified copy of a current certificate of commercial/court registration of the shareholder.
The power of attorney should contain:
• A statement on the rights of the proxy in the cases of further included issues and / or proposals for decisions under Art. 118, para 2, item 4 of the Public Offering of Securities Act in connection with Art. 223a of the Commercial Law;
• A statement on the rights of the proxy in the hypothesis of Art. 231, para 1 of the Commercial Law;
• A statement on the right of the proxy to make substantive proposals for decisions on the items included in the agenda until the discussion on the respective issue - Art.115, para 3 of the Public Offering of Securities Act. In this case, the authorizing officer should explicitly indicate in the power of attorney a way to vote or give the proxy the right to vote at his own discretion.
Pursuant to Art. 116, para 4 of POSA the re-authorization with the rights granted to the proxy according to the power of attorney given to him, as well as the power of attorney given in violation and / or in inconsistency with the provisions of Art. 116, para 1 of the POSA is void.
A commercial / court registration certificate as well as a power of attorney for representation in the General Meeting issued in a foreign language must be accompanied by a translation into Bulgarian, certified in accordance with Art. 2a, para 2 of the Regulations on legalizations, certification and translation of documents and other papers. The translation of official documents is done by an interpreter engaged at a company that has signed a contract with the Ministry of Foreign Affairs. The fact that the translator is registered with such a company is certified by the Ministry of Foreign Affairs with the signature of the translator or with an explicit certificate together with a statement by the translator that he has not been removed from the list at the Ministry of Foreign Affairs. If there is a discrepancy between the texts, the data in the Bulgarian translation will be accepted as valid.
The Board of directors of Sopharma AD shall provide a sample paper power of attorney together with the materials for the General meeting. The power of attorney form is also available on the company's website at www.sopharmagroup.com.
In view of the technical support of the registration procedure for participation in the General Meeting of Shareholders, copies of the power of attorney should be submitted to the company on paper or in electronic form at the latest by the end of the working day preceding the date of the General Meeting; namely 17:00 14 June 2018.
Sopharma AD will receive and accept valid electronic notifications and proxies by e-mail to the following e-mail: ir@sopharma.bg the electronic messages should be signed with an universal electronic signature (UES) by the legal representative or natural person and accompanied by an electronic document (electronic sample) of the power of attorney, which is also signed with an universal electronic signature (UES) by the legal representative.
Pursuant to Art. 16a, para 3 of the Articles of Association of the Company, the Board of directors informs shareholders that at the General Meeting scheduled for 15 June 2018, and in the absence of a quorum on that date - for 29 June 2018, voting by correspondence and electronic means will be accepted, observing following rules:
1. Pursuant to Art. 16a of the Articles of Association, shareholders may exercise their voting rights before the date of the meeting by correspondence.
2. The voting right at the General Meeting of Shareholders of Sopharma AD, exercised through correspondence, is an explicit, written, notarized statement of will, issued by a shareholder of the company, which is for the particular meeting of the General Meeting of Shareholders and contains data on: identification of the shareholder in accordance with the requirements for registration for participation in the General Meeting of Shareholders; the number of shares the shareholder owns; the agenda of the items proposed for discussion at the particular meeting of the General Meeting of Shareholders of the Company, according to the Invitation to the General Meeting announced in the Commercial Register; proposals for decisions on each of the items on the agenda; the way of voting on each of the items on the agenda (for each of the items on the agenda only one of the following voting methods should be mentioned: "For", "Against" or "Abstain"); date and signature.
3. The necessary data for identifying a shareholder - natural person is: the full names, a single civilian number (EGN) and an address. The necessary data for identification of a shareholder - legal entity is: name, registered office and address of management, unified identification code (UIC) and the full name of the representative of the company.
4. The declaration referred to in para 2 above, made in a foreign language, shall be accompanied by a translation into Bulgarian language, certified in accordance with Art. 2a, para 2 of the Regulations on legalization, certification and translation of documents and other papers. The translation of official documents is done by an interpreter engaged at a company that has signed a contract with the Ministry of Foreign Affairs. The fact that the translator is registered with such a company is certified by the Ministry of Foreign Affairs with the signature of the translator or with an explicit certificate together with a statement by the translator that he has not been removed from the list at the Ministry of Foreign Affairs. If there is a discrepancy between the texts, the data in the Bulgarian translation will be accepted.
5. In case the voting right is exercised through correspondence by a shareholder - legal person, the explicit statement must be accompanied by an original or a certified copy of a current certificate of commercial registration of the respective shareholder company. A certificate of commercial registration issued in a foreign language must be accompanied by a translation into Bulgarian, subject to the conditions set forth in para 4 above.
6. As a valid means of exercising voting rights through correspondence, the shareholders of Sopharma AD may use any of the following exhaustively listed methods: mail - by letter sent to the company with a return receipt, certifying the moment of receiving the letter from the company; e-mail - via an electronic message that must be signed with an universal electronic signature (UES) by the shareholder and accompanied by an electronic document (electronic sample) of the statement, which is also signed with an universal electronic signature (UES) by the shareholder; courier - by letter sent to the company by a courier service chosen by the shareholder.
7. Sopharma AD shall accept the validity of the vote by correspondence only if the written statement with the vote of the respective shareholder, irrespective of the preferred method of sending, was received by the company not later than 14 June 2018, which is the last business day, prior to the date set for the General Meeting of Shareholders.
8. In case a shareholder of Sopharma AD, who exercised his / her voting right through correspondence, attends the General Meeting personally on 15 June 2018, the voting rights exercised by him by correspondence shall be valid unless the shareholder states differently upon registration for participation in the meeting. In such cases, in items on which the shareholder votes in person at the General Meeting, the voting rights he has exercised through correspondence will not be honored.
9. Address for correspondence by mail or courier: Sofia, 1756, 5 Lachezar Stanchev Str., Sopharma Business Towers, Building A, fl. 11 for Sopharma AD - to the attention of the Investor Relations Director.
Address for correspondence via e-mail: ir@sopharma.bg
Pursuant to Art. 227, para 3 of the Commercial Law, in the absence of a quorum of the date of the General Meeting of Shareholders announced by this invitation, the same shall be held on 29 June 2018 at 11:00 AM on the same place and on the same agenda. In this case, items on the agenda may not be included under the order of Art. 223a of the Commercial Law."
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.05.2018 13:22
SOPHARMA AD (18/2018) Issued refusal by the Registry Agency on the transformation through merger between Sopharma AD and Unipharm AD
02.05.2018 13:22SOPHARMA AD (18/2018) Issued refusal by the Registry Agency on the transformation through merger between Sopharma AD and Unipharm AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on April 30, 2018, the Registry Agency issued a refusal ą 20180411164207 of the declared transformation of Unipharm AD into Sopharma AD under the Transformation Agreement of September, 14 2017 and the Additional Agreement of November, 8 2017.
The companies are considering to launch a new transformation procedure as soon as possible.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.04.2018 17:40
SOPHARMA AD (17/2018) Annual audited consolidated financial report for 2017
27.04.2018 17:40SOPHARMA AD (17/2018) Annual audited consolidated financial report for 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Audited Financial Report according to IFRS
Notes to the financial report
Management report
Financial Report according to BFCS standards
Auditor's report
Corporate Governance Declaration
Declaration by responsible directors
Non-financial Declaration to the Annual Financial Statements
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.04.2018 13:53
SOPHARMA AD (16/2018) Financial report for the period ending 31.03.2018
27.04.2018 13:53SOPHARMA AD (16/2018) Financial report for the period ending 31.03.2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial report according to IFRS as at 31 March 2018
2. Notes to the financial report as at 31 March 2018
3. Management report as at 31 March 2018
4. Insider information as at 31 March 2018
5. Additional information as at 31 March 2018
6. Financial report according to BFCS standards as at 31 March 2018
7. Annex 9 as at 31 March 2018
8. Declaration as at 31 March 2018
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.04.2018 11:33
SOPHARMA AD (15/2018) Notification concerning the General Meeting of Shareholders of Sopharma AD
11.04.2018 11:33SOPHARMA AD (15/2018) Notification concerning the General Meeting of Shareholders of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that the filed on March 29, 2018 in the Commercial Register invitation for convening the Regular General Meeting of Shareholders of Sopharma AD on 11 May was not announced in accordance with the requirement of Art. 223, para 5 of the Commercial Law and the GMS cannot be conducted on this date.
The Board of Directors will propose another date for the GMS and will take the appropriate actions to convene it in the shortest possible time.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.04.2018 13:14
SOPHARMA AD (14/2018) Sales revenues for March 2018
05.04.2018 13:14SOPHARMA AD (14/2018) Sales revenues for March 2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, April 5, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for March 2018 the Company recorded a decrease of sales revenues of 10% compared to the same month of 2017, including 1% increase of domestic sales and a decrease of 19% of export sales.
For the first three months of this year, revenues from sales of products decreased by 3% compared to the same period of 2017, including 0.5% increase of domestic sales and 6% decrease of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.03.2018 13:34
SOPHARMA AD (13/2018) Annual audited individual financial statements of Sopharma AD for 2017
29.03.2018 13:34SOPHARMA AD (13/2018) Annual audited individual financial statements of Sopharma AD for 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Audited Financial Report according to IFRS
Notes to the financial report
Management report
Financial Report according to BFCS standards
Auditor's report
Corporate Governance Declaration
Report regarding the application of the remuneration policy
Declaration by responsible directors
Non-financial Declaration to the Annual Financial Statement
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.03.2018 13:11
SOPHARMA AD (12/2018) Sales revenues for the first two months of 2018
06.03.2018 13:11SOPHARMA AD (12/2018) Sales revenues for the first two months of 2018
Podstawa prawna: art. 17. 1 MAR.
Sofia, Bulgaria, March 6, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for February 2018 the Company recorded an increase of sales revenues of 2% compared to the same month of 2017, including 8% increase of domestic sales and same level of export sales.
For the first two months of this year, revenues from sales increased by 1% compared to the same period of 2017, including 2% increase of export sales and same level of domestic sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.03.2018 15:07
SOPHARMA AD (11/2018) PRELIMINARY CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2017
01.03.2018 15:07SOPHARMA AD (11/2018) PRELIMINARY CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration of the responsible directors
6. Annex 9
7. Additional information
8. List of insider information under Art. 7 of Regulation (EU) 596/2014
9. Financial results for 2017
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.02.2018 13:18
SOPHARMA AD (10/2018) MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 23 February 2018
28.02.2018 13:18SOPHARMA AD (10/2018) MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 23 February 2018
Podstawa prawna: art. 17. 1 MAR.
MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 23 February 2018
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.02.2018 16:54
SOPHARMA AD (9/2018) Decisions taken at the Extraordinary General Meeting of Shareholders of Sopharma AD, held on 23.02.2018
23.02.2018 16:54SOPHARMA AD (9/2018) Decisions taken at the Extraordinary General Meeting of Shareholders of Sopharma AD, held on 23.02.2018
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 23.02.2018 an Extraordinary general meeting of shareholders took place.
The General meeting of shareholders approved the decision for transformation of Sopharma AD, UIC: 831902088 by merging Unipharm AD, UIC: 831537465 into it. As a result of the merger, the entire property of Unipharm AD, UIC: 831537465 will be transferred to Sopharma AD, UIC: 831902088 under the conditions of general succession.
The General meeting of shareholders approved the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017, Additional Agreement No. 1 of 08.11.2017 to it (the "Contract for transformation through merger ").
The General meeting of shareholders approved the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.
The General meeting of shareholders approved the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.
The General meeting of shareholders approved changes in the Company's Articles of Association which allows the payment of an interim dividend on the basis of a 6-month financial statement under the Public Offering of Securities Act.
The General Meeting of Shareholders, on the grounds of Art.187b of the Commercial Law and Art.111, para 5 of POSA, approved a resolution for the acquisition of own shares from the capital of the Company under the following conditions: up to 10% of the total number of shares issued by the company, but not more than 3% in each calendar year; term of the acquisition - no longer than 5 (five) years; minimum price for acquisition - not less than the nominal value per share of the company's capital; maximum price for acquisition - BGN 5.50 per share;
The minutes of the General Meeting of Shareholders of Sopharma AD, held on 23.02.2018, will be sent to you within the statutory term. All conversion documents are available as part of the materials of the extraordinary general meeting.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.02.2018 15:31
SOPHARMA AD (8/2018) Treasury shares
08.02.2018 15:31SOPHARMA AD (8/2018) Treasury shares
Podstawa prawna: art. 17. 1 MAR.
Sofia, Bulgaria, February 8, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 29 December 2017 the Company bought 1186 own shares representing 0.00088% of the share capital of the Company, at a total value of 5080.82 BGN on the Bulgarian Stock Exchange, the average price per share was 4.28 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 8 904 000, representing 6.61% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.02.2018 13:01
SOPHARMA AD (7/2018) Sales revenues for January 2018
05.02.2018 13:01SOPHARMA AD (7/2018) Sales revenues for January 2018
Podstawa prawna: art. 17. 1 MAR.
Sofia, Bulgaria, February 5, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for January 2018 the Company recorded an increase of sales revenues of 3% compared to the same month of 2017, including 5% increase of export sales and same level of domestic sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.01.2018 14:58
SOPHARMA AD (6/2018) The shareholding of CUPF Allianz Bulgaria in the capital of Sopharma AD falls under 5%
30.01.2018 14:58SOPHARMA AD (6/2018) The shareholding of CUPF Allianz Bulgaria in the capital of Sopharma AD falls under 5%
Podstawa prawna: art. 17. 1 MAR.
Sofia, Bulgaria, January 30, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) received a notification for the sale of 250 000 shares, representing 0.19% of its capital, by CUPF Allianz Bulgaria. After the transaction the share of CUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.99%.
The date of the registration of the transaction with the Central Depository is 24 January 2018.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.01.2018 14:37
SOPHARMA AD (5/2018) PRELIMINARY INDIVIDUAL FINANCIAL STATEMENTS FOR 2017
30.01.2018 14:37SOPHARMA AD (5/2018) PRELIMINARY INDIVIDUAL FINANCIAL STATEMENTS FOR 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
PRELIMINARY INDIVIDUAL FINANCIAL STATEMENTS FOR 2017
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration of the responsible directors
6. Insiders' information
7. Additional information
8. List of insider information under Art. 7 of Regulation (EU) 596/2014
9. Results for 2017
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.01.2018 16:00
SOPHARMA AD (4/2018) CORRECTION_Invitation to the Extraordinary Meeting of Shareholders of Sopharma AD - 23 February 2018
17.01.2018 16:00SOPHARMA AD (4/2018) CORRECTION_Invitation to the Extraordinary Meeting of Shareholders of Sopharma AD - 23 February 2018
Podstawa prawna: art. 17. 1 MAR.
1. Taking a decision for transformation through merger of Unipharm AD into Sopharma AD.
Draft decision: GMS transforms Sopharma AD by merging Unipharm AD into it. As a result of the merger, the entire property of Unipharm AD will be transferred to Sopharma AD under the conditions of general succession.
2. Approval of the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017 and of Additional Agreement No1 of 08.11.2017 to it.
Draft decision: The GMS approves the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017, Additional Agreement No. 1 of 08.11.2017 to it (the "Contract for transformation through merger ").
3. Approval of the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.
Draft decision: The GMS approves the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.
4. Approval of the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.
Draft decision: The GMS approves the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.
5. Approval of changes in the Company's Articles of Association.
Draft decision: The GMS approves changes in the Company's Articles of Association according to a proposal of the Board of Directors, included in the materials for the EGMS.
6. Taking a decision for acquisition of own shares.
Draft decision: The General Meeting of Shareholders, on the grounds of Art.187b of the Commercial Law and Art.111, para 5 of POSA, approves a resolution for the acquisition of own shares from the capital of the Company under the following conditions: up to 10% of the total number of shares issued by the company, but not more than 3% in each calendar year; term of the acquisition
- no longer than 5 (five) years; minimum price for acquisition - not less than the nominal value per share of the company's capital; maximum price for acquisition - BGN 5.50 per share; The General Meeting empowers the Board of Directors of the company to determine all other parameters of the acquisition and to carry out the necessary factual and legal actions for the implementation of the decision of the General Meeting of Shareholders.
7. Miscellaneous.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.01.2018 18:40
Sopharma chce skupić do 10 proc. akcji własnych
16.01.2018 18:40Sopharma chce skupić do 10 proc. akcji własnych
Skup miałby trwać do pięciu lat. Minimalna cena nabycia to nie mniej niż nominalna wartość jednej akcji, a maksymalna cena nabycia to 5,50 nowego lewa bułgarskiego. Według średniego kursu NBP z wtorku oznacza to kwotę 11,72 zł za akcję. (PAP Biznes)
sar/ ana/
- 16.01.2018 18:08
SOPHARMA AD (4/2018) Invtation to the Extraordinary General Meeting of Shareholders of Sopharma AD and Materials - 23 February 2018
16.01.2018 18:08SOPHARMA AD (4/2018) Invtation to the Extraordinary General Meeting of Shareholders of Sopharma AD and Materials - 23 February 2018
Podstawa prawna: art. 17. 1 MAR.
1. Taking a decision for transformation through merger of Unipharm AD into Sopharma AD.
Draft decision: GMS transforms Sopharma AD by merging Unipharm AD into it. As a result of the merger, the entire property of Unipharm AD will be transferred to Sopharma AD under the conditions of general succession.
2. Approval of the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017 and of Additional Agreement No1 of 08.11.2017 to it.
Draft decision: The GMS approves the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017, Additional Agreement No. 1 of 08.11.2017 to it (the "Contract for transformation through merger ").
3. Approval of the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.
Draft decision: The GMS approves the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.
4. Approval of the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.
Draft decision: The GMS approves the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.
5. Approval of changes in the Company's Articles of Association.
Draft decision: The GMS approves changes in the Company's Articles of Association according to a proposal of the Board of Directors, included in the materials for the EGMS.
6. Taking a decision for acquisition of own shares.
Draft decision: The General Meeting of Shareholders, on the grounds of Art.187b of the Commercial Law and Art.111, para 5 of POSA, approves a resolution for the acquisition of own shares from the capital of the Company under the following conditions: up to 10% of the total number of shares issued by the company, but not more than 3% in each calendar year; term of the acquisition
- no longer than 5 (five) years; minimum price for acquisition - not less than the nominal value per share of the company's capital; maximum price for acquisition - BGN 5.50 per share; The General Meeting empowers the Board of Directors of the company to determine all other parameters of the acquisition and to carry out the necessary factual and legal actions for the implementation of the decision of the General Meeting of Shareholders.
7. Miscellaneous.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.01.2018 13:12
SOPHARMA AD (3/2018) Sales revenues for 2017
09.01.2018 13:12SOPHARMA AD (3/2018) Sales revenues for 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that for December 2017 the Company recorded an increase of sales revenues of 21% compared to the same month of 2016, including 73% increase of domestic sales and 4% increase of export sales.
For 2017, revenues from sales increased by 13% compared to 2016, including 3% increase of domestic sales and a 20% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2018 16:05
SOPHARMA AD (2/2018) Notification of insiders' transactions
02.01.2018 16:05SOPHARMA AD (2/2018) Notification of insiders' transactions
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
29.12.2017 Buy 1 354 4.2800
29.12.2017 Buy 705 4.2810
29.12.2017 Buy 1 568 4.2830
29.12.2017 Buy 873 4.2830
29.12.2017 Buy 500 4.2830
29.12.2017 Buy 427 4.2830
29.12.2017 Buy 473 4.2830
29.12.2017 Buy 1 073 4.2830
29.12.2017 Buy 27 4.2830
29.12.2017 Buy 500 4.2830
29.12.2017 Buy 81 4.2830
29.12.2017 Buy 269 4.2830
29.12.2017 Buy 1 619 4.2830
29.12.2017 Buy 31 4.2830
29.12.2017 Buy 181 4.2830
29.12.2017 Buy 1 319 4.2830
29.12.2017 Buy 400 4.2830
29.12.2017 Buy 81 4.2830
29.12.2017 Buy 1 519 4.2830
29.12.2017 Buy 719 4.2830
29.12.2017 Buy 281 4.2830
29.12.2017 Buy 672 4.2830
29.12.2017 Buy 328 4.2840
29.12.2017 Buy 200 4.2750
29.12.2017 Buy 300 4.2750
29.12.2017 Buy 500 4.2750
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.01.2018 08:53
SOPHARMA AD (1/2018) Notification of insiders' transactions
02.01.2018 08:53SOPHARMA AD (1/2018) Notification of insiders' transactions
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
29.12.2017 Buy 200 4.2750
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.12.2017 13:32
SOPHARMA AD (135/2017) Notifiation for insiders' transations
28.12.2017 13:32SOPHARMA AD (135/2017) Notifiation for insiders' transations
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
21.12.2017 Buy 1 609 4.2700
21.12.2017 Buy 3 391 4.2700
21.12.2017 Buy 121 4.2700
21.12.2017 Buy 199 4.2700
21.12.2017 Buy 1 000 4.2700
21.12.2017 Buy 500 4.2700
21.12.2017 Buy 130 4.2700
22.12.2017 Buy 1 628 4.2700
22.12.2017 Buy 372 4.2700
22.12.2017 Buy 950 4.2830
22.12.2017 Buy 100 4.2830
22.12.2017 Buy 1 490 4.2830
22.12.2017 Buy 510 4.2830
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.12.2017 15:49
SOPHARMA AD (134/2017) Nofication for received approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD
21.12.2017 15:49SOPHARMA AD (134/2017) Nofication for received approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 20 December 2018 Sopharma AD received an approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD and reports of the boards of directors and the independent evaluators. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0. 891512, meaning that one share of Unipharm AD will be exchanged for 0. 891512 shares of Sopharma AD from the treasury shares available to the receiving company.
The terms and conditions of the merger are available in detail in the Contract for transformation through merger and the reports of the boards of directors and the independent evaluators which are subject to approval by the general meetings of shareholders of both companies. The procedures for convening general meetings for both companies will be initiated in the beginning of 2018.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.12.2017 13:38
SOPHARMA AD (133/2017) Notification of insiders' transactions
21.12.2017 13:38SOPHARMA AD (133/2017) Notification of insiders' transactions
Podstawa prawna: art. 17. 1 MAR.
Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
20.12.2017 Buy 5 000 4.2700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.12.2017 13:33
SOPHARMA AD (132/2017) Notification of insiders' transactions
21.12.2017 13:33SOPHARMA AD (132/2017) Notification of insiders' transactions
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
20.12.2017 Buy 543 4.2700
20.12.2017 Buy 3 000 4.2700
20.12.2017 Buy 3 000 4.2700
20.12.2017 Buy 1 457 4.2700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.12.2017 13:18
SOPHARMA AD (131/2017) Notification for aqcuisition of treasury shares from 20 December 2017
21.12.2017 13:18SOPHARMA AD (131/2017) Notification for aqcuisition of treasury shares from 20 December 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD hereby informs that on 20 December 2017 the Company bought 10 934 own shares representing 0.0081% of the share capital of the Company, at a total value of 46 697.52 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 9 032 980, representing 6.70 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2017 16:29
SOPHARMA AD (130/2017) Notification for insiders' transactions
20.12.2017 16:29SOPHARMA AD (130/2017) Notification for insiders' transactions
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
19.12.2017 Buy 300 4.2820
19.12.2017 Buy 108 4.2800
19.12.2017 Buy 400 4.2800
19.12.2017 Buy 192 4.2800
19.12.2017 Buy 22 4.2750
19.12.2017 Buy 450 4.2750
19.12.2017 Buy 28 4.2750
19.12.2017 Buy 500 4.2710
19.12.2017 Buy 1 000 4.2700
19.12.2017 Buy 1 000 4.2700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2017 09:51
SOPHARMA AD (129/2017) Notification of insiders' transactions
19.12.2017 09:51SOPHARMA AD (129/2017) Notification of insiders' transactions
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
18.12.2017 Buy 200 4.2850
18.12.2017 Buy 45 4.2900
18.12.2017 Buy 15 4.2900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2017 09:28
SOPHARMA AD (128/2017) Notification of insiders' transactions
19.12.2017 09:28SOPHARMA AD (128/2017) Notification of insiders' transactions
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
18.12.2017 Buy 1 455 4.2900
18.12.2017 Buy 45 4.2900
18.12.2017 Buy 500 4.2900
18.12.2017 Buy 500 4.2900
18.12.2017 Buy 1 800 4.2850
18.12.2017 Buy 200 4.2820
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.12.2017 09:22
SOPHARMA AD (127/2017) Notification of insiders' transactions
19.12.2017 09:22SOPHARMA AD (127/2017) Notification of insiders' transactions
Podstawa prawna: art. 17. 1 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
14.12.2017 Buy 600 4.285
15.12.2017 Buy 335 4.290
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.12.2017 14:39
SOPHARMA AD (126/2017) Notification of insiders' transactions - Mr. Ognian Donev
18.12.2017 14:39SOPHARMA AD (126/2017) Notification of insiders' transactions - Mr. Ognian Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
15.12.2017 Buy 76 4.2880
15.12.2017 Buy 500 4.2900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.12.2017 13:15
SOPHARMA AD (125/2017) Acquisition of treasury shares from 15 December 2017
18.12.2017 13:15SOPHARMA AD (125/2017) Acquisition of treasury shares from 15 December 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD hereby informs that on 15 December 2017 the Company bought 130 166 own shares representing 0.0966% of the share capital of the Company, at a total value of 558 151.81 BGN on the Bulgarian Stock Exchange, the average price per share was 4.2880 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 9 022 046, representing 6.693 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.12.2017 13:30
SOPHARMA AD (124/2017) Current report re insiders transactions -124-Donev
15.12.2017 13:30SOPHARMA AD (124/2017) Current report re insiders transactions -124-Donev
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
14.12.2017 Buy 4 000 4.2850
14.12.2017 Buy 224 4.2850
14.12.2017 Buy 500 4.2800
14.12.2017 Buy 100 4.2890
14.12.2017 Buy 100 4.2810
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.12.2017 13:21
SOPHARMA AD (123/2017) Acquisition of own shares from 14 December 2017
15.12.2017 13:21SOPHARMA AD (123/2017) Acquisition of own shares from 14 December 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD hereby informs that on 14 December 2017 the Company bought 3 000 own shares representing 0.0022% of the share capital of the Company, at a total value of 12 855.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.285 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 8 891 880, representing 6.60 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.12.2017 13:16
SOPHARMA AD (122/2017) Current report re insiders transactions -122-Donev
14.12.2017 13:16SOPHARMA AD (122/2017) Current report re insiders transactions -122-Donev
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
13.12.2017 Buy 165 4.2960
13.12.2017 Buy 5 000 4.2800
13.12.2017 Buy 835 4.2800
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.12.2017 13:09
SOPHARMA AD (121/2017) Acquisition of own shares from 13 December 2017
14.12.2017 13:09SOPHARMA AD (121/2017) Acquisition of own shares from 13 December 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD hereby informs that on 13 December 2017 the Company bought 6 251 own shares representing 0.0046% of the share capital of the Company, at a total value of 26 753.18 BGN on the Bulgarian Stock Exchange, the average price per share was 4.28 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 8 888 880, representing 6.59 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2017 15:56
SOPHARMA AD (120/2017) Current report 120 re insiders transactions
12.12.2017 15:56SOPHARMA AD (120/2017) Current report 120 re insiders transactions
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
05.12.2017 Buy 3000 4.27
06.12.2017 Buy 4000 4.27
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2017 10:55
SOPHARMA AD (119/2017) Current report re insiders transactions -119-Donev
12.12.2017 10:55SOPHARMA AD (119/2017) Current report re insiders transactions -119-Donev
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
08.12.2017 Buy 2 000 4.2700
11.12.2017 Buy 3 000 4.2700
11.12.2017 Buy 2 000 4.2700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2017 16:16
SOPHARMA AD (118/2017) Current report 118 re insiders transactions-DIH
08.12.2017 16:16SOPHARMA AD (118/2017) Current report 118 re insiders transactions-DIH
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
05.12.2017 Buy 3000 4.27
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2017 16:12
SOPHARMA AD (117/2017) Current report 117 re insiders transactions-Elpharma
08.12.2017 16:12SOPHARMA AD (117/2017) Current report 117 re insiders transactions-Elpharma
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
05.12.2017 Buy 2 000 4.2700
06.12.2017 Buy 1 000 4.2700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2017 16:08
SOPHARMA AD (116/2017) Current report 116 re insiders transactions -Doneva
08.12.2017 16:08SOPHARMA AD (116/2017) Current report 116 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
05.12.2017 Buy 7 000 4.2700
05.12.2017 Buy 6 500 4.2700
05.12.2017 Buy 6 500 4.2700
06.12.2017 Buy 600 4.2700
07.12.2017 Buy 200 4.2700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2017 16:03
SOPHARMA AD (115/2017) Current report re insiders transactions -115-Donev
08.12.2017 16:03SOPHARMA AD (115/2017) Current report re insiders transactions -115-Donev
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
05.12.2017 Buy 6000 4.27
05.12.2017 Buy 2000 4.27
06.12.2017 Buy 400 000 4.27
06.12.2017 Buy 6 000 4.27
06.12.2017 Buy 6 000 4.27
06.12.2017 Buy 2 000 4.27
06.12.2017 Buy 3 000 4.27
06.12.2017 Buy 567 4.27
07.12.2017 Buy 2000 4.27
07.12.2017 Buy 1000 4.27
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2017 14:55
SOPHARMA AD (114/2017) Correction of notification from Rompharm Company OOD
08.12.2017 14:55SOPHARMA AD (114/2017) Correction of notification from Rompharm Company OOD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 8 December 2017 the Company received two notifications from Rompharm Company OOD for the sale of shares from the capital of Sopharma AD.
The first notification concerns the sale of 6 000 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 15% to 12.88%. The date of the registration of the transaction with the Central Depository is 7 December 2017.
The first notification concerns the sale of 4 685 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 10% to 9.41%. The date of the registration of the transaction with the Central Depository is 8 December 2017.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2017 13:29
SOPHARMA AD (113/2017) Notification from Rompharm Company OOD
08.12.2017 13:29SOPHARMA AD (113/2017) Notification from Rompharm Company OOD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that on 8 December 2017 the Company received two notifications from Rompharm Company OOD for the sale of shares from the capital of Sopharma AD.
The first notification concerns the sale of 5 000 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 15% to 12.88%. The date of the registration of the transaction with the Central Depository is 7 December 2017.
The first notification concerns the sale of 4 685 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 10% to 9.41%. The date of the registration of the transaction with the Central Depository is 8 December 2017.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2017 13:25
SOPHARMA AD (112/2017) Notification for acquisition of own shares
08.12.2017 13:25SOPHARMA AD (112/2017) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD hereby informs that on 7 December 2017 the Company bought 105 844 own shares representing 0.0785% of the share capital of the Company, at a total value of 451 979.92 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 8 882 629, representing 6.590% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.12.2017 13:19
SOPHARMA AD (111/2017) Notification for acquisition of own shares
08.12.2017 13:19SOPHARMA AD (111/2017) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD hereby informs that on 6 December 2017 the Company bought 2 691 292 own shares representing 1.997% of the share capital of the Company, at a total value of 11 491 816.84 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 8 776 785, representing 6.511% of the share capital of the Company. With these transactions Sopharma AD passes the 5% threshold for treasury shares.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.12.2017 13:39
SOPHARMA AD (110/2017) Notification for acquisition of own shares
07.12.2017 13:39SOPHARMA AD (110/2017) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD hereby informs that on 6 December 2017 the Company bought 3 061 292 own shares representing 2.271% of the share capital of the Company, at a total value of 13 071 716.84 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 9 146 785, representing 6.786% of the share capital of the Company. With these transactions Sopharma AD passed the threshold of 5% for the treasury shares.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.12.2017 16:03
SOPHARMA AD (109/2017) Notification for acquisition of own shares
06.12.2017 16:03SOPHARMA AD (109/2017) Notification for acquisition of own shares
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
SOPHARMA AD hereby informs that from 1st to 5th December 2017 the Company bought 924 732 own shares representing 0.686% of the share capital of the Company, at a total value of 3 948 605.64 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 6 085 493, representing 4.51% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.12.2017 13:12
SOPHARMA AD (108/2017) Sales revenues for the eleven months of 2017
04.12.2017 13:12SOPHARMA AD (108/2017) Sales revenues for the eleven months of 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sopharma AD notifies that for November 2017 the Company recorded an increase of sales revenues of 11% compared to the same month of 2016, including 11% increase of domestic sales and 12% increase of export sales.
For the first eleven months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 1% decrease of domestic sales and a 21% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.11.2017 13:17
SOPHARMA AD (108/2017) CONSILIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2017
29.11.2017 13:17SOPHARMA AD (108/2017) CONSILIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
CONSILIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2017
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration of the responsible directors
6. Annex 9
7. Additional information
8. List of insider information under Art. 7 of Regulation (EU) 596/2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.11.2017 13:20
SOPHARMA AD (107/2017) Award from the Vienna Economic Forum "Vienna future dialogue 2017"
16.11.2017 13:20SOPHARMA AD (107/2017) Award from the Vienna Economic Forum "Vienna future dialogue 2017"
Podstawa prawna: art. 17. 1 MAR.
We would like to notify that within the fourteenth meeting of the Vienna Economic Forum "Vienna future dialogue 2017" Ognian Donev PhD, Chairman of the Board of Directors and Executive Director of Sopharma AD received the Forum award for "Contribution to the economic development on national and regional level".
In 2015 Mr. Donev was elected vice-president of the Vienna Economic Forum and on the November meeting this year he was invited to moderate the panel "Digital economy - expectations and reality". Each year the Forum gathers guests from different areas - politicians, economists, business leaders etc.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.11.2017 13:15
SOPHARMA AD (106/2017) The company BRIZ, a subsidiary of Sopharma, was awarded with the Paracelsus award.
16.11.2017 13:15SOPHARMA AD (106/2017) The company BRIZ, a subsidiary of Sopharma, was awarded with the Paracelsus award.
Podstawa prawna: art. 17. 1 MAR.
We would like to notify that within the fourteenth meeting of the Vienna Economic Forum "Vienna future dialogue 2017" Ognian Donev PhD, Chairman of the Board of Directors and Executive Director of Sopharma AD received the Forum award for "Contribution to the economic development on national and regional level".
In 2015 Mr. Donev was elected vice-president of the Vienna Economic Forum and on the November meeting this year he was invited to moderate the panel "Digital economy - expectations and reality". Each year the Forum gathers guests from different areas - politicians, economists, business leaders etc.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.11.2017 10:47
SOPHARMA AD (105/2017) Meeting with investors of Sopharma AD
06.11.2017 10:47SOPHARMA AD (105/2017) Meeting with investors of Sopharma AD
Podstawa prawna: art. 17. 1 MAR.
We would like to notify that an Annual meeting with the investors of Sopharma AD was held on 3 November 2017, which started at 2.30 pm and ended at 6.30 pm. The following announcement regarding the liability was made:
"Please note that at the Annual Meeting with the Investors of SOPHARMA AD (" the Company ") can be made oral and written "forward looking statements" about future events, which are essentially uncertain because they do not concern only past or current facts. All such statements are also based on a number of assumptions, expectations, forecasts and preliminary data for future events, determined by factors beyond the control of SOPHARMA AD, which are therefore uncertain and should not be considered as a reliable indicator of future results. The Company undertakes no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, except as may be required by applicable law. The information and opinions set forth in this meeting are current as of the date of the meeting and are subject to change without prior notice. Neither the information disclosed at this meeting, nor any part of it, nor the fact of its distribution, may serve as a ground upon which a party may invoke or in relation to which to sign a contract or to make an investment decision.
Sopharma AD is not responsible neither for decisions and actions taken based on the content of the information from this meeting nor for damages caused as a result of such actions and decisions.
The information, statements and opinions submitted at this meeting are for information purposes only and do not constitute a public offer under any applicable legislation or an offer for sale or solicitation for an offer for the purchase or subscribe of securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments. None of the securities referred to herein have been or will be, registered under the US Securities Act 1933 or any subsequent amendments, or under the securities laws of any state or other jurisdiction of the United States or in Australia, Canada or Japan or in any other country where such an offer or invitation would be illegal (the "other countries") and there will be no public offering of such securities in the United States. This information does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States or other countries.
Neither the Company, nor any member of the management of Sopharma AD, nor any of its representatives, directors or employees, accepts any liability whatsoever with connection with the information provided at this meeting or in relation to any loss from its use or from any relince placed on it. "
At the meeting, Sopharma AD, Sopharma Group and Sopharma Trading AD were introduced by short presentations about the financial results for the first nine months of 2017.
During the discussion session, a number of questions were asked, as a result of which the companies provided explanations regarding the following main areas of their activity:
1. Capital Investments - Sopharma AD announced that currently have been made decisions for exploring the possibilities for construction of two production facilities - in Kazanlak - extraction power and in Sofia new lyophilic production.
2. The registration of the product TABEX in the USA - Mr. Donev announced that at this stage, details are still unknown, as the start of clinical tests will begin in 2018.
3. Optimization, improvement of the operating result - Mr. Donev replied that this is mainly due to the optimization of the processes in the Group and in the Company, which continue with the intentions of the merger of Unipharm AD, whose documents are subject of approval by the FSC. In addition, Mr. Donev mentioned the projects for renovation of "Momina krepost" AD with European funds, which will allow the company to be more competitive and to offer better products.
4. External Markets - The new, rapidly growing but small-scale markets like Vietnam and the improvement of the macroeconomic environment in Russia and Ukraine were mentioned.
5. Shareholder Structure - Mr. Donev commented that at a meeting with the management of Romfarm, that he was allowed to cite, it was shared that Rompharm had left their trusted management package and that they were not the initiators of the recent actions during the last few months, as well as that they did not intend to go below the price of 4.27 BGN.
6. Sopharma Group - Mr. Dimitrov commented on the state of the Serbian market, namely that its maturity determines the possibility of big growth, as it was in Bulgaria about 10 years ago. Sopharma Trading AD considers that Lekovit's post-acquisition phase is going very well and that the plans for the Group, while preserving the macroeconomic framework, are at least doubling sales revenue over the next three years.
7. Retail at Sopharma Trading AD - questions about the "SOpharmacy" chain and its development, Mr. Dimitrov replied that all pharmacies grow faster than the market.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.11.2017 12:01
SOPHARMA AD (104/2017) Sales revenues for the first ten months of 2017
03.11.2017 12:01SOPHARMA AD (104/2017) Sales revenues for the first ten months of 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that for October 2017 the Company recorded an increase of sales revenues of 7% compared to the same month of 2016, including 3% increase of domestic sales and 12% increase of export sales.
For the first ten months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 2% decrease of domestic sales and a 23% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.10.2017 13:37
SOPHARMA AD (103/2017) INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 September 2017
30.10.2017 13:37SOPHARMA AD (103/2017) INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 September 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 September 2017
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration of the responsible directors
6. Insiders' information
7. Additional information
8. List of insider information under Art. 7 of Regulation (EU) 596/2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.10.2017 13:01
SOPHARMA AD (102/2017) Annual Meeting with Investors
05.10.2017 13:01SOPHARMA AD (102/2017) Annual Meeting with Investors
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION
We would like to notify that on November 3 2017 (Friday) Sopharma AD organizes an Annual Meeting with Investors, on which the Sopharma AD and Sopharma Trading AD will present the main goals achieved and the new challenges. The meeting will take place in the Conference center of Sopharma Business Towers, Sofia. We kindly request that all interested parties notify us not later than October 20 2017 by e-mail irevents@sopharma.bg or by telephone +3592 8134 319 in order to receive their registration forms. Places are limited.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.10.2017 14:28
SOPHARMA AD (101/2017) Sales revenues for the first nine months of 2017
04.10.2017 14:28SOPHARMA AD (101/2017) Sales revenues for the first nine months of 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that for September 2017 the Company recorded an increase of sales revenues of 8% compared to the same month of 2016, including 1% decrease of domestic sales and 11% increase of export sales.
For the first nine months of this year, revenues from sales increased by 16% compared to the same period of 2016, including 2% increase of domestic sales and a 25% increase of export sales. After the merger of Medica AD, from the beginning of the year the Company recorded an increase of sales revenues of 25%, including 29% increase of export sales and 19% increase of domestic sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.10.2017 11:23
SOPHARMA AD (100/2017) Current report 100 re insiders transactions -Doneva
02.10.2017 11:23SOPHARMA AD (100/2017) Current report 100 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
28.09.2017 Sale 400 4.3900
28.09.2017 Sale 100 4.3900
28.09.2017 Sale 500 4.3900
28.09.2017 Sale 500 4.3900
28.09.2017 Sale 234 4.3900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.09.2017 13:08
SOPHARMA AD (99/2017) Acquisition of own shares from 26 September 2017
29.09.2017 13:08SOPHARMA AD (99/2017) Acquisition of own shares from 26 September 2017
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that on 26 September 2017 the Company bought 1000 own shares representing 0.00074% of the share capital of the Company, at a total value of 4400.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.4 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 160 761, representing 3.83 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.09.2017 08:56
SOPHARMA AD (98/2017) Current report 98 re insiders transactions -Doneva
28.09.2017 08:56SOPHARMA AD (98/2017) Current report 98 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
27.09.2017 Buy 500 4.3900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.09.2017 13:13
SOPHARMA AD (97/2017) Notification from Sopharma AD under Art. 44n of ORDINANCE ą 13 of 22.12.
27.09.2017 13:13SOPHARMA AD (97/2017) Notification from Sopharma AD under Art. 44n of ORDINANCE ą 13 of 22.12.
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that in conjunction with the tender offering made on the grounds of Art. 149 para. 6 of the Public Offering of Securities Act and the right of the shareholders who have not accepted the offer under Art. 157b, we provide information for the fulfillment of the obligation of Sopharma AD under this Article:
1. The offeror has bought a total of 125 530 shares with voting right of Unipharm AD;
2. 17 shareholders have applied for share buy-back under the right given to them by Art. 157b of POSA.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.09.2017 08:52
SOPHARMA AD (96/2017) Current report 96 re insiders transactions -Doneva
27.09.2017 08:52SOPHARMA AD (96/2017) Current report 96 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
26.09.2017 Sale 850 4.4000
26.09.2017 Sale 111 4.4300
26.09.2017 Sale 26 4.4300
26.09.2017 Sale 363 4.4300
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2017 13:04
SOPHARMA AD (95/2017) Acquisition of own shares - 21.09.2017
25.09.2017 13:04SOPHARMA AD (95/2017) Acquisition of own shares - 21.09.2017
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that on 21 September 2017 the Company bought 6635 own shares representing 0.0049% of the share capital of the Company, at a total value of 28750.33.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 159 761, representing 3.83 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.09.2017 11:32
SOPHARMA AD (94/2017) Current report 94 re insiders transactions -Donev
25.09.2017 11:32SOPHARMA AD (94/2017) Current report 94 re insiders transactions -Donev
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
21.09.2017 Sale 700 4.3100
21.09.2017 Sale 300 4.3100
21.09.2017 Sale 1 000 4.3600
21.09.2017 Sale 1 000 4.3600
21.09.2017 Sale 500 4.3600
21.09.2017 Sale 115 4.3450
21.09.2017 Sale 885 4.3450
21.09.2017 Sale 500 4.3010
21.09.2017 Sale 126 4.3000
21.09.2017 Sale 174 4.3000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.09.2017 13:18
SOPHARMA AD (93/2017) Current report 93 re insiders transactions - Donev Investments Holding AD
21.09.2017 13:18SOPHARMA AD (93/2017) Current report 93 re insiders transactions - Donev Investments Holding AD
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
20.09.2017 Sale 4.290 150
20.09.2017 Sale 4.290 100
20.09.2017 Sale 4.330 500
20.09.2017 Sale 4.301 150
20.09.2017 Sale 4.301 1 850
20.09.2017 Sale 4.301 750
20.09.2017 Sale 4.330 500
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.09.2017 13:11
SOPHARMA AD (92/2017) Notification for acquisition of own shares - 20 September 2017
21.09.2017 13:11SOPHARMA AD (92/2017) Notification for acquisition of own shares - 20 September 2017
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that from 20 September 2017 the Company bought 5650 own shares representing 0.0042% of the share capital of the Company, at a total value of 24 441.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 153 126, representing 3.82 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.09.2017 10:10
SOPHARMA AD (91/2017) Current report 91 re insiders transactions -Doneva
21.09.2017 10:10SOPHARMA AD (91/2017) Current report 91 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
20.09.2017 Sale 50 4.3000
20.09.2017 Sale 50 4.3000
20.09.2017 Sale 100 4.2910
20.09.2017 Sale 104 4.3010
20.09.2017 Sale 150 4.3100
20.09.2017 Sale 150 4.3100
20.09.2017 Sale 1 000 4.3300
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.09.2017 13:16
SOPHARMA AD (90/2017) Notification
20.09.2017 13:16SOPHARMA AD (90/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that from 18 September 2017 up to and including 19 September 2017 Sopharma AD acquired 12 927 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 157b from the LOPS.
The term under art. 157b expired on 19 September 2017.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.09.2017 09:15
SOPHARMA AD (89/2017) NOTIFICATION OF INSIDERS' TRANSACTIONS
20.09.2017 09:15SOPHARMA AD (89/2017) NOTIFICATION OF INSIDERS' TRANSACTIONS
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date of the transaction Operation Number of shares Unit price (BGN)
19.09.2017 Buy 1 000 4.1400
19.09.2017 Buy 695 4.1400
19.09.2017 Buy 305 4.1400
19.09.2017 Buy 200 4.1300
19.09.2017 Sale 600 4.2450
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.09.2017 15:59
SOPHARMA AD (88/2017) Current report 88 re insiders transactions -Donev
19.09.2017 15:59SOPHARMA AD (88/2017) Current report 88 re insiders transactions -Donev
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
18.09.2017 Buy 408 4.2100
18.09.2017 Buy 4 000 4.2100
18.09.2017 Buy 592 4.2100
18.09.2017 Buy 5 533 4.2000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.09.2017 13:43
SOPHARMA AD (87/2017) Current report 87 re insiders transactions
19.09.2017 13:43SOPHARMA AD (87/2017) Current report 87 re insiders transactions
Podstawa prawna: art. 17. 1 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
14.09.2017 Buy 151 4.410
15.09.2017 Buy 200 4.380
15.09.2017 Buy 500 4.330
18.09.2017 Buy 3 000 4.280
18.09.2017 Buy 1 312 4.230
18.09.2017 Buy 180 4.230
18.09.2017 Buy 1 000 4.230
18.09.2017 Buy 1 508 4.230
18.09.2017 Buy 382 4.220
18.09.2017 Buy 5 218 4.220
18.09.2017 Buy 2 000 4.210
18.09.2017 Buy 1 272 4.200
18.09.2017 Buy 4 328 4.200
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.09.2017 13:38
SOPHARMA AD (86/2017) Notification
19.09.2017 13:38SOPHARMA AD (86/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that on 18 September 2017 Sopharma AD acquired 345 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.
We kindly remind all shareholders of Unipharm AD who did not take part in the tender offering extended by Sopharma AD that they have the right to that their shares be redeemed until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the offer under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the offered offering of 4.35 BGN per share.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 19.09.2017 13:16
SOPHARMA AD (85/2017) Notification for acquisition of own shares
19.09.2017 13:16SOPHARMA AD (85/2017) Notification for acquisition of own shares
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that from 15 September 2017 up to and including 18 September 2017 the Company bought 10 600 own shares representing 0.0079% of the share capital of the Company, at a total value of 44 878.01 BGN on the Bulgarian Stock Exchange, the average price per share was 4.23 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 329 317, representing 3.95 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.09.2017 16:46
SOPHARMA AD (84/2017) Notification for treasury shares from 15.09.2017
18.09.2017 16:46SOPHARMA AD (84/2017) Notification for treasury shares from 15.09.2017
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that 15 September 2017 the Company bought 15 695 own shares representing 0.011% of the share capital of the Company, at a total value of 67 954.41 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 318 717, representing 3.95 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.09.2017 16:09
SOPHARMA AD (83/2017) Current report 83 re insiders transactions - Elpharma
15.09.2017 16:09SOPHARMA AD (83/2017) Current report 83 re insiders transactions - Elpharma
Podstawa prawna: art. 17. 1 MAR.
Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
12.09.2017 Buy 1 000 4.5000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.09.2017 16:02
SOPHARMA AD (82/2017) Acquisition of own shares from 12.09.2017 up to including 14.09.2017
15.09.2017 16:02SOPHARMA AD (82/2017) Acquisition of own shares from 12.09.2017 up to including 14.09.2017
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD hereby informs that from 12 September 2017 up to and including 14 September 2017 the Company bought 50 000 own shares representing 0.037% of the share capital of the Company, at a total value of 222 085.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.44 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 303 022, representing 3.93 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.09.2017 09:34
SOPHARMA AD (81/2017) Current report 81 re insiders transactions -Doneva
15.09.2017 09:34SOPHARMA AD (81/2017) Current report 81 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
12.09.2017 Buy 2 000 4.5000
12.09.2017 Buy 120 4.4800
12.09.2017 Buy 100 4.4800
12.09.2017 Buy 1 780 4.4800
13.09.2017 Buy 1 000 4.4600
13.09.2017 Buy 1 000 4.4550
13.09.2017 Buy 2 000 4.3700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.09.2017 09:10
SOPHARMA AD (80/2017) Current report 80 re insiders transactions -Donev
15.09.2017 09:10SOPHARMA AD (80/2017) Current report 80 re insiders transactions -Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
12.09.2017 Buy 3 000 4.5010
13.09.2017 Buy 200 4.4000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.09.2017 08:50
SOPHARMA AD (79/2017) Current report 79 re insiders transactions - DIH
15.09.2017 08:50SOPHARMA AD (79/2017) Current report 79 re insiders transactions - DIH
Podstawa prawna: art. 17. 1 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
07.09.2017 Buy 3000 4.68
07.09.2017 Buy 1000 4.68
07.09.2017 Buy 1900 4.68
07.09.2017 Buy 100 4.68
08.09.2017 Buy 500 4.607
08.09.2017 Buy 1000 4.596
11.09.2017 Buy 1000 4.565
11.09.2017 Buy 121 4.550
11.09.2017 Buy 379 4.550
12.09.2017 Buy 2000 4.501
13.09.2017 Buy 1000 4.461
13.09.2017 Buy 5000 4.460
13.09.2017 Buy 5000 4.370
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.09.2017 13:19
SOPHARMA AD (78/2017) Notification for s signed contract for transformation through merger of Unipharm AD in Sopharma AD
14.09.2017 13:19SOPHARMA AD (78/2017) Notification for s signed contract for transformation through merger of Unipharm AD in Sopharma AD
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD announces that on 14 September, 2017 in accordance with art. 262e and the following from the Commercial Code Unipharm AD and Sopharma AD signed a contract for transformation through merger of Unipharm AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0. 891512, meaning that one share of Unipharm AD will be exchanged for 0. 891512 shares of Sopharma AD. The companies have hired the services of certified appraisers whose reports are a necessary prerequisite for the filing of the documents for transformation with the FSC. As of this moment the responsible Deputy Chairman of the FSC has not issued an approval in accordance with art. 124 from the LPOS of the transformation contract, of the reports of the BoD according to art. 262k from the Commercial code and the report of the appraiser under art. 262o from the Commercial Code.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2017 15:42
SOPHARMA AD (77/2017) Decision of initiation of a procedure for transformation through merger of Unipharm AD in Sopharma AD
12.09.2017 15:42SOPHARMA AD (77/2017) Decision of initiation of a procedure for transformation through merger of Unipharm AD in Sopharma AD
Podstawa prawna: art. 17. 1 MAR.
The Board of Directors of Sopharma notifies that it took a decision to initiate a procedure for merging Unipharm AD, VAT number 831537465 based in the city of Sofia on 3, "Trayko Stanoev" Str. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses "Elana Trading" AD VAT number 831470130, based on 5, Lachezar Stanchev Str. for a consultant in relation to the merger.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2017 14:57
SOPHARMA AD (76/2017) Current report re insiders transactions -76-Donev
12.09.2017 14:57SOPHARMA AD (76/2017) Current report re insiders transactions -76-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
11.09.2017 Buy 200 4.5800
11.09.2017 Buy 200 4.5700
11.09.2017 Buy 1 000 4.5150
11.09.2017 Buy 570 4.5150
11.09.2017 Buy 200 4.5200
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2017 14:54
SOPHARMA AD (75/2016) Current report 75 re insiders transactions -Doneva
12.09.2017 14:54SOPHARMA AD (75/2016) Current report 75 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
11.09.2017 Buy 471 4.5500
11.09.2017 Buy 29 4.5500
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2017 13:16
SOPHARMA AD (74/2017) Current report 74 buy back 12092017
12.09.2017 13:16SOPHARMA AD (74/2017) Current report 74 buy back 12092017
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that on 11 September 2017 the Company bought 10 000 own shares representing 0.0074% of the share capital of the Company, at a total value of 45 125.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.51 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 255 102, representing 3.90 % of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2017 14:24
SOPHARMA AD (73/2017) Current report 73 re insiders transactions - Elpharma
11.09.2017 14:24SOPHARMA AD (73/2017) Current report 73 re insiders transactions - Elpharma
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
08.09.2017 Buy 200 4.6450
08.09.2017 Buy 1 000 4.6050
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2017 13:24
SOPHARMA AD (72/2017) Current report re insiders transactions -72-Donev
11.09.2017 13:24SOPHARMA AD (72/2017) Current report re insiders transactions -72-Donev
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
8.09.2017 Buy 500 4.6150
8.09.2017 Buy 500 4.6120
8.09.2017 Buy 2 000 4.6050
8.09.2017 Buy 2 615 4.6020
8.09.2017 Buy 385 4.6020
8.09.2017 Buy 200 4.5900
8.09.2017 Buy 200 4.5800
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2017 13:13
SOPHARMA AD (71/2017) Current report 71 re insiders transactions -Doneva
11.09.2017 13:13SOPHARMA AD (71/2017) Current report 71 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
08.09.2017 Sale 1 000 4.5960
08.09.2017 Sale 200 4.5900
08.09.2017 Sale 100 4.5900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.09.2017 12:26
SOPHARMA AD (70/2017) Notification
11.09.2017 12:26SOPHARMA AD (70/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that on 8 September 2017 Sopharma AD acquired 111 066 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.
We kindly remind all shareholders of Unipharm AD who did not take part in the tender offering extended by Sopharma AD that they have the right to that their shares be redeemed until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the offer under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the offered offering of 4.35 BGN per share.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.09.2017 09:32
SOPHARMA AD (69/2017) Current report re insiders transactions -69-Donev
08.09.2017 09:32SOPHARMA AD (69/2017) Current report re insiders transactions -69-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
7.09.2017 Buy 300 4.6950
7.09.2017 Buy 100 4.6990
7.09.2017 Buy 500 4.7000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.09.2017 11:58
SOPHARMA AD (68/2017) Current report 68 re insiders transactions - Donev Investments Holding
07.09.2017 11:58SOPHARMA AD (68/2017) Current report 68 re insiders transactions - Donev Investments Holding
Podstawa prawna: art. 17. 1 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
01.09.2017 Buy 2000 4.600
01.09.2017 Buy 2000 4.700
01.09.2017 Buy 2000 4.705
01.09.2017 Buy 350 4.720
01.09.2017 Buy 515 4.740
01.09.2017 Buy 485 4.740
01.09.2017 Buy 15 4.720
01.09.2017 Buy 1 000 4.690
01.09.2017 Buy 500 4.690
01.09.2017 Buy 200 4.700
01.09.2017 Buy 500 4.770
01.09.2017 Buy 500 4.790
04.09.2017 Buy 1000 4.77
04.09.2017 Buy 1000 4.765
04.09.2017 Buy 2000 4.745
04.09.2017 Buy 1000 4.72
05.09.2017 Buy 20 4.640
05.09.2017 Buy 700 4.650
05.09.2017 Buy 1000 4.660
05.09.2017 Buy 1000 4.660
05.09.2017 Buy 1000 4.660
05.09.2017 Buy 1000 4.660
05.09.2017 Buy 1000 4.660
05.09.2017 Buy 1000 4.660
05.09.2017 Buy 1000 4.660
05.09.2017 Buy 1000 4.660
05.09.2017 Buy 957 4.660
05.09.2017 Buy 43 4.660
05.09.2017 Buy 612 4.660
05.09.2017 Buy 20 4.660
05.09.2017 Buy 100 4.684
05.09.2017 Buy 2 368 4.660
05.09.2017 Buy 1 000 4.640
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.09.2017 17:22
SOPHARMA AD (67/2017) Current report 67 re insiders transactions -Doneva
05.09.2017 17:22SOPHARMA AD (67/2017) Current report 67 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
01.09.2017 Buy 200 4.7000
01.09.2017 Buy 100 4.7000
01.09.2017 Buy 500 4.7450
04.09.2017 Buy 42 4.7600
04.09.2017 Buy 100 4.7610
04.09.2017 Buy 70 4.7610
04.09.2017 Buy 288 4.7600
04.09.2017 Buy 1 000 4.7700
04.09.2017 Buy 1 000 4.7650
04.09.2017 Buy 400 4.7570
04.09.2017 Buy 112 4.7600
04.09.2017 Buy 2 000 4.7450
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.09.2017 17:19
SOPHARMA AD (66/2017) Current report re insiders transactions -66-Donev
05.09.2017 17:19SOPHARMA AD (66/2017) Current report re insiders transactions -66-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
01.09.2017 Buy 500 4.6050
01.09.2017 Buy 5 000 4.6000
01.09.2017 Buy 2 320 4.6000
01.09.2017 Buy 85 4.6500
01.09.2017 Buy 1 915 4.6500
01.09.2017 Buy 2 680 4.6000
01.09.2017 Buy 100 4.7450
01.09.2017 Buy 170 4.7490
01.09.2017 Buy 140 4.7500
01.09.2017 Buy 185 4.7940
01.09.2017 Buy 100 4.7950
01.09.2017 Buy 700 4.7950
01.09.2017 Buy 165 4.7970
01.09.2017 Buy 1 000 4.7980
01.09.2017 Buy 300 4.8000
01.09.2017 Buy 2 961 4.8000
01.09.2017 Buy 574 4.8000
01.09.2017 Buy 160 4.7990
01.09.2017 Buy 1 4.8000
01.09.2017 Buy 1 839 4.8000
01.09.2017 Buy 1 000 4.8050
01.09.2017 Buy 85 4.8000
01.09.2017 Buy 915 4.8000
01.09.2017 Buy 190 4.7500
01.09.2017 Buy 20 4.7400
01.09.2017 Buy 495 4.7400
01.09.2017 Buy 485 4.7400
01.09.2017 Buy 100 4.7000
01.09.2017 Buy 250 4.7190
01.09.2017 Buy 170 4.7440
01.09.2017 Buy 500 4.7450
01.09.2017 Buy 340 4.7790
01.09.2017 Buy 233 4.7800
01.09.2017 Buy 170 4.7870
01.09.2017 Buy 180 4.7890
01.09.2017 Buy 3 000 4.7900
01.09.2017 Buy 407 4.7900
01.09.2017 Buy 3 000 4.7200
01.09.2017 Buy 500 4.7900
01.09.2017 Buy 300 4.7880
01.09.2017 Buy 25 4.7880
01.09.2017 Buy 200 4.7890
01.09.2017 Buy 790 4.7890
01.09.2017 Buy 185 4.7890
01.09.2017 Buy 1 000 4.7500
04.09.2017 Buy 1 000 4.7700
04.09.2017 Buy 2 000 4.7700
04.09.2017 Buy 288 4.7600
04.09.2017 Buy 112 4.7600
04.09.2017 Buy 300 4.7400
04.09.2017 Buy 5 000 4.6500
04.09.2017 Buy 1 000 4.6500
05.09.2017 Buy 300 4.6890
05.09.2017 Buy 300 4.6890
05.09.2017 Buy 300 4.6890
05.09.2017 Buy 300 4.6890
05.09.2017 Buy 500 4.6850
05.09.2017 Buy 434 4.6850
05.09.2017 Buy 500 4.6850
05.09.2017 Buy 800 4.6650
05.09.2017 Buy 200 4.6650
05.09.2017 Buy 700 4.6850
05.09.2017 Buy 300 4.6890
05.09.2017 Buy 300 4.6890
05.09.2017 Buy 100 4.6890
05.09.2017 Buy 300 4.6890
05.09.2017 Buy 300 4.6890
05.09.2017 Buy 200 4.6890
05.09.2017 Buy 31 4.6890
05.09.2017 Buy 269 4.6890
05.09.2017 Buy 400 4.6900
05.09.2017 Buy 700 4.6900
05.09.2017 Buy 585 4.6900
05.09.2017 Buy 40 4.6900
05.09.2017 Buy 271 4.6800
05.09.2017 Buy 735 4.6800
05.09.2017 Buy 1 500 4.6700
05.09.2017 Buy 2 000 4.6650
05.09.2017 Buy 964 4.6400
05.09.2017 Buy 1 000 4.6590
05.09.2017 Buy 500 4.7000
05.09.2017 Buy 230 4.7000
05.09.2017 Buy 770 4.7000
05.09.2017 Buy 66 4.6500
05.09.2017 Buy 270 4.7000
05.09.2017 Buy 230 4.7000
05.09.2017 Buy 3 000 4.7000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.09.2017 13:27
SOPHARMA AD (65/2017) Sales revenues for the first eight months of 2017
05.09.2017 13:27SOPHARMA AD (65/2017) Sales revenues for the first eight months of 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that for August 2017 the Company recorded an increase of sales revenues of 12% compared to the same month of 2016, including 12% increase of domestic sales and 12% increase of export sales.
For the first eight months of this year, revenues from sales increased by 17% compared to the same period of 2016, including 3% increase of domestic sales and a 27% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 31.08.2017 16:13
SOPHARMA AD (64/2017) Notification
31.08.2017 16:13SOPHARMA AD (64/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
We hereby notify you that due to technical errors we publish a revised management report of Sopharma Group as at 30 June 2017.
We apologize for the inconvenience.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.08.2017 16:59
SOPHARMA AD (63/2017) INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2017
29.08.2017 16:59SOPHARMA AD (63/2017) INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration of the responsible directors
6. Insiders' information
7. Additional information
8. List of insider information under Art. 7 of Regulation (EU) 596/2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.08.2017 15:57
SOPHARMA AD (59/2017) Notification
16.08.2017 15:57SOPHARMA AD (59/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that on 2 August 2017 Sopharma AD acquired 1537 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.
We kindly remind all shareholders of Unipharm AD who did not take part in the tender offering extended by Sopharma AD that they have the right to that their shares be redeemed until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the offer under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the offered offering of 4.35 BGN per share.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.08.2017 16:08
SOPHARMA AD (62/2017) Insider transactions
15.08.2017 16:08SOPHARMA AD (62/2017) Insider transactions
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that " Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
01.06.2017 Buy 503000 3.98
06.06.2017 Sale 200 4.305
06.06.2017 Sale 100 4.310
06.06.2017 Sale 1200 4.302
07.06.2017 Sale 1000 4.32
07.06.2017 Sale 1000 4.32
07.06.2017 Sale 500 4.34
07.06.2017 Sale 10 4.34
07.06.2017 Sale 290 4.34
07.06.2017 Sale 218 4.35
07.06.2017 Sale 282 4.35
07.06.2017 Sale 500 4.355
07.06.2017 Sale 1000 4.33
07.06.2017 Sale 1000 4.33
08.06.2017 Sale 1500 4.302
08.06.2017 Sale 290 4.302
08.06.2017 Sale 30 4.302
08.06.2017 Sale 1000 4.302
08.06.2017 Sale 1000 4.302
08.06.2017 Sale 1000 4.302
08.06.2017 Sale 1000 4.302
09.06.2017 Sale 325 4.29
09.06.2017 Sale 100 4.29
09.06.2017 Sale 123 4.29
09.06.2017 Sale 277 4.29
12.06.2017 Sale 45 4.35
12.06.2017 Sale 205 4.35
12.06.2017 Sale 159 4.40
12.06.2017 Sale 340 4.40
12.06.2017 Sale 1 4.40
13.06.2017 Sale 150 4.395
15.06.2017 Buy 300 4.25
16.06.2017 Sale 245 4.315
16.06.2017 Sale 100 4.315
16.06.2017 Sale 155 4.315
16.06.2017 Sale 245 4.315
16.06.2017 Sale 100 4.315
16.06.2017 Sale 155 4.315
16.06.2017 Sale 100 4.340
16.06.2017 Sale 100 4.340
30.06.2017 Buy 100 4.552
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.08.2017 15:25
SOPHARMA AD (61/2017) Notification for transformation throough merger of Medika AD in Sopharma AD
09.08.2017 15:25SOPHARMA AD (61/2017) Notification for transformation throough merger of Medika AD in Sopharma AD
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that the transformation through merger of Medika AD in Sopharma AD has been registered with the Commercial Register with number 20170808155501.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.08.2017 13:10
SOPHARMA AD (60/2017) Notification - revenues for the first seven months of 2017
04.08.2017 13:10SOPHARMA AD (60/2017) Notification - revenues for the first seven months of 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that for July 2017 the Company recorded an increase of sales revenues of 17% compared to the same month of 2016, including 2% increase of domestic sales and 25% increase of export sales.
For the first seven months of this year, revenues from sales increased by 18% compared to the same period of 2016, including 1% increase of domestic sales and a 30% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.08.2017 10:51
SOPHARMA AD (58/2017) Notification for the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals
02.08.2017 10:51SOPHARMA AD (58/2017) Notification for the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals was successfully closed today and as a result of which the stockholders of Achieve have become the majority stockholders of OncoGenex. OncoGenex has been renamed Achieve Life Sciences (NASDAQ: ACHV).
The company announced that "Cytisine is a drug of global public health importance and the transition of Achieve to the public markets is a critical step in advancing our development program," commented Rick Stewart, Chairman and CEO of Achieve Life Science.
The whole press release may be found at http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=1030091.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 31.07.2017 13:35
SOPHARMA AD (57/2017) Notification
31.07.2017 13:35SOPHARMA AD (57/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that the stabilization of the economic environment on our main export markets and the optimization of the operations of Sopharma AD led to 73% increase of the operating profit from BGN 14 310 thousand for the first half of 2016 BGN 24 698 thousand for the first half of 2017 and of 50% increase of EBITDA from BGN 21 318 thousand for the fisrst half of 2016 to BGN 32 048 thousand for the first half of 2017.
"Our efforts towards improving the way we operate, to further improve the synergy after the merger with Bulgarian Rose - Sevtopolis AD, to optimize or trade activities and to start new, interesting and profitable projects are reconfirmed in our financial results. We also appereciate the fact that factors outside of our control also improved leading to fast growth. We are proud that our subsidiary Sopharma Trading AD received a green light from to start larger projects in Serbia.", comments Ognian Donev, PhD, Executive director and Chariman of the Board of directors of Sopharma AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 31.07.2017 13:20
SOPHARMA AD (56/2017) INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 June 2017
31.07.2017 13:20SOPHARMA AD (56/2017) INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 June 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 June 2017
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration of the responsible directors
6. Insiders' information
7. Additional information
8. List of insider information under Art. 7 of Regulation (EU) 596/2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.07.2017 15:12
SOPHARMA AD (55/2017) Sopharma" AD acquired 75% from the capital of "Aromania"
21.07.2017 15:12SOPHARMA AD (55/2017) Sopharma" AD acquired 75% from the capital of "Aromania"
Podstawa prawna: art. 17. 1 MAR.
We would like to notify that "Sopharma" AD acquired 75% from the capital of the successful start-up for development and registration of food additives "Aromania" (www.arolife.bg).
For the nearly two years since its establishment "Aromania" has more than 20 registered products and for 12 of them the company either has or has flied a different form of patent protection - trade mark, industrial design or useful model. Two of the products are leaders in their categories. For 2016 the revenues from sales of the company are 1,279 thousand BGN.
Sopharma will use this platform for a wider presence on the food additives market and to proudly enter the society of the "Bulgarian business angels".
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.07.2017 14:57
SOPHARMA AD (54/2017) Dividend payment
17.07.2017 14:57SOPHARMA AD (54/2017) Dividend payment
Podstawa prawna: art. 17. 1 MAR.
We would like to notify that in interest of its shareholders Sopharma AD will initiate dividend payment of the voted on the AGM held on 2 June 2017 dividend of 0.10 BGN earlier than planned on 24 July 2017.
The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. 16 June 2017.
In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.07.2017 12:55
SOPHARMA AD (53/2017) Sales revenues for the first six months of 2017
04.07.2017 12:55SOPHARMA AD (53/2017) Sales revenues for the first six months of 2017
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that for June 2017 the Company recorded an increase of sales revenues of 31% compared to the same month of 2016, including 2% decrease of domestic sales and 59% increase of export sales.
For the first six months of this year, revenues from sales increased by 18% compared to the same period of 2016, including 1% increase of domestic sales and a 30% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.06.2017 16:50
SOPHARMA AD (52/2017) Current report -52 re insiders transactions -Donev
30.06.2017 16:50SOPHARMA AD (52/2017) Current report -52 re insiders transactions -Donev
Podstawa prawna: art. 19. 3 MAR.
NOTIFICATION OF INSIDERS' TRANSACTIONS
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
28.6.2017 10:13 Buy 200 4.4650
28.6.2017 10:14 Buy 1 800 4.4650
28.6.2017 10:22 Buy 234 4.4990
28.6.2017 10:22 Buy 69 4.4990
28.6.2017 10:22 Buy 470 4.4990
28.6.2017 10:22 Buy 427 4.5000
28.6.2017 10:22 Buy 1 000 4.5000
28.6.2017 10:36 Buy 250 4.5290
28.6.2017 10:36 Buy 750 4.5300
28.6.2017 10:42 Buy 1 000 4.5400
28.6.2017 10:57 Buy 624 4.5500
28.6.2017 10:57 Buy 376 4.5500
29.6.2017 10:42 Buy 400 4.5500
29.6.2017 10:46 Buy 1 000 4.5310
30.6.2017 10:44 Buy 1 000 4.5000
30.6.2017 10:44 Buy 848 4.5000
30.6.2017 10:49 Buy 152 4.5000
30.6.2017 10:55 Buy 600 4.5000
30.6.2017 15:31 Buy 2 000 4.5000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.06.2017 09:27
SOPHARMA AD (51/2017) Current report -51- re insiders transactions Donev
28.06.2017 09:27SOPHARMA AD (51/2017) Current report -51- re insiders transactions Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
26.6.2017 10:22 Buy 2 000 4.4000
26.6.2017 10:28 Buy 280 4.4000
26.6.2017 12:27 Buy 200 4.4000
26.6.2017 13:20 Buy 300 4.4000
26.6.2017 13:30 Buy 500 4.4000
26.6.2017 13:31 Buy 124 4.4000
26.6.2017 13:50 Buy 376 4.4000
26.6.2017 15:23 Buy 300 4.4400
26.6.2017 16:24 Buy 190 4.4400
26.6.2017 16:24 Buy 363 4.4470
26.6.2017 16:42 Buy 100 4.4470
26.6.2017 16:42 Buy 47 4.4470
26.6.2017 17:00 Buy 100 4.4480
26.6.2017 17:00 Buy 300 4.4480
27.6.2017 10:14 Buy 100 4.4500
27.6.2017 10:22 Buy 4 200 4.4500
27.6.2017 12:37 Buy 100 4.4920
27.6.2017 15:56 Buy 250 4.4650
27.6.2017 15:58 Buy 250 4.4890
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 26.06.2017 14:30
SOPHARMA AD (50/2017) Current report-50 re insiders transactions -Donev
26.06.2017 14:30SOPHARMA AD (50/2017) Current report-50 re insiders transactions -Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
22.06.2017 Buy 150 4.4330
22.06.2017 Buy 600 4.4000
22.06.2017 Buy 490 4.4000
22.06.2017 Buy 400 4.4000
22.06.2017 Buy 1 000 4.4000
22.06.2017 Buy 320 4.4000
22.06.2017 Buy 500 4.4000
22.06.2017 Buy 180 4.4000
22.06.2017 Buy 795 4.4000
22.06.2017 Buy 205 4.4000
22.06.2017 Buy 1 000 4.4000
22.06.2017 Buy 1 000 4.4000
23.06.2017 Buy 220 4.3990
23.06.2017 Buy 300 4.4000
23.06.2017 Buy 200 4.4100
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.06.2017 20:52
SOPHARMA AD (49/2017) Current report re insider transactions - 49-Donev
21.06.2017 20:52SOPHARMA AD (49/2017) Current report re insider transactions - 49-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
16.06.2017 Buy 100 4.3150
16.06.2017 Buy 60 4.3160
16.06.2017 Buy 40 4.3160
16.06.2017 Buy 200 4.3000
16.06.2017 Buy 120 4.3200
16.06.2017 Buy 60 4.2950
16.06.2017 Buy 200 4.3190
16.06.2017 Buy 100 4.3400
20.06.2017 Buy 500 4.4200
20.06.2017 Buy 100 4.4580
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.06.2017 14:55
SOPHARMA AD (48/2017) Tender offer submitted by Sopharma AD to the shareholders of Unipharm AD
21.06.2017 14:55SOPHARMA AD (48/2017) Tender offer submitted by Sopharma AD to the shareholders of Unipharm AD
Podstawa prawna: art. 17. 1 MAR.
On the grounds of Art. 157 of POSA in connection with Art. 154 of the Public Offering of Securities Act and in connection with the expired deadline for acceptance of the tender offer submitted by Sopharma AD to the shareholders of Unipharm AD, we inform you about the results of the tender offering submitted by Sopharma AD for the purchase of the shares of the other shareholders of Unipharm AD.
Company, object of the offer: Unipharm AD, with management address Sofia 1797, Studentski grad, zh.k. Darvenitsa, Trayko Stanoev Str.
Tender offeror: Sopharma AD, with address: Sofia, Nadezhda district, 16, Iliensko shose Str.
Authorized investment intermediary: Elana Trading AD, with management address: Sofia, Sredets, 4, Kuzman Shapkarev Str., and license issued by FSC for carrying out activity as an investment intermediary on the basis of Decision No. 171 -IP / 08.03.2006
Price offered per share: BGN 4.35 (four leva thirty-five stotinki) Number of persons accepted the tender offer: 65 Shareholder with total number of shares: 1 125 021, representing 18.75% of the capital of Unipharm AD.
As a result of the tender offer and after the conclusion of the transactions with the shareholders that have accepted it, Sopharma AD will directly own 96.63% of the shares of Unipharm AD. Sopharma AD has the right, within three months from the closing date of the tender offer, to submit, after obtaining the approval of the FSC, an offer for the purchase of the shares of the remaining shareholders of Unipharm AD on the grounds of Art. 157a of POSA. In addition, according to the provisions of Art. 157b of the POSA, each shareholder is entitled to require from Sopharma AD to redeem his/her shares until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the proposal under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the tender offering of BGN 4.35 per share.
The results of the tender offering were published by the tender offeror in the newspapers "Capital Daily" and "Sega" as of 21.06.2017.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.06.2017 14:11
SOPHARMA AD (47/2017) Current report 47 re insiders transactions -Doneva
16.06.2017 14:11SOPHARMA AD (47/2017) Current report 47 re insiders transactions -Doneva
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
14.06.2017 Buy 100 4.37
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.06.2017 14:05
SOPHARMA AD (46/2017) Current report re insiders transactions -46-Donev
16.06.2017 14:05SOPHARMA AD (46/2017) Current report re insiders transactions -46-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
15.06.2017 Buy 100 4.2890
15.06.2017 Buy 200 4.3100
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.06.2017 16:10
SOPHARMA AD (45/2017) Current report 45 re insiders transactions
15.06.2017 16:10SOPHARMA AD (45/2017) Current report 45 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
12.06.2017 Buy 500 4.3600
13.06.2017 Buy 100 4.3750
13.06.2017 Buy 70 4.3900
13.06.2017 Buy 30 4.3900
14.06.2017 Buy 100 4.4000
14.06.2017 Buy 250 4.4000
14.06.2017 Buy 120 4.3810
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.06.2017 13:48
SOPHARMA AD (44/2017) Notification for merger of Achieve Lifesciences and Oncogenex
15.06.2017 13:48SOPHARMA AD (44/2017) Notification for merger of Achieve Lifesciences and Oncogenex
Podstawa prawna: art. 17. 1 MAR.
We are pleased to announce that the next step in the process of merging Achieve Lifesciences and Oncogenex has been completed with the approval of the merger by the US SEC. OncoGenex will hold a special shareholder meeting on 1 August 2017 to vote the merger. Shortly after the newly formed entity will trade on NASDAQ stock exchange under the ticker symbol ACHV.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.06.2017 11:03
SOPHARMA AD (43/2017) Current report re insiders transactions -43-Donev
15.06.2017 11:03SOPHARMA AD (43/2017) Current report re insiders transactions -43-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
13.06.2017 Buy 800 4.4100
13.06.2017 Buy 22 4.4100
13.06.2017 Buy 178 4.4100
13.06.2017 Buy 200 4.3900
13.06.2017 Buy 350 4.3900
13.06.2017 Buy 250 4.3900
14.06.2017 Buy 50 4.4000
14.06.2017 Buy 50 4.4000
14.06.2017 Buy 100 4.4000
14.06.2017 Buy 700 4.4000
14.06.2017 Buy 150 4.4000
14.06.2017 Buy 650 4.4000
14.06.2017 Buy 57 4.3800
14.06.2017 Buy 23 4.3700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.06.2017 12:49
SOPHARMA AD (42/2017) Current report 42 re insiders transactions -Doneva
14.06.2017 12:49SOPHARMA AD (42/2017) Current report 42 re insiders transactions -Doneva
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
12.06.2017 Buy 300 4.3720
13.06.2017 Buy 700 4.41
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.06.2017 08:45
SOPHARMA AD (41/2017) Current report 41 re insiders transactions-Donev
13.06.2017 08:45SOPHARMA AD (41/2017) Current report 41 re insiders transactions-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
12.06.2017 Buy 4.3200 27
12.06.2017 Buy 4.3710 324
12.06.2017 Buy 4.3710 26
12.06.2017 Buy 4.4000 263
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.06.2017 15:57
SOPHARMA AD (40/2017) Current report re insiders transactions -40-Donev
12.06.2017 15:57SOPHARMA AD (40/2017) Current report re insiders transactions -40-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
09.06.2017 Buy 191 4.2760
09.06.2017 Buy 59 4.2760
09.06.2017 Buy 100 4.2900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.06.2017 13:18
SOPHARMA AD (39/2017) Notification for date of divident payment
12.06.2017 13:18SOPHARMA AD (39/2017) Notification for date of divident payment
Podstawa prawna: art. 17. 1 MAR.
We would like to notify that Sopharma AD will initiate dividend payment of the voted on the AGM held on 2 June 2017 dividend of 0.10 BGN on 21 August 2017.
The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. 16 June 2017.
In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.06.2017 12:25
SOPHARMA AD (38/2017) Current report re insiders transactions -38-Donev
12.06.2017 12:25SOPHARMA AD (38/2017) Current report re insiders transactions -38-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
08.06.2017 Buy 10 4.302
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.06.2017 12:10
SOPHARMA AD (37/2017) Current report 37 re insiders transactions
12.06.2017 12:10SOPHARMA AD (37/2017) Current report 37 re insiders transactions
Podstawa prawna: art. 17. 1 MAR.
Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
08.06.2017 Buy 100 4.3000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.06.2017 14:23
SOPHARMA AD (36/2017) Current report 36 re insiders transactions -Doneva
09.06.2017 14:23SOPHARMA AD (36/2017) Current report 36 re insiders transactions -Doneva
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
05.06.2017 Buy 2000 4.269
06.06.2017 Buy 1 850 4.3
06.06.2017 Buy 150 4.3
06.06.2017 Buy 1 000 4.3
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.06.2017 20:26
SOPHARMA AD (35/2017) Current report 35 re insiders transactions
08.06.2017 20:26SOPHARMA AD (35/2017) Current report 35 re insiders transactions
Podstawa prawna: art. 17. 1 MAR.
Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
05.06.2017 Buy 765 4.3000
05.06.2017 Buy 150 4.3000
05.06.2017 Buy 85 4.3000
05.06.2017 Buy 1 000 4.2810
05.06.2017 Buy 100 4.2700
07.06.2017 Buy 500 4.2950
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.06.2017 13:20
SOPHARMA AD (34/2017) Disclosure of share participation
08.06.2017 13:20SOPHARMA AD (34/2017) Disclosure of share participation
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") announces that on 7 June 2017 the Company received a notification for the acquisition of 503 000 shares, representing 0.37% of its capital, by "Donev investments holding" AD. After the transaction, the share of "Donev investments holding" AD in the capital of Sopharma AD reached 25.15%.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.06.2017 10:03
SOPHARMA AD (32/2017) Current report re insiders transactions -32-Donev
08.06.2017 10:03SOPHARMA AD (32/2017) Current report re insiders transactions -32-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
05.06.2017 Buy 125 4.3680
05.06.2017 Buy 125 4.3680
05.06.2017 Buy 125 4.3680
05.06.2017 Buy 125 4.3680
05.06.2017 Buy 125 4.3680
05.06.2017 Buy 125 4.3680
05.06.2017 Buy 125 4.3680
05.06.2017 Buy 125 4.3680
05.06.2017 Buy 80 4.3690
05.06.2017 Buy 500 4.3700
05.06.2017 Buy 2 420 4.3750
05.06.2017 Buy 850 4.3650
05.06.2017 Buy 850 4.3650
05.06.2017 Buy 850 4.3650
05.06.2017 Buy 450 4.3650
05.06.2017 Buy 3 000 4.3200
05.06.2017 Buy 3 000 4.3200
05.06.2017 Buy 150 4.3200
05.06.2017 Buy 850 4.3200
05.06.2017 Buy 200 4.3020
05.06.2017 Buy 300 4.3020
05.06.2017 Buy 3 000 4.3000
05.06.2017 Buy 1 000 4.2990
05.06.2017 Buy 2 000 4.3000
05.06.2017 Buy 1 750 4.3000
05.06.2017 Buy 650 4.3000
05.06.2017 Buy 1 000 4.3000
05.06.2017 Buy 500 4.3000
05.06.2017 Buy 500 4.3000
05.06.2017 Buy 50 4.3000
05.06.2017 Buy 1 000 4.2700
05.06.2017 Buy 2 000 4.2600
05.06.2017 Buy 254 4.2800
05.06.2017 Buy 137 4.2500
05.06.2017 Buy 200 4.2800
05.06.2017 Buy 4 4.2800
05.06.2017 Buy 50 4.2400
05.06.2017 Buy 54 4.2800
07.06.2017 Buy 1 000 4.3200
07.06.2017 Buy 201 4.3300
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.06.2017 20:48
SOPHARMA AD (31/2017) Current report 31 re insiders transactions - Donev
07.06.2017 20:48SOPHARMA AD (31/2017) Current report 31 re insiders transactions - Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
01.06.2017 Buy 7 500 3.9810
01.06.2017 Buy 7 000 3.9810
01.06.2017 Buy 7 000 3.9800
01.06.2017 Buy 7 000 3.9800
01.06.2017 Buy 7 000 3.9800
01.06.2017 Buy 900 4.0300
01.06.2017 Buy 500 4.0480
01.06.2017 Buy 500 4.0480
01.06.2017 Buy 500 4.0490
01.06.2017 Buy 500 4.0490
01.06.2017 Buy 50 4.0410
01.06.2017 Buy 100 4.0410
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.06.2017 17:29
SOPHARMA AD (30/2017) CORRECTION - MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 2 JUNE 2017
07.06.2017 17:29SOPHARMA AD (30/2017) CORRECTION - MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 2 JUNE 2017
Podstawa prawna: art. 17. 1 MAR.
MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 2 JUNE 2017
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.06.2017 17:10
SOPHARMA AD (30/2017) MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 2 JUNE 2017
06.06.2017 17:10SOPHARMA AD (30/2017) MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 2 JUNE 2017
Podstawa prawna: art. 17. 1 MAR.
MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 2 JUNE 2017
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.06.2017 13:03
SOPHARMA AD (29/2017) Sales revenues for the first five months of 2017
05.06.2017 13:03SOPHARMA AD (29/2017) Sales revenues for the first five months of 2017
Podstawa prawna: art. 17. 1 MAR.
For the first five months of this year, revenues from sales increased by 15% compared to the same period of 2016, including 2% increase of domestic sales and 25% increase of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.06.2017 15:48
Sopharma wypłaci 0,10 BGN dywidendy na akcję
02.06.2017 15:48Sopharma wypłaci 0,10 BGN dywidendy na akcję
Jak podano, dzień dywidendy ustalono na 14 dni od daty walnego zgromadzenia, a jej wypłata ma nastąpić w terminie trzech miesięcy.
W 2016 roku spółka wypłaciła 0,07 BGN dywidendy na akcję. (PAP Biznes)
sar/ osz/
- 02.06.2017 15:33
SOPHARMA AD (28/2017) Notification for divident payment
02.06.2017 15:33SOPHARMA AD (28/2017) Notification for divident payment
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD hereby notifies all shareholders of the Company about the decision of the AGM of Sopharma AD that took place on June 2th, 2017 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:
AGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.10 BGN /ten stotinki/ per share with dividend right.
The persons eligable for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken.
After the exact amount of the dividend has been determined, based on a list of shareholders, provided. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country. Payment of dividend will commence within three months from the date of the AGM, on which the payment of dividend was approved.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.05.2017 16:34
SOPHARMA AD (27/2017) CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 MARCH 2017
30.05.2017 16:34SOPHARMA AD (27/2017) CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 MARCH 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Annex 9
7. Additional information
8. List of insider information of reg. 596(EU)/2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.05.2017 12:33
SOPHARMA AD (26/2017) Additional issues on the agenda of the Annual General Meeting of Shareholders of Sopharma AD
05.05.2017 12:33SOPHARMA AD (26/2017) Additional issues on the agenda of the Annual General Meeting of Shareholders of Sopharma AD
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that regarding listing of additional issues on the agenda of the Annual General Meeting of Shareholders of Sopharma AD, scheduled for 02.06.2017, we present an updated invitation. Materials related to the new issues are published together with the other materials for the meeting on 02.06.2017
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.05.2017 13:08
SOPHARMA AD (25/2017) Sales revenues for the first four months of 2017
03.05.2017 13:08SOPHARMA AD (25/2017) Sales revenues for the first four months of 2017
Podstawa prawna: art. 17. 1 MAR.
For the first four months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 1% increase of domestic sales and 18% increase of export sales.
Please, make the above information public.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.05.2017 13:57
SOPHARMA AD (24/2017) Notification for a technical mistake concerning the second date for the AGM
02.05.2017 13:57SOPHARMA AD (24/2017) Notification for a technical mistake concerning the second date for the AGM
Podstawa prawna: art. 17. 1 MAR.
Dear Shareholders,
Тhe invitation for the Annual General Meeting of shareholders of Sopharma AD convened for 2 June, 2017 published in x3news, investor.bg and the website of the company www.sopharmagroup.bg contains a technical mistake concerning the second date for the AGM, which is announced in case of lack of quorum on 2 June 2017:
In the first paragraph of the invitation the listed second date is 16 July 2017 and in the last paragraph the listed second date is 16 June 2017.
We would hereby like to advise all shareholders that the correct second date under the conditions of art. 227, para 3 of the Commercial code for the Annual General Meeting of shareholders of Sopharma AD is 16 June 2017.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.04.2017 20:34
SOPHARMA AD (23/2017) Invitation for Annual General Meeting of the Shareholders of Sopharma AD
28.04.2017 20:34SOPHARMA AD (23/2017) Invitation for Annual General Meeting of the Shareholders of Sopharma AD
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Invitation for Annual General Meeting of the Shareholders of Sopharma AD and materials.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.04.2017 20:23
SOPHARMA AD (22/2017) Audited Consolidated Financial Statements of Sopharma for 2016
28.04.2017 20:23SOPHARMA AD (22/2017) Audited Consolidated Financial Statements of Sopharma for 2016
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
ANNUAL AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Auditors' report
6. Corporate governance declaration
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.04.2017 14:05
SOPHARMA AD (21/2017) INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 March 2017
28.04.2017 14:05SOPHARMA AD (21/2017) INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 March 2017
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration of the responsible directors
6. Insider information
7. Additional information
8. List of insider information under Art. 7 of Regulation (EU) 596/2014
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 26.04.2017 13:09
SOPHARMA AD (19/2017) Notification - Approval for transformation
26.04.2017 13:09SOPHARMA AD (19/2017) Notification - Approval for transformation
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") notifies that on 25 April 2017 the Financial Supervision Commission approved the Contract for transformation through merger and the additional annex to it, signed on 31 January 2017 between Sopharma AD, hereinafter referred to as "Acquirer" and Medica AD, hereinafter referred to as "Acquiree" in accordance with the requirements of art. 262d and following of the Commercial Act (CA). As a result the assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD will be terminated without liquidation. The Financial Supervision Commission also approved the reports of the management of the two companies, prepared in accordance with the regulations of art.262i of the CA and the reports of the appointed examiners of the participants in the transformation under art. 262M of the CA from 13 October 2014.
As a result of the merger, all shareholders of the Acquiree Medica AD, with the exception of the Acquirer Sopharma AD, which is also a shareholder of the Acquiree, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, art. 1 of the CA shall receive 0.8813 shares of the capital of Sopharma AD.
The merger is subject to approval by the shareholders of the two companies on the respective General Meetings.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 25.04.2017 16:08
SOPHARMA AD (18/2017) MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 24 APRIL 2017
25.04.2017 16:08SOPHARMA AD (18/2017) MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 24 APRIL 2017
Podstawa prawna: art. 17. 1 MAR.
MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 24 APRIL 2017
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.04.2017 15:26
SOPHARMA AD (17/2017) Extraordinary General Meeting, convened by the Board of Directors for 24 April 2017 at 11:00
20.04.2017 15:26SOPHARMA AD (17/2017) Extraordinary General Meeting, convened by the Board of Directors for 24 April 2017 at 11:00
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") hereby notifies all shareholders of the Company, that the Extraordinary General Meeting, convened by the Board of Directors for 24 April 2017 at 11:00 will take place at Sopharma Business Towers, Building B, floor 3, 5 Lachezar Stanchev Str.. The registration begins at 9:30.
All shareholders of the company are invited to participate at the General Meeting in person or by proxy.
As a prerequisite for the technical provisioning of the Extraordinary General Meeting of Shareholders, copies of all letters of attorney must be presented to the Company on paper or electronically at mdnedkova@sopharma.bg by the end of the workday preceding the date of the AGM, namely 5 p.m. on 21 April 2017.
We would like to thank all shareholders for their understanding and cooperation.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.04.2017 16:19
SOPHARMA AD (16/2017) Sopharma AD acquired 51% of RAP Pharma International
18.04.2017 16:19SOPHARMA AD (16/2017) Sopharma AD acquired 51% of RAP Pharma International
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD notifies that after receiving a permission from the Moldova Competition Commission, Sopharma AD acquired 51% of the Moldova pharmaceutical distributor RAP Pharma International.
RAP PHARMA INTERNATIONAL (RAP) was established in 2004 and in 2014 started its activities in the pharmaceutical sector after receiving a license for pharmaceutical wholesaling and distribution. Currently the company owns 10 pharmacies and is the most intensively developing company in the Republic of Moldova. The revenues of the company for 2016 increased with almost 40% to 3 million EUR. The company has 79 employees and is one of the 7 distributors in Moldova owning a pharmacies network. The retail market in Moldova for 2016 according to Pharmexpert is about 100 million EUR (a precise statistics is not available). Currently the company is a distributor of the products of Sopharma AD, Medica AD, Momina krepost AD, STADA, GRINDEX - Baltics, POLPHARMA, LEKPHARM - Belarus, FARMA PRIM - Moldova, FLUMED FARM - Moldova, BALKAN PHARMACEUTICALS - Moldova etc.. Since 2016 RAP Pharma is added in the list of companies supplying medicinal products to the State Hospitals in the Republic of Moldova through a centralized tender.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.04.2017 14:07
SOPHARMA AD (15/2017) Notification
06.04.2017 14:07SOPHARMA AD (15/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") hereby notifies that on 5 April 2017 Sopharma AD received a decision from the Commission for Protection of Competition that the acquisition of shares of the capital of Doverie Obedinen Holding AD is not subject to preliminary notification under art. 24, para 2 from the Law on Competition at this stage.
Sopharma AD will undertake the respective actions once it reaches the thresholds requiring a tender offering to the remaining shareholders of Doverie Obedinen Holding AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.04.2017 12:07
SOPHARMA AD (14/2017) Sopharma monthly March 2017
04.04.2017 12:07SOPHARMA AD (14/2017) Sopharma monthly March 2017
Podstawa prawna: art. 17. 1 MAR.
For the first quarter of this year, revenues from sales increased by 12% compared to the same period of 2016, including 4% decrease of domestic sales and 24% increase of export sales.
"Sales on the Russian market in March reassert the uptrend since the beginning of the year and are a real indicator of improving the economic situation. At present, our forecast are that export sales will grow also over the next few months.", said Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of "Sopharma" AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 31.03.2017 13:37
SOPHARMA AD (13/2017) ANNUAL AUDITED INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
31.03.2017 13:37SOPHARMA AD (13/2017) ANNUAL AUDITED INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
ANNUAL AUDITED INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration of the responsible directors
6. Auditors' report
7. Report regarding the application of the remuneration policy
8. Corporate governance declaration
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.03.2017 13:09
SOPHARMA AD (12/2017) Notification for a signed annex to the Contract for transformation through merger - Medica AD
21.03.2017 13:09SOPHARMA AD (12/2017) Notification for a signed annex to the Contract for transformation through merger - Medica AD
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") notifies that on 20 March 2017 Sopharma AD, Sofia, UIC 831902088 and Medica AD, Sofia, UIC 000000993 signed an annex to the Contract for transformation through merger reflecting the comments by the FSC. All documents will be filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA) after an independent certified evaluator prepares a report.
As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.8831 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.03.2017 15:37
SOPHARMA AD (11/2017) Extraordinary General Meeting of the shareholders of Sopharma AD
17.03.2017 15:37SOPHARMA AD (11/2017) Extraordinary General Meeting of the shareholders of Sopharma AD
Podstawa prawna: art. 17. 1 MAR.
Extraordinary General Meeting of the Shareholders of Sopharma AD
1. Invitation to the Extraordinary General Meeting of Shareholders of Sopharma AD, 24 April 2017
2. Minutes of the Meeting of the Board of Directors of Sopharma AD
3. Substantiated report
4. Letter of Attorney - Sample
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.03.2017 13:12
SOPHARMA AD (10/2017) Notification
09.03.2017 13:12SOPHARMA AD (10/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD announces that Sopharma AD received a final prohibition from the Bulgarian Financial Supervision Commission (FSC) to extend a tender offering to the shareholders of Unipharm AD. Sopharma AD is preparing a new tender offering which reflects the comments of the FSC.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.03.2017 13:54
SOPHARMA AD (9/2017) CORRECTION-Sales revenues for the first two months of 2017
07.03.2017 13:54SOPHARMA AD (9/2017) CORRECTION-Sales revenues for the first two months of 2017
Podstawa prawna: art. 17. 1 MAR.
For the first two months of this year, revenues from sales increased by 8% compared to the same period of 2016, including 5% decrease of domestic sales and 16% increase of export sales.
"We are very pleased with the results on the Russian market from the begining of this year and the trend is strenghteining in February reaching 40% increase in export sales.
We are hopeful also with regards to the registration of our product Tabex in the USA. After the news about the merger of Achieve and OncoGenex the good news continue. You can read more abou the cooperation of Achieve with NIH here: www.oncogenex.com.
The preliminary consolidated report of Sopharma Group for 2016 shows that even though the period was relatively difficult on our foreign markets, we still managed to reach a satisfactory EBITDA of 70 million BGN and a net profit of a little bit more than 50 million BGN. Analysis of the main indicators shows improved profitability due to optimization of main expenses and in the light of a maximum market price of a bit over 3 BGN for the year P/E is 8.31 and ROE is 10.9% compared to 5.3% for 2015.", says Mr. Ognian Donev, PhD, CEO and Chairman of the Board of directors of Sopharma AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.03.2017 13:04
SOPHARMA AD (9/2017) Sales revenues for the first two months of 2017
07.03.2017 13:04SOPHARMA AD (9/2017) Sales revenues for the first two months of 2017
Podstawa prawna: art. 17. 1 MAR.
For the first two months of this year, revenues from sales increased by 8% compared to the same period of 2016, including 5% decrease of domestic sales and 16% increase of export sales.
"We are very pleased with the results on the Russian market from the begining of this year and the trend is strenghteining in February reaching 40% increase in export sales.
We are hopeful also with regards to the registration of our product Tabex in the USA. After the news about the merger of Achieve and OncoGenex the good news continue. You can read more abou the cooperation of Achieve with NIH here:
The preliminary consolidated report of Sopharma Group for 2016 shows that even though the period was relatively difficult on our foreign markets, we still managed to reach a satisfactory EBITDA of 70 million BGN and a net profit of a little bit more than 50 million BGN. Analysis of the main indicators shows improved profitability due to optimization of main expenses and in the light of a maximum market price of a bit over 3 BGN for the year P/E is 8.31 and ROE is 10.9% compared to 5.3% for 2015.", says Mr. Ognian Donev, PhD, CEO and Chairman of the Board of directors of Sopharma AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.03.2017 12:57
SOPHARMA AD (8/2017) PRELIMINARY ANNUAL CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
01.03.2017 12:57SOPHARMA AD (8/2017) PRELIMINARY ANNUAL CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
PRELIMINARY ANNUAL CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Annex 9
7. Additional Information
8. List of insider information
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.02.2017 16:06
SOPHARMA AD (7/2017) Notification
27.02.2017 16:06SOPHARMA AD (7/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD announces that the Competition Council of The Republic of Moldova allows the acquisition of over 51% of RAP Pharma International SRL by Sopharma AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.02.2017 13:11
SOPHARMA AD (6/2017) Notification for signed contract for merger between Sopharma AD and Medica AD
13.02.2017 13:11SOPHARMA AD (6/2017) Notification for signed contract for merger between Sopharma AD and Medica AD
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") notifies that on 13 February 2017 the Contract for merger, as well as reports of the management bodies of the companies involved in the transformation of the company under art. 262i of the CA and the report of the examiner under art. 262m of the CA for transformation through merger between Sopharma AD, Sofia, UIC 831902088 and Medica AD, Kazanluk, UIC 000000993 were filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA). As a result of the merger, all assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD shall be terminated without liquidation.
As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.9486 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.02.2017 13:08
SOPHARMA AD (5/2017) Sopharma monthly January 2017
03.02.2017 13:08SOPHARMA AD (5/2017) Sopharma monthly January 2017
Podstawa prawna: art. 17. 1 MAR.
For the first month of this year, revenues from sales decreased by 4% compared to the same period of 2015, including 5% decrease of domestic sales and 4% decrease of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.02.2017 13:37
SOPHARMA AD (4/2017) Notification
02.02.2017 13:37SOPHARMA AD (4/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD announces that on 31 January, 2017 in accordance with art. 262e and the following from the Commercial Code Medica AD and Sopharma AD signed a contract for transformation through merger of Medica AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0.9486, meaning that one share of Medica AD will be exchanged for 0.9486 shares of Sopharma AD. The companies have hired the services of certified appraisers whose report is a necessary prerequisite for the filing of the documents for transformation with the FSC. As of this moment the deputy Chairman "Investment Supervision" has not issued an approval in accordance with art. 124 from the LPOS of the transformation contract, of the reports of the BoD according to art. 262k from the Commercial code and the report of the appraiser under art. 262o from the Commercial Code.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 30.01.2017 17:29
SOPHARMA AD (3/2017) INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
30.01.2017 17:29SOPHARMA AD (3/2017) INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Insider Information
7. Additional Information
8. List of insider information
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.01.2017 14:27
SOPHARMA AD (2/2017) Sales revenues for 2016
09.01.2017 14:27SOPHARMA AD (2/2017) Sales revenues for 2016
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD hereby notifies that the revenues from sales for 2016 decrease with 5% compared to 2015, including 2% decrease in domestic sales mainly due to the overall market price erosion (for the same period the company has a 7% increase in sales in packages) and a 6% decrease in export sales.
"In the past few months we see some signs for economic and political stabilization in Russia, which give us certain security for the results of 2017. We are optimistic for the trend of recovery of the sales in the Ukraine. After the restructuring of our export activities our local teams work systematically for the increase of the results on a number of markets like Poland, Belarus, Latvia, etc. We are very proud with the successful registrations of new products which we are yet to develop. An excellent example is Tuspan - the coughing syrup, which will be available on a number of European markets even this year in case of successful and timely procedures. This year started with a long-awaited news concerning our project of registration of our product Tabex in the USA. In case a restructuring takes place between Achieve and Oncogenex (our remaining shares in the capital of Extab will be transformed in shares in Achieve in case of such restructuring) there will be two advantages for us: first, the new joint team of the two companies will have a much bigger chance of a successful registration of Tabex and second, "Sopharma" AD will become a shareholder in a public company traded on NASDAQ.", says Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors, "Sopharma" AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.01.2017 13:06
SOPHARMA AD (1/2017) Notification
06.01.2017 13:06SOPHARMA AD (1/2017) Notification
Podstawa prawna: art. 17. 1 MAR.
2017 starts with good news concerning the registration and further development of our product Tabex. The buyer of the share of Sopharma AD in Extab - Achieve - is undertaking a merger with another strong player in the development and registration of innovative medicines - Oncogenex, a publicly traded company on NASDAQ (http://in.reuters.com/article/idINFWN1EV0QP). The procedure is expected to be completed by mid 2017 subject to approval from the US FSC. Sopharma AD will own approximately 3.5% in the newly created company, which will aim at filing the IND for Tabex in 2017.
Apart from the work on Tabex, the new company is also active in the development of other medicines, including one to facilitate the process of treating certain types of cancer.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.12.2016 15:28
SOPHARMA AD (127/2016) Current report re insiders transactions -127-Donev
29.12.2016 15:28SOPHARMA AD (127/2016) Current report re insiders transactions -127-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
2016-12-27, 10:14 Buy 1 000 2.9300
2016-12-27, 10:19 Buy 15 2.9300
2016-12-27, 10:19 Buy 495 2.9350
2016-12-27, 14:46 Buy 90 2.9890
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.12.2016 15:02
SOPHARMA AD (126/2016) Current report re insiders transactions -126-Donev
27.12.2016 15:02SOPHARMA AD (126/2016) Current report re insiders transactions -126-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
2016-12-22 08:10 Buy 3 000 2.9350
2016-12-22 08:12 Buy 2 000 2.9350
2016-12-22 08:15 Buy 5 000 2.9350
2016-12-22 08:25 Buy 5 000 2.9350
2016-12-22 08:31 Buy 3 500 2.9350
2016-12-22 08:41 Buy 1 500 2.9350
2016-12-22 08:50 Buy 5 000 2.9400
2016-12-22 08:59 Buy 5 000 2.9350
2016-12-22 09:04 Buy 927 2.9350
2016-12-22 09:04 Buy 1 073 2.9400
2016-12-22 09:06 Buy 1 000 2.9400
2016-12-22 10:07 Buy 927 2.9400
2016-12-22 10:07 Buy 73 2.9450
2016-12-22 13:23 Buy 226 2.9350
2016-12-23 11:42 Buy 200 2.9440
2016-12-23 12:20 Buy 274 2.9440
2016-12-23 12:36 Buy 300 2.9300
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 23.12.2016 15:08
SOPHARMA AD (125/2016) Current report 125 re insiders transactions-Sopharma Trading AD
23.12.2016 15:08SOPHARMA AD (125/2016) Current report 125 re insiders transactions-Sopharma Trading AD
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
22.12.2016 10:10 Sale 3 000 2.9350
22.12.2016 10:12 Sale 2 000 2.9350
22.12.2016 10:15 Sale 5 000 2.9350
22.12.2016 10:25 Sale 5 000 2.9350
22.12.2016 10:30 Sale 900 2.9300
22.12.2016 10:31 Sale 3 500 2.9350
22.12.2016 10:41 Sale 1 500 2.9350
22.12.2016 10:45 Sale 500 2.9450
22.12.2016 10:50 Sale 5 000 2.9400
22.12.2016 10:59 Sale 5 000 2.9350
22.12.2016 11:04 Sale 927 2.9350
22.12.2016 11:04 Sale 1 073 2.9400
22.12.2016 11:06 Sale 1 000 2.9400
22.12.2016 11:07 Sale 100 2.9400
22.12.2016 12:07 Sale 927 2.9400
22.12.2016 12:07 Sale 73 2.9450
22.12.2016 15:21 Sale 201 2.9350
22.12.2016 15:23 Sale 226 2.9350
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.12.2016 17:22
SOPHARMA AD (124/2016) Current report 124 re insiders transactions-Sopharma Trading AD
22.12.2016 17:22SOPHARMA AD (124/2016) Current report 124 re insiders transactions-Sopharma Trading AD
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
19.12.2016 12:24 Sale 1 000 2.9200
19.12.2016 12:25 Sale 500 2.9200
19.12.2016 12:33 Sale 150 2.9220
19.12.2016 12:33 Sale 2 000 2.9200
19.12.2016 12:33 Sale 2 500 2.9200
19.12.2016 12:34 Sale 350 2.9200
19.12.2016 12:42 Sale 3 000 2.9200
19.12.2016 13:15 Sale 400 2.9350
19.12.2016 14:21 Sale 600 2.9350
19.12.2016 14:27 Sale 3 000 2.9200
19.12.2016 14:27 Sale 210 2.9200
19.12.2016 16:52 Sale 250 2.9160
19.12.2016 16:52 Sale 150 2.9160
19.12.2016 16:52 Sale 1 402 2.9150
19.12.2016 16:52 Sale 5 000 2.9150
19.12.2016 16:52 Sale 1 698 2.9150
20.12.2016 10:36 Sale 3 000 2.9200
20.12.2016 10:47 Sale 1 100 2.9200
20.12.2016 12:48 Sale 3 000 2.9300
20.12.2016 12:50 Sale 2 000 2.9300
20.12.2016 13:01 Sale 5 000 2.9300
20.12.2016 14:10 Sale 270 2.9400
20.12.2016 16:45 Sale 730 2.9400
21.12.2016 12:52 Sale 1 000 2.9450
21.12.2016 12:52 Sale 613 2.9450
21.12.2016 13:11 Sale 250 2.9450
21.12.2016 13:33 Sale 137 2.9450
21.12.2016 15:52 Sale 103 2.9400
21.12.2016 15:55 Sale 270 2.9400
21.12.2016 16:34 Sale 400 2.9350
21.12.2016 16:34 Sale 300 2.9360
21.12.2016 16:35 Sale 4 000 2.9350
21.12.2016 16:36 Sale 300 2.9350
21.12.2016 16:39 Sale 5 000 2.9350
21.12.2016 16:41 Sale 700 2.9350
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 22.12.2016 16:35
SOPHARMA AD (123/2016) Current report re insiders transactions -123-Donev
22.12.2016 16:35SOPHARMA AD (123/2016) Current report re insiders transactions -123-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
2016-12-19 08:30 Buy 359 2.9150
2016-12-19 10:24 Buy 1 000 2.9200
2016-12-19 10:25 Buy 500 2.9200
2016-12-19 10:33 Buy 2 500 2.9200
2016-12-19 10:42 Buy 3 000 2.9200
2016-12-19 12:47 Buy 3 000 2.9200
2016-12-19 13:49 Buy 243 2.9150
2016-12-19 13:52 Buy 700 2.9150
2016-12-19 14:52 Buy 5 000 2.9150
2016-12-19 14:52 Buy 1 698 2.9150
2016-12-19 15:00 Buy 295 2.9300
2016-12-19 15:00 Buy 205 2.9300
2016-12-20 08:17 Buy 5 000 2.9100
2016-12-20 08:23 Buy 4 000 2.9100
2016-12-20 08:36 Buy 3 000 2.9200
2016-12-20 10:48 Buy 3 000 2.9300
2016-12-20 11:01 Buy 5 000 2.9300
2016-12-20 12:10 Buy 230 2.9390
2016-12-20 12:10 Buy 270 2.9400
2016-12-20 14:45 Buy 730 2.9400
2016-12-20 15:00 Buy 705 2.9490
2016-12-20 15:00 Buy 231 2.9490
2016-12-20 15:00 Buy 64 2.9490
2016-12-21 08:15 Buy 557 2.9490
2016-12-21 08:27 Buy 2 000 2.9500
2016-12-21 08:28 Buy 2 000 2.9500
2016-12-21 08:29 Buy 2 000 2.9500
2016-12-21 08:33 Buy 1 000 2.9500
2016-12-21 08:51 Buy 100 2.9500
2016-12-21 10:52 Buy 1 000 2.9450
2016-12-21 10:52 Buy 613 2.9450
2016-12-21 14:35 Buy 400 2.9350
2016-12-21 14:36 Buy 300 2.9350
2016-12-21 14:39 Buy 5 000 2.9350
2016-12-21 14:41 Buy 700 2.9350
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2016 12:36
SOPHARMA AD (122/2016) Current report 122 re insiders transactions-Sopharma Trading AD
20.12.2016 12:36SOPHARMA AD (122/2016) Current report 122 re insiders transactions-Sopharma Trading AD
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
2016-12-14 Sale 70 2.9850
2016-12-15 Sale 3 000 2.9800
2016-12-16 Sale 1 379 2.9500
2016-12-16 Sale 1 000 2.9500
2016-12-16 Sale 621 2.9500
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2016 12:33
SOPHARMA AD (121/2016) Current report 121 re insiders transactions
20.12.2016 12:33SOPHARMA AD (121/2016) Current report 121 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
2016-12-15 Buy 1000 2.990
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.12.2016 11:55
SOPHARMA AD (120/2016) Current report re insiders transactions -120-Donev
20.12.2016 11:55SOPHARMA AD (120/2016) Current report re insiders transactions -120-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
2016-12-15 08:47 Buy 3 000 2.9800
2016-12-15 08:53 Buy 1 000 2.9600
2016-12-15 13:14 Buy 865 2.9600
2016-12-15 13:50 Buy 135 2.9600
2016-12-15 14:40 Buy 1 000 2.9570
2016-12-15 14:40 Buy 1 449 2.9550
2016-12-15 14:40 Buy 551 2.9550
2016-12-15 14:40 Buy 3 000 2.9500
2016-12-15 14:42 Buy 2 000 2.9200
2016-12-15 14:43 Buy 800 2.9150
2016-12-15 14:44 Buy 1 200 2.9150
2016-12-15 14:45 Buy 358 2.9150
2016-12-15 14:50 Buy 297 2.9600
2016-12-16 08:15 Buy 220 2.9730
2016-12-16 08:49 Buy 150 2.9510
2016-12-16 09:21 Buy 290 2.9510
2016-12-16 10:43 Buy 500 2.9530
2016-12-16 10:43 Buy 560 2.9510
2016-12-16 10:43 Buy 401 2.9500
2016-12-16 11:10 Buy 1 000 2.9500
2016-12-16 12:47 Buy 1 379 2.9500
2016-12-16 13:31 Buy 1 000 2.9500
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.12.2016 14:57
SOPHARMA AD (119/2016) Current report 119 re insiders transactions-Sopharma Trading AD
16.12.2016 14:57SOPHARMA AD (119/2016) Current report 119 re insiders transactions-Sopharma Trading AD
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
2016-12-15 Sale 3 000 2.9800
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.12.2016 09:51
SOPHARMA AD (118/2016) Current report 118 re insiders transactions
16.12.2016 09:51SOPHARMA AD (118/2016) Current report 118 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the the transaction Operation Number of shares Unit price (BGN)
2016-12-13 Buy 1000 2.995
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.12.2016 17:27
SOPHARMA AD (117/2016) Current report 117 re insiders transactions
15.12.2016 17:27SOPHARMA AD (117/2016) Current report 117 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date and time of the transaction Operation Number of shares Unit price (BGN)
12.12.2016 Sale 2500 3.000
13.12.2016 Sale 500 2.992
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.12.2016 17:24
SOPHARMA AD (116/2016) Current report re insiders transactions -116-Donev
15.12.2016 17:24SOPHARMA AD (116/2016) Current report re insiders transactions -116-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)
2016-12-12 08:43 Buy 1 000 2.9900
2016-12-12 09:44 Buy 240 3.0000
2016-12-12 09:50 Buy 2 500 3.0000
2016-12-12 09:50 Buy 240 3.0000
2016-12-12 09:50 Buy 193 3.0000
2016-12-12 10:47 Buy 240 3.0000
2016-12-12 10:47 Buy 2 760 3.0000
2016-12-12 11:26 Buy 240 3.0000
2016-12-12 11:26 Buy 520 3.0000
2016-12-12 11:26 Buy 240 3.0000
2016-12-12 11:49 Buy 1 520 3.0000
2016-12-12 11:49 Buy 480 3.0000
2016-12-12 11:52 Buy 2 000 2.9800
2016-12-12 11:56 Buy 1 000 2.9800
2016-12-12 12:43 Buy 1 000 2.9800
2016-12-12 12:53 Buy 350 2.9800
2016-12-12 13:18 Buy 250 2.9990
2016-12-12 13:18 Buy 250 2.9990
2016-12-12 13:18 Buy 150 2.9990
2016-12-12 13:19 Buy 44 2.9800
2016-12-12 14:41 Buy 80 2.9990
2016-12-12 14:41 Buy 100 2.9990
2016-12-12 14:41 Buy 320 2.9990
2016-12-13 08:34 Buy 1 000 2.9950
2016-12-13 08:48 Buy 260 2.9990
2016-12-13 08:48 Buy 250 2.9990
2016-12-13 08:48 Buy 490 2.9990
2016-12-13 10:09 Buy 2 000 2.9950
2016-12-13 10:14 Buy 456 2.9980
2016-12-13 10:22 Buy 4 282 2.9980
2016-12-13 10:22 Buy 718 2.9980
2016-12-13 14:04 Buy 500 2.9920
2016-12-13 14:05 Buy 500 2.9920
2016-12-13 14:26 Buy 268 2.9940
2016-12-13 14:26 Buy 732 2.9970
2016-12-13 14:30 Buy 1 000 2.9970
2016-12-13 14:30 Buy 747 2.9970
2016-12-13 14:30 Buy 253 2.9970
2016-12-13 14:47 Buy 800 2.9900
2016-12-13 14:52 Buy 1 640 2.9800
2016-12-13 14:53 Buy 95 2.9800
2016-12-14 08:13 Buy 1 465 2.9900
2016-12-14 08:25 Buy 1 000 2.9800
2016-12-14 08:27 Buy 300 2.9800
2016-12-14 08:28 Buy 250 2.9800
2016-12-14 08:52 Buy 450 2.9800
2016-12-14 08:58 Buy 185 2.9700
2016-12-14 09:46 Buy 1 800 2.9700
2016-12-14 10:18 Buy 985 2.9700
2016-12-14 10:18 Buy 15 2.9700
2016-12-14 11:04 Buy 140 2.9700
2016-12-14 11:19 Buy 520 2.9700
2016-12-12 08:43 Buy 200 2.9700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.12.2016 14:42
SOPHARMA AD (115/2016) Current report 115 tender offer - Unipharm AD
15.12.2016 14:42SOPHARMA AD (115/2016) Current report 115 tender offer - Unipharm AD
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") hereby notifies that on 14 December 2016 Sopharma AD filed with the Financial Supervision Commission a tender offering for the shares of all other shareholders in Unipharm AD.
Sopharma AD as a offeree states that it does not own 1 342 234 shares, representing 22.37% from the total number of sahres with ISIN BG1100154076 and from the votes in the general meeting of Unipharm AD and files the tender offering to the remaining sahreholders owning ordinary shares of Unipharma AD for the purchase of those shares.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.12.2016 10:45
SOPHARMA AD (114/2016) Current report 114 re insiders transactions
14.12.2016 10:45SOPHARMA AD (114/2016) Current report 114 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
2016-12-14 Buy 1000 2.980
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 13.12.2016 12:56
SOPHARMA AD (113/2016) Current report 113 re insiders transactions
13.12.2016 12:56SOPHARMA AD (113/2016) Current report 113 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
2016-12-12 Buy 1000 2.985
2016-12-13 Buy 3000 2.990
2016-12-13 Buy 46 2.990
2016-12-13 Buy 454 2.990
2016-12-13 Buy 1500 2.990
2016-12-13 Buy 1600 2.990
2016-12-13 Buy 3000 2.990
2016-12-13 Buy 3000 2.990
2016-12-13 Buy 250 2.995
2016-12-13 Buy 7 2.995
2016-12-13 Buy 143 2.997
2016-12-13 Buy 500 2.997
2016-12-13 Buy 357 2.997
2016-12-13 Buy 143 2.997
2016-12-13 Buy 357 2.997
2016-12-13 Buy 325 2.998
2016-12-13 Buy 450 2.998
2016-12-13 Buy 406 3.000
2016-12-13 Buy 500 3.005
2016-12-13 Buy 80 3.000
2016-12-13 Buy 500 3.010
2016-12-13 Buy 220 3.000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2016 15:15
SOPHARMA AD (112/2016) Current report re insiders transactions -112-Donev
12.12.2016 15:15SOPHARMA AD (112/2016) Current report re insiders transactions -112-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time(UTC) of the settlement Operation Number of shares Unit price (BGN)
2016-12-08 08:28 Buy 3 000 2.9890
2016-12-08 08:33 Buy 840 2.9700
2016-12-08 08:36 Buy 2 000 2.9900
2016-12-08 08:49 Buy 180 2.9900
2016-12-08 08:49 Buy 1 000 2.9900
2016-12-08 08:49 Buy 1 980 2.9900
2016-12-08 08:50 Buy 3 000 2.9900
2016-12-08 08:50 Buy 2 980 2.9900
2016-12-08 08:50 Buy 20 2.9900
2016-12-08 08:54 Buy 280 2.9900
2016-12-08 08:54 Buy 720 2.9900
2016-12-08 09:00 Buy 2 000 2.9900
2016-12-08 09:01 Buy 1 950 2.9900
2016-12-08 09:01 Buy 1 050 2.9900
2016-12-08 09:05 Buy 3 000 2.9900
2016-12-08 09:06 Buy 2 000 2.9900
2016-12-08 09:13 Buy 3 000 2.9900
2016-12-09 09:16 Buy 1 000 3.0100
2016-12-09 09:21 Buy 1 000 3.0150
2016-12-09 11:29 Buy 835 3.0150
2016-12-09 11:29 Buy 165 3.0150
2016-12-09 13:26 Buy 1 000 3.0000
2016-12-09 13:29 Buy 1 000 2.9900
2016-12-09 13:42 Buy 1 087 2.9850
2016-12-09 13:51 Buy 40 2.9850
2016-12-09 14:39 Buy 1 400 2.9850
2016-12-09 14:54 Buy 300 3.0000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2016 09:52
SOPHARMA AD (111/2016) Current report 111 re insiders transactions
12.12.2016 09:52SOPHARMA AD (111/2016) Current report 111 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date and time of settlement Operation Number of shares Unit price (BGN)
12.12.2016 Sale 399 2.9900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.12.2016 09:25
SOPHARMA AD (110/2016) Current report 110 re insiders transactions
12.12.2016 09:25SOPHARMA AD (110/2016) Current report 110 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
12.12.2016 Sale 3 000 2.9900
12.12.2016 Sale 143 2.9970
12.12.2016 Sale 357 2.9970
12.12.2016 Sale 500 3.0050
12.12.2016 Sale 500 3.0050
12.12.2016 Sale 250 3.0010
12.12.2016 Sale 1 550 3.0000
12.12.2016 Sale 200 3.0000
12.12.2016 Sale 500 3.0100
13.12.2016 Sale 1 000 3.0100
13.12.2016 Sale 1 000 3.0150
13.12.2016 Sale 165 3.0150
13.12.2016 Sale 835 3.0150
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.12.2016 11:15
SOPHARMA AD (109/2016) Current report 109 re insiders transactions
09.12.2016 11:15SOPHARMA AD (109/2016) Current report 109 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
"Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:
Date and time of settlement Operation Number of shares Unit price (BGN)
09.12.2016 Sale 5000 2.9770
09.12.2016 Sale 1000 2.9550
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 09.12.2016 10:58
SOPHARMA AD (108/2016) Current report re insiders transactions -108-Donev
09.12.2016 10:58SOPHARMA AD (108/2016) Current report re insiders transactions -108-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
09.08.2016 Buy 365 2.9740
09.08.2016 Buy 123 2.9740
09.08.2016 Buy 82 2.9750
09.08.2016 Buy 430 2.9770
09.08.2016 Buy 365 2.9770
09.08.2016 Buy 5 000 2.9770
09.08.2016 Buy 415 2.9770
09.08.2016 Buy 410 2.9770
09.08.2016 Buy 175 2.9770
09.08.2016 Buy 635 2.9850
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 07.12.2016 15:39
SOPHARMA AD (107/2016) Current report 107 re insiders transactions
07.12.2016 15:39SOPHARMA AD (107/2016) Current report 107 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
Sopharma AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that the company ELPHARMA related to him, executed the following transactions related to shares of the Company:
Date and time of settlement Operation Number of shares Unit price (BGN)
5.12.2016 Sale 4 000 2.9700
5.12.2016 Sale 450 2.9700
5.12.2016 Sale 500 2.9700
5.12.2016 Sale 50 2.9700
6.12.2016 Sale 520 2.9900
6.12.2016 Sale 81 2.9900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.12.2016 16:55
SOPHARMA AD (106/2016) Current report 106 re insiders transactions
06.12.2016 16:55SOPHARMA AD (106/2016) Current report 106 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
05.12.2016 Buy 310 2.989
05.12.2016 Buy 720 2.996
05.12.2016 Buy 2000 2.998
05.12.2016 Buy 2601 2.990
05.12.2016 Buy 399 2.990
05.12.2016 Buy 2000 2.968
06.12.2016 Buy 1000 2.960
06.12.2016 Buy 316 2.980
06.12.2016 Buy 684 2.989
06.12.2016 Buy 924 2.980
06.12.2016 Buy 476 2.989
06.12.2016 Buy 600 2.989
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.12.2016 14:22
SOPHARMA AD (104/2016) Current report re insiders transactions -105-Donev
06.12.2016 14:22SOPHARMA AD (104/2016) Current report re insiders transactions -105-Donev
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
5.12.2016 Buy 4 940 3.0000
5.12.2016 Buy 60 3.0000
5.12.2016 Buy 5 000 3.0000
5.12.2016 Buy 8 000 2.9900
5.12.2016 Buy 2 821 2.9800
5.12.2016 Buy 4 179 2.9900
5.12.2016 Buy 1 250 2.9750
5.12.2016 Buy 750 2.9750
5.12.2016 Buy 740 2.9700
5.12.2016 Buy 4 000 2.9700
5.12.2016 Buy 2 000 2.9700
5.12.2016 Buy 260 2.9700
5.12.2016 Buy 4 000 2.9700
5.12.2016 Buy 860 2.9700
5.12.2016 Buy 1 140 2.9700
6.12.2016 Buy 1 161 2.9450
6.12.2016 Buy 1 000 2.9550
6.12.2016 Buy 1 000 2.9600
6.12.2016 Buy 180 2.9800
6.12.2016 Buy 558 2.9890
6.12.2016 Buy 81 2.9900
6.12.2016 Buy 520 2.9900
6.12.2016 Buy 500 2.9800
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.12.2016 15:05
SOPHARMA AD (104/2016) Sopharma monthly November 2016
05.12.2016 15:05SOPHARMA AD (104/2016) Sopharma monthly November 2016
Podstawa prawna: art. 17. 1 MAR.
For the first eleven months of this year, revenues from sales decreased by 5% compared to the same period of 2015, including 2% increase of domestic sales and 10% decrease of export sales. "The Russian market remains uncertain, which does not allow us to make forecasts for the year-end sales results, but we managed to limit the decrease of sales revenues in the second half of 2016.", states Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of Sopharma AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.11.2016 14:48
SOPHARMA AD (103/2016) CONSOLIDATED FINANCIAL STATEMENTS FOR Q3 2016
29.11.2016 14:48SOPHARMA AD (103/2016) CONSOLIDATED FINANCIAL STATEMENTS FOR Q3 2016
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
CONSOLIDATED FINANCIAL STATEMENTS FOR Q3 2016
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Additional information
7. Annex 9
8. List of insider information
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.11.2016 14:02
SOPHARMA AD (102/2016) Notification for disclosure of share participation
18.11.2016 14:02SOPHARMA AD (102/2016) Notification for disclosure of share participation
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") announces that on 18 November 2016 the Company received a notification for the acquisition of 505 364 shares, representing 0.37% of its capital, by ZUPF Allianz Bulgaria. After the transaction the share of ZUPF Allianz Bulgaria in the capital of Sopharma AD reached 5.17%.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.11.2016 16:42
SOPHARMA AD (101/2016) Notification for disclosure of share participation
16.11.2016 16:42SOPHARMA AD (101/2016) Notification for disclosure of share participation
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") announces that on 16 November 2016 the Company received a notification for the sale of 342 680 shares, representing 0.25% of its capital, by ZUPF Allianz Bulgaria. After the transaction the share of ZUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.80%.
The date of the registration of the transaction with the Central Depository is 11 November 2016.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.11.2016 13:21
SOPHARMA AD (100/2016) Notification - Sopharma AD has acquired a total of 68% of the capital of Veta Pharma AD
11.11.2016 13:21SOPHARMA AD (100/2016) Notification - Sopharma AD has acquired a total of 68% of the capital of Veta Pharma AD
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD hereby notifies that following a decision of the Board of directors as of the moment Sopharma AD has acquired a total of 68% of the capital of Veta Pharma AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.11.2016 15:14
SOPHARMA AD (99/2016) Notification - Veta Pharma AD
04.11.2016 15:14SOPHARMA AD (99/2016) Notification - Veta Pharma AD
Podstawa prawna: art. 17. 1 MAR.
The Board of Directors of Sopharma AD decided to purchase up to 100% of the capital of "Veta Pharma" AD for a price not exceeding 2.12 BGN per share. The Board authorised the Executive Director to undertake all necessary legal actions thereby.
"Veta Pharma" AD is a modern and dynamic Bulgarian pharmaceutical porducer of 47 different products divided in three categories: medicinal products, food additives and cosmetic products. The volume of sales for 2015 exceeds 3 million packages on the Bulgarian pharmaceutical market. 50 people work at the company.
"Veta Pharma" AD plans, produces and distributes its products in accordance with the Good Manufacturing Practice (GMP) and the standards applied by the Bulgarian and European legal framewok.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.11.2016 14:50
SOPHARMA AD (98/2016) Sopharma monthly October 2016
04.11.2016 14:50SOPHARMA AD (98/2016) Sopharma monthly October 2016
Podstawa prawna: art. 17. 1 MAR.
For the first ten months of this year, revenues from sales decreased by 6% compared to the same period of 2015, including 1% increase of domestic sales and 11% decrease of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 31.10.2016 15:09
SOPHARMA AD (97/2016) INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2016
31.10.2016 15:09SOPHARMA AD (97/2016) INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2016
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2016
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Insider Information
7. Additional Information
8. List of insider information
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 17.10.2016 13:25
SOPHARMA AD (96/2016) Notification
17.10.2016 13:25SOPHARMA AD (96/2016) Notification
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that in accordance with its transparency policy and led by the internationally accepted best practices in the area of corporate governance Sopharma AD will continue to publish its individual and consolidated quarterly financial statements in full in service of its shareholders and the investment community.
We also notify that the company now publishes all regulated information on the web site www.sopharmagroup.eu - the new website of Sopharma Group.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.10.2016 17:10
SOPHARMA AD (95/2016) Current report 95 re insiders transactions
14.10.2016 17:10SOPHARMA AD (95/2016) Current report 95 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
Sopharma AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that the company ELPHARMA related to him, executed the following transactions related to shares of the Company:
Date and time of settlement Operation Number of shares Unit price (BGN)
29.9.2016 Sale 2 000 2.8480
30.9.2016 Sale 2 371 2.9300
30.9.2016 Sale 2 629 2.9300
30.9.2016 Sale 1 000 2.9450
30.9.2016 Sale 204 2.9450
30.9.2016 Sale 1 500 2.9450
30.9.2016 Sale 296 2.9450
30.9.2016 Sale 2 000 2.9900
3.10.2016 Sale 10 3.0400
3.10.2016 Sale 990 3.0400
3.10.2016 Sale 1 030 3.0550
3.10.2016 Sale 970 3.0550
3.10.2016 Sale 1 000 3.0550
3.10.2016 Sale 1 893 3.0550
3.10.2016 Sale 3 000 2.9700
3.10.2016 Sale 150 2.9700
3.10.2016 Sale 3 400 2.9700
3.10.2016 Sale 1 450 2.9700
3.10.2016 Sale 1 450 2.9700
3.10.2016 Sale 1 550 2.9700
3.10.2016 Sale 3 000 2.9700
3.10.2016 Sale 270 2.9620
3.10.2016 Sale 341 2.9630
3.10.2016 Sale 341 2.9630
3.10.2016 Sale 341 2.9630
3.10.2016 Sale 341 2.9630
3.10.2016 Sale 295 2.9630
3.10.2016 Sale 71 2.9630
4.10.2016 Sale 2 000 2.9600
4.10.2016 Sale 3 400 2.9550
4.10.2016 Sale 240 2.9550
4.10.2016 Sale 306 2.9550
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.10.2016 15:15
SOPHARMA AD (95/2016) Notification - current report 95
10.10.2016 15:15SOPHARMA AD (95/2016) Notification - current report 95
Podstawa prawna: art. 17. 1 MAR.
In accordance with the provisions of art. 27, para 3 from Ordinance 2 on the prospectuses Sopharma AD and due to change in the internet address of the corporate website of the company, Sopharma hereby advises that the company published and disseminated information to the public in the last 12 months in the Republic of Bulgaria and in other member states in the following ways:
1. Through the unified information system of the Bulgarian Stock Exchange E-register - www.fsc.bg;
2. Through X3news information agency - http://www.x3news.com;
3. Through the electroinc media Investor.bg - www.investor.bg;
4. Through Infostock bulletin - www.infostock.bg/;
5. Through the internet web site of the company - http://www.sopharmagroup.bg ;
http://www.sopharmagroup.com
http://www.sopharmagroup.net
http://www.sopharmagroup.eu
6. Through the Polish Financial Supervision Commission system ESPI;
7. Through the Polish Press Agency - www.pap.pl
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 06.10.2016 13:20
SOPHARMA AD (94/2016) Notification
06.10.2016 13:20SOPHARMA AD (94/2016) Notification
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that as a result of its intention to express interest in acquiring a commercial company operating on the territory of the Republic of Moldova, as a first step Sopharma AD filed a request for approval of concentration with the competent authorities in the Republic of Moldova.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.10.2016 15:58
SOPHARMA AD (93/2016) Notification
05.10.2016 15:58SOPHARMA AD (93/2016) Notification
Podstawa prawna: art. 17. 1 MAR.
We would like to notify that Board of directors of Sopharma AD discussed a proposal filed by Homogen AD on October 4, 2016 for the sale of shares from the capital of Veta Farma AD. The Board of directors of Sopharma AD authorizes the Executive director to negotiate with representatives of the seller.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.10.2016 13:16
SOPHARMA AD (92/2016) Sopharma monthly September 2016
05.10.2016 13:16SOPHARMA AD (92/2016) Sopharma monthly September 2016
Podstawa prawna: art. 17. 1 MAR.
For the first nine months of this year, revenues from sales decreased by 3% compared to the same period of 2015, including 1% increase of domestic sales and a 5% decrease of export sales. "We are witnessing a positive trend in September, but it is hard to forecast whether it will be stable. However, we managed to a certain extent to compensate the weaker performance of the Russian market in the first half of this year.", comments Ognian Donev, PhD, Chariman of the Board of Directors and Executive director of Sopharma AD.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.10.2016 15:36
SOPHARMA AD (91/2016) Current report 91 buy back 04102016
04.10.2016 15:36SOPHARMA AD (91/2016) Current report 91 buy back 04102016
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD hereby informs that from 29 September 2016 up to and including 30 September 2016 the Company bought 57 328 own shares representing 0.027% of the share capital of the Company, at a total value of 171 228.54 BGN on the Bulgarian Stock Exchange, the average price per share was 2.99 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 662 414, representing 4.20% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 03.10.2016 17:19
SOPHARMA AD (90/2016) SPHTRCurrent report 90 re insiders transactions
03.10.2016 17:19SOPHARMA AD (90/2016) SPHTRCurrent report 90 re insiders transactions
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
30.9.2016 Sale 3 000 2.9300
30.9.2016 Sale 1 459 2.9300
30.9.2016 Sale 170 2.9300
30.9.2016 Sale 371 2.9300
30.9.2016 Sale 500 2.9300
30.9.2016 Sale 2 000 2.9350
3.10.2016 Sale 2 430 3.0550
3.10.2016 Sale 2 570 3.0550
3.10.2016 Sale 130 2.9700
3.10.2016 Sale 20 2.9700
3.10.2016 Sale 3 400 2.9700
3.10.2016 Sale 1 450 2.9700
3.10.2016 Sale 1 150 2.9700
3.10.2016 Sale 1 850 2.9700
4.10.2016 Sale 470 2.9300
4.10.2016 Sale 280 2.9300
4.10.2016 Sale 250 2.9300
4.10.2016 Sale 2 000 2.9550
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.09.2016 16:25
SOPHARMA AD (89/2016) Current report 89 buy back 29092016
29.09.2016 16:25SOPHARMA AD (89/2016) Current report 89 buy back 29092016
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD hereby informs that from 27 September up to and including 28 September 2016 the Company bought 97 705 own shares representing 0.07% of the share capital of the Company, at a total value of 285 115.51 BGN on the Bulgarian Stock Exchange, the average price per share was 2.91 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 605 086, representing 4.16% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.09.2016 14:40
SOPHARMA AD (88/2016) Current report 88 buy back 27092016
27.09.2016 14:40SOPHARMA AD (88/2016) Current report 88 buy back 27092016
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that from 15 September up to and including 26 September 2016 the Company bought 27 669 own shares representing 0.02% of the share capital of the Company, at a total value of 77 250.62 BGN on the Bulgarian Stock Exchange, the average price per share was 2.79 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 507 381, representing 4.085% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 20.09.2016 13:36
SOPHARMA AD (87/2016) SPH Notification
20.09.2016 13:36SOPHARMA AD (87/2016) SPH Notification
Podstawa prawna: art. 17. 1 MAR.
We would like to notify that on October 7 2016 (Friday) Sopharma AD organizes an Annual Meeting with Investors, on which the company will also present the new web site of Sopharma Group. The meeting will take place in the Conference center of Sopharma Business Towers, Sofia. We kindly request that all interested parties notify us not later than September 30 2016 by e-mail irevents@sopharma.bg or by telephone +3592 8134 319 in order to receive their registration forms. Places are limited.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.09.2016 14:17
SOPHARMA AD (86/2016) SPHTRCurrent report 86 re insiders transactions
16.09.2016 14:17SOPHARMA AD (86/2016) SPHTRCurrent report 86 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
14.9.2016 Buy 500 2.7100
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.09.2016 16:42
SOPHARMA AD (85/2016) Current report 85 buy back 15092016
15.09.2016 16:42SOPHARMA AD (85/2016) Current report 85 buy back 15092016
Podstawa prawna: art. 19. 3 MAR.
SOPHARMA AD hereby informs that from 8 September up to and including 14 September 2016 the Company bought 11 024 own shares representing 0.0082% of the share capital of the Company, at a total value of 30 167.82 BGN on the Bulgarian Stock Exchange, the average price per share was 2.73 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 479 712, representing 4.065% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 12.09.2016 13:47
SOPHARMA AD (84/2016) Current report 84 Alianz above 5% 12092016
12.09.2016 13:47SOPHARMA AD (84/2016) Current report 84 Alianz above 5% 12092016
Podstawa prawna: art. 17. 1 MAR.
Sopharma AD (the "Company") announces that on 12 September 2016 the Company received a notification for the acquisition of 81 401 shares, representing 0.06 % of its capital, by ZUPF Allianz Bulgaria. After the transaction the share of ZUPF Allianz Bulgaria in the capital of Sopharma AD reached 5.05%.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.09.2016 13:28
SOPHARMA AD (83/2016) Sopharma monthly August 2016
02.09.2016 13:28SOPHARMA AD (83/2016) Sopharma monthly August 2016
Podstawa prawna: art. 17. 1 MAR.
For the first eight months of this year, revenues from sales decreased by 4% compared to the same period of 2015, including 5% increase of domestic sales and a 10% decrease of export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 29.08.2016 17:39
SOPHARMA AD (82/2016) INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2016
29.08.2016 17:39SOPHARMA AD (82/2016) INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2016
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2016
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Additional Information
7. Annex 9
8. Lisn of insider information
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.08.2016 14:22
SOPHARMA AD (81/2016) Notification - current report 81
18.08.2016 14:22SOPHARMA AD (81/2016) Notification - current report 81
Podstawa prawna: art. 17. 1 MAR.
In accordance with the provisions of paragraph 38 from the Ordinance on the Prospectuses Sopharma AD hereby advises that it is in contractual relationship with Service Financial Markets EOOD - www.x3news.com and Investor.bg - www.investor.bg and uses these platforms in order to disseminate periodic and other regulated information.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 16.08.2016 14:02
SOPHARMA AD (80/2016) Notification - current report 80
16.08.2016 14:02SOPHARMA AD (80/2016) Notification - current report 80
Podstawa prawna: art. 17. 1 MAR.
In accordance with the provisions of art. 27, para 3 from Ordinance 2 on the prospectuses Sopharma AD hereby advises that the company has published and disseminated information to the public in the last 12 months in the Republic of Bulgaria and in other member states in the following ways:
1. Through the unified information system of the Bulgarian Stock Exchange E-register - www.fsc.bg;
2. Through X3news information agency - http://www.x3news.com;
3. Through the electroinc media Investor.bg - www.investor.bg;
4. Through Infostock bulletin - www.infostock.bg/;
5. Through the internet web site of the company - www.sopharma.bg;
6. Through the Polish Financial Supervision Commission system ESPI;
7. Through the Polish Press Agency - www.pap.pl
Please, make the above information public.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 15.08.2016 14:46
SOPHARMA AD (79/2016) Current report 79 re insiders transactions
15.08.2016 14:46SOPHARMA AD (79/2016) Current report 79 re insiders transactions
Podstawa prawna: art. 19. 3 MAR.
Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
08.08.2016 Sale 80 2.79
08.08.2016 Sale 200 2.79
08.08.2016 Sale 220 2.79
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 10.08.2016 15:08
SOPHARMA AD (78/2016) Current report 78 buy back 10082016
10.08.2016 15:08SOPHARMA AD (78/2016) Current report 78 buy back 10082016
Podstawa prawna: art. 17. 1 MAR.
SOPHARMA AD hereby informs that on 8 August 2016 the Company bought 450 own shares representing 0.00033% of the share capital of the Company, at a total value of 1242.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.76 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 468 688, representing 4.06% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.08.2016 14:24
SOPHARMA AD (77/2016) Current report 77 re insiders transactions
08.08.2016 14:24SOPHARMA AD (77/2016) Current report 77 re insiders transactions
Podstawa prawna: Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
02.08.2016 Buy 250 2.70
02.08.2016 Sale 800 2.735
02.08.2016 Sale 200 2.735
02.08.2016 Sale 250 2.749
02.08.2016 Sale 50 2.739
02.08.2016 Sale 100 2.739
02.08.2016 Sale 50 2.739
02.08.2016 Sale 250 2.76
03.08.2016 Sale 500 2.75
03.08.2016 Sale 140 2.75
03.08.2016 Sale 300 2.76
04.08.2016 Sale 500 2.78
05.08.2016 Sale 500 2.78
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 08.08.2016 11:37
SOPHARMA AD (76/2016) Current report 76 re insiders transactions
08.08.2016 11:37SOPHARMA AD (76/2016) Current report 76 re insiders transactions
Podstawa prawna: Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
25.07.2016 Buy 1 500 2.555
25.07.2016 Sale 12 2.685
26.07.2016 Sale 308 2.685
26.07.2016 Sale 500 2.690
27.07.2016 Sale 500 2.695
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.08.2016 13:57
SOPHARMA AD (75/2016) Current report 75 buy back 05082016
05.08.2016 13:57SOPHARMA AD (75/2016) Current report 75 buy back 05082016
Podstawa prawna: SOPHARMA AD hereby informs that from 2 August 2016 up to and including 4 August 2016 the Company bought 4 464 own shares representing 0.0033% of the share capital of the Company, at a total value of 12 410.83 BGN on the Bulgarian Stock Exchange, the average price per share was 2.78 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 468 238, representing 4.06% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.08.2016 13:21
SOPHARMA AD (74/2016) Sopharma monthly July 2016
05.08.2016 13:21SOPHARMA AD (74/2016) Sopharma monthly July 2016
Podstawa prawna: For the first seven months of this year, revenues from sales decreased by 3% compared to the same period of 2015, including same level of domestic sales and a 4% decrease of export sales.
The good results in July led to reduced decrease of revenues for the period which was mainly due to the instability of the Russian market.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 02.08.2016 16:31
SOPHARMA AD (73/2016) Current report 73 buy back 02082016
02.08.2016 16:31SOPHARMA AD (73/2016) Current report 73 buy back 02082016
Podstawa prawna: SOPHARMA AD hereby informs that from 29 July 2016 up to and including 1 August 2016 the Company bought 10 853 own shares representing 0.0081% of the share capital of the Company, at a total value of 29 813.99 BGN on the Bulgarian Stock Exchange, the average price per share was 2.75 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 463 774, representing 4.05% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 01.08.2016 13:00
SOPHARMA AD (72/2016) Current report 72 buy back 29072016
01.08.2016 13:00SOPHARMA AD (72/2016) Current report 72 buy back 29072016
Podstawa prawna:
SOPHARMA AD hereby informs that on 28 July 2016 the Company bought 2968 own shares representing 0.0022% of the share capital of the Company, at a total value of 8011.26 BGN on the Bulgarian Stock Exchange, the average price per share was 2.70 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 452 921, representing 4.05% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 28.07.2016 13:05
SOPHARMA AD (71/2016) INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2016
28.07.2016 13:05SOPHARMA AD (71/2016) INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2016
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2016
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Insider Information
7. Additional Information
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.07.2016 16:46
SOPHARMA AD (70/2016) Current report 70 re insiders transactions
27.07.2016 16:46SOPHARMA AD (70/2016) Current report 70 re insiders transactions
Podstawa prawna: Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
12.07.2016 Buy 500 2.55
14.07.2016 Buy 320 2.55
18.07.2016 Sale 500 2.59
18.07.2016 Sale 250 2.59
19.07.2016 Sale 200 2.595
19.07.2016 Sale 300 2.595
22.07.2016 Sale 500 2.65
19.07.2016 Buy 5 000 2.555
19.07.2016 Buy 5 000 2.555
19.07.2016 Buy 5 000 2.555
19.07.2016 Buy 5 000 2.555
19.07.2016 Buy 3 500 2.555
19.07.2016 Buy 5 000 2.555
19.07.2016 Buy 5 000 2.555
19.07.2016 Buy 4 000 2.555
21.07.2016 Buy 51 2.62
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 27.07.2016 14:15
SOPHARMA AD (69/2016) SPH Notification- paying of dividents 2016
27.07.2016 14:15SOPHARMA AD (69/2016) SPH Notification- paying of dividents 2016
Podstawa prawna: SOPHARMA AD hereby informs that the Company will commence the paying of dividends for 2015 on 3 August 2016 in accordance with a List of Entitled Persons as at 1 July 2016, prepared by the Central Depository.
Pursuant to the Regulations of the Central Depository AD the dividend will be paid out as follows: to shareholders with client accounts at an investment intermediary - through the investment intermediary, to shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.
The gross dividend, voted on the AGM, amounts to 0.07 BGN (seven stotinki) per share.
The net amount of the dividend (only for physical persons) is 0.0665 BGN per share.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 21.07.2016 15:55
SOPHARMA AD (68/2016) Current report 68 buy back 21072016
21.07.2016 15:55SOPHARMA AD (68/2016) Current report 68 buy back 21072016
Podstawa prawna: SOPHARMA AD hereby informs that from 14 July 2016 up to and including 20 July 2016 the Company bought 46 842 own shares representing 0.035% of the share capital of the Company, at a total value of 120 105.05 BGN on the Bulgarian Stock Exchange, the average price per share was 2.56 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 445 715, representing 4.04% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 18.07.2016 12:10
SOPHARMA AD (67/2016) Current report 67 re insiders transactions
18.07.2016 12:10SOPHARMA AD (67/2016) Current report 67 re insiders transactions
Podstawa prawna: Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
14.07.2016 Buy 300 2.5500
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 14.07.2016 14:27
SOPHARMA AD (66/2016) Current report 66 buy back 14072016
14.07.2016 14:27SOPHARMA AD (66/2016) Current report 66 buy back 14072016
Podstawa prawna: SOPHARMA AD hereby informs that from 7 July 2016 up to and including 13 July 2016 the Company bought 177 877 own shares representing 0.13% of the share capital of the Company, at a total value of 454 531.32 BGN on the Bulgarian Stock Exchange, the average price per share was 2.555 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 398 873, representing 4.01% of the share capital of the Company.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.07.2016 15:40
SOPHARMA AD (65/2016) Current report 65 re insiders transactions
11.07.2016 15:40SOPHARMA AD (65/2016) Current report 65 re insiders transactions
Podstawa prawna: Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
06.07.2016 Sale 5 2.61
04.07.2016 Sale 100 2.61
04.07.2016 Sale 60 2.61
07.07.2016 Sale 300 2.595
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 11.07.2016 15:30
SOPHARMA AD (64/2016) Current report 64 re insiders transactions
11.07.2016 15:30SOPHARMA AD (64/2016) Current report 64 re insiders transactions
Podstawa prawna: Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
12.07.2016 Buy 300 2.5400
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 05.07.2016 16:37
SOPHARMA AD (63/2016) Current report 63 re insiders transactions
05.07.2016 16:37SOPHARMA AD (63/2016) Current report 63 re insiders transactions
Podstawa prawna: Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
28.06.2016 Buy 100 2.60
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
- 04.07.2016 14:22
SOPHARMA AD Current report 62 re insiders transactions
04.07.2016 14:22SOPHARMA AD Current report 62 re insiders transactions
Podstawa prawna: Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
4.7.2016 Buy 60 2.6100
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 04.07.2016 14:09
SOPHARMA AD Sopharma monthly June 2016
04.07.2016 14:09SOPHARMA AD Sopharma monthly June 2016
Podstawa prawna: For the first six months of this year, revenues from sales decreased by 10% compared to the same period of 2015, including 3% decrease of domestic sales and a 15% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 28.06.2016 10:00
SOPHARMA AD Current report 60 re insiders transactions
28.06.2016 10:00SOPHARMA AD Current report 60 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
27.6.2016 Buy 30 2.6500
28.6.2016 Buy 200 2.5900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 21.06.2016 13:47
SOPHARMA AD Notification - proxy voting on the Annual General Meeting
21.06.2016 13:47SOPHARMA AD Notification - proxy voting on the Annual General Meeting
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
The Board of Directors of Sopharma AD (the "Company") hereby informs about proxy voting on the Annual General Meeting of Shareholders of Sopharma AD, held on 17 June 2016 in Sofia, 5 Lachezar Stanchev Str., as follows:
1. In accordance with a power of attorney by Michael Kania, VP and Sean Garrison, VP in their capacity as shareholders of The Bank of New York Mellon-/BNY/ Omnibus Account, a company organized and operating under the laws of the State of New York, USA, with seat at One Wall Street, New York, New York 10286, USA/new address 225 Liberty Street, New York, New York, U.S.A./, authorize Yavor Bogomilov Dojdevski, Sofia to represent The Bank of New York Mellon-/BNY/ Omnibus Account, a shareholder with 225 237 shares.
2. In accordance with a power of attorney by Michael Kania, VP and Sean Garrison, VP in their capacity as shareholders of The Bank of New York Mellon-/Mellon/ Omnibus Account, a company organized and operating under the laws of the State of New York, USA, with seat at One Wall Street, New York, New York 10286, USA/new address 225 Liberty Street, New York, New York, U.S.A./, authorize Yavor Bogomilov Dojdevski, Sofia to represent The Bank of New York Mellon-/ Mellon / Omnibus Account, a shareholder with 80,400 shares.
3. In accordance with a power of attorney by Miroslav Krumov Marinov, CEO and Daniela Petkova Panova, Chairman of the Management Board of PAC "Doverie" AD, UID 831190986, jointly representing the shareholders UPF "Doverie", UID 130474628, holding 5 462 488 shares were represented by Ivan Petrov Baltov, Sofia.
4. In accordance with a power of attorney by Ventsislav Simeonov Stoev, a shareholder, holding 153 804 share, authorize Boris Anchev Borisov, Sofia.
5. In accordance with a power of attorney by Radoslava Georgieva Maslarska and Momchil Stanchev Tikov, in their capacity as lawful representatives of Elana Trading AD, UID 831470130, a shareholder, holding 29 953 shares, authorize attorney Tatiana Angelova Puncheva-Vassileva, Bracigovo.
6. In accordance with a notarized power of attorney under ą7942 from 6 June 2016 by Notary Petya Angelova, reg. ą 496 of the Penal Code, Valentina Doncheva Koleva, Targovishte, as a shareholder holding 1 share authorizes Nikolay Yankov Kolev, Targovishte.
7. In accordance with a power of attorney by Atanas Atanasov Petrov, in his capacity as Executive Director of NN Pension Insurance Company EAD, Sofia, Triaditsa, 49B Bulgaria Blvd, ent. A, floor 7 with UID 121708719, acting on behalf of each of the managed pension funds by the Company, namely: NN Universal Pension Fund, UID 130478014, a shareholder holding 2 836 203 shares, NN Professional Pension Fund UID 130432636, a shareholder holding 201 174 shares and NN Voluntary Pension Fund, UID 130437051, a shareholder holding 388 141 shares, authorizes Tsvetomir Serafimov Iliev, Sofia.
8. In accordance with a power of attorney by Strahil Nikolov Vidinov,CEO, and Vladislav Rusev Rusev, Procurator of the Pension Insurance Company Allianz Bulgaria AD, Sofia, UID 121050885, managing and representing ZUPF Allianz Bulgaria, Sofia, UID 130477720, holding 6,726,310 shares, ZPPF Allianz Bulgaria, Sofia, UID 130430119, holding 674 833 shares and VPF Allianz Bulgaria, Sofia, UID 130401021, holding 1 465 555 shares, authorizes Georgi Alexandrov Babev, Sofia.
9. In accordance with a power of attorney by Nikolay Ivanov Marev, CEO and legal representative of the Pension Insurance Company "DSK-Rodina" AD, Sofia, UID 121507164, managing and representing UPF DSK-Rodina" AD, Sofia, UID 130479810, holding 3 438 004 shares, PPF "DSK-Rodina" AD, Sofia, UID 130432485, holding 349 232 shares and DPF "DSK-Rodina" AD, Sofia, UID 130409819, holding 209 757 shares, DPF professional schemes "DSK-Rodina" AD, Sofia, UID 175456360, holding 39 456 shares authorizes Konstantin Dimitrov Abrashev, Sofia.
10. In accordance with a power of attorney by Katina Slavkova Peicheva, executive director and Ivan Borisov Kutlov, Procurator, in their capacity as representatives of OBB Asset Management AD, Sofia, 5 Sveta Sofia Str., UIC 131239768, in its capacity as managing company of CF OBB Premium Shares, UIC 131562547, a shareholder holding 277 490 shares, and managing company of IC OBB Balanced Fund AD, UIC 131326575, a shareholder holding 61 448 shares, authorize Marieta Tihomirova Damiyanova Babeva ,Sofia.
11. In accordance with a power of attorney by Dimityr Georgiev Dimitrov, in his capacity as lawful representatives of Sopharma Trading AD, UID 103267194, a shareholder, holding 139 900 shares, authorize attorney Ventsislav Stefanov Marinov, Sofia.
Więcej na: biznes.pap.pl
kom espi zdz
- 20.06.2016 17:48
SOPHARMA AD MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 17 JUNE 2016
20.06.2016 17:48SOPHARMA AD MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 17 JUNE 2016
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
MINUTES OF THE ANNUAL GENERAL MEETING
OF SHAREHOLDERS OF
SOPHARMA AD - SOFIA, 17 JUNE 2016
Więcej na: biznes.pap.pl
kom espi zdz
- 20.06.2016 14:05
SOPHARMA AD Current report 57 re insiders transactions
20.06.2016 14:05SOPHARMA AD Current report 57 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
13.06.2016 Sale 150 2.69
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 20.06.2016 11:49
SOPHARMA AD Current report 56 re insiders transactions
20.06.2016 11:49SOPHARMA AD Current report 56 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
20.6.2016 Buy 100 2.6410
20.6.2016 Buy 80 2.6690
20.6.2016 Buy 20 2.6600
21.6.2016 Buy 185 2.6700
21.6.2016 Buy 115 2.6700
21.6.2016 Buy 100 2.6700
21.6.2016 Buy 300 2.6600
21.6.2016 Buy 500 2.6300
21.6.2016 Buy 250 2.6410
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 17.06.2016 17:25
SOPHARMA AD Notification AGM
17.06.2016 17:25SOPHARMA AD Notification AGM
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that on the regular General Meeting of Shareholders of Sopharma AD, conducted on 17 June 2016 in Sofia, 5 Lachezar Stanchev Str., were taken the following decisions:
AGM approved the Annual report of the Board of Directors of the Company for 2015.
AGM approved the Annual report of the Investor Relations Director for 2015;
AGM approved the Audit report on the audit of the annual financial statements of the Company for 2015;
AGM approved the audited annual financial statements of the Company for 2015;
AGM approved the audited annual consolidated financial statements of the Company for 2015;
AGM approved the report of the Audit Committee for 2015;
AGM approved the proposal by the Board of Directors for the distribution of the profit generated in 2015 and the undistributed profit from past periods as follows: the total amount of the profit, subject to distribution, is 25 846 056.41 BGN /twenty-five million, eight hundred and forty-six thousand, fifty-six leva and forty-one stotinki/, of which the profit for 2015 amounts to 25 353 856.99 BGN /twenty-five million, three hundred and fifty-three thousand, eight hundred and fifty-six leva and ninety-nine stotinki/ and undistributed profit from past periods amounts to 492 199.42 BGN /four hundred and ninety-two thousand, one hundred and ninety-nine leva and forty-two stotinki/. After the allocation of 10% to the statutory reserve, a dividend shall be distributed to shareholders at the amount of 0.07 BGN /seven stotinki/ per share with dividend right. The remaining sum after the allocation of the divided shall be allocated to the additional reserves of the Company.
AGM discharged from liability the members of the Board of Directors for their activities in 2015;
AGM elected a registered auditor to audit and certify the annual financial statements of the Company for 2016 according to the proposal of the Audit Committee, included in the agenda materials.
AGM approved the Report of the Board of Directors about the application of the Remuneration policy for the members of the Board of Directors of the Company in 2015.
On the basis of art. 24, par. 3, letter A of the Company's Articles of Association AGM decided: the regular monthly remuneration of the members of the Board of Directors, as well as the regular monthly remuneration of the Executive Director in 2016 shall remain the same.
Pursuant to art. 24, par. 3, letter B of the Articles of Association an additional fee of 1% /one percent/ of the net profit for 2015 according to the approved annual financial statements, shall be paid to the Executive Director of the Company;
AGM approved the decision for the distribution of 2% /two percent/ of the net profit for 2015 among the members of the senior management of the Company in compliance with the requirements of art. 26a, item 12 of the Articles of Association of the Company.
AGM approved the continuation of the mandate of the Board of Directors in its current composition for a new five-year term from the date of expiration of the current mandate until 29 June 2021.
AGM approved the changes in the Articles of Association of the Company according to the proposal of the Board of Directors.
AGM approved the Substantiated report, prepared by the Board of Directors, for transactions under art. 114, par. 1 of POSA.
AGM authorized the Board of Directors of the Company to conclude a contract for manufacturing according to the terms and conditions, listed in Chapter 1 of the Substantiated report.
AGM authorized the Board of Directors of the Company to conclude a contract for provisioning of collateral in the form of a corporate guarantee according to the terms and conditions, listed in Chapter 2 of the Substantiated report.
AGM authorized the Board of Directors of the Company to conclude a contract for provisioning of collateral in the form of a corporate guarantee according to the terms and conditions, listed in Chapter 3 of the Substantiated report.
AGM authorized the Board of Directors of the Company to conclude a contract for manufacturing according to the terms and conditions, listed in Chapter 4 of the Substantiated report.
Więcej na: biznes.pap.pl
kom espi zdz
- 17.06.2016 16:10
SOPHARMA AD Current report 54 SPH Annual General Meeting - 17.06.2016
17.06.2016 16:10SOPHARMA AD Current report 54 SPH Annual General Meeting - 17.06.2016
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
Sopharma AD hereby notifies all shareholders of the Company about the decision of the AGM of Sopharma AD that took place on June 17th, 2016 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:
AGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.07 BGN /seven stotinki/ per share with dividend right.
The persons eligable for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken.
After the exact amount of the dividend has been determined, based on a list of shareholders, provided. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country. Payment of dividend will commence within three months from the date of the AGM, on which the payment of dividend was approved.
Więcej na: biznes.pap.pl
kom espi zdz
- 13.06.2016 11:58
SOPHARMA AD Current report 53 re insiders transactions
13.06.2016 11:58SOPHARMA AD Current report 53 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
8.6.2016 Buy 100 2.6430
8.6.2016 Buy 50 2.6430
9.6.2016 Buy 100 2.6900
10.6.2016 Buy 253 2.6430
10.6.2016 Buy 97 2.6430
10.6.2016 Buy 500 2.6210
13.6.2016 Buy 150 2.6900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 06.06.2016 13:00
SOPHARMA AD Sopharma monthly May 2016
06.06.2016 13:00SOPHARMA AD Sopharma monthly May 2016
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
For the first five months of this year, revenues from sales decreased by 13% compared to the same period of 2015, including 3% decrease of domestic sales and a 19% decrease of export sales, which is due to the lower number of workdays in the month of May.
Więcej na: biznes.pap.pl
kom espi zdz
- 06.06.2016 08:58
SOPHARMA AD Current report 51 re insiders transactions
06.06.2016 08:58SOPHARMA AD Current report 51 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
1.6.2016 Buy 1 500 2.7290
1.6.2016 Buy 500 2.6810
1.6.2016 Buy 2 2.6810
1.6.2016 Buy 998 2.6810
1.6.2016 Buy 600 2.6800
1.6.2016 Buy 200 2.7250
3.6.2016 Buy 400 2.6750
3.6.2016 Buy 1 000 2.6700
3.6.2016 Buy 250 2.6620
3.6.2016 Buy 200 2.7000
6.6.2016 Buy 400 2.7100
6.6.2016 Buy 160 2.7090
7.6.2016 Buy 1 000 2.6650
7.6.2016 Buy 670 2.6640
7.6.2016 Buy 330 2.6640
7.6.2016 Buy 800 2.6600
7.6.2016 Buy 800 2.6500
7.6.2016 Buy 200 2.6600
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 30.05.2016 14:17
SOPHARMA AD CONSOLIDATED FINANCIAL STATEMENTS FOR Q1 2016
30.05.2016 14:17SOPHARMA AD CONSOLIDATED FINANCIAL STATEMENTS FOR Q1 2016
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
CONSOLIDATED FINANCIAL STATEMENTS FOR Q1 2016
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
Więcej na: biznes.pap.pl
kom espi zdz
- 30.05.2016 10:11
SOPHARMA AD Current report 49 re insiders transactions
30.05.2016 10:11SOPHARMA AD Current report 49 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
30.5.2016 Buy 500 2.6810
30.5.2016 Buy 750 2.6620
31.5.2016 Buy 300 2.7250
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 25.05.2016 11:45
SOPHARMA AD SPHTRCurrent report 48 re insiders transactions
25.05.2016 11:45SOPHARMA AD SPHTRCurrent report 48 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
18.5.2016 Buy 500 2.7400
18.5.2016 Buy 396 2.7200
18.5.2016 Buy 250 2.7150
18.5.2016 Buy 100 2.7200
19.5.2016 Buy 500 2.7440
19.5.2016 Buy 500 2.7150
19.5.2016 Buy 70 2.7150
19.5.2016 Buy 200 2.7490
19.5.2016 Buy 1 000 2.7400
20.5.2016 Buy 200 2.7400
20.5.2016 Buy 164 2.7110
20.5.2016 Buy 180 2.7150
20.5.2016 Buy 836 2.7110
20.5.2016 Buy 1 000 2.7000
20.5.2016 Buy 1 000 2.6800
25.5.2016 Buy 1 000 2.6710
25.5.2016 Buy 300 2.7000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 19.05.2016 13:41
SOPHARMA AD Notification - current report 47
19.05.2016 13:41SOPHARMA AD Notification - current report 47
Podstawa prawna: Inne uregulowania
We would like to notify you that on 16 May 2016 expired the three-month period under art. 157b of the POSA after the completion of the tender offer, in which each shareholder who did not participate in the tender offer may request from Sopharma AD to buy their shares with voting rights. The price per share of Medica AD in the proposal under art. 157a and upon the execution of the shareholder rights under art. 157b under the provisions of art. 157a par. 3 was equal to the price in the conducted tender offer of 3.50 BGN per share.
As a result of the conducted tender offer and after the completion of the transactions with shareholders in the period under art. 157b, Sopharma AD has bought a total of 3,135,006 shares and directly owns 97.94% of the shares with voting rights of Medica AD.
Więcej na: biznes.pap.pl
kom espi zdz
- 16.05.2016 12:03
Sopharma planuje wypłacić 0,07 BGN dywidendy na akcję
16.05.2016 12:03Sopharma planuje wypłacić 0,07 BGN dywidendy na akcję
Walne Sopharmy zwołano na 17 czerwca. (PAP)
seb/ jtt/
- 16.05.2016 11:23
SOPHARMA AD INVITATION TO THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - 17 JUNE 2016
16.05.2016 11:23SOPHARMA AD INVITATION TO THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - 17 JUNE 2016
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
INVITATION TO THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - 17 JUNE 2016
Więcej na: biznes.pap.pl
kom espi zdz
- 16.05.2016 09:50
SOPHARMA AD SPHTRCurrent report 45 re insiders transactions
16.05.2016 09:50SOPHARMA AD SPHTRCurrent report 45 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
13.5.2016 Buy 600 2.7400
13.5.2016 Buy 1 000 2.7400
14.5.2016 Buy 680 2.7470
14.5.2016 Buy 1 320 2.7470
16.5.2016 Buy 500 2.7450
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 11.05.2016 13:04
SOPHARMA AD Notification
11.05.2016 13:04SOPHARMA AD Notification
Podstawa prawna: Inne uregulowania
The Board of Directors of SOPHARMA AD (the "Company") hereby informs that for April 2016 Sopharma AD realized a decrease of sales revenues of 19% compared to the same month of last year, including retention of the level of domestic sales and 29% decrease of export sales.
For the first four months of 2016 sales revenues decreased by 4% compared to the same period of 2015, including a 6% increase of domestic sales and a 10% decrease of export sales. In the past two months there has been a sharp decline in the purchasing power of the population in Russia and conservative use of resources by households as the indexation of the prices has outpaced the indexation of wages. We expect that this trend will continue in the summer months, which are traditionally weak.
Więcej na: biznes.pap.pl
kom espi zdz
- 10.05.2016 14:24
SOPHARMA AD Notification
10.05.2016 14:24SOPHARMA AD Notification
Podstawa prawna: Inne uregulowania
The Board of Directors of SOPHARMA AD (the "Company") hereby informs that the Board of Directors of Sopharma AD authorized the executive director of the company to enter into a contract for the sale of the shareholding of Sopharma AD in the capital of Ivanchich and Sons, Serbia. The transaction was concluded on May 9th, 2016 in Belgrade, Serbia. The parameters of the transaction are subject to confidentiality clauses in the interest of the all parties. Sopharma AD will continue its activities on the Serbian market through its daughter company Sopharma Trading AD.
Więcej na: biznes.pap.pl
kom espi zdz
- 03.05.2016 16:15
SOPHARMA AD NOTIFICATION OF INSIDERS' TRANSACTIONS
03.05.2016 16:15SOPHARMA AD NOTIFICATION OF INSIDERS' TRANSACTIONS
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
27.4.2016 Buy 400 2.6600
3.5.2016 Buy 500 2.6850
3.5.2016 Buy 1 000 2.6660
3.5.2016 Buy 560 2.6210
3.5.2016 Buy 185 2.6660
3.5.2016 Buy 114 2.6850
3.5.2016 Buy 400 2.6850
4.5.2016 Buy 500 2.7000
4.5.2016 Buy 500 2.6950
4.5.2016 Buy 400 2.6630
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 28.04.2016 12:46
SOPHARMA AD CONSOLIDATED ANNUAL AUDITED FINANCIAL STATEMENTS FOR 2015
28.04.2016 12:46SOPHARMA AD CONSOLIDATED ANNUAL AUDITED FINANCIAL STATEMENTS FOR 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
CONSOLIDATED ANNUAL AUDITED FINANCIAL STATEMENTS FOR 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Auditor's report
Więcej na: biznes.pap.pl
kom espi zdz
- 28.04.2016 11:53
SOPHARMA AD Notification
28.04.2016 11:53SOPHARMA AD Notification
Podstawa prawna: Inne uregulowania
Sopharma AD notifies that in connection with the Easter Holiday the results for April 2016 will be published on 11 May 2016
Więcej na: biznes.pap.pl
kom espi zdz
- 27.04.2016 13:18
SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 MARCH 2016
27.04.2016 13:18SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 MARCH 2016
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Insider Information
7. Additional Information
Więcej na: biznes.pap.pl
kom espi zdz
- 25.04.2016 16:28
SOPHARMA AD SPHTRCurrent report 38 re insiders transactions
25.04.2016 16:28SOPHARMA AD SPHTRCurrent report 38 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
20.4.2016 Buy 270 2.6300
20.4.2016 Buy 967 2.6200
20.4.2016 Buy 95 2.6300
20.4.2016 Buy 260 2.6200
21.4.2016 Buy 200 2.6200
21.4.2016 Buy 1 423 2.6200
21.4.2016 Buy 577 2.6200
21.4.2016 Buy 573 2.6200
21.4.2016 Buy 125 2.6470
26.4.2016 Buy 200 2.6800
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 18.04.2016 16:48
SOPHARMA AD SPHTRCurrent report 37 re insiders transactions
18.04.2016 16:48SOPHARMA AD SPHTRCurrent report 37 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
6.4.2016 Buy 200 2.6900
6.4.2016 Buy 900 2.7000
6.4.2016 Buy 500 2.7000
6.4.2016 Buy 500 2.7000
6.4.2016 Buy 500 2.7000
6.4.2016 Buy 800 2.7000
6.4.2016 Buy 240 2.7000
7.4.2016 Buy 80 2.6800
7.4.2016 Buy 1 500 2.6900
7.4.2016 Buy 500 2.6900
7.4.2016 Buy 325 2.6650
7.4.2016 Buy 110 2.6650
8.4.2016 Buy 500 2.6650
11.4.2016 Buy 500 2.6930
12.4.2016 Buy 100 2.6900
12.4.2016 Buy 400 2.6900
12.4.2016 Buy 500 2.6800
31.3.2016 Buy 200 2.7000
31.3.2016 Buy 149 2.7040
31.3.2016 Buy 200 2.7000
1.4.2016 Buy 220 2.7000
1.4.2016 Buy 200 2.7000
1.4.2016 Buy 100 2.7000
1.4.2016 Buy 200 2.7000
1.4.2016 Buy 200 2.7000
1.4.2016 Buy 100 2.7000
1.4.2016 Buy 100 2.7000
1.4.2016 Buy 200 2.7000
1.4.2016 Buy 200 2.7000
1.4.2016 Buy 200 2.7000
1.4.2016 Buy 200 2.7000
1.4.2016 Buy 96 2.7000
1.4.2016 Buy 250 2.6950
1.4.2016 Buy 500 2.6850
1.4.2016 Buy 250 2.6850
1.4.2016 Buy 195 2.6850
4.4.2016 Buy 500 2.6850
4.4.2016 Buy 160 2.6850
4.4.2016 Buy 340 2.6850
5.4.2016 Buy 69 2.6950
13.4.2016 Buy 200 2.6700
13.4.2016 Buy 115 2.6600
13.4.2016 Buy 65 2.6650
13.4.2016 Buy 385 2.6600
18.4.2016 Buy 500 2.6800
18.4.2016 Buy 100 2.6770
18.4.2016 Buy 500 2.6700
18.4.2016 Buy 135 2.6300
18.4.2016 Buy 500 2.6300
19.4.2016 Buy 320 2.6700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 12.04.2016 08:18
SOPHARMA AD Current report 36 re insiders transactions
12.04.2016 08:18SOPHARMA AD Current report 36 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
06.04.2016 Sale 400 2.700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.04.2016 13:12
SOPHARMA AD Sopharma monthly March 2016
05.04.2016 13:12SOPHARMA AD Sopharma monthly March 2016
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for March 2016 the Company recorded a decrease of sales revenues of 19% compared to the same month of 2015, including 17% increase of domestic sales and 36% decrease of export sales.
For the first three months of this year, revenues from sales increased by 2% compared to the same period of 2015, including 8% increase of domestic sales and a 1% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.04.2016 10:55
SOPHARMA AD Current report 34 re insiders transactions
05.04.2016 10:55SOPHARMA AD Current report 34 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
28.03.2016 Sale 5 2.71
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 30.03.2016 13:42
SOPHARMA AD INDIVIDUAL AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2015
30.03.2016 13:42SOPHARMA AD INDIVIDUAL AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
INDIVIDUAL AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management Report
4. Comply or Explain Report
5. Auditor's Report
6. Appendix 11
7. Report Regarding the Application of the Remuneration Policy for the Members of the Board of Directors of Sopharma AD for 2015
8. Declaration
9. Scorecard
10. Templates of the financial reports approved by the Bulgarian FSC
Więcej na: biznes.pap.pl
kom espi zdz
- 29.03.2016 14:11
SOPHARMA AD Current report 32 re insiders transactions
29.03.2016 14:11SOPHARMA AD Current report 32 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
24.03.2016 Sale 500 2.68
25.03.2016 Sale 300 2.70
24.03.2016 Sale 500 2.68
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 28.03.2016 11:14
SOPHARMA AD SPHTRCurrent report 31 re insiders transactions
28.03.2016 11:14SOPHARMA AD SPHTRCurrent report 31 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
25.3.2016 Buy 300 2.7000
28.3.2016 Buy 200 2.6900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 25.03.2016 08:26
SOPHARMA AD Current report 30 re insiders transactions
25.03.2016 08:26SOPHARMA AD Current report 30 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
14.03.2016 Sale 100 2.67
14.03.2016 Sale 500 2.67
16.03.2016 Sale 293 2.68
16.03.2016 Sale 290 2.69
14.03.2016 Sale 400 2.67
16.03.2016 Sale 107 2.68
16.03.2016 Sale 200 2.68
16.03.2016 Sale 300 2.69
16.03.2016 Sale 10 2.69
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 15.03.2016 15:55
SOPHARMA AD Current report 29 re insiders transactions
15.03.2016 15:55SOPHARMA AD Current report 29 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
09.03.2016 Sale 360 2.68
09.03.2016 Buy 495 2.619
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 14.03.2016 12:41
SOPHARMA AD SPHTR Current report 28 re insiders transactions
14.03.2016 12:41SOPHARMA AD SPHTR Current report 28 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
10.3.2016 Buy 45 2.6700
10.3.2016 Buy 155 2.6700
11.3.2016 Buy 146 2.6300
14.3.2016 Buy 267 2.6690
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 02.03.2016 13:01
SOPHARMA AD Sopharma monthly February 2016
02.03.2016 13:01SOPHARMA AD Sopharma monthly February 2016
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for February 2016 the Company recorded a decrease of sales revenues of 2% compared to the same month of 2015, including 7% increase of domestic sales and 7% decrease of export sales.
For the first two months of this year, revenues from sales increased by 17% compared to the same period of 2015, including 4% increase of domestic sales and a 28% increase of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 29.02.2016 16:26
SOPHARMA AD Current report 26 re insiders transactions
29.02.2016 16:26SOPHARMA AD Current report 26 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
22.02.2016 Sale 300 2.68
22.02.2016 Sale 200 2.68
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 29.02.2016 16:24
SOPHARMA AD SPHTRCurrent report 25 re insiders transactions
29.02.2016 16:24SOPHARMA AD SPHTRCurrent report 25 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
24.2.2016 Buy 250 2.6500
24.2.2016 Buy 70 2.6700
25.2.2016 Buy 342 2.6320
26.2.2016 Buy 236 2.6900
29.2.2016 Buy 110 2.6420
29.2.2016 Buy 360 2.6420
29.2.2016 Buy 30 2.6420
29.2.2016 Buy 301 2.6410
29.2.2016 Buy 199 2.6410
29.2.2016 Buy 158 2.6320
29.2.2016 Buy 500 2.6200
1.3.2016 Buy 168 2.6200
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 29.02.2016 14:07
SOPHARMA AD CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2015
29.02.2016 14:07SOPHARMA AD CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
Więcej na: biznes.pap.pl
kom espi zdz
- 26.02.2016 13:14
SOPHARMA AD Current report 23 Notification
26.02.2016 13:14SOPHARMA AD Current report 23 Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
In relation to the right of the shareholders of Medica AD under art. 157b from the LPOS to request from the majority shareholder of Medica AD Sopharma AD to buy out their shares with voting right, we hereby inform you that Sopharma AD will use the services of investment intermediary Elana Trading AD for this process. Sopharma AD hereby kindly asks all shareholders who would like to exercise this right to file their written request for buy out, with all details concerning the shareholder and the shares owned by him with Elana Trading www.elana.net. In that respect we advise all such shareholders that they can contact Elana Trading Ad by email at brokers@elana.net and by telephone at 02/81 000 25 and 02/81 00026. We hereby notify also that the right under art. 157b from the LPOS can be exercised before May 16 2016 and that the majority shareholder Sopharma AD is obligated to conclude the transaction within one month from receiving the written request.
Więcej na: biznes.pap.pl
kom espi zdz
- 22.02.2016 16:17
SOPHARMA AD Current report 22 re insiders transactions
22.02.2016 16:17SOPHARMA AD Current report 22 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
19.02.2016 Buy 230 2.645
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 22.02.2016 09:53
SOPHARMA AD SPHTRCurrent report 21 re insiders transactions
22.02.2016 09:53SOPHARMA AD SPHTRCurrent report 21 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
19.2.2016 Buy 75 2.5950
19.2.2016 Buy 4 2.6440
19.2.2016 Buy 196 2.6440
22.2.2016 Buy 85 2.6400
22.2.2016 Buy 115 2.6400
22.2.2016 Buy 100 2.6050
23.2.2016 Buy 2 000 2.6230
23.2.2016 Buy 500 2.6200
23.2.2016 Buy 100 2.6770
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 19.02.2016 13:14
SOPHARMA AD Current report 20 Notification ENG
19.02.2016 13:14SOPHARMA AD Current report 20 Notification ENG
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
The Board of Directors of SOPHARMA AD (the "Company") hereby informs of the results of conducted tender offer:
Company, subject to the offer: Medica AD, with management address in Sofia 1504, Oborishte district, 82 Knyaz Alexander Dondukov Blvd;
Tender offeror: Sopharma AD, with address: Sofia, Nadezhda district, 16 Iliensko shose Str..
Authorized investment intermediary: Elana Trading AD, with management address: Sofia, Sredetz district, 4 Kuzman Shapkarov Str. and FSC-issued licence for investment intermediary operation based on Decision ą 171-IP/08.03.2006.
Offered price per share: 3.50 BGN (three leva and fifty stotinki). Number of shareholders, who accepted the tender offer: 68 shareholders with a total amount of shares: 3 099 701 representing 30.79% of the capital of Medika AD.
As a result of the conducted tender offer and after completion of the transactions with the shareholders who have accepted it, Sopharma AD will hold directly 97.50% of the shares with voting rights of Medika AD. Sopharma AD has the right within three months from the closing date of the tender offer, after receiving an approval by the FSC to make an offer to buy the shares of the remaining shareholders of Medika AD on the basis of art. 157a of POSA. Furthermore, according to art 157b of POSA every shareholder has the right to make a request to Sopharma to sell their shares with voting rights until 16 May 2016. The request must be submitted in writing and must contain information about the shareholder and their shares. The request must be submitted to the authorized investment intermediary Elana Trading AD. The price for one share of Medika AD under the offer under art. 157a and upon executing of the rights of the shareholders under art. 157b in accordance with the regulations of art. 157a, par. 3 is equal to the share price of the conducted tender offer of 3.50 BGN per share.
The results of the tender offer have been published by the tender offeror in the daily newspapers Capital Daily and Sega on 18 February 2016.
Więcej na: biznes.pap.pl
kom espi zdz
- 16.02.2016 11:05
SOPHARMA AD Current report 19 re insiders transactions
16.02.2016 11:05SOPHARMA AD Current report 19 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
08.02.2016 Buy 103 2.603
08.02.2016 Buy 500 2.60
08.02.2016 Buy 897 2.603
10.02.2016 Buy 364 2.60
10.02.2016 Buy 364 2.60
10.02.2016 Buy 364 2.60
10.02.2016 Buy 272 2.60
10.02.2016 Buy 92 2.60
10.02.2016 Buy 44 2.60
12.02.2016 Buy 500 2.58
12.02.2016 Buy 700 2.58
12.02.2016 Buy 400 2.58
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 15.02.2016 12:37
SOPHARMA AD SPHTR Current report 18 re insiders transactions
15.02.2016 12:37SOPHARMA AD SPHTR Current report 18 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
10.2.2016 Buy 200 2.5950
10.2.2016 Buy 300 2.6000
10.2.2016 Buy 364 2.6000
10.2.2016 Buy 364 2.6000
10.2.2016 Buy 364 2.6000
10.2.2016 Buy 272 2.6000
10.2.2016 Buy 680 2.6000
10.2.2016 Buy 320 2.6000
11.2.2016 Buy 1 000 2.6000
11.2.2016 Buy 500 2.6000
12.2.2016 Buy 158 2.6000
12.2.2016 Buy 742 2.6000
12.2.2016 Buy 416 2.6000
12.2.2016 Buy 584 2.6000
12.2.2016 Buy 70 2.5800
12.2.2016 Buy 1 930 2.5800
12.2.2016 Buy 500 2.5800
12.2.2016 Buy 500 2.5800
12.2.2016 Buy 1 000 2.5800
12.2.2016 Buy 35 2.5720
12.2.2016 Buy 420 2.5800
12.2.2016 Buy 1 000 2.5800
12.2.2016 Buy 100 2.6000
12.2.2016 Buy 2 000 2.5800
12.2.2016 Buy 1 145 2.5800
12.2.2016 Buy 100 2.6000
12.2.2016 Buy 855 2.5800
12.2.2016 Buy 655 2.5800
12.2.2016 Buy 1 345 2.5800
15.2.2016 Buy 500 2.5800
15.2.2016 Buy 1 000 2.5700
15.2.2016 Buy 260 2.5690
15.2.2016 Buy 290 2.5690
15.2.2016 Buy 170 2.5700
16.2.2016 Buy 100 2.5950
16.2.2016 Buy 348 2.5950
16.2.2016 Buy 352 2.5950
16.2.2016 Buy 396 2.5950
16.2.2016 Buy 452 2.5950
16.2.2016 Buy 452 2.5950
16.2.2016 Buy 452 2.5950
16.2.2016 Buy 92 2.5950
16.2.2016 Buy 56 2.5950
16.2.2016 Buy 452 2.5950
16.2.2016 Buy 436 2.5950
16.2.2016 Buy 360 2.5950
16.2.2016 Buy 752 2.5950
16.2.2016 Buy 1 000 2.5950
16.2.2016 Buy 1 000 2.5700
16.2.2016 Buy 100 2.5700
16.2.2016 Buy 2 000 2.5700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 08.02.2016 13:49
SOPHARMA AD Current report 17 re insiders transactions
08.02.2016 13:49SOPHARMA AD Current report 17 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
02.02.2016 Buy 100 2.64
05.02.2016 Buy 500 2.621
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 08.02.2016 11:44
SOPHARMA AD SPHTRCurrent report 16 re insiders transactions
08.02.2016 11:44SOPHARMA AD SPHTRCurrent report 16 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
4.2.2016 Buy 1 000 2.6210
8.2.2016 Buy 500 2.6020
8.2.2016 Buy 18 2.6000
8.2.2016 Buy 982 2.6000
8.2.2016 Buy 1 000 2.6000
8.2.2016 Buy 1 000 2.6000
8.2.2016 Buy 500 2.6020
8.2.2016 Buy 1 000 2.6000
9.2.2016 Buy 950 2.6400
9.2.2016 Buy 139 2.6000
9.2.2016 Buy 1 861 2.6000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 04.02.2016 14:50
SOPHARMA AD Sopharma monthly January 2016
04.02.2016 14:50SOPHARMA AD Sopharma monthly January 2016
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for January 2016 the Company recorded an increase of sales revenues of 40% compared to the same month of 2015, including 2% increase in domestic sales and 99% increase in export sales. The increase in export sales is due to the low baseline from 2015, when due to the volatility of the Russian ruble the sales on the Russian market were temporarily stopped.
Więcej na: biznes.pap.pl
kom espi zdz
- 02.02.2016 13:31
SOPHARMA AD Current report 14 re insiders transactions
02.02.2016 13:31SOPHARMA AD Current report 14 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
25.01.2016 Buy 130 2.60
25.01.2016 Buy 870 2.60
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 01.02.2016 09:15
SOPHARMA AD SPHTRCurrent report 13 re insiders transactions
01.02.2016 09:15SOPHARMA AD SPHTRCurrent report 13 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
27.1.2016 Sale 300 2.6500
27.1.2016 Sale 300 2.6700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 29.01.2016 16:09
SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2015
29.01.2016 16:09SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Insider Information
7. Additional Information
Więcej na: biznes.pap.pl
kom espi zdz
- 25.01.2016 16:30
SOPHARMA AD Current report 11 re insiders transactions
25.01.2016 16:30SOPHARMA AD Current report 11 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
18.01.2016 Buy 104 2.715
18.01.2016 Buy 335 2.711
19.01.2016 Buy 467 2.720
21.01.2016 Buy 500 2.667
21.01.2016 Buy 500 2.610
21.01.2016 Buy 500 2.620
22.01.2016 Buy 500 2.620
22.01.2016 Buy 2 000 2.600
22.01.2016 Buy 1 000 2.600
22.01.2016 Buy 500 2.620
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 25.01.2016 10:14
SOPHARMA AD SPHTR Current report 10 re insiders transactions
25.01.2016 10:14SOPHARMA AD SPHTR Current report 10 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
22.1.2016 Buy 500 2.6200
22.1.2016 Buy 500 2.6200
22.1.2016 Buy 640 2.6250
22.1.2016 Buy 2 000 2.6000
22.1.2016 Buy 500 2.6000
22.1.2016 Buy 1 000 2.6000
22.1.2016 Buy 200 2.5900
22.1.2016 Buy 300 2.5900
25.1.2016 Buy 1 000 2.5900
25.1.2016 Buy 1 000 2.5900
26.1.2016 Buy 1 000 2.5920
26.1.2016 Buy 2 000 2.6000
26.1.2016 Buy 100 2.6000
26.1.2016 Buy 1 900 2.6000
26.1.2016 Sale 200 2.6500
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 22.01.2016 13:10
SOPHARMA AD Notification for termination of the Contract for transformation through merger
22.01.2016 13:10SOPHARMA AD Notification for termination of the Contract for transformation through merger
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that on 21 January 2016 Sopharma AD deposited with the Finacnial Supervision Commission an agreement for termination of the Contract for transformation through merger in accordance with the requirements of art. 262d and following of the Commercial Act (CA) between Sopharma AD, Sofia, UIC 831902088, hereinafter referred to as "receiving company" and Momina Krepost AD, Veliko Tarnovo, Str. Magistralna 23, UIC 104055543, hereinafter referred to as "transferring company". The decision for termination was taken in the best interest for both companies and in order for them to maintain their market positions.
Więcej na: biznes.pap.pl
kom espi zdz
- 21.01.2016 16:04
SOPHARMA AD Current report 8 buy back 21012016
21.01.2016 16:04SOPHARMA AD Current report 8 buy back 21012016
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 14 January 2016 up to and including 20 January 2016 the Company bought 2000 own shares representing 0.0015% of the share capital of the Company, at a total value of 5 312.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.66 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 221 296, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 18.01.2016 15:34
SOPHARMA AD Current report 7 re insiders transactions
18.01.2016 15:34SOPHARMA AD Current report 7 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
12.01.2016 Buy 600 2.738
13.01.2016 Buy 241 2.735
13.01.2016 Buy 133 2.735
14.01.2016 Buy 396 2.715
15.01.2016 Buy 23 2.722
15.01.2016 Buy 477 2.722
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 13.01.2016 13:32
SOPHARMA AD Notification 13.01.2016
13.01.2016 13:32SOPHARMA AD Notification 13.01.2016
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that at the start of the financial year Sopharma's Commercial Director has left the management of the Company.
Vladimir Stoychev joined the team of Sopharma AD in September 2001 as a warehouse manager for export goods. Later he was transferred to the position of Head of the Kazakhstan office. His good work lead eventually to his promotion to Commercial Director of Sopharma AD in 2007. The management team of the company wishes Mr. Stoychev success in his new professional endeavors.
The Executive Director of the company will temporarily be responsible for the export markets.
Więcej na: biznes.pap.pl
kom espi zdz
- 12.01.2016 08:24
SOPHARMA AD Current report 5 re insiders transactions
12.01.2016 08:24SOPHARMA AD Current report 5 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
07.01.2016 Sale 500 2.70
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 11.01.2016 14:56
SOPHARMA AD Sopharma monthly December 2015
11.01.2016 14:56SOPHARMA AD Sopharma monthly December 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for December 2015 the Company recorded an increase of sales revenues of 8% compared to the same month of 2014, including 16% increase in domestic sales and 32% increase in export sales. The increase in export sales is mainly due to an increase in sales on the Russian market by 45%. The management has planned to sustain the export activity in the months January and December 2016, as well as to improve the rhythm of sales in Russia in the summer months. Our expectations are for a better performance of our products, if the current macroeconomic environment remain stable. The expected increase for January 2016 is also high, mainly due to the low baseline from 2015, when due to the volatility of the Russian ruble the sales on the Russian market were temporarily stopped.
Sales revenues for 2015 decreased by 14% compared to the same period of 2014, including 0.3% increase of domestic sales and a 20% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 11.01.2016 12:44
SOPHARMA AD SPHTRCurrent report 3 re insiders transactions
11.01.2016 12:44SOPHARMA AD SPHTRCurrent report 3 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
6.1.2016 Sale 500 2.7450
7.1.2016 Sale 400 2.6900
7.1.2016 Sale 500 2.6990
8.1.2016 Sale 500 2.7400
8.1.2016 Sale 500 2.7690
8.1.2016 Sale 359 2.7780
8.1.2016 Sale 90 2.7780
8.1.2016 Sale 51 2.7780
12.1.2016 Sale 600 2.7380
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.01.2016 15:17
SOPHARMA AD Current report 2 re insiders transactions
05.01.2016 15:17SOPHARMA AD Current report 2 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
28.12.2015 Sale 10 2.64
28.12.2015 Sale 210 2.64
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 04.01.2016 10:36
SOPHARMA AD SPHTRCurrent report 1 re insiders transactions
04.01.2016 10:36SOPHARMA AD SPHTRCurrent report 1 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
5.1.2016 Sale 100 2.6900
5.1.2016 Sale 200 2.6900
5.1.2016 Sale 200 2.6900
5.1.2016 Sale 500 2.6900
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 28.12.2015 10:04
SOPHARMA AD Current report 117 re insiders transactions
28.12.2015 10:04SOPHARMA AD Current report 117 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
14.12.2015 Sale 271 2.575
14.12.2015 Sale 200 2.575
17.12.2015 Buy 500 2.504
18.12.2015 Buy 362 2.501
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 28.12.2015 10:01
SOPHARMA AD SPHTRCurrent report 116 re insiders transactions
28.12.2015 10:01SOPHARMA AD SPHTRCurrent report 116 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
17.12.2015 Buy 1 2.5050
17.12.2015 Buy 499 2.5040
18.12.2015 Buy 200 2.5790
18.12.2015 Buy 310 2.5780
22.12.2015 Buy 200 2.5940
22.12.2015 Buy 200 2.5950
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 14.12.2015 11:58
SOPHARMA AD SPHTRCurrent report 115 re insiders transactions
14.12.2015 11:58SOPHARMA AD SPHTRCurrent report 115 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
30.11.2015 Buy 24 2.517
30.11.2015 Buy 476 2.517
30.11.2015 Buy 890 2.503
09.12.2015 Buy 1000 2.51
14.12.2015 Buy 271 2.575
14.12.2015 Buy 200 2.575
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 08.12.2015 10:10
SOPHARMA AD Current report 114 re insiders transactions
08.12.2015 10:10SOPHARMA AD Current report 114 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
30.11.2015 Buy 1 000 2.530
30.11.2015 Buy 300 2.589
30.11.2015 Buy 1 000 2.513
30.11.2015 Buy 278 2.517
30.11.2015 Buy 344 2.517
30.11.2015 Buy 500 2.503
30.11.2015 Buy 66 2.520
30.11.2015 Buy 222 2.517
30.11.2015 Buy 156 2.517
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 07.12.2015 10:16
SOPHARMA AD SPHTRCurrent report 113 re insiders transactions
07.12.2015 10:16SOPHARMA AD SPHTRCurrent report 113 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
2.12.2015 Buy 500 2.5090
8.12.2015 Sale 400 2.5800
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 04.12.2015 13:34
SOPHARMA AD Sopharma monthly November 2015
04.12.2015 13:34SOPHARMA AD Sopharma monthly November 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for November 2015 the Company recorded a decrease of sales revenues of 5% compared to the same month of 2014, including 3% increase of domestic sales and 9% decrease of export sales.
For the first eleven months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 2% increase of domestic sales and a 23% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 30.11.2015 09:58
SOPHARMA AD SPHTRCurrent report 111 re insiders transactions
30.11.2015 09:58SOPHARMA AD SPHTRCurrent report 111 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
26.11.2015 Buy 500 2.6280
26.11.2015 Buy 500 2.6220
27.11.2015 Buy 500 2.6000
26.11.2015 Buy 8 2.5800
27.11.2015 Buy 492 2.5800
27.11.2015 Buy 350 2.5410
27.11.2015 Buy 150 2.5450
27.11.2015 Buy 400 2.5250
27.11.2015 Buy 100 2.5250
30.11.2015 Buy 739 2.5400
30.11.2015 Buy 1 000 2.5200
30.11.2015 Buy 44 2.5170
30.11.2015 Buy 678 2.5170
30.11.2015 Buy 278 2.5170
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 27.11.2015 14:05
SOPHARMA AD CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2015
27.11.2015 14:05SOPHARMA AD CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
Więcej na: biznes.pap.pl
kom espi zdz
- 26.11.2015 09:25
SOPHARMA AD Current report 109 re insiders transactions
26.11.2015 09:25SOPHARMA AD Current report 109 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
16.11.2015 Buy 500 2.70
20.11.2015 Buy 1 648 2.65
20.11.2015 Buy 352 2.65
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 23.11.2015 09:21
SOPHARMA AD SPHTRCurrent report 108 re insiders transactions
23.11.2015 09:21SOPHARMA AD SPHTRCurrent report 108 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
18.11.2015 Buy 824 2.6520
20.11.2015 Buy 176 2.6520
23.11.2015 Buy 1 000 2.6290
23.11.2015 Buy 465 2.6500
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 19.11.2015 16:17
SOPHARMA AD SPHTRCurrent report 107 re insiders transactions
19.11.2015 16:17SOPHARMA AD SPHTRCurrent report 107 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
3.11.2015 Buy 443 2.6500
3.11.2015 Buy 400 2.6490
3.11.2015 Buy 1 000 2.6500
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 17.11.2015 09:31
SOPHARMA AD Current report 106 re insiders transactions
17.11.2015 09:31SOPHARMA AD Current report 106 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
09.11.2015 Buy 1 000 2.65
10.11.2015 Sale 300 2.75
10.11.2015 Sale 300 2.77
11.11.2015 Sale 300 2.776
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 16.11.2015 09:42
SOPHARMA AD SPHTRCurrent report 105 re insiders transactions
16.11.2015 09:42SOPHARMA AD SPHTRCurrent report 105 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
12.11.2015 Sale 450 2.8200
12.11.2015 Sale 500 2.8200
12.11.2015 Buy 287 2.7620
12.11.2015 Buy 13 2.7620
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 09.11.2015 12:56
SOPHARMA AD Current report 104 re insiders transactions
09.11.2015 12:56SOPHARMA AD Current report 104 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
03.11.2015 Buy 500 2.65
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 09.11.2015 12:52
SOPHARMA AD SPHTRCurrent report 103 re insiders transactions
09.11.2015 12:52SOPHARMA AD SPHTRCurrent report 103 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
4.11.2015 Buy 145 2.6500
4.11.2015 Buy 855 2.6500
6.11.2015 Buy 1 000 2.6500
9.11.2015 Buy 124 2.6490
9.11.2015 Buy 802 2.6500
9.11.2015 Buy 74 2.6500
9.11.2015 Buy 185 2.6700
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.11.2015 13:11
SOPHARMA AD Sopharma monthly October 2015
05.11.2015 13:11SOPHARMA AD Sopharma monthly October 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for October 2015 the Company recorded same level of sales revenues compared to the same month of 2014, including 2% increase of domestic sales and 2% decrease of export sales.
For the first ten months of this year, revenues from sales decreased by 16% compared to the same period of 2014, including 2% increase of domestic sales and a 25% decrease of export sales
Więcej na: biznes.pap.pl
kom espi zdz
- 04.11.2015 15:16
SOPHARMA AD Current report 101 re insiders transactions
04.11.2015 15:16SOPHARMA AD Current report 101 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
27.10.2015 Buy 175 2.670
27.10.2015 Buy 5 2.652
27.10.2015 Buy 300 2.670
28.10.2015 Buy 400 2.652
28.10.2015 Buy 900 2.670
28.10.2015 Buy 900 2.670
28.10.2015 Buy 300 2.656
28.10.2015 Buy 400 2.667
28.10.2015 Buy 194 2.668
28.10.2015 Buy 156 2.666
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 02.11.2015 16:49
SOPHARMA AD Current report 100 re insiders transactions
02.11.2015 16:49SOPHARMA AD Current report 100 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
28.10.2015 Buy 1 000 2.6690
28.10.2015 Buy 1 000 2.6530
29.10.2015 Buy 300 2.6230
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 30.10.2015 13:24
SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2015
30.10.2015 13:24SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Insider Information
7. Additional Information
Więcej na: biznes.pap.pl
kom espi zdz
- 28.10.2015 09:24
SOPHARMA AD Current report 98 re insiders transactions
28.10.2015 09:24SOPHARMA AD Current report 98 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
21.10.2015 Buy 1 000 2.59
21.10.2015 Buy 1 000 2.57
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 26.10.2015 14:42
SOPHARMA AD Current report 97 Medika AD above 65%
26.10.2015 14:42SOPHARMA AD Current report 97 Medika AD above 65%
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") announces that on 22 October 2015 the Company bought 3 080 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 66.72%.
Więcej na: biznes.pap.pl
kom espi zdz
- 20.10.2015 14:58
SOPHARMA AD Current report 96 re insiders transactions
20.10.2015 14:58SOPHARMA AD Current report 96 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
15.10.2015 Buy 231 2.67
15.10.2015 Buy 325 2.635
16.10.2015 Buy 1 000 2.605
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 12.10.2015 14:48
SOPHARMA AD Current report 95 re insiders transactions
12.10.2015 14:48SOPHARMA AD Current report 95 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
07.10.2015 Buy 150 2.59
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 08.10.2015 13:10
SOPHARMA AD Notification
08.10.2015 13:10SOPHARMA AD Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that on 30 September 2015 Sopharma AD, Sofia, UIC 831902088, hereinafter referred to as "receiving company" and Momina Krepost AD, Veliko Tarnovo, Str. Magistralna 23, UIC 104055543, hereinafter referred to as "transferring company" signed a Contract for transformation through merger in accordance with the requirements of art. 262d and following of the Commercial Act (CA), as a result of which all assets of Momina Krepost AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Momina Krepost AD shall be terminated without liquidation.
Pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA) the Contract for transformation, as well as reports of the management bodies of the companies involved in the transformation of the company under art. 262i of the CA and the report of the examiner under art. 262m of the CA have been submitted and are subject to approval by the deputy chairman of the Financial Supervision Commission, managing the "Investment Supervision" division.
According to the signed contract, in connection with the implementation of the transformation shall be carried out a transfer of shares of the receiving company Sopharma AD, owned by the receiving company, which shares will be distributed among the shareholders of the transferring company Momina Krepost AD (except the shareholder Sopharma AD). The capital of the receiving company Sopharma AD will not be increased through the issuing of new dematerialized registered shares. For one share of Momina Krepost AD each shareholder pursuant to art. 261b, app. 1 of the CA will receive 0.655675 shares of the capital of Sopharma AD. This ratio, as well as all other documents, related to the transformation are due for a review by the FSC.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.10.2015 13:15
SOPHARMA AD Current report 93 re insiders transactions
05.10.2015 13:15SOPHARMA AD Current report 93 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
01.10.2015 Buy 80 2.601
01.10.2015 Buy 100 2.601
01.10.2015 Buy 317 2.601
02.10.2015 Buy 200 2.64
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.10.2015 13:09
SOPHARMA AD Sopharma monthly September 2015
05.10.2015 13:09SOPHARMA AD Sopharma monthly September 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for September 2015 the Company recorded a decrease of sales revenues of 35% compared to the same month of 2014, including 1% increase of domestic sales and 48% decrease of export sales.
For the first nine months of this year, revenues from sales decreased by 18% compared to the same period of 2014, including 2% increase of domestic sales and a 27% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 28.09.2015 15:56
SOPHARMA AD Current report 91 - Notification
28.09.2015 15:56SOPHARMA AD Current report 91 - Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
The Board of Directors of SOPHARMA AD (the "Company") hereby informs that in order to facilitate the operational work of Sopharma AD, the Board of Directors decided to appoint Ivan Badinski, MPharm, director of Cooperation and Licenses, Sopharma AD as procurator of the company. Mr. Badinski has been working in Sopharma AD since 1997 as a member of the Board of Directors of the Company. At the end of 1997 he became its Chief Commercial Officer, and from August 1998 to October 2000 its CEO, then continued his work in the company and today occupies the position of Cooperation and Licenses Director.
This fact was entered in the Trade Register on 25 September 2015.
Więcej na: biznes.pap.pl
kom espi zdz
- 28.09.2015 12:38
SOPHARMA AD Current report 90 re insiders transactions
28.09.2015 12:38SOPHARMA AD Current report 90 re insiders transactions
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
23.09.2015 Buy 1 000 2.645
23.09.2015 Buy 1 000 2.648
24.09.2015 Buy 1 000 2.602
24.09.2015 Buy 500 2.602
24.09.2015 Buy 1 000 2.602
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 25.09.2015 14:34
SOPHARMA AD Current report 89 - Notification
25.09.2015 14:34SOPHARMA AD Current report 89 - Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
The Board of Directors of Sopharma notifies that on its meeting carried out on September 18, 2015 it took a decision to initiate a procedure for merging Momina krepost AD, VAT number 104055543 based in the city of Veliko Tarnovo on 23, "Magistralna" Blvd. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses "Elana Trading" AD VAT number 831470130, based on 4, Kuzman Shapkarev Str. for a consultant in relation to the merger.
Więcej na: biznes.pap.pl
kom espi zdz
- 18.09.2015 16:14
SOPHARMA AD Current report 88 re insiders transactions
18.09.2015 16:14SOPHARMA AD Current report 88 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
14.09.2015 Buy 200 2.69
14.09.2015 Buy 200 2.69
14.09.2015 Buy 350 2.671
17.09.2015 Buy 20 2.70
17.09.2015 Buy 150 2.70
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 15.09.2015 16:28
SOPHARMA AD Current report 87 re insiders transactions
15.09.2015 16:28SOPHARMA AD Current report 87 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
10.09.2015 Buy 500 2.68
11.09.2015 Buy 1 000 2.70
11.09.2015 Buy 170 2.685
11.09.2015 Buy 100 2.685
11.09.2015 Buy 165 2.685
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 10.09.2015 13:17
SOPHARMA AD Current report 86 buy back 10092015
10.09.2015 13:17SOPHARMA AD Current report 86 buy back 10092015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 3 September 2015 up to and including 9 September 2015 the Company bought 43 614 own shares representing 0.032% of the share capital of the Company.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 219 296, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 07.09.2015 14:49
SOPHARMA AD Current report 85 re insiders transactions
07.09.2015 14:49SOPHARMA AD Current report 85 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
31.08.2015 Buy 80 2.631
01.09.2015 Buy 500 2.633
02.09.2015 Buy 1 000 2.63
03.09.2015 Buy 500 2.672
03.09.2015 Buy 472 2.672
03.09.2015 Buy 200 2.74
01.09.2015 Sale 33 2.71
01.09.2015 Sale 500 2.68
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 04.09.2015 13:55
SOPHARMA AD CORRECTION Sopharma monthly August 2015
04.09.2015 13:55SOPHARMA AD CORRECTION Sopharma monthly August 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for September 2015 the Company recorded an increase of sales revenues of 1% compared to the same month of 2014, including 5% decrease of domestic sales and 4% increase of export sales.
For the first eight months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 9% increase of domestic sales and a 26% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 04.09.2015 13:14
SOPHARMA AD Sopharma monthly August 2015
04.09.2015 13:14SOPHARMA AD Sopharma monthly August 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for September 2015 the Company recorded an increase of sales revenues of 1% compared to the same month of 2014, including 5% decrease of domestic sales and 4% increase of export sales.
For the first eight months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 9% increase of domestic sales and a 26% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 01.09.2015 12:16
SOPHARMA AD Current report 83 re insiders transactions
01.09.2015 12:16SOPHARMA AD Current report 83 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
25.08.2015 Buy 93 2.723
25.08.2015 Buy 209 2.724
25.08.2015 Buy 1 578 2.725
26.08.2015 Buy 300 2.692
27.08.2015 Buy 500 2.69
27.08.2015 Buy 500 2.651
28.08.2015 Buy 100 2.67
28.08.2015 Buy 300 2.64
28.08.2015 Buy 166 2.68
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 28.08.2015 13:30
SOPHARMA AD CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2015
28.08.2015 13:30SOPHARMA AD CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
Więcej na: biznes.pap.pl
kom espi zdz
- 27.08.2015 13:09
SOPHARMA AD Current report 81 buy back 27082015
27.08.2015 13:09SOPHARMA AD Current report 81 buy back 27082015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 20 August 2015 up to and including 26 August 2015 the Company bought 500 own shares representing 0.0004% of the share capital of the Company, at a total value of 1320.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.64 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 175 682, representing 3.84% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 26.08.2015 13:42
SOPHARMA AD Current report 80 re insiders transactions
26.08.2015 13:42SOPHARMA AD Current report 80 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
17.08.2015 Buy 75 2.69
21.08.2015 Buy 130 2.724
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 11.08.2015 16:19
SOPHARMA AD Current report 79 re insiders transactions
11.08.2015 16:19SOPHARMA AD Current report 79 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
03.08.2015 Buy 350 2.757
03.08.2015 Sale 110 2.80
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 06.08.2015 13:50
SOPHARMA AD ACQUISITION OF OWN SHARES
06.08.2015 13:50SOPHARMA AD ACQUISITION OF OWN SHARES
Podstawa prawna: Inne uregulowania
SOPHARMA AD hereby informs that from 29 July 2015 up to and including 05 August 2015 the Company bought 350 own shares representing 0.00026% of the share capital of the Company, at a total value of 975.90 BGN on the Bulgarian Stock Exchange, the average price per share was 2.703 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 175 182, representing 3.84% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.08.2015 13:15
SOPHARMA AD Notification
05.08.2015 13:15SOPHARMA AD Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") hereby notifies that on 3 August 2015 Sopharma AD received a notification of disclosure of shareholdings from Telekomplekt invest AD regarding the purchasing of 108 700 shares. After this transaction the share of Telekomplekt invest AD in the capital of Sopharma AD reached 20.07%.
The date of registration of the transaction with the Central Depository AD is 31 July 2015.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.08.2015 13:11
SOPHARMA AD Sopharma monthly July 2015
05.08.2015 13:11SOPHARMA AD Sopharma monthly July 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for July 2015 the Company recorded a decrease of sales revenues of 27% compared to the same month of 2014, including same level of domestic sales and 56% decrease of export sales.
For the first seven months of this year, revenues from sales decreased by 18% compared to the same period of 2014, including 9% increase of domestic sales and a 30% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 04.08.2015 14:38
SOPHARMA AD Current report 75 re insiders transactions
04.08.2015 14:38SOPHARMA AD Current report 75 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
27.07.2015 Sale 214 2.88
31.07.2015 Sale 100 2.80
31.07.2015 Sale 40 2.80
31.07.2015 Buy 1 000 2.76
31.07.2015 Buy 2 000 2.76
31.07.2015 Buy 500 2.76
31.07.2015 Buy 1 000 2.76
31.07.2015 Buy 300 2.76
31.07.2015 Buy 500 2.76
31.07.2015 Buy 800 2.759
31.07.2015 Buy 500 2.76
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 04.08.2015 14:10
SOPHARMA AD Notification
04.08.2015 14:10SOPHARMA AD Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") hereby notifies that on 4 August 2015 Sopharma AD received a notification of disclosure of shareholdings from Telso AD regarding the selling of 397 057 shares. After this transaction the share of Telso AD in the capital of Sopharma AD decreased below 5%.
The date of registration of the transaction with the Central Depository AD is 31 July 2015.
Więcej na: biznes.pap.pl
kom espi zdz
- 03.08.2015 11:28
SOPHARMA AD Current report 73 re insiders transactions
03.08.2015 11:28SOPHARMA AD Current report 73 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that the company ELPHARMA related to him, executed the following transactions related to shares of the Company:
Date and time of settlement Operation Number of shares Unit price (BGN)
31.07.2015 Buy 50 191 2.7600
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 31.07.2015 11:14
SOPHARMA AD Current report 72 Doverie Obedinen Holding over 10%
31.07.2015 11:14SOPHARMA AD Current report 72 Doverie Obedinen Holding over 10%
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") announces that on 28 July 2015 the Company bought 937 000 ordinary registered shares with voting rights of the capital of United Holding Doverie AD. After this transaction, the share of Sopharma AD in the capital of United Holding Doverie AD increased to 14.898%.
Więcej na: biznes.pap.pl
kom espi zdz
- 31.07.2015 11:10
SOPHARMA AD Current report 71 buy back 30072015
31.07.2015 11:10SOPHARMA AD Current report 71 buy back 30072015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 23 July 2015 up to and including 28 July 2015 the Company bought 5000 own shares representing 0.0037% of the share capital of the Company, at a total value of 13 800.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.76 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 174 832, representing 3.84% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 30.07.2015 14:13
SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2015
30.07.2015 14:13SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Templates of the financial reports approved by the Bulgarian FSC
5. Declaration
6. Insider Information
7. Additional Information
Więcej na: biznes.pap.pl
kom espi zdz
- 20.07.2015 13:52
SOPHARMA AD Current report 69 re insiders transactions
20.07.2015 13:52SOPHARMA AD Current report 69 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
14.07.2015 Sale 200 2.90
14.07.2015 Sale 300 2.90
15.07.2015 Sale 50 2.90
15.07.2015 Sale 150 2.90
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 20.07.2015 13:30
SOPHARMA AD Current report 68 Medika AD above 35%
20.07.2015 13:30SOPHARMA AD Current report 68 Medika AD above 35%
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") announces that on 16 July 2015 the Company bought 240 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 36.10%.
Więcej na: biznes.pap.pl
kom espi zdz
- 16.07.2015 14:42
SOPHARMA AD Current report 67 buy back 16072015
16.07.2015 14:42SOPHARMA AD Current report 67 buy back 16072015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 09 July 2015 up to and including 15 July 2015 the Company bought 500 own shares representing 0.00037% of the share capital of the Company, at a total value of 1444.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.888 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 169 832, representing 3.84% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 13.07.2015 14:50
SOPHARMA AD Current report 66 re insiders transactions
13.07.2015 14:50SOPHARMA AD Current report 66 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
07.07.2015 Sale 300 3.04
07.07.2015 Sale 19 3.04
07.07.2015 Sale 181 3.04
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 09.07.2015 13:25
SOPHARMA AD Notification
09.07.2015 13:25SOPHARMA AD Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
The Board of Directors of SOPHARMA AD (the "Company") hereby informs of the results of the tender offering for the shares of Momina Krepost AD, published in two national newspapers: Capital Daily and Sega on 1 July 2015.
In connection with the requirements of art. 37, par. 1 of Ordinance ą13 for tender offers for the purchase and exchange of shares, Sopharma AD as a tender offeror, who has made a tender offering under art. 149, par. 6 of POSA to purchase all shares of other shareholders of Momina Krepost AD, informs on the following results of the tender offering:
- shareholders who have accepted the tender offering: 38 shareholders with a total number of shares: 211 991,
- as a result of the conducted tender offering and after completion of the transactions with shares of shareholders who have accepted it, Sopharma AD now holds directly 92.62% of the shares from the capital of Momina Krepost AD.
Please, give publicity to the present information
Więcej na: biznes.pap.pl
kom espi zdz
- 07.07.2015 08:57
SOPHARMA AD Current report 64 re insiders transactions
07.07.2015 08:57SOPHARMA AD Current report 64 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
30.06.2015 Sale 500 3.088
01.07.2015 Buy 11 3.05
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 03.07.2015 13:37
SOPHARMA AD Sopharma monthly June 2015
03.07.2015 13:37SOPHARMA AD Sopharma monthly June 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for June 2015 the Company recorded a decrease of sales revenues of 36% compared to the same month of 2014, including same level of domestic sales and 51% decrease of export sales.
For the six months of this year, revenues from sales decreased by 16% compared to the same period of 2014, including 13% increase of domestic sales and a 28% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 30.06.2015 11:58
SOPHARMA AD Current report 62 re insiders transactions
30.06.2015 11:58SOPHARMA AD Current report 62 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
25.06.2015 Sale 200 3.1
25.06.2015 Sale 500 3.1
25.06.2015 Sale 55 3.12
26.06.2015 Sale 100 3.12
26.06.2015 Sale 145 3.12
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 22.06.2015 16:24
SOPHARMA AD Current report 61 re insiders transactions
22.06.2015 16:24SOPHARMA AD Current report 61 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
15.06.2015 Sale 300 3.17
17.06.2015 Sale 103 3.13
17.06.2015 Sale 197 3.13
19.06.2015 Sale 50 3.079
19.06.2015 Sale 300 3.1
19.06.2015 Sale 79 3.074
19.06.2015 Sale 300 3.068
19.06.2015 Sale 279 3.065
19.06.2015 Sale 320 3.079
19.06.2015 Sale 300 3.074
19.06.2015 Sale 100 3.071
19.06.2015 Sale 200 3.07
19.06.2015 Sale 19321 3.065
19.06.2015 Sale 300 3.067
19.06.2015 Sale 20400 3.065
19.06.2015 Sale 221 3.065
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 22.06.2015 15:53
SOPHARMA AD MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 19 JUNE 2015
22.06.2015 15:53SOPHARMA AD MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 19 JUNE 2015
Podstawa prawna: Art. 71 Ustawy o ofercie - wnioski o zwolnienie z obowiązku przekazania zawiadomienia, o którym mowa w art. 70 pkt 1 Ustawy o ofercie
MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 19 JUNE 2015
Więcej na: biznes.pap.pl
kom espi zdz
- 19.06.2015 16:08
SOPHARMA AD Notification AGM - 19.06.2015
19.06.2015 16:08SOPHARMA AD Notification AGM - 19.06.2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that on the regular General Meeting of Shareholders of Sopharma AD, conducted on 19 June 2015 in Sofia, 5 Lachezar Stanchev Str., were taken the following decisions:
1. Approval of the proposal by the Board of Directors for the distribution of the profit generated in 2014 and the undistributed profit from past periods as follows: net profit for 2014 amounts to 26 532 491.96 BGN /twenty-six million, five hundred and thirty-two thousand, four hundred and ninety-one leva and ninety-six stotinki/. The undistributed profit from past periods amounts to 2 620 712.71 /two million, six hundred and twenty thousand, seven hundred and twelve leva and seventy-one stotinki/. The total amount of the profit, subject to distribution, is 29 153 204.67 /twenty-nine million, one hundred and fifty-three thousand, two hundred and four leva and sixty-seven stotinki/. After the allocation of 10% to the statutory reserve, amounting to 2 915 320.46 BGN /two million, nine hundred and fifteen thousand, three hundred and twenty leva and forty-six stotinki/, the remaining sum, amounting to 26 237 884.21 BGN /twenty-six million, two hundred and thirty-seven thousand, eight hundred and eighty-four leva and twenty-one stotinki/ shall be allocated to the additional reserves of the Company. No dividend shall be paid to the shareholders;
2. Election of AFA OOD with address of management in Sofia, 38 Oborishte Str. as a registered auditor for auditing and verification of the Annual financial statements of the Company for 2015, according to a proposal by the Audit Committee.
3. Approval of decision under art. 24, par. 3, letter B of the Company's Articles of Association for the payment of an additional fee of 1% /one percent/ of the net profit for 2014 according to the approved annual financial statement to the Executive Director of the Company;
4. Approval of decision for the distribution of 2% /two percent/ of the net profit for 2014 among the members of the senior management of the Company in compliance with the requirements of art. 26a, item 12 of the Articles of Association of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 18.06.2015 13:40
SOPHARMA AD Current report 58 buy back 18062015
18.06.2015 13:40SOPHARMA AD Current report 58 buy back 18062015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 11 June 2015 up to and including 17 June 2015 the Company bought 200 own shares representing 0.00015% of the share capital of the Company, at a total value of 6 13.20 BGN on the Bulgarian Stock Exchange, the average price per share was 3.07 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 169 332, representing 3.83% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 15.06.2015 15:59
SOPHARMA AD Current report 57 re insiders transactions
15.06.2015 15:59SOPHARMA AD Current report 57 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
09.06.2015 Sale 50 3.15
09.06.2015 Sale 320 3.091
10.06.2015 Sale 400 3.111
10.06.2015 Sale 100 3.121
11.06.2015 Sale 300 3.15
12.06.2015 Sale 10 3.15
12.06.2015 Sale 387 3.13
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 15.06.2015 13:15
SOPHARMA AD Current report 56 SPH AGM - 19.06.2015
15.06.2015 13:15SOPHARMA AD Current report 56 SPH AGM - 19.06.2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") hereby notifies all shareholders of the Company, that the Annual General Meeting, convened by the Board of Directors for 19 June 2015 at 11:00 will take place at Sopharma Business Towers, Building B, floor 3, 5 Lachezar Stanchev Str.. The registration begins at 9:30.
All shareholders of the company are invited to participate at the General Meeting in person or by proxy.
As a prerequisite for the technical provisioning of the Annual General Meeting of Shareholders, copies of all letters of attorney and up-to-date accompanying documents must be presented to the Company on paper or electronically by the end of the workday preceding the date of the AGM, namely 5 p.m. on 18 June 2015.
On the basis of art. 16, par 3 of the Company's Articles of Association the Board of Directors notifies the shareholders that the General Meeting, scheduled for 19 June 2015 will accept voting by correspondence or electronic means in accordance with the rules included in the invitation for the AGM available on the web site of the company.
We would like to thank all shareholders for their understanding and cooperation.
Więcej na: biznes.pap.pl
kom espi zdz
- 12.06.2015 13:01
SOPHARMA AD Notification
12.06.2015 13:01SOPHARMA AD Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
The Board of Directors of SOPHARMA AD (the "Company") hereby informs that in order to achieve synergies in the Sopharma Group, optimization of the management of products in the domestic market and higher efficiency of resources, the team responsible for the products produced by Sopharma AD and intended for the free market (OTC products) in being transferred to Sopharma Trading AD. The management of both companies believes that this is a logical step in improving the performance and quality of the work of the Group.
Więcej na: biznes.pap.pl
kom espi zdz
- 09.06.2015 12:07
SOPHARMA AD Current report 54 re insiders transactions
09.06.2015 12:07SOPHARMA AD Current report 54 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
5.06.2015 Sale 400 3.085
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.06.2015 13:14
SOPHARMA AD Sopharma monthly May 2015
05.06.2015 13:14SOPHARMA AD Sopharma monthly May 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for May 2015 the Company recorded an increase of sales revenues of 3% compared to the same month of 2014, including 14% increase of domestic sales and 2% decrease of export sales.
For the five months of this year, revenues from sales decreased by 12% compared to the same period of 2014, including 16% increase of domestic sales and a 22% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 03.06.2015 09:09
SOPHARMA AD Current report 52 re insiders transactions
03.06.2015 09:09SOPHARMA AD Current report 52 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
26.05.2015 Sale 200 3.19
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 29.05.2015 15:00
SOPHARMA AD Consolidated Interim Financial Statements for the period 1 January to 31 March 2015
29.05.2015 15:00SOPHARMA AD Consolidated Interim Financial Statements for the period 1 January to 31 March 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
Consolidated Interim Financial Statements for the period 1 January to 31 March 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
Więcej na: biznes.pap.pl
kom espi zdz
- 28.05.2015 14:55
SOPHARMA AD Current report 50 buy back 28052015
28.05.2015 14:55SOPHARMA AD Current report 50 buy back 28052015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 21 May 2015 up to and including 27 May 2015 the Company bought 2000 own shares representing 0.0015% of the share capital of the Company, at a total value of 6 130.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.07 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 169 132, representing 3.83% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 21.05.2015 13:18
SOPHARMA AD Current report 49 buy back 21052015
21.05.2015 13:18SOPHARMA AD Current report 49 buy back 21052015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 14 May 2015 up to and including 20 May 2015 the Company bought 3312 own shares representing 0.0025% of the share capital of the Company, at a total value of 10 274.19 BGN on the Bulgarian Stock Exchange, the average price per share was 3.10 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 167 132, representing 3.83% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 19.05.2015 15:32
SOPHARMA AD Current report 48 re insiders transactions
19.05.2015 15:32SOPHARMA AD Current report 48 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
11.05.2015 Sale 300 3.28
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 19.05.2015 14:04
SOPHARMA AD Notification
19.05.2015 14:04SOPHARMA AD Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD informs that today Sopharma reached an agreement for the sale of 75% of the capital of Extab Corporation. After the transaction Sophama will remain a shareholder in the company with 5%.
Więcej na: biznes.pap.pl
kom espi zdz
- 15.05.2015 14:29
SOPHARMA AD NOTIFICATION
15.05.2015 14:29SOPHARMA AD NOTIFICATION
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD informs that the Board of Directors of Sopharma AD authorized the Executive Director of the company to undertake negotiations for the sale of the shares of Extab Corporation owned by Sopharma AD.
Więcej na: biznes.pap.pl
kom espi zdz
- 14.05.2015 14:16
SOPHARMA AD Annual General Meeting of Shareholders of Sopharma AD-19.06.2015
14.05.2015 14:16SOPHARMA AD Annual General Meeting of Shareholders of Sopharma AD-19.06.2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Annual General Meeting of Shareholders of Sopharma AD-19.06.2015
1. Invitation to the Annual General Meeting of Shareholders of Sopharma AD-19.06.2015
2. Minutes of the Meeting of the Board of Directors of Sopharma AD
3. Report of the Investor Relations Director for 2014
4. Report Regarding the Application of the Remuneration Policy
5. Letter of Attorney- sample
6. Audited Financial Statements for 2014
7. Audited Consolidated Financial Statements for 2014
Więcej na: biznes.pap.pl
kom espi zdz
- 12.05.2015 13:45
SOPHARMA AD Current report 44 re insiders transactions
12.05.2015 13:45SOPHARMA AD Current report 44 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
04.05.2015 Sale 100 3.18
04.05.2015 Sale 292 3.18
05.05.2015 Sale 200 3.199
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 07.05.2015 13:24
SOPHARMA AD Current report 43 re insiders transactions
07.05.2015 13:24SOPHARMA AD Current report 43 re insiders transactions
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
27.04.2015 Sale 10 3.29
28.04.2015 Sale 400 3.15
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 07.05.2015 13:07
SOPHARMA AD Sopharma monthly April 2015
07.05.2015 13:07SOPHARMA AD Sopharma monthly April 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for April 2015 the Company recorded an increase of sales revenues of 2% compared to the same month of 2014, including 8% increase of domestic sales and 1% decrease of export sales.
For the four months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 16% increase of domestic sales and a 28% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 30.04.2015 17:33
SOPHARMA AD Audited Consolidated Financial Statements for 2014
30.04.2015 17:33SOPHARMA AD Audited Consolidated Financial Statements for 2014
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
Audited Consolidated Financial Statements for 2014
1. Audited Financial Statements
2. Notes to the Financial Statements
3. Management report
4 Independent Auditor's Report
Więcej na: biznes.pap.pl
kom espi zdz
- 30.04.2015 12:48
SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 MARCH 2015
30.04.2015 12:48SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 MARCH 2015
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe
INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 MARCH 2015
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Insider Information
5. Additional Information
Więcej na: biznes.pap.pl
kom espi zdz
- 28.04.2015 08:57
SOPHARMA AD Current report 39 re insiders transactions
28.04.2015 08:57SOPHARMA AD Current report 39 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osób mających dostęp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
24.04.2015 Sale 125 3.152
24.04.2015 Sale 175 3.152
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 06.04.2015 13:10
SOPHARMA AD Current report 38 re insiders transactions
06.04.2015 13:10SOPHARMA AD Current report 38 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
30.03.2015 Sale 320 3.49
30.03.2015 Sale 1200 3.45
01.04.2015 Sale 482 3.49
02.04.2015 Sale 61 3.422
02.04.2015 Sale 189 3.422
02.04.2015 Sale 100 3.422
02.04.2015 Sale 150 3.422
03.04.2015 Sale 17 3.43
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 03.04.2015 14:00
SOPHARMA AD Sopharma monthly March 2015
03.04.2015 14:00SOPHARMA AD Sopharma monthly March 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for March 2015 the Company recorded a decrease of sales revenues of 7% compared to the same month of 2014, including 32% increase of domestic sales and 21% decrease of export sales.
For the three months of this year, revenues from sales decreased by 21% compared to the same period of 2014, including 20% increase of domestic sales and a 35% decrease of export sales.
In March 2015 the subsidiary of Sopharma AD, Sopharma Ukraine EOOD, with a core business in trading with pharmaceutical products, increased its capital to 317 531 502 UAH.
Więcej na: biznes.pap.pl
kom espi zdz
- 02.04.2015 13:38
SOPHARMA AD Current report 36 buy back 02042015
02.04.2015 13:38SOPHARMA AD Current report 36 buy back 02042015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 26 March 2015 up to and including 1 April 2015 the Company bought 664 own shares representing 0.00049% of the share capital of the Company, at a total value of 2310.8 BGN on the Bulgarian Stock Exchange, the average price per share was 3.48 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 163 820, representing 3.83% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 31.03.2015 10:29
SOPHARMA AD SEPARATE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2014
31.03.2015 10:29SOPHARMA AD SEPARATE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2014
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieї№ce i okresowe
SEPARATE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2014
1. Financial Statements
2. Notes to the Financial Statements
3. Management Report
4. Comply or Explain Report
5. Auditor's Report
6. Appendixs 11
7. Report Regarding the Application of the Remuneration Policy for the Members of the Board of Directors of Sopharma AD for 2014
Więcej na: biznes.pap.pl
kom espi zdz
- 30.03.2015 15:42
SOPHARMA AD Current report 34 re insiders transactions
30.03.2015 15:42SOPHARMA AD Current report 34 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
25.03.2015 Sale 500 3.44
26.03.2015 Sale 300 3.46
26.03.2015 Sale 300 3.46
27.03.2015 Sale 180 3.49
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 26.03.2015 13:33
SOPHARMA AD Current report 33 buy back 26032015
26.03.2015 13:33SOPHARMA AD Current report 33 buy back 26032015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 19 March 2015 up to and including 25 March 2015 the Company bought 15 200 own shares representing 0.011% of the share capital of the Company, at a total value of 52 440.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.45 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 163 156, representing 3.83% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 24.03.2015 15:40
SOPHARMA AD Current report 32 re insiders transactions
24.03.2015 15:40SOPHARMA AD Current report 32 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
16.03.2015 Sale 100 3.331
16.03.2015 Sale 200 3.331
17.03.2015 Sale 122 3.40
17.03.2015 Sale 33 3.40
17.03.2015 Sale 19 3.40
17.03.2015 Sale 39 3.40
18.03.2015 Sale 115 3.435
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 19.03.2015 13:41
SOPHARMA AD Notifications for disclosure of share participation 31 190315
19.03.2015 13:41SOPHARMA AD Notifications for disclosure of share participation 31 190315
Podstawa prawna: Art. 70 pkt 1 Ustawy o ofercie - nabycie lub zbycie znacznego pakietu akcji
Sopharma AD (the "Company") announces that on 19 March 2015 the Company received Notifications for disclosure of share participation under art. 145 of POSA from Donev Investments Holding AD, Telecomplect Invest AD and Telso AD for change in their share participation in Sopharma AD due to the capital increase of Sopharma AD through the merger of Bulgarian Rose Sevtopolis AD.
- Donev Investments Holding AD - the share participation in Sopharma AD decreases from 25.26% to 24.74%;
- Telecomplect Invest AD - the share participation in Sopharma AD decreases from 20.41% to 19.99%;
- Telso AD - the share participation in Sopharma AD increases from 4.98% to 5.29%;
The date of registration of the transaction in the Central Depository AD is 6 March 2015.
Więcej na: biznes.pap.pl
kom espi zdz
- 17.03.2015 12:55
SOPHARMA AD Current report 30 re insiders transactions
17.03.2015 12:55SOPHARMA AD Current report 30 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
12.03.2015 Sale 37 3.160
13.03.2015 Sale 63 3.160
13.03.2015 Sale 400 3.300
13.03.2015 Sale 500 3.300
13.03.2015 Sale 100 3.300
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 12.03.2015 13:42
SOPHARMA AD Current report 29 buy back 12032015
12.03.2015 13:42SOPHARMA AD Current report 29 buy back 12032015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 5 March 2015 up to and including 11 March 2015 the Company bought 900 own shares representing 0.00067% of the share capital of the Company, at a total value of 2 970.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.30 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 147 956, representing 3.82% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 10.03.2015 13:37
SOPHARMA AD Current report 28 Momina krepost
10.03.2015 13:37SOPHARMA AD Current report 28 Momina krepost
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that on 6 March 2015 the Company bought 458 250 shares from the capital of Momina krepost AD. After this transaction, the share of Sopharma AD in the capital of Momina krepost AD increased to 80.09%.
Więcej na: biznes.pap.pl
kom espi zdz
- 06.03.2015 09:56
SOPHARMA AD Current report 27 Notification
06.03.2015 09:56SOPHARMA AD Current report 27 Notification
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
The Board of directors of Sopharma AD hereby notifies that as part of the process related to the merger of Bulgarian Rose - Sevtopolis AD into Sopharma AD the company has undertaken the registriton of the capital increase in the Central Depository AD. After communication with the Central Depository and with their kind assistance the calculation of the distribution of shares will be carried our under the provisions of the contract for merger signed between the two parties on June 19, 2014 and for the convenience of the shareholders for those that have more than one client account the calculaiton will be carried out baes on the total number of shares and the distribution between the different accounts will be carried our proportionally (the remainder will be distributed into the last account).
We hereby notify that until the new issuance from the capital increase is registered into the public register of the Financial Supervision Commission the shares of Sopharma AD will be blocked and will not be traded.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.03.2015 13:34
SOPHARMA AD Sopharma monthly February 2015
05.03.2015 13:34SOPHARMA AD Sopharma monthly February 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for February 2015 the Company recorded a decrease of sales revenues of 16% compared to the same month of 2014, including 14% increase of domestic sales and 28% decrease of export sales. In February, the Russian market returned to the normal pace of sales, corresponding to this time of the year. The situation in Ukraine still restricts exports to this market.
For the two months of this year, revenues from sales decreased by 29% compared to the same period of 2014, including 12% increase of domestic sales and a 44% decrease of export sales.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.03.2015 13:31
SOPHARMA AD Current report 24 buy back 05032015
05.03.2015 13:31SOPHARMA AD Current report 24 buy back 05032015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 26 February 2015 up to and including 4 March 2015 the Company bought 1 000 own shares representing 0.00076% of the share capital of the Company, at a total value of 3 280.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.28 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 147 056, representing 3.90% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.03.2015 13:29
SOPHARMA AD Current report 25 Medika AD above 30%
05.03.2015 13:29SOPHARMA AD Current report 25 Medika AD above 30%
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that on 5 March 2015 the Company bought 605 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 30.42%.
Więcej na: biznes.pap.pl
kom espi zdz
- 04.03.2015 15:55
SOPHARMA AD Current report 23 re insiders transactions
04.03.2015 15:55SOPHARMA AD Current report 23 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
27.02.2015 Buy 255 3.370
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 27.02.2015 14:24
SOPHARMA AD SPH GROUP 2014 Q4
27.02.2015 14:24SOPHARMA AD SPH GROUP 2014 Q4
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieї№ce i okresowe
Consolidated Interim Financial Statements for the period 1 January to 31 December 2014
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
Więcej na: biznes.pap.pl
kom espi zdz
- 26.02.2015 13:46
SOPHARMA AD NOTIFICATION 26022015
26.02.2015 13:46SOPHARMA AD NOTIFICATION 26022015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
The Board of Directors hereby notifies that the transformation through merger of Bulgarian Rose - Sevtopolis AD in Sopharma AD has been registered with the Commercial Register with number 20150226134200. The registered capital of Sopharma AD is 134 797 899 BGN.
Sopharma AD is now undertaking all necessary actions for registration of the new issuance of 2 797 899 shares, with nominal value of 1.00 BGN with the Central Depository AD.
Więcej na: biznes.pap.pl
kom espi zdz
- 26.02.2015 13:21
SOPHARMA AD Current report 20 buy back 26022015
26.02.2015 13:21SOPHARMA AD Current report 20 buy back 26022015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 19 February 2015 up to and including 25 February 2015 the Company bought 2 385 own shares representing 0.0018% of the share capital of the Company, at a total value of 8 195.40 BGN on the Bulgarian Stock Exchange, the average price per share was 3.44 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 146 056, representing 3.90% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 19.02.2015 14:08
SOPHARMA AD Current report 19 buy back 19022015
19.02.2015 14:08SOPHARMA AD Current report 19 buy back 19022015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 12 February 2015 up to and including 18 February 2015 the Company bought 7 150 own shares representing 0.0054% of the share capital of the Company, at a total value of 25 608.50 BGN on the Bulgarian Stock Exchange, the average price per share was 3.58 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 143 671, representing 3.90% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 16.02.2015 15:34
SOPHARMA AD Current report 18 re insiders transactions
16.02.2015 15:34SOPHARMA AD Current report 18 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
10.02.2015 Buy 35 3.516
10.02.2015 Sale 300 3.600
13.02.2015 Sale 200 3.560
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 12.02.2015 09:47
SOPHARMA AD ACQUISITION OF OWN SHARES
12.02.2015 09:47SOPHARMA AD ACQUISITION OF OWN SHARES
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 10 February 2015 up to and including 13 February 2015 the Company bought 10 500 own shares representing 0.0080% of the share capital of the Company, at a total value of 37 792 BGN on the Bulgarian Stock Exchange, the average price per share was 3.599 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 136 521, representing 3.89% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 10.02.2015 14:01
SOPHARMA AD NOTIFICATION OF INSIDERS' TRANSACTIONS
10.02.2015 14:01SOPHARMA AD NOTIFICATION OF INSIDERS' TRANSACTIONS
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
05.02.2015 Sale 300 3.64
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.02.2015 14:08
SOPHARMA AD NOTIFICATION
05.02.2015 14:08SOPHARMA AD NOTIFICATION
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieї№ce i okresowe
Sopharma AD notifies that for January 2015 the Company recorded a decrease of sales revenues of 43% compared to the same month of 2014, including 11% increase of domestic sales and 61% decrease of export sales. The volatility of the RUB caused us to undertake actions to adjust the prices for our main export market - Russia, which prevented us from exporting during the period.
Our forecast is that this slowdown in the beginning of the year will be compensated already in the first quarter.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.02.2015 13:56
SOPHARMA AD ACQUISITION OF OWN SHARES
05.02.2015 13:56SOPHARMA AD ACQUISITION OF OWN SHARES
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 29 January 2015 up to and including 4 February 2015 the Company bought 3 200 own shares representing 0.0024% of the share capital of the Company, at a total value of 11 534.90 BGN on the Bulgarian Stock Exchange, the average price per share was 3.605 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 126 021, representing 3.88% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 03.02.2015 13:07
SOPHARMA AD Current report 13 re insiders transactions
03.02.2015 13:07SOPHARMA AD Current report 13 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
27.01.2015 Sale 200 3.700
28.01.2015 Sale 100 3.700
28.01.2015 Sale 300 3.700
28.01.2015 Buy 100 3.600
29.01.2015 Sale 150 3.630
29.01.2015 Sale 200 3.700
29.01.2015 Sale 1300 3.630
29.01.2015 Sale 450 3.630
29.01.2015 Sale 500 3.650
29.01.2015 Sale 500 3.650
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 30.01.2015 14:24
SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2014
30.01.2015 14:24SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2014
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieї№ce i okresowe
INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2014
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Insider Information
5. Additional Information
Więcej na: biznes.pap.pl
kom espi zdz
- 29.01.2015 13:50
SOPHARMA AD Current report 11 buy back 29012015
29.01.2015 13:50SOPHARMA AD Current report 11 buy back 29012015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 22 January 2015 up to and including 28 January 2015 the Company bought 1 694 own shares representing 0.0013% of the share capital of the Company, to the total value of 6 204.72 BGN on the Bulgarian Stock Exchange, the average price per share was 3.66 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 122 821, representing 3.88% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 27.01.2015 13:46
SOPHARMA AD Current report 10 re insiders transactions
27.01.2015 13:46SOPHARMA AD Current report 10 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
19.01.2015 Sale 225 3.69
19.01.2015 Sale 275 3.69
20.01.2015 Sale 200 3.78
21.01.2015 Sale 300 3.79
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 22.01.2015 13:11
SOPHARMA AD Current report 9 buy back 22012015
22.01.2015 13:11SOPHARMA AD Current report 9 buy back 22012015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 15 January 2015 up to and including 21 January 2015 the Company bought 1 000 own shares representing 0.00076% of the share capital of the Company, to the total value of 3 720.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.72 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 121 127, representing 3.88% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 22.01.2015 07:57
SOPHARMA AD Current report 8 re insiders transactions
22.01.2015 07:57SOPHARMA AD Current report 8 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
12.01.2015 Sale 250 3.87
16.01.2015 Sale 100 3.70
16.01.2015 Sale 300 3.70
16.01.2015 Sale 45 3.70
16.01.2015 Sale 73 3.70
16.01.2015 Sale 100 3.70
16.01.2015 Sale 100 3.70
16.01.2015 Sale 100 3.70
15.01.2015 Sale 300 3.78
16.01.2015 Sale 60 3.70
16.01.2015 Sale 27 3.70
16.01.2015 Sale 113 3.70
16.01.2015 Sale 127 3.70
16.01.2015 Sale 200 3.70
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 15.01.2015 14:23
SOPHARMA AD Current report 7 buy back 15012015
15.01.2015 14:23SOPHARMA AD Current report 7 buy back 15012015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 8 January 2015 up to and including 14 January 2015 the Company bought 2 677 own shares representing 0.002% of the share capital of the Company, to the total value of 9 957.10 BGN on the Bulgarian Stock Exchange, the average price per share was 3.72 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 120 127, representing 3.88% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 14.01.2015 12:59
SOPHARMA AD Current report 6 re insiders transactions
14.01.2015 12:59SOPHARMA AD Current report 6 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
05.01.2015 Sale 150 3.90
05.01.2015 Sale 142 3.86
05.01.2015 Sale 8 3.86
07.01.2015 Sale 500 3.87
08.01.2015 Sale 300 3.88
09.01.2015 Sale 500 3.87
09.01.2015 Sale 300 3.87
09.01.2015 Sale 400 3.87
09.01.2015 Sale 400 3.87
05.01.2015 Buy 100 3.8
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 09.01.2015 15:44
SOPHARMA AD MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 9 JANUARY 2015
09.01.2015 15:44SOPHARMA AD MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 9 JANUARY 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
We would hereby like to notify tha the Extraordinary General Meeting of Shareholders of Sopharma AD held on January 9, 2015 in Sofia took a decision for trnasformation of Sopharma AD throught the merger of Bulgarian Rose - Sevtopolis AD based in the city of Kazanlak, UIC 123007916. As a result the whole property of Bulgarian Rose - Sevtopolis AD will be transferred to Sopharma AD with the full rights.
The merger procedure will start according to the Contract for transofrmation through merger of Bulgarian Rose - Sevtopolis AD in Sopharma AD signed on June 19, 2014 and its Additional Agreements 1, 2 and 3.
All related applications are available on the internet page of Sopharma AD www.sopharma.bg and must be filed at the company address on 16, Iliensko Shose Str. in Sofia.
Więcej na: biznes.pap.pl
kom espi zdz
- 08.01.2015 13:30
SOPHARMA AD Monthly December 2014
08.01.2015 13:30SOPHARMA AD Monthly December 2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD notifies that for December 2014 the Company recorded a decrease of sales revenues of 29% compared to the same month of 2013, including 20% decrease of domestic sales and 36% decrease of export sales.
During the past year Sopharma AD recorded a decrease of sales revenues of 7%, including 1% increase of domestic sales and 10% decrease of export sales compared to 2013.
Więcej na: biznes.pap.pl
kom espi mra
- 08.01.2015 13:23
SOPHARMA AD Current report 3 buy back 8 01 2015
08.01.2015 13:23SOPHARMA AD Current report 3 buy back 8 01 2015
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 18 December 2014 up to and including 7 January 2015 the Company bought 3897 own shares representing 0.003% of the share capital of the Company, to the total value of 15 019.98 BGN on the Bulgarian Stock Exchange, the average price per share was 3.85 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 117 450, representing 3.88% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 07.01.2015 13:30
SOPHARMA AD Current report 2 re insiders transactions
07.01.2015 13:30SOPHARMA AD Current report 2 re insiders transactions
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN) 15.12.2014 Sale 200 3.852 15.12.2014 Sale 3000 3.85 18.12.2014 Sale 290 3.85 18.12.2014 Sale 210 3.85 29.12.2014 Sale 250 3.90 29.12.2014 Sale 250 3.90 29.12.2014 Sale 450 3.80 29.12.2014 Sale 150 3.90 19.12.2014 Buy 8 3.791 19.12.2014 Buy 10 3.79 19.12.2014 Buy 982 3.79 30.12.2014 Sale 200 3.85 30.12.2014 Sale 165 3.85 The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi amp/
- 05.01.2015 16:17
SOPHARMA AD Current report re insiders transactions - 1-Donev
05.01.2015 16:17SOPHARMA AD Current report re insiders transactions - 1-Donev
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN) 29.12.2014 Sale 1900 3.75
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 19.12.2014 12:37
SOPHARMA AD Minutes of EGM of Shareholders of Sopharma AD - 19.12.2014
19.12.2014 12:37SOPHARMA AD Minutes of EGM of Shareholders of Sopharma AD - 19.12.2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Minutes of EGM of Shareholders of Sopharma AD - 19.12.2014
Więcej na: biznes.pap.pl
kom espi mra
- 18.12.2014 13:28
SOPHARMA AD Current report 133 buy back 18 12 2014
18.12.2014 13:28SOPHARMA AD Current report 133 buy back 18 12 2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 11 December 2014 up to and including 17 December 2014 the Company bought 510 own shares representing 0.00039% of the share capital of the Company, to the total value of 1964.01 BGN on the Bulgarian Stock Exchange, the average price per share was 3.85 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 113 553, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 16.12.2014 08:25
SOPHARMA AD Current report 132 re insiders transactions
16.12.2014 08:25SOPHARMA AD Current report 132 re insiders transactions
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
10.12.2014 Sale 260 3.919
10.12.2014 Sale 5000 3.88
08.12.2014 Sale 250 3.89
10.12.2014 Sale 100 3.98
10.12.2014 Sale 200 3.98
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 12.12.2014 13:59
SOPHARMA AD Current report 131 buy back 12122014
12.12.2014 13:59SOPHARMA AD Current report 131 buy back 12122014
SOPHARMA AD hereby informs that from 4 December 2014 up to and including 10 December 2014 the Company bought 200 own shares representing 0.00015% of the share capital of the Company, to the total value of 796 BGN on the Bulgarian Stock Exchange, the average price per share was 3.98 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 113 043, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi abs/
- 08.12.2014 13:56
SOPHARMA AD Current report 130 re insiders transactions
08.12.2014 13:56SOPHARMA AD Current report 130 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN) 01.12.2014 Sale 650 3.82 02.12.2014 Sale 2000 3.75 02.12.2014 Sale 12 3.75 03.12.2014 Sale 250 3.89 04.12.2014 Sale 20 3.84 04.12.2014 Sale 130 3.84 05.12.2014 Sale 200 3.87
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 08.12.2014 11:23
SOPHARMA AD Invitation To The Extraordinary General Meeting Of Shareholders Of Sopharma Ad - 9 January 2015
08.12.2014 11:23SOPHARMA AD Invitation To The Extraordinary General Meeting Of Shareholders Of Sopharma Ad - 9 January 2015
Podstawa prawna: INVITATION TO THE EXTRAORDINARY
GENERAL MEETING OF SHAREHOLDERS
OF SOPHARMA AD - 9 JANUARY 2015
Więcej na: biznes.pap.pl
kom espi mra
- 08.12.2014 10:28
SOPHARMA AD Sopharma monthly November 2014
08.12.2014 10:28SOPHARMA AD Sopharma monthly November 2014
Sopharma AD notifies that for November 2014 the Company recorded a decrease of sales revenues of 7% compared to the same month of 2013, including 4% increase of domestic sales and 11% decrease of export sales.
During the past eleven months Sopharma AD recorded a decrease of sales revenues of 4%, including 4% increase of domestic sales and 7% decrease of export sales compared to the same period of 2013.
Więcej na: biznes.pap.pl
kom espi dom
- 04.12.2014 14:23
SOPHARMA AD Current report 127 buy back 04122014
04.12.2014 14:23SOPHARMA AD Current report 127 buy back 04122014
SOPHARMA AD hereby informs that from 27 November 2014 up to and including 3 December 2014 the Company bought 2 180 own shares representing 0.0017% of the share capital of the Company, to the total value of 8 285.7 BGN on the Bulgarian Stock Exchange, the average price per share was 3.80 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 112 843, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi abs/
- 02.12.2014 11:08
SOPHARMA AD Current report 126 re insiders transactions
02.12.2014 11:08SOPHARMA AD Current report 126 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
28.11.2014 Buy 711 3.65
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 28.11.2014 15:48
SOPHARMA AD Consolidated Interim Financial Statements for the period 1 January to 30 September 2014.
28.11.2014 15:48SOPHARMA AD Consolidated Interim Financial Statements for the period 1 January to 30 September 2014.
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieї№ce i okresowe
Consolidated Condensed Interim Financial Statements for the period 1 January to 30 September 2014
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
Więcej na: biznes.pap.pl
kom espi pif/
- 27.11.2014 14:34
SOPHARMA AD Current report 124 buy back 27112014
27.11.2014 14:34SOPHARMA AD Current report 124 buy back 27112014
SOPHARMA AD hereby informs that from 20 November 2014 up to and including 26 November 2014 the Company bought 1 211 own shares representing 0.0009% of the share capital of the Company, to the total value of 4 479.49 BGN on the Bulgarian Stock Exchange, the average price per share was 3.70 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 110 663, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi abs/
- 24.11.2014 13:24
SOPHARMA AD Current report 123 re insiders transactions
24.11.2014 13:24SOPHARMA AD Current report 123 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the Company) announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company Donev Investments Holding AD related to him, executed the following transactions related to shares in the Company:
of the settlement Operation Number of shares Unit price (BGN) 20.11.2014 Buy 289.00 3.65 20.11.2014 Buy 250.00 3.66 21.11.2014 Sale 100 3.719 21.11.2014 Sale 200 3.719 The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi amp/
- 24.11.2014 09:58
SOPHARMA AD Current report 122 re insiders transactions
24.11.2014 09:58SOPHARMA AD Current report 122 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Sopharma Trading AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
19.11.2014 Buy 357 3.73
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 20.11.2014 13:53
SOPHARMA AD Current report 121 buy back 20.11.2014
20.11.2014 13:53SOPHARMA AD Current report 121 buy back 20.11.2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 13 November 2014 up to and including 19 November 2014 the Company bought 300 own shares representing 0.0002% of the share capital of the Company, to the total value of 1109.8 BGN on the Bulgarian Stock Exchange, the average price per share was 3.70 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 109 452, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 18.11.2014 10:51
SOPHARMA AD INVITATION FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - 19122014
18.11.2014 10:51SOPHARMA AD INVITATION FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - 19122014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
1. Invitation
2. Letter of Attorney
3. Minutes of the Meeting of the Board of directors of Sopharma AD
4. Substantiated Report
5. Contract for transformation by merger
6. Supplementary agreement 1
7. Supplementary agreement 2
8. Justification report of the fair price of the shares of Sopharma AD
9. Justification report of the fair price of the shares of Bulgarian Rose - Sevtopolis AD
Więcej na: biznes.pap.pl
kom espi amp/
- 17.11.2014 13:02
SOPHARMA AD Current report 119 re insiders transactions
17.11.2014 13:02SOPHARMA AD Current report 119 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
14.11.2014 Buy 150 3.88
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 13.11.2014 13:03
SOPHARMA AD Current report 118 buy back 13112014
13.11.2014 13:03SOPHARMA AD Current report 118 buy back 13112014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 6 November 2014 up to and including 12 November 2014 the Company bought 2 100 own shares representing 0.0016% of the share capital of the Company, to the total value of 8 201.8 BGN on the Bulgarian Stock Exchange, the average price per share was 3.91 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 109 152, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi amp/
- 10.11.2014 15:10
SOPHARMA AD Notification - Approval for transformation
10.11.2014 15:10SOPHARMA AD Notification - Approval for transformation
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that on 7 November 2014 the Financial Supervision Commission approved the Contract for transformation through merger and two additional annexes to it, signed on 19 June 2014 between Sopharma AD, Sofia, UIC 831902088, hereinafter referred to as "Acquirer" and Bulgarian Rose - Sevtopolis AD, Kazanlak, UIC 123007916, hereinafter referred to as "Acquiree" in accordance with the requirements of art. 262d and following of the Commercial Act (CA). As a result the assets of Bulgarian Rose - Sevtopolis AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Bulgarian Rose - Sevtopolis AD will be terminated without liquidation. The Financial Supervision Commission also approved the reports of the management of the two companies, prepared in accordance with the regulations of art.262i of the CA and the report of the appointed common examiner of the participants in the transformation under art. 262M of the CA from 13 October 2014.
According to the signed contract, in connection with the implementation of the merger shall be carried out a capital increase of the Acquirer Sopharma AD through issuing of new shares, which shall be distributed among the shareholders of the Acquiree Bulgarian Rose - Sevtopolis AD (except the shareholder Sopharma AD). The capital of the Acquirer Sopharma AD shall be increased from 132,000,000 BGN to up to 134,798,527 through the issuing of up to 2,798,527 new ordinary registered shares.
As a result of the merger, all shareholders of the Acquiree Bulgarian Rose - Sevtopolis AD, with the exception of the Acquirer Sopharma AD, which is also a shareholder of the Acquiree, will receive shares of Sopharma AD and become shareholders of it. Against one share of Bulgarian Rose - Sevtopolis AD each shareholder pursuant to art. 261b, art. 1 of the CA shall receive 0.463768 shares of the capital of Sopharma AD.
Extraordinary General Meetings of Shareholders of the two companies shall be convened. The deadline for the registration of the transformation in the Commercial Register is 12 February 2015.
The Acquiree shall submit a request to the Bulgarian Stock Exchange - Sofia AD for delisting of its shares after the end of the trading session on 3 December 2014. The request is a subject to a review and decision by the governing body of BSE - Sofia AD.
Więcej na: biznes.pap.pl
kom espi amp/
- 06.11.2014 13:35
SOPHARMA AD Current report 116 buy back 06.11.2014
06.11.2014 13:35SOPHARMA AD Current report 116 buy back 06.11.2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 30 October 2014 up to and including 05 November 2014 the Company bought 1 000 own shares representing 0.0008% of the share capital of the Company, to the total value of 3 900 BGN on the Bulgarian Stock Exchange, the average price per share was 3.90 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 107 052, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 05.11.2014 14:41
SOPHARMA AD Monthly October 2014
05.11.2014 14:41SOPHARMA AD Monthly October 2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that for October 2014 the Company recorded an increase of sales revenues of 4% compared to the same month of 2013, including 12% increase of domestic sales and 1% increase of export sales.
During the past ten months Sopharma AD recorded a decrease of sales revenues of 4%, including 4% increase of domestic sales and 7% decrease of export sales compared to the same period of 2013.
Więcej na: biznes.pap.pl
kom espi mra
- 04.11.2014 14:43
SOPHARMA AD Short name of the issuer
04.11.2014 14:43SOPHARMA AD Short name of the issuer
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") announces that on 4 November 2014 the Company bought 400 010 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 23.20%.
Więcej na: biznes.pap.pl
kom espi mra
- 03.11.2014 13:54
SOPHARMA AD Current report 112 Medika AD above 15%
03.11.2014 13:54SOPHARMA AD Current report 112 Medika AD above 15%
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") announces that on 3 November 2014 the Company bought 500 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 19,22%.
Więcej na: biznes.pap.pl
kom espi mra
- 30.10.2014 13:26
SOPHARMA AD Interim Financial Statements For The Period Ending 30 September 2014
30.10.2014 13:26SOPHARMA AD Interim Financial Statements For The Period Ending 30 September 2014
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieї№ce i okresowe
INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2014
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Insider Information
5. Additional Information
Więcej na: biznes.pap.pl
kom espi mra
- 30.10.2014 13:09
SOPHARMA AD Current report 111 buy back 30102014
30.10.2014 13:09SOPHARMA AD Current report 111 buy back 30102014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 23 October 2014 up to and including 29 October 2014 the Company bought 1 375 own shares representing 0.001% of the share capital of the Company, to the total value of 5389.9 BGN on the Bulgarian Stock Exchange, the average price per share was 3.92 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 106 052, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 28.10.2014 14:38
SOPHARMA AD Current report 110 re insiders transactions
28.10.2014 14:38SOPHARMA AD Current report 110 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
22.10.2014 Sale 200 4
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 23.10.2014 13:06
SOPHARMA AD Current report 109 buy back 23102014
23.10.2014 13:06SOPHARMA AD Current report 109 buy back 23102014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 16 October 2014 up to and including 22 October 2014 the Company bought 1 819 own shares representing 0.0014% of the share capital of the Company, to the total value of 7 188.11 BGN on the Bulgarian Stock Exchange, the average price per share was 3.95 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 104 677, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 20.10.2014 09:49
SOPHARMA AD 108/2014
20.10.2014 09:49SOPHARMA AD 108/2014
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
21.10.2014 Sale 100 3.9500
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 16.10.2014 14:31
SOPHARMA AD Current report 107 buy back 16102014
16.10.2014 14:31SOPHARMA AD Current report 107 buy back 16102014
SOPHARMA AD hereby informs that from 9 October 2014 up to and including 15 October 2014 the Company bought 1 745 own shares representing 0.0013% of the share capital of the Company, to the total value of 6 955.83 BGN on the Bulgarian Stock Exchange, the average price per share was 3.99 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 102 858, representing 3.87% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi abs/
- 15.10.2014 11:13
SOPHARMA AD Current report 106 re insiders transactions
15.10.2014 11:13SOPHARMA AD Current report 106 re insiders transactions
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
06.10.2014 Buy 500 4.00
06.10.2014 Buy 2000 4.00
06.10.2014 Buy 1500 4.00
08.10.2014 Buy 950 3.94
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi abs/
- 09.10.2014 13:56
SOPHARMA AD - buy back
09.10.2014 13:56SOPHARMA AD - buy back
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 2 October 2014 up to and including 8 October 2014 the Company bought 14 015 own shares representing 0.011% of the share capital of the Company, to the total value of 56 025.88 BGN on the Bulgarian Stock Exchange, the average price per share was 3.998 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 101 113, representing 3.86% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi pif/
- 06.10.2014 16:07
SOPHARMA AD Current report 104 re insiders transactions
06.10.2014 16:07SOPHARMA AD Current report 104 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Current report No. 104/2014
Dated 6 October 2014
NOTIFICATION OF INSIDERS' TRANSACTIONS
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
29.09.2014 Sale 100 4.03
30.09.2014 Sale 200 4.03
30.09.2014 Sale 50 4.03
01.10.2014 Sale 200 4.035
01.10.2014 Sale 200 4.035
01.10.2014 Sale 300 4.035
03.10.2014 Sale 500 4.035
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Legal grounds: Art.160.4 of the Act on Trading in Financial Instruments of 29 July 2005.
Signatures of individuals authorized to represent the Company:
Więcej na: biznes.pap.pl
kom espi abs/
- 03.10.2014 08:54
SOPHARMA AD NOTIFICATION
03.10.2014 08:54SOPHARMA AD NOTIFICATION
Sopharma AD (the "Company") notifies that for September 2014 the Company recorded an increase of sales revenues of 3% compared to the same month of 2013, including 6% increase of domestic sales and 2% increase of export sales.
During the past nine months Sopharma AD recorded a decrease of sales revenues of 5%, including 3% increase of domestic sales and 8% decrease of export sales compared to the same period of 2013.
Więcej na: biznes.pap.pl
kom espi abs/
- 02.10.2014 12:23
SOPHARMA AD Acquisition of own shares
02.10.2014 12:23SOPHARMA AD Acquisition of own shares
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD hereby informs that from 25 September 2014 up to and including 01 October 2014 the Company bought 1 400 own shares representing 0.0011% of the share capital of the Company, to the total value of 5 644.50 BGN on the Bulgarian Stock Exchange, the average price per share was 4.03 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 087 098, representing 3.85% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi amp/
- 30.09.2014 13:38
SOPHARMA AD Current report 101 re insiders transactions
30.09.2014 13:38SOPHARMA AD Current report 101 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN) 25.09.2014 Buy 2000 3.91 25.09.2014 Buy 10 3.97 25.09.2014 Buy 90 3.97 23.09.2014 Sale 300 4.06 23.09.2014 Sale 1000 4.03 24.09.2014 Sale 1000 4.01 25.09.2014 Sale 500 4.04 25.09.2014 Sale 500 4.04
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 25.09.2014 11:49
SOPHARMA AD Current report 100 buy back 25092014
25.09.2014 11:49SOPHARMA AD Current report 100 buy back 25092014
SOPHARMA AD hereby informs that from 18 September 2014 up to and including 24 September 2014 the Company bought 7 343 own shares representing 0.0056% of the share capital of the Company, to the total value of 29 212.2 BGN on the Bulgarian Stock Exchange, the average price per share was 3.98 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 085 698, representing 3.85% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi abs/
- 24.09.2014 14:02
SOPHARMA AD Current report 99 re insiders transactions
24.09.2014 14:02SOPHARMA AD Current report 99 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN) 15.09.2014 Sale 200 4.185 15.09.2014 Sale 200 4.185 15.09.2014 Sale 100 4.185
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 18.09.2014 13:34
SOPHARMA AD Current report 98 buy back 18092014
18.09.2014 13:34SOPHARMA AD Current report 98 buy back 18092014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 11 September 2014 up to and including 17 September 2014 the Company bought 2 500 own shares representing 0.0019% of the share capital of the Company, to the total value of 10 222.5 BGN on the Bulgarian Stock Exchange, the average price per share was 4.09 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 078 355, representing 3.85% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 16.09.2014 14:32
SOPHARMA AD Current report re insiders transactions - 97-Donev
16.09.2014 14:32SOPHARMA AD Current report re insiders transactions - 97-Donev
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN) 16.09.2014 Buy 2000 4.1000
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 16.09.2014 13:18
SOPHARMA AD - insiders transactions
16.09.2014 13:18SOPHARMA AD - insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
09.09.2014 Buy 1000 4.132
10.09.2014 Buy 1000 4.125
12.09.2014 Buy 1000 4.125
08.09.2014 Sale 500 4.22
05.09.2014 Sale 1000 4.23
09.09.2014 Sale 500 4.21
10.09.2014 Sale 600 4.21
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi pif/
- 11.09.2014 13:33
SOPHARMA AD - buy back
11.09.2014 13:33SOPHARMA AD - buy back
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 4 September2014 up to and including 10 September 2014 the Company bought 3800 own shares representing 0.0029% of the share capital of the Company, to the total value of 15 868.8 BGN on the Bulgarian Stock Exchange, the average price per share was 4.18 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 075 855, representing 3.85% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi pif/
- 09.09.2014 08:30
SOPHARMA AD Current report 94 re insiders transactions
09.09.2014 08:30SOPHARMA AD Current report 94 re insiders transactions
Sopharma AD (the Company) announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company Donev Investments Holding AD related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
02.09.2014 Buy 1000 4.175
03.09.2014 Sale 400 4.23
03.09.2014 Sale 50 4.23
03.09.2014 Sale 50 4.23
05.09.2014 Sale 1000 4.23
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi zdz
- 05.09.2014 12:49
SOPHARMA AD SPH Notification- paying of dividents
05.09.2014 12:49SOPHARMA AD SPH Notification- paying of dividents
SOPHARMA AD hereby informs that the Company will commence the paying of dividends for 2013 on 11 September 2014 in accordance with a List of Entitled Persons as at 4 July 2014, prepared by the Central Depository.
Pursuant to the Regulations of the Central Depository AD the dividend will be paid out as follows: to shareholders with client accounts at an investment intermediary - through the investment intermediary, to shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.
The gross dividend, voted on the AGM, amounts to 0.07 BGN (seven stotinki) per share.
The net amount of the dividend (only for physical persons) is 0.0665 BGN per share.
Więcej na: biznes.pap.pl
kom espi abs/
- 05.09.2014 12:26
SOPHARMA AD Sopharma monthly August 2014
05.09.2014 12:26SOPHARMA AD Sopharma monthly August 2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that for August 2014 the Company recorded a decrease of sales revenues of 11% compared to the same period of 2013, including 9% increase of domestic sales and 19% decrease of export sales.
During the past eight months Sopharma AD recorded a decrease of sales revenues of 6%, including 3% increase of domestic sales and 9% decrease of export sales compared to 2013.
Więcej na: biznes.pap.pl
kom espi amp/
- 04.09.2014 13:19
SOPHARMA AD Current report 91 buy back 4092014
04.09.2014 13:19SOPHARMA AD Current report 91 buy back 4092014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 28 August 2014 up to and including 3 September 2014 the Company bought 4900 own shares representing 0.0037% of the share capital of the Company, to the total value of 20 687.8 BGN on the Bulgarian Stock Exchange, the average price per share was 4.222 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 072 055, representing 3.84% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 29.08.2014 13:18
SOPHARMA AD Consolidated financial statements of Sopharma Group for the six months of 2014
29.08.2014 13:18SOPHARMA AD Consolidated financial statements of Sopharma Group for the six months of 2014
Podstawa prawna: Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieї№ce i okresowe
Consolidated financial statements of Sopharma Group for the six months of 2014
1. Consolidated financial statements
2. Notes to the consolidated financial statements
3. Management report
Więcej na: biznes.pap.pl
kom espi mra
- 28.08.2014 11:46
SOPHARMA AD ACQUISITION OF OWN SHARES
28.08.2014 11:46SOPHARMA AD ACQUISITION OF OWN SHARES
SOPHARMA AD (the "Company") hereby informs that from 21August 2014 up to and including 27 August 2014 the Company bought 1 280 own shares representing 0.00097% of the share capital of the Company, to the total value of 5 400.92 BGN on the Bulgarian Stock Exchange, the average price per share was 4.219 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 067 155, representing 3.84% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi abs/
- 21.08.2014 11:03
SOPHARMA AD ACQUISITION OF OWN SHARES
21.08.2014 11:03SOPHARMA AD ACQUISITION OF OWN SHARES
SOPHARMA AD (the "Company") hereby informs that from 14 August 2014 up to and including 20 August 2014 the Company bought 773 own shares representing 0.0006% of the share capital of the Company, to the total value of 3 261.40 BGN on the Bulgarian Stock Exchange, the average price per share was 4.22 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 065 875, representing 3.84 % of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi zdz
- 18.08.2014 13:41
SOPHARMA AD notification of insiders' transactions
18.08.2014 13:41SOPHARMA AD notification of insiders' transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Date and time of the settlement Operation Number of shares Unit price (BGN) 13.08.2014 Buy 468 4.170 11.08.2014 Sale 125 4.26 11.08.2014 Sale 175 4.26 14.08.2014 Sale 100 4.228 14.08.2014 Sale 200 4.228 14.08.2014 Sale 200 4.228
Więcej na: biznes.pap.pl
kom espi mra
- 14.08.2014 13:52
SOPHARMA AD Current report 87 buy back 14082014
14.08.2014 13:52SOPHARMA AD Current report 87 buy back 14082014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 07 August 2014 up to and including 13 August 2014 the Company bought 3 468 own shares representing 0.0026% of the share capital of the Company, to the total value of 14 632.56 BGN on the Bulgarian Stock Exchange, the average price per share was 4.22 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 065 102, representing 3.84 % of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 11.08.2014 13:36
SOPHARMA AD Current report 86 re insiders transactions
11.08.2014 13:36SOPHARMA AD Current report 86 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
06.08.2014 Sale 500 4.21
06.08.2014 Sale 250 4.22
07.08.2014 Sale 750 4.23
07.08.2014 Sale 250 4.23
08.08.2014 Sale 750 4.25
08.08.2014 Sale 250 4.25
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi pif/
- 07.08.2014 15:16
SOPHARMA AD Current report 85 buy back 07082014
07.08.2014 15:16SOPHARMA AD Current report 85 buy back 07082014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 31 July 2014 up to and including 6 August 2014 the Company bought 14 606 own shares representing 0.011% of the share capital of the Company, to the total value of 61 172.17BGN on the Bulgarian Stock Exchange, the average price per share was 4.19 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 061 634, representing 3.83% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 05.08.2014 13:29
SOPHARMA AD Sopharma monthly July 2014
05.08.2014 13:29SOPHARMA AD Sopharma monthly July 2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that for July 2014 the Company recorded an increase of sales revenues of 7% compared to the same period of 2013, including 2% increase of domestic sales and 16% increase of export sales.
During the past seven months Sopharma AD recorded a decrease of sales revenues of 4%, including 2% increase of domestic sales and 7% decrease of export sales compared to 2013.
Więcej na: biznes.pap.pl
kom espi mra
- 04.08.2014 13:24
SOPHARMA AD Current report 83 - insiders transactions
04.08.2014 13:24SOPHARMA AD Current report 83 - insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
29.07.2014 Sale 500 4.149
30.07.2014 Sale 500 4.149
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi pif/
- 31.07.2014 15:39
SOPHARMA AD Current report 82 buy back
31.07.2014 15:39SOPHARMA AD Current report 82 buy back
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 24 July 2014 up to and including 30 July 2014 the Company bought 16 450 own shares representing 0.012% of the share capital of the Company, to the total value of 68 247.25 BGN on the Bulgarian Stock Exchange, the average price per share was 4.15 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 047 028, representing 3.82% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi pif/
- 30.07.2014 13:55
SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2014
30.07.2014 13:55SOPHARMA AD INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2014
INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 JUNE 2014
1. Financial Statements
2. Notes to the Financial Statements
3. Management report
4. Insider Information
5. Additional Information
Więcej na: biznes.pap.pl
kom espi abs/
- 24.07.2014 16:22
SOPHARMA AD - Current report 80 / buy back
24.07.2014 16:22SOPHARMA AD - Current report 80 / buy back
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 17 July 2014 up to and including 23 July 2014 the Company bought 6 476 own shares representing 0.005% of the share capital of the Company, to the total value of 26 747.69 BGN on the Bulgarian Stock Exchange, the average price per share was 4.13 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 030 578, representing 3.81% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi pif/
- 21.07.2014 13:57
SOPHARMA AD Current report 79 re insiders transactions
21.07.2014 13:57SOPHARMA AD Current report 79 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
17.07.2014 Buy 500 4.101
17.07.2014 Buy 1000 4.150
17.07.2014 Buy 1000 4.150
17.07.2014 Buy 2000 4.120
17.07.2014 Buy 2000 4.101
17.07.2014 Buy 200 4.150
17.07.2014 Buy 100 4.120
17.07.2014 Buy 1000 4.150
17.07.2014 Buy 1000 4.150
17.07.2014 Buy 1000 4.150
17.07.2014 Buy 1000 4.150
17.07.2014 Buy 2000 4.150
18.07.2014 Buy 1000 4.075
18.07.2014 Buy 100 4.100
18.07.2014 Buy 250 4.100
18.07.2014 Buy 440 4.100
18.07.2014 Buy 250 4.100
14.07.2014 Sale 300 4.29
14.07.2014 Sale 200 4.29
16.07.2014 Sale 500 4.2
17.07.2014 Sale 200 4.24
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Legal grounds: Art.160.4 of the Act on Trading in Financial Instruments of 29 July 2005.
Signatures of individuals authorized to represent the Company:
Ognian Donev
Więcej na: biznes.pap.pl
kom espi pif/
- 17.07.2014 14:42
SOPHARMA AD Current report 78 buy back 17072014
17.07.2014 14:42SOPHARMA AD Current report 78 buy back 17072014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 10 July 2014 up to and including 16 July 2014 the Company bought 24 177 own shares representing 0.018% of the share capital of the Company, to the total value of 99 990.82 BGN on the Bulgarian Stock Exchange, the average price per share was 4.14 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 024 102, representing 3.81% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 14.07.2014 14:56
SOPHARMA AD Current report 77 re insiders transactions
14.07.2014 14:56SOPHARMA AD Current report 77 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
07.07.2014 Sale 500 4.32 07.07.2014 Sale 300 4.31 09.07.2014 Sale 90 4.45 10.07.2014 Sale 30 4.25 10.07.2014 Sale 270 4.25 11.07.2014 Sale 20 4.25 11.07.2014 Sale 380 4.25
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 10.07.2014 15:19
SOPHARMA AD Current report 76 buy back 10072014
10.07.2014 15:19SOPHARMA AD Current report 76 buy back 10072014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 3 July 2014 up to and including 9 July 2014 the Company bought 1 277 own shares representing 0.001% of the share capital of the Company, to the total value of 5 512.97 BGN on the Bulgarian Stock Exchange, the average price per share was 4.32 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 4 999 925, representing 3.79% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi mra
- 07.07.2014 12:22
SOPHARMA AD Current report 75 re insiders transactions
07.07.2014 12:22SOPHARMA AD Current report 75 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN)
30.06.2014 Buy 500 4.145
30.06.2014 Buy 405 4.150
30.06.2014 Buy 1000 4.051
01.07.2014 Buy 166 4.075
01.07.2014 Buy 205 4.020
01.07.2014 Buy 1600 4.020
01.07.2014 Buy 195 4.020
02.07.2014 Buy 4300 4.190
02.07.2014 Buy 4000 4.250
30.06.2014 Sale 500 4.195
30.06.2014 Sale 100 4.180
01.07.2014 Sale 500 4.100
01.07.2014 Sale 200 4.100
01.07.2014 Sale 100 4.100
01.07.2014 Sale 100 4.100
01.07.2014 Sale 500 4.110
01.07.2014 Sale 500 4.150
01.07.2014 Sale 500 4.210
02.07.2014 Sale 3000 4.295
02.07.2014 Sale 500 4.390
03.07.2014 Sale 20 4.390
03.07.2014 Sale 780 4.390
03.07.2014 Sale 30 4.390
03.07.2014 Sale 370 4.390
04.07.2014 Sale 500 4.390
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 04.07.2014 13:01
SOPHARMA AD Sopharma monthly June 2014
04.07.2014 13:01SOPHARMA AD Sopharma monthly June 2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that for June 2014 the Company recorded a decrease of sales revenues of 8% compared to the same period of 2013, including 7% decrease of domestic sales and 9% decrease of export sales, mainly due to the situation in eastern Ukraine.
During the past six months Sopharma AD recorded a decrease of sales revenues of 6%, including 2% increase of domestic sales and 8% decrease of export sales compared to 2013.
Więcej na: biznes.pap.pl
kom espi pif/
- 03.07.2014 16:50
SOPHARMA AD Current report 73 Notification BRS ENG
03.07.2014 16:50SOPHARMA AD Current report 73 Notification BRS ENG
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
The Board of Directors of Sopharma AD (the "Company") hereby notifies that on 2 July 2014 Sopharma AD submitted for approval the signed merger agreement between Bulgarian Rose - Sevtopolis AD and Sopharma AD and all accompanying documents to the Financial Supervision Commission.
Więcej na: biznes.pap.pl
kom espi pif/
- 03.07.2014 15:08
SOPHARMA AD Current report 72 buy back
03.07.2014 15:08SOPHARMA AD Current report 72 buy back
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 26 June 2014 up to and including 2 July 2014 the Company bought 27 776 own shares representing 0.021% of the share capital of the Company, to the total value of 115 083.07 BGN on the Bulgarian Stock Exchange, the average price per share was 4.14 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 4 999 048, representing 3.79% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi pif/
- 30.06.2014 14:02
SOPHARMA AD Current report 71 re insiders transactions
30.06.2014 14:02SOPHARMA AD Current report 71 re insiders transactions
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time of the settlement Operation Number of shares Unit price (BGN) 23.06.2014 Buy 320 4.250 23.06.2014 Buy 150 4.150 24.06.2014 Buy 470 4.050 24.06.2014 Buy 30 4.050 24.06.2014 Buy 4000 4.005 24.06.2014 Buy 578 4.070 25.06.2014 Buy 10 4.150 25.06.2014 Buy 400 4.180 26.06.2014 Buy 137 4.190 24.06.2014 Sale 170 4.16 26.06.2014 Sale 2000 4.25
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi abs/
- 26.06.2014 15:31
SOPHARMA AD Current report 70 buy back
26.06.2014 15:31SOPHARMA AD Current report 70 buy back
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
SOPHARMA AD (the "Company") hereby informs that from 19 June 2014 up to and including 25 June 2014 the Company bought 19 720 own shares representing 0.015% of the share capital of the Company, to the total value of 81 006.5 BGN on the Bulgarian Stock Exchange, the average price per share was 4.11 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 4 971 272, representing 3.77% of the share capital of the Company.
Więcej na: biznes.pap.pl
kom espi pif/
- 23.06.2014 15:33
SOPHARMA AD Current report 69 re insiders transactions
23.06.2014 15:33SOPHARMA AD Current report 69 re insiders transactions
The Board of Directors of Sopharma AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time Operation Number of shares Unit price (BGN)
16.6.2014 Buy 500 4,430
17.6.2014 Buy 340 4,310
17.6.2014 Buy 500 4,395
18.6.2014 Buy 370 4,300
18.6.2014 Buy 180 4,300
18.6.2014 Buy 450 4,300
18.6.2014 Buy 50 4,420
19.6.2014 Buy 14 4,300
19.6.2014 Buy 399 4,300
19.6.2014 Buy 187 4,300
20.6.2014 Buy 500 4,150
20.6.2014 Buy 170 4,150
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi abs/
- 23.06.2014 13:56
SOPHARMA AD Minutes Of The Annula General Meeting Of Shareholders Of Sopharma Ad - Sofia, 20 June 2014
23.06.2014 13:56SOPHARMA AD Minutes Of The Annula General Meeting Of Shareholders Of Sopharma Ad - Sofia, 20 June 2014
Podstawa prawna: Inne uregulowania
MINUTES OF THE ANNULA GENERAL MEETING
OF SHAREHOLDERS OF
SOPHARMA AD - SOFIA, 20 JUNE 2014
І. Constituting the General Meeting of Shareholders
The General Meeting of Shareholders of Sopharma AD was held on 20 June 2014, at 11.00 in the headquarters of the Company in Sofia, 5 Lachezar Stanchev Str., Sopharma Business Towers, building B. It was attended by shareholders and their representatives, as per the annex to the Minutes listing the present shareholders and representatives of shareholders, as well as the number of shares present and represented.
The AGM was opened by the Executive Director of Sopharma AD Mr. Ognian Donev.
After the shareholders and their representatives were registered for attendance at the General Meeting of Shareholders and due verification was conducted, the AGM established that:
The registered capital of the company is 132 million BGN, divided into 132,000,000 registered dematerialized shares with voting rights in the General Meeting with a nominal value of BGN 1.
According to the Book of Shareholders of the Company, as at 6 June 2014 - the date, as of which the persons, registered in the Book of Shareholders, are entitled to vote at the present General Meeting, Sopharma AD has bought back 4 938 535 shares, representing 3.74% of the capital of the Company. Pursuant to art. 187a, par. 3 of the Commercial Act, the Company suspends the exercising of rights on these shares until their transfer. Shares with voting rights at the AGM on 20 June 2014 amount to 127 061 465.
Forty-six shareholders were registered for participation at the General Meeting. 48 736 604 shares are represented personally at the General Meeting and 35 878 152 shares - by proxy. The total number of the represented shares with voting rights is 84 614 756, which is 64.102% or more than ½ of the capital.
Under the provisions of the Articles of Association of the Company there is a quorum for holding the General Meeting and it may be conducted and take valid decisions.
ELECTION OF MANAGEMENT BODY OF THE SESSION OF THE GENERAL MEETING:
1. Proposals for the management body of the session:
For Chairperson - Galina Ivanova Angelova
For Secretary - Ivanka Atanassova Panova
For Tellers: Alexander Popov - chairperson,
Maria Nedeva,
Kristina Atanasova,
Jeni Asenova,
Zvezdelina Dimitrova,
Daniela Nacheva,
Ani Miteva
Voting results:
Total valid votes cast: 84 614 756 or 100 % of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100 % of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
AGM elected the proposed persons for Chairperson, Secretary and Tellers on the regular session of the GMS, which takes place in Sofia on 20 June 2014.
FINDINGS OF THE CHAIRPERSON AND THE SECRETARY OF THE MEETING:
After opening the session of the AGM, the Chairperson and the Secretary notified the shareholders about the following circumstances:
1. The invitation to the AGM was announced in the Commercial Register - registration № 20140510151053, and on the electronic site of the Company. The announcement was within the statutory period under art. 223, par. 5 of the Commercial Act and in compliance with the requirements of the Public Offering of Securities Act for notifications to the Financial Supervision Commission, the Bulgarian Stock Exchange and the Central Depository regarding the convening of the Annual General Meeting of Shareholders, the agenda and the draft decisions.
2. According to a list of the present and represented shareholders, certified by the Chairperson and the Secretary, 46 shareholders attended the Annual General Meeting, with 48 736 604 shares personally represented and 35 878 152 shares - by a proxy. The total number of shares represented is 84 614 756, all of which with voting rights, which represents 64.102% or more than ½ of the capital.
All represented and registered shares for the work of the GMS are entitled to one vote in the General Meeting.
3. Sixteen shareholders are represented by a power of attorney. The powers of attorney are meeting in form and content all the requirements of the POSA and the rules for proxy voting, adopted by the Company. Powers of attorney have been provided electronically and within the period determined in the Invitation to the AGM by eight shareholders, holding a total of 6 104 413 shares.
4. The following members of the Board of Directors are present at the AGM:
Ognian Ivanov Donev - Chairperson of the Board of Directors and Executive Director;
Vessela Liubenova Stoeva - Deputy-Chairperson of the Board of Directors;
Andrey Liudmilov Breshkov - Member of the Board of Directors;
Ognian Kirilov Palaveev - Member of the Board of Directors.
5. There was no correspondence voting by mail or by electronic means, subject to the conditions of art. 16 of the Articles of Association of the Company.
6. The following persons attended as guests the General Meeting:
Non-shareholders: Zorka Tsvetkova, Vasil Naidenov, Valia Iordanova, Valia Brankova and Iordan Srebkov
Shareholders, not registered for participation: Dimitar Todorov Andoliev and Rumen Liubenov Spasov.
The Chairperson requested the agreement or disagreement by voting of the shareholders regarding the presence of the guests.
After voting with results:
Total valid votes cast: 84 614 756 or 100 % of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none,
The majority of shareholders attending the General Meeting and the representatives of shareholders agreed to allow the guests to be present in the room of the General Meeting without voting rights.
The agenda, announced in the Commercial Register is as follows:
1. Approval of the Annual report of the Board of Directors of the Company for 2013; Draft decision: AGM approves the Annual report of the Board of Directors of the Company for 2013;
2. Approval of the Annual report of the Investor Relations Director for 2013; Draft decision: AGM approves the Annual report of the Investor Relations Director for 2013;
3. Approval of the Audit report on the audit of the annual financial statements of the Company for 2013; Draft decision: AGM approves the Audit report on the audit of the annual financial statements of the Company for 2013;
4. Approval of the audited annual financial statements of the Company for 2013; Draft decision: AGM approves the audited annual financial statements of the Company for 2013;
5. Approval of the audited annual consolidated financial statements of the Company for 2013; Draft decision: AGM approves the audited annual consolidated financial statements of the Company for 2013;
6. Approval of the report of the Audit Committee for 2013; Draft decision: AGM approves the report of the Audit Committee for 2013;
7. Approval of a decision on the distribution of the Company's net profit for 2013 and undistributed profit from past periods; Draft decision: AGM approves the proposal by the Board of Directors for the distribution of the profit generated in 2013 and the undistributed profit from past periods as follows: net profit for 2013 amounts to 33 660 187.31 BGN /thirty-three million, six hundred and sixty thousand, one hundred and eighty-seven leva and thirty-one stotinki/. The undistributed profit from past periods amounts to 1 383 460.18 /one million, three hundred and eighty-three thousand, four hundred and sixty leva and eighteen stotinki/. The total amount of the profit, subject to distribution, is 35 043 647.49 /thirty-five million, forty-three thousand, six hundred and forty-seven leva and forty-nine stotinki/.
After the allocation of 10% to the statutory reserve, amounting to 3 504 364.75 BGN /three million, five hundred and four thousand, three hundred and sixty-four leva and seventy-five stotinki/, from the remaining sum, amounting to 31 539 282.74 BGN /thirty-one million, five hundred and thirty-nine thousand, two hundred and eighty-two leva and seventy-four stotinki/ shall be paid a gross dividend of 0.07 BGN /seven stotinki/ per share with dividend right. After the exact amount of the dividend has been determined, based on a list of shareholders, provided by the Central Depository AD, entitled to receive a dividend as per art.115c of POSA, the remainder of the net profit shall be allocated to the additional reserves of the Company. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country. Payment of dividend will commence within three months from the date of the AGM, on which the payment of dividend was approved;
8. Approval of decision to discharge from liability the members of the Board of Directors for their activities in 2013; Draft decision: AGM discharges from liability the members of the Board of Directors for their activities in 2013;
9. Election of a registered auditor of the Company for 2014; Draft decision: AGM elects a registered auditor to audit and certify the annual financial statements of the Company for 2014 according to the proposal of the Audit Committee, included in the agenda materials.
10. Approval of the Report of the Board of Directors about the application of the Remuneration policy for the members of the Board of Directors of the Company in 2013; Draft decision: AGM approves the Report of the Board of Directors about the application of the Remuneration policy for the members of the Board of Directors of the Company in 2013.
11. Determining the remuneration of the members of the Board of Directors for 2014; Draft decision: On the basis of art. 24, par. 3, letter A of the Company's Articles of Association AGM decided: the regular monthly remuneration of the members of the Board of Directors, as well as the regular monthly remuneration of the Executive Director in 2014 shall remain the same.
12. Approval of decision under art. 24, par. 3, letter B of the Company's Articles of Association; Draft decision: Pursuant to art. 24, par. 3, letter B of the Articles of Association an additional fee of 0,4% /four tenths of one percent/ of the net profit for 2013 according to the approved annual financial statements, shall be paid to the Executive Director of the Company;
13. Approval of decision determining the percent of the net profit for 2013 to be distributed among the members of the senior management of the Company in compliance with the requirements of art. 26a, item 12 of the Articles of Association of the Company; Draft decision: AGM approves the decision for the distribution of 2% /two percent/ of the net profit for 2013 among the members of the senior management of the Company in compliance with the requirements of art. 26a, item 12 of the Articles of Association of the Company
14. Approval of decision for continuation of the mandate of the Audit Committee of the Company - Draft decision: AGM approves the decision to continue the mandate of the Audit Committee for a term of 3 /three/ years as of the date of the AGM.
15. Miscellaneous.
Not all shares with voting rights issued by the Company were represented at the AGM and therefore under art. 231, par. 1 of the Commercial Act reviewing issued not covered by the agenda is not possible.
After publishing of the invitation in the Commercial Register, no additional items under art.223a of the Commercial Act or additional draft decisions on the announced items of the agenda under art.118, par.2, item 4 of POSA have been added to the announced agenda of the AGM, so that only the draft decisions submitted by the Board of Directors shall be voted on.
The announced agenda does not include items requiring a qualified majority for a decision on them - the decisions on the agenda shall be taken by a simple majority of the shares registered for participation.
The materials related to the agenda items of the General Meeting are available to shareholders at the time of the announcement of the invitation in the Commercial Register of the Registry Agency, and in the room where the General Meeting takes place. The materials of the General Meeting are also available in digital form on the official website of the company.
ІІ. DEBATES AND DECISIONS ON THE ITEM
On item 1 of the agenda:
Approval of the annual report of the Board of Directors of the Company for 2013
No questions or statements on this agenda item were received, therefore the Chairperson read the draft decision of the Board of Directors on item 1 of the agenda, namely: AGM approves the Annual Report of the Board of Directors of the Company for 2013.
The Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the Annual Report of the Board of Directors of the Company for 2013.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 2 of the agenda:
Approval of the annual report of the Investor Relations Director for 2013
The Chairperson presented the annual report of the Investor Relations Director for the reporting period, which is part of the materials of the agenda, to the shareholders and read the draft decision of the Board of Directors on this item of the agenda, namely: AGM approves the Report of the Investor Relations Director for 2013.
No questions or statements on this agenda item were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the Report of the Investor Relations Director for 2013.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 3 of the agenda:
Approval of the Auditor's report on the audit of the annual financial statements of the Company for 2013
The Chairperson presented to the shareholders the Auditor's report on the audit of the annual financial statements of the Company for 2013, which is part of the materials of the agenda.
The Chairperson read the draft decision of the Board of Directors on item 3 of the agenda, namely: AGM approves the Auditor's report on the audit of the annual financial statements of the company for 2013;
No questions or statements on this agenda item were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the Auditor's report on the audit of the annual financial statements of the company for 2013.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 4 of the agenda:
Approval of the audited annual financial statements for 2013
The annual financial statements have been presented to the shareholders in their entirety as part of the materials of the agenda.
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely: AGM approves the audited annual financial statements of the Company for 2013.
No questions or statements on the audited annual financial statements were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the audited annual financial statements of the Company for 2013.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 5 of the agenda:
Approval of the audited annual consolidated financial statements of the Company for 2013
The audited consolidated annual financial statements of the Company for 2013 have been presented to the shareholders in their entirety as part of the materials of the agenda.
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely: AGM approves the audited annual consolidated financial statements of the Company for 2013.
No questions or statements on the audited consolidated annual financial statements were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the audited annual consolidated financial statements of the Company for 2013.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 6 of the agenda:
Approval of the report of the Audit Committee on its work in 2013
The report of the Audit Committee on its work in 2013 has been presented to the shareholders in its entirety as part of the materials of the agenda.
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely: AGM approves the report of the Audit Committee on its work in 2013.
No questions or statements on this item were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the report of the Audit Committee on its work in 2013.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 7 of the agenda:
Approval of a decision on the distribution of the Company's net profit for 2013 and undistributed profit from past periods
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely:
AGM approves the proposal by the Board of Directors for the distribution of the profit generated in 2013 and the undistributed profit from past periods as follows: net profit for 2013 amounts to 33 660 187.31 BGN /thirty-three million, six hundred and sixty thousand, one hundred and eighty-seven leva and thirty-one stotinki/. The undistributed profit from past periods amounts to 1 383 460.18 /one million, three hundred and eighty-three thousand, four hundred and sixty leva and eighteen stotinki/. The total amount of the profit, subject to distribution, is 35 043 647.49 /thirty-five million, forty-three thousand, six hundred and forty-seven leva and forty-nine stotinki/.
After the allocation of 10% to the statutory reserve, amounting to 3 504 364.75 BGN /three million, five hundred and four thousand, three hundred and sixty-four leva and seventy-five stotinki/, from the remaining sum, amounting to 31 539 282.74 BGN /thirty-one million, five hundred and thirty-nine thousand, two hundred and eighty-two leva and seventy-four stotinki/ shall be paid a gross dividend of 0.07 BGN /seven stotinki/ per share with dividend right. After the exact amount of the dividend has been determined, based on a list of shareholders, provided by the Central Depository AD, entitled to receive a dividend as per art.115c of POSA, the remainder of the net profit shall be allocated to the additional reserves of the Company. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country. Payment of dividend will commence within three months from the date of the AGM, on which the payment of dividend was approved;
The Chairperson acquainted the shareholders with the provisions of Art. 115v of the Public Offering of Securities Act, under which entitled to receive dividends are those shareholders, registered with the Central Depository on the 14th day following the General Meeting, on which the annual financial statements has been approved and the decision for profit distribution has been taken. The Central Depository provides to the Company a list of shareholders entitled to receive dividends.
No questions or statements on this item of the agenda were received, therefore the draft decision of the Board of Directors was put to the vote
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the proposal by the Board of Directors for the distribution of the profit generated in 2013 and the undistributed profit from past periods as follows: net profit for 2013 amounts to 33 660 187.31 BGN /thirty-three million, six hundred and sixty thousand, one hundred and eighty-seven leva and thirty-one stotinki/. The undistributed profit from past periods amounts to 1 383 460.18 /one million, three hundred and eighty-three thousand, four hundred and sixty leva and eighteen stotinki/. The total amount of the profit, subject to distribution, is 35 043 647.49 /thirty-five million, forty-three thousand, six hundred and forty-seven leva and forty-nine stotinki/.
After the allocation of 10% to the statutory reserve, amounting to 3 504 364.75 BGN /three million, five hundred and four thousand, three hundred and sixty-four leva and seventy-five stotinki/, from the remaining sum, amounting to 31 539 282.74 BGN /thirty-one million, five hundred and thirty-nine thousand, two hundred and eighty-two leva and seventy-four stotinki/ shall be paid a gross dividend of 0.07 BGN /seven stotinki/ per share with dividend right. After the exact amount of the dividend has been determined, based on a list of shareholders, provided by the Central Depository AD, entitled to receive a dividend as per art.115c of POSA, the remainder of the net profit shall be allocated to the additional reserves of the Company. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country. Payment of dividend will commence within three months from the date of the AGM, on which the payment of dividend was approved;
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 8 of the agenda
Adoption of a resolution to discharge from responsibility/liability the Board of Directors for their work in 2013
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely: AGM discharges from liability the Board of Directors for their work in 2013.
No questions or statements on this agenda item were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM discharges from liability the Board of Directors for their work in 2013.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 9 of the agenda
Election of a registered auditor of the Company for 2014.
The Chairperson read the draft decision by the Board of Directors on this agenda item, namely: AGM elects a register auditor to audit and certify the Annual financial statements of the Company for 2014 according to the proposal of the Audit Committee, included in the agenda materials..
The proposal of the Audit Committee of the Company is that the Board of Directors should propose to the AGM as registered auditor for the audit and certification of the annual financial statements of the Company in 2014 the audit company AFA OOD, with address of management Sofia, 38 Oborishte Str..
The Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM elects the audit company AFA OOD, with address of management Sofia, 38 Oborishte Str. for the audit and certification of the annual financial statements of the Company in 2014 in compliance with the proposal by the Audit Committee, included in the materials of the agenda.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 10 of the agenda
Approval of the Report of the Board of Directors about the application of the Remuneration policy for the members of the Board of Directors of the Company in 2013.
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely: AGM approves the Report of the Board of Directors about the application of the Remuneration policy for the members of the Board of Directors of the Company in 2013.
No questions or statements this item were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the Report of the Board of Directors about the application of the Remuneration policy for the members of the Board of Directors of the Company in 2013.
On item 11 of the agenda
Determining the remuneration of the members of the Board of Directors for 2014.
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely: On the basis of art. 24, par. 3, letter A of the Company's Articles of Association AGM decided: the regular monthly remuneration of the members of the Board of Directors, as well as the regular monthly remuneration of the Executive Director in 2014 shall remain the same.
No questions or statements on this agenda item were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 579 758 shares or 99,96% of the represented capital and 64,076% of the registered capital
VOTED"AGAINST": 34 998 shares or 0,04% of the represented capital and 0,026% of the registered capital
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: On the basis of art. 24, par. 3, letter A of the Company's Articles of Association AGM decided: the regular monthly remuneration of the members of the Board of Directors, as well as the regular monthly remuneration of the Executive Director in 2014 shall remain the same.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 12 of the agenda
Approval of decision under art. 24, par. 3, letter B of the Company's Articles of Association
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely: Pursuant to art. 24, par. 3, letter B of the Articles of Association an additional fee of 0,4% /four tenths of one percent/ of the net profit for 2013 according to the approved annual financial statements, shall be paid to the Executive Director of the Company;
No questions or statements on the audited annual financial statements were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 579 758 shares or 99,96% of the represented capital and 64,076% of the registered capital
VOTED"AGAINST": 34 998 shares or 0,04% of the represented capital and 0,026% of the registered capital
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: Pursuant to art. 24, par. 3, letter B of the Articles of Association an additional fee of 0,4% /four tenths of one percent/ of the net profit for 2013 according to the approved annual financial statements, shall be paid to the Executive Director of the Company;
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 13 of the agenda
Approval of decision determining the percent of the net profit for 2013 to be distributed among the members of the senior management of the Company in compliance with the requirements of art. 26a, item 12 of the Articles of Association of the Company
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely: AGM approves the decision for the distribution of 2% /two percent/ of the net profit for 2013 among the members of the senior management of the Company in compliance with the requirements of art. 26a, item 12 of the Articles of Association of the Company.
No questions or statements on the proposal for the inclusion of a new article 11a in the Articles of Association were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote:
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 579 758 shares or 99,96% of the represented capital and 64,076% of the registered capital
VOTED"AGAINST": 34 998 shares or 0,04% of the represented capital and 0,026% of the registered capital
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the decision for the distribution of 2% /two percent/ of the net profit for 2013 among the members of the senior management of the Company in compliance with the requirements of art. 26a, item 12 of the Articles of Association of the Company.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 14 of the agenda
Approval of decision for continuation of the mandate of the Audit Committee of the Company
The Chairperson read the draft decision of the Board of Directors on this item of the agenda, namely: Draft decision: AGM approves the decision to continue the mandate of the Audit Committee for a term of 3 /three/ years as of the date of the AGM.
No questions or statements on this agenda item were received, therefore the Chairperson put the draft decision of the Board of Directors to the vote.
Voting results:
Total valid votes cast: 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED "FOR": 84 614 756 shares or 100% of the represented capital and 64,102% of the registered capital
VOTED"AGAINST": none
VOTED"ABSTAINED": none
Under these results the AGM took the following DECISION: AGM approves the decision to continue the mandate of the Audit Committee for a term of 3 /three/ years as of the date of the AGM.
The decision was taken with a majority as per the Commercial Act and the Articles of Association of the Company.
No objections to the manner of voting and the results were received.
On item 15 of the agenda
Miscellaneous.
No questions were raised by shareholders.
The agenda of the Annual General Meeting of Shareholders of Sopharma AD was exhausted, therefore the Chairperson closed the meeting.
The present minutes were prepared and signed in three identical copies. An integral part of these minutes are: the list of the present shareholders and shareholder representatives with the number of shares owned and represented by them, the powers of attorney by shareholders for representation at the General Meeting, current certificates of commercial registration for shareholders - legal entities and the materials for the convening of the General Meeting, conducted on 20 June 2014, Sofia.
CHAIRPERSON OF THE AGM
.........................
SECRETARY OF THE AGM
............................
TELLERS:
1. .................................... 2. ....................................
3. .................................... 4. ....................................
5. .................................... 6. ....................................
7. ....................................
Sofia
20 June 2014
Więcej na: biznes.pap.pl
kom espi mra
- 20.06.2014 16:52
SOPHARMA AD Current report 67 Notification 20.06.2014
20.06.2014 16:52SOPHARMA AD Current report 67 Notification 20.06.2014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that on 19 June 2014 Sopharma AD, Sofia, UIC 831902088, hereinafter referred to as "receiving company" and Bulgarian Rose - Sevtopolis AD, Kazanluk, UIC 123007916, hereinafter referred to as "transferring company" signed a Contract for transformation through merger in accordance with the requirements of art. 262d and following of the Commercial Act (CA), as a result of which all assets of Bulgarian Rose - Sevtopolis AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Bulgarian Rose - Sevtopolis shall be terminated without liquidation.
Pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA) the Contract for merger, as well as reports of the management bodies of the companies involved in the transformation of the company under art. 262i of the CA and the report of the examiner under art. 262m of the CA must be approved by the deputy chairman of the Financial Supervision Commission, managing the "Investment Supervision" division.
According to the signed contract, in connection with the implementation of the merger shall be carried out a capital increase of the receiving company Sopharma AD through issuing of new shares to be distributed among the shareholders of the transferring company Bulgarian Rose - Sevtopolis AD (except the shareholder Sopharma AD).
As a result of the merger, all shareholders of the transferring company Bulgarian Rose - Sevtopolis AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Bulgarian Rose - Sevtopolis AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.419404 shares of the capital of Sopharma AD.
Więcej na: biznes.pap.pl
kom espi zdz
- 20.06.2014 16:45
SOPHARMA AD Current report 66 AGM 20062014
20.06.2014 16:45SOPHARMA AD Current report 66 AGM 20062014
Podstawa prawna: Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Sopharma AD (the "Company") notifies that on the regular General Meeting of Shareholders of Sopharma AD, conducted on 20 June 2014 in Sofia, 5 Lachezar Stanchev Str., were taken the following decisions:
1. Approval of the proposal by the Board of Directors for the distribution of the profit generated in 2013 and the undistributed profit from past periods as follows: net profit for 2013 amounts to 33 660 187.31 BGN /thirty-three million, six hundred and sixty thousand, one hundred and eighty-seven leva and thirty-one stotinki/. The undistributed profit from past periods amounts to 1 383 460.18 /one million, three hundred and eighty-three thousand, four hundred and sixty leva and eighteen stotinki/. The total amount of the profit, subject to distribution, is 35 043 647.49 /thirty-five million, forty-three thousand, six hundred and forty-seven leva and forty-nine stotinki/.
After the allocation of 10% to the statutory reserve, amounting to 3 504 364.75 BGN /three million, five hundred and four thousand, three hundred and sixty-four leva and seventy-five stotinki/, from the remaining sum, amounting to 31 539 282.74 BGN /thirty-one million, five hundred and thirty-nine thousand, two hundred and eighty-two leva and seventy-four stotinki/ shall be paid a gross dividend of 0.07 BGN /seven stotinki/ per share with dividend right. After the exact amount of the dividend has been determined, based on a list of shareholders, provided by the Central Depository AD, entitled to receive a dividend as per art.115c of POSA, the remainder of the net profit shall be allocated to the additional reserves of the Company. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country. Payment of dividend will commence within three months from the date of the AGM, on which the payment of dividend was approved;
2. Election of AFA OOD with address of management in Sofia, 38 Oborishte Str. as a registered auditor for auditing and verification of the Annual financial statements of the Company for 2014, according to a proposal by the Audit Committee.
3. Approval of decision for continuation of the mandate of the Audit Committee of the Company for a term of 3 /three/ years as of the date of the AGM.
Więcej na: biznes.pap.pl
kom espi zdz
- 18.06.2014 07:55
SOPHARMA AD Current report 64 re insiders transactions
18.06.2014 07:55SOPHARMA AD Current report 64 re insiders transactions
Podstawa prawna: Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych
Sopharma AD (the "Company") announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:
Date and time Operation Number Unit price
of the of (BGN)
settlement shares
09.06.2014 Buy 500 4.390
09.06.2014 Buy 310 4.375
09.06.2014 Buy 150 4.375
09.06.2014 Buy 19 4.375
10.06.2014 Buy 100 4.440
10.06.2014 Buy 72 4.370
10.06.2014 Buy 286 4.370
10.06.2014 Buy 142 4.370
10.06.2014 Buy 228 4.350
10.06.2014 Buy 272 4.350
11.06.2014 Buy 200 4.360
12.06.2014 Buy 80 4.400
12.06.2014 Buy 200 4.420
The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.
Więcej na: biznes.pap.pl
kom espi mra
- 16.06.2014 16:12
SOPHARMA AD Current report 63 - Notification
16.06.2014 16:12SOPHARMA AD Current report 63 - Notification
Podstawa prawna: Inne uregulowania
The Board of Directors of Sopharma notifies that on its meeting carried out on June 16, 2014 it took a decision to initiate a procedure for merging Bulgarian Rose - Sevtopolis AD, VAT number 123007916 based in the city of Kazanlak on 110, "23d pehoten polk" Blvd. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses "Elana Trading" AD VAT number 831470130 , based on 4, Kuzman Shapkarev Str. for a consultant in relation to the merger.
Więcej na: biznes.pap.pl
kom espi amp/
- 16.06.2014 14:08
SOPHARMA AD Current report 62 SPH AGM - 20.06.2014
16.06.2014 14:08SOPHARMA AD Current report 62 SPH AGM - 20.06.2014
Sopharma AD (the "Company") hereby notifies all shareholders of the Company, that the Annual General Meeting, convened by the Board of Directors for 20 June 2014 at 11:00 will take place at Sopharma Business Towers, Building B, floor 3, 5 Lachezar Stanchev Str.. The registration begins at 9:30.
All shareholders of the company are invited to participate at the General Meeting in person or by proxy.
As a prerequisite for the technical provisioning of the Annual General Meeting of Shareholders, copies of all letters of attorney must be presented to the Company on paper or electronically by the end of the workday preceding the date of the AGM, namely 5 p.m. on 19 June 2014.
We would like to thank all shareholders for their understanding and cooperation.
Więcej na: biznes.pap.pl
kom espi abs/
- 12.06.2014 13:16
SOPHARMA AD Current report 61 buy back 12062014